{"docstore/data": {"2edaf5ee-f6bd-4f52-b31d-58e8dc046f98": {"__data__": {"id_": "2edaf5ee-f6bd-4f52-b31d-58e8dc046f98", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01b5d416-1e80-4778-9006-fc61daa8daff", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c19003677df13110fcae1a4f6a739e723b0f636452f3a41fe6f7dd95fbb67027", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a98623b5-99be-4658-90a4-ede42cdf4eac", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": "(MCK ) \nQ4 2023 Earnings Call    "}, "hash": "31a2fd77ec353cd487f0f2f8bfad574bc87ef66f5942fe5b27a2eb55c83adb6f", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a98623b5-99be-4658-90a4-ede42cdf4eac": {"__data__": {"id_": "a98623b5-99be-4658-90a4-ede42cdf4eac", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": "(MCK ) \nQ4 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01b5d416-1e80-4778-9006-fc61daa8daff", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c19003677df13110fcae1a4f6a739e723b0f636452f3a41fe6f7dd95fbb67027", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2edaf5ee-f6bd-4f52-b31d-58e8dc046f98", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950ce02435fb2e5d88bcc313a79621c1db053972e7c57f2bb51c70ac966ef794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da2de88b-0bc2-468a-8ce6-a72f541e813b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "c2e34fa84111cd8c38cdc03fab631a7820408be0deb374e89058f3aa4e37f652", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call    ", "start_char_idx": 166, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da2de88b-0bc2-468a-8ce6-a72f541e813b": {"__data__": {"id_": "da2de88b-0bc2-468a-8ce6-a72f541e813b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a98623b5-99be-4658-90a4-ede42cdf4eac", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": "(MCK ) \nQ4 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "281d057126afb82a33b78170db089e30830533b15ebfb56554347683a3e59f48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cfa0bf8-b8f4-4946-a606-0195ab6bb916", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n"}, "hash": "b8da65d0567af3425c93ed29250588755b98dd5864af768122daa0eacd583ffd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cfa0bf8-b8f4-4946-a606-0195ab6bb916": {"__data__": {"id_": "4cfa0bf8-b8f4-4946-a606-0195ab6bb916", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da2de88b-0bc2-468a-8ce6-a72f541e813b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1274579828615326d2bfacdf550f85b8f1b135bcb3b249cf73abfc112f8aaadc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad6873e-55ef-4063-82aa-36021d4a5f9d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "90dabc052c0dddebe9b8f490f3da572e5dd0eeb877d5d4aa7be145e20b22de47", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad6873e-55ef-4063-82aa-36021d4a5f9d": {"__data__": {"id_": "8ad6873e-55ef-4063-82aa-36021d4a5f9d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cfa0bf8-b8f4-4946-a606-0195ab6bb916", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f879525d20f1632004ec5b61e6015bfb3ae762e8ef36d9c209aa3e70741a6d4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af61f22c-f662-4ee2-9723-95feef61f940", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "91b650c73d638893b0aced985aee03612d861a7fadbf5543eab44dd2032c7e06", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 271, "end_char_idx": 343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af61f22c-f662-4ee2-9723-95feef61f940": {"__data__": {"id_": "af61f22c-f662-4ee2-9723-95feef61f940", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad6873e-55ef-4063-82aa-36021d4a5f9d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c2a2929e61eb27c7b0323124297fb431d322a423f42c3bccbc2804e714c18f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4727e84-c82f-465a-9c8b-9646cd6618e3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "1c6c47b8730fa7a9465bc0f57d56933c8fa236536f79902d8d88c1357b7254cd", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 343, "end_char_idx": 433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4727e84-c82f-465a-9c8b-9646cd6618e3": {"__data__": {"id_": "a4727e84-c82f-465a-9c8b-9646cd6618e3", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af61f22c-f662-4ee2-9723-95feef61f940", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8e941e701e4c019299f481f4e8310caa1d5ad5373bb3588897e3e325110941f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af8f3443-0c5d-40c4-a224-5c1cb7077014", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "da49b8848de1c6ce54db3f221504b204fee49af4045b69cc28c20a7c53c333f2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 433, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af8f3443-0c5d-40c4-a224-5c1cb7077014": {"__data__": {"id_": "af8f3443-0c5d-40c4-a224-5c1cb7077014", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4727e84-c82f-465a-9c8b-9646cd6618e3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1987d91c1fd7d4c6a032f1ec65eecf8e384494224c0baa2c0229e5e196bfe84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49be17a-f3c2-4284-b16f-a2afcf9b6895", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "cc4fc502dca9aa82a22f3648c20bf02fc0896e74c20e77c772995bf7a8d5d18f", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 812, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b49be17a-f3c2-4284-b16f-a2afcf9b6895": {"__data__": {"id_": "b49be17a-f3c2-4284-b16f-a2afcf9b6895", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af8f3443-0c5d-40c4-a224-5c1cb7077014", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b811107ec5a70c427a8c64f6e7aee5294fbfd98ea06dd125b567c56eb9ad8d89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11780e35-9889-4c22-b78e-5e5abe27c6db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "51eba973546be22a2bb71514108e8dc377a6e09295556c32fe89236fc17130ce", "class_name": "RelatedNodeInfo"}}, "text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1003, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11780e35-9889-4c22-b78e-5e5abe27c6db": {"__data__": {"id_": "11780e35-9889-4c22-b78e-5e5abe27c6db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49be17a-f3c2-4284-b16f-a2afcf9b6895", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11bdd9f232a603a8e68fea905adc672a0bd2a297a3cece6c50b19519def98f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30658792-6b3f-4d22-8f6a-d507f3f912c6", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "77b2d48e365253f66363d48ea4f626d221ed8241599c6c4da097992d086a2401", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 1059, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30658792-6b3f-4d22-8f6a-d507f3f912c6": {"__data__": {"id_": "30658792-6b3f-4d22-8f6a-d507f3f912c6", "embedding": null, "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11780e35-9889-4c22-b78e-5e5abe27c6db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15c86be29947b6446fcbb9bee93584f11f791670f62791016d8ca89469f2084f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eef01c7-223e-44e8-b1fb-962b96f54c68", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. "}, "hash": "89b164336167b1e28831c7411f937b5916589dee6dec50a99c46c993565a4080", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1163, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eef01c7-223e-44e8-b1fb-962b96f54c68": {"__data__": {"id_": "9eef01c7-223e-44e8-b1fb-962b96f54c68", "embedding": null, "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30658792-6b3f-4d22-8f6a-d507f3f912c6", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nCharles Rhyee  \nAnalys t, TD Cowen  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff2531ade4befc2a7a7210184ca012ec4e19f0aefedd0dcc16bdf53fefaea940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3622332-983c-4b0d-812f-c01415d8ce55", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Rice  \nAnalyst, Credit Suisse  \n  "}, "hash": "6f06597c1c84d139f563effdb8e2bc40c79bfe7e735197c835dce18f5d1a803b", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "start_char_idx": 1214, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3622332-983c-4b0d-812f-c01415d8ce55": {"__data__": {"id_": "e3622332-983c-4b0d-812f-c01415d8ce55", "embedding": null, "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Rice  \nAnalyst, Credit Suisse  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718581c3dfba893a834f9ef0f98b7f7fdf6afadcd1d0a77825d396c705442815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eef01c7-223e-44e8-b1fb-962b96f54c68", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J. ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d02dd700b8f021026e1df4e6394d0cbbe97c8cf87977bb54eaabdd046f8426d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42bf4fe6-2eb0-4706-9043-5b7005e34b49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "original_text": "McKesson Corp.  "}, "hash": "876d6e3d8f0d61709ec4c1c93109304ac492f4ab0ad93c20e0d45c55a0260e58", "class_name": "RelatedNodeInfo"}}, "text": "Rice  \nAnalyst, Credit Suisse  \n  ", "start_char_idx": 1270, "end_char_idx": 1304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42bf4fe6-2eb0-4706-9043-5b7005e34b49": {"__data__": {"id_": "42bf4fe6-2eb0-4706-9043-5b7005e34b49", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3622332-983c-4b0d-812f-c01415d8ce55", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \nA.J.  Rice  \nAnalyst, Credit Suisse  \n  ", "original_text": "Rice  \nAnalyst, Credit Suisse  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ab335c0d16984efd4857b51fd67d46ef6e1e6c3fd502f4bba85aed0774a688e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0aa65b7-7942-4d72-bc96-4c4b23abeed0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call. "}, "hash": "fc7dfab956b7313838bce607926042b6def6e360b1430790214f767f6c12cb0b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0aa65b7-7942-4d72-bc96-4c4b23abeed0": {"__data__": {"id_": "a0aa65b7-7942-4d72-bc96-4c4b23abeed0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42bf4fe6-2eb0-4706-9043-5b7005e34b49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ef70b90e10d110526293d18f001bc1d79e1dbbd8b6e663c9fa9392bf4682515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f697c527-4c4a-450b-97c7-fb635975b4d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised \nthat today's conference is being recorded.  \n \n"}, "hash": "5350852909c49e326cf8656c85c86ae53ea6e97b5f18b4ef380c6bdc0b5b348e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call. ", "start_char_idx": 16, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f697c527-4c4a-450b-97c7-fb635975b4d6": {"__data__": {"id_": "f697c527-4c4a-450b-97c7-fb635975b4d6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised \nthat today's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0aa65b7-7942-4d72-bc96-4c4b23abeed0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d10cf837f86f4d27587956760c93e4a59a02533a2a761ea5b1bede8040a044f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. "}, "hash": "4d485d2ffcf8a0cd48cb713f4bef3ad604775553935df5965d329e81df0b0e5f", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised \nthat today's conference is being recorded.  \n \n", "start_char_idx": 303, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1": {"__data__": {"id_": "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f697c527-4c4a-450b-97c7-fb635975b4d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised \nthat today's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49a18699830d97c188744caef41e23ad9d47a2d1f06d906ee02e42e3669d80b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "original_text": "Please go ahead.  \n "}, "hash": "d50f064c3ef1510746ff89b97d68efd286669eaed5766dd74fe5a563971f3408", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "start_char_idx": 369, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c": {"__data__": {"id_": "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd6de03e776231a368e1373f317cf2a1dab311e34575c9d9c217475d391f174c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfff62fc-4375-489c-bcc4-c2e9d46b464b", "node_type": "1", "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n"}, "hash": "13fe71c89252c07c4731f7e49fed22f3b50560b28b02216c9b30a7e97ba5f4f1", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 467, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfff62fc-4375-489c-bcc4-c2e9d46b464b": {"__data__": {"id_": "bfff62fc-4375-489c-bcc4-c2e9d46b464b", "embedding": null, "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd072ca5e6c137f8bb9cceebd1a9393695c9c17efc4d7ae24224fee057241c4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "original_text": "Thank you, operator. "}, "hash": "37879d20877f125738845d9d2be718cd65430bd4f4f584c72ca3b6438d369db7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "start_char_idx": 487, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58": {"__data__": {"id_": "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfff62fc-4375-489c-bcc4-c2e9d46b464b", "node_type": "1", "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e2e276d9d5ce8f3a8ca10971091ffa01fe67c8aeb4edf0ff3a17c24c462a901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. "}, "hash": "42dd01856136c69c6fa44ed9bc037145216e1ac19ec11e2f8534e588ec2ca81d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 806, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad": {"__data__": {"id_": "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2654514f389aeb698755dd59dd3f480ae86d17463e55c26bc008c886f8b01a75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e222da5f-3f00-4ca3-8490-63ce7b16c86b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. "}, "hash": "1c65a035e292396a0fd30c8dce99ee1a6f46c65e3d056854265f2b2a99b14a63", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "start_char_idx": 827, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e222da5f-3f00-4ca3-8490-63ce7b16c86b": {"__data__": {"id_": "e222da5f-3f00-4ca3-8490-63ce7b16c86b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "549b51927a34b536054ee43a110447d2998f9393f1bd7553b30edbd062fbb3db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21021643-c8f7-40b6-8035-d054d928011a", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n"}, "hash": "89f5f590d17dfd160d31052235a855c973f802cf15387cb2ef60cf1ce6629ed0", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "start_char_idx": 922, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21021643-c8f7-40b6-8035-d054d928011a": {"__data__": {"id_": "21021643-c8f7-40b6-8035-d054d928011a", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e222da5f-3f00-4ca3-8490-63ce7b16c86b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c812a898746421bcc5a2d589e75ebcbe388e6e213bf690b0b1a6330eb5c7cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba5af0ba-fbc5-420b-81d4-4981222f2568", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "8382aa09d68ccd3dd9cd1857dcee5d1a544459f97b2e8cd6283ee97e6bbacf20", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "start_char_idx": 1034, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba5af0ba-fbc5-420b-81d4-4981222f2568": {"__data__": {"id_": "ba5af0ba-fbc5-420b-81d4-4981222f2568", "embedding": null, "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21021643-c8f7-40b6-8035-d054d928011a", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9d3a700396df373ec5818b1ebccb3bb66b85452288ce6169ac870713e677172", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "419a6e76-87c2-4565-afa5-bad7ce10fbbb", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n"}, "hash": "a68cb788c0a7ab5768035073e9c3465f19b2216292e0d768db1ab758a5093793", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 1136, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "419a6e76-87c2-4565-afa5-bad7ce10fbbb": {"__data__": {"id_": "419a6e76-87c2-4565-afa5-bad7ce10fbbb", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba5af0ba-fbc5-420b-81d4-4981222f2568", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Fourth Quarter Fiscal 2023 \nEarnings Call.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be64b5dce5f389348d0c0fb325da9ba335812c1c476173524cb1848a7f10b48e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba46ad75-431f-49b8-bb1d-c143c46e4e4b", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. "}, "hash": "950cc6f2f0731659fa9c891a527b0bba13ee5d2e02e2ea392dd0aac9506fd5ae", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "start_char_idx": 1264, "end_char_idx": 1634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba46ad75-431f-49b8-bb1d-c143c46e4e4b": {"__data__": {"id_": "ba46ad75-431f-49b8-bb1d-c143c46e4e4b", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "419a6e76-87c2-4565-afa5-bad7ce10fbbb", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and\u202fBritt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca30e83fe857751f7b3954195b9990418eec7b4a9cb8f232bbc5e9c44fb0bb6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ac01a8c-1ff0-48ad-938c-a2efa385304b", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n"}, "hash": "1c23bb7f2f3370f800adf4cb52e3ef67e550ca8c177d9ca3f3aa7a0390d50b61", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "start_char_idx": 1634, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ac01a8c-1ff0-48ad-938c-a2efa385304b": {"__data__": {"id_": "3ac01a8c-1ff0-48ad-938c-a2efa385304b", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba46ad75-431f-49b8-bb1d-c143c46e4e4b", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a que stion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d00c274d364d8b1f1de585f1544c3096f2f0eb44224699e0b81a0634b8c5895c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "f7716ec66d1bed75551fb39a8539842e80c6135bf6293964f6fddfa680ced66e", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "start_char_idx": 1853, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75": {"__data__": {"id_": "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ac01a8c-1ff0-48ad-938c-a2efa385304b", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d0ee7df46b23fa326ebd1f82d62db70c3e5666134d1e16965dca326734e86b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42a87841-1f04-4876-95d1-daee31c8a13e", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "e5afd21ba7a51649d241e14775332c89462bdbedcf38ca9c452936347baa26d6", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1961, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42a87841-1f04-4876-95d1-daee31c8a13e": {"__data__": {"id_": "42a87841-1f04-4876-95d1-daee31c8a13e", "embedding": null, "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's\u202fearnings release\u202fand presentation slides \navailable  on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially different from those \nin our forward -looking statements . \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23e0d37f15f11784c5411524d762ecd399c458f6de2bbef447e8f22f822c256f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "627aeba7-8346-44b2-8167-78afae96be7f", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "original_text": "Thank you, Nicole, and\u202fgood afternoon, everyone. "}, "hash": "3bd3137b4b507981051fd9cf18f4b9db1784ff14cd56bb0d06550c7cc3d01dec", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2005, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "627aeba7-8346-44b2-8167-78afae96be7f": {"__data__": {"id_": "627aeba7-8346-44b2-8167-78afae96be7f", "embedding": null, "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "original_text": "Thank you, Nicole, and\u202fgood afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42a87841-1f04-4876-95d1-daee31c8a13e", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's\u202fearnings release\u202fand presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a010f7725aefea7071898312bc881083193d5b61cdbd93c039b662ee58ac2314", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65152bff-bb56-4bc0-bf63-87deb9454799", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "original_text": "Appreciate you joining us for our call today. "}, "hash": "912ab462c0de5addbd075fa32bfd6db7d3c4cfb66fc9668dcd250d10467db673", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Nicole, and\u202fgood afternoon, everyone. ", "start_char_idx": 2335, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65152bff-bb56-4bc0-bf63-87deb9454799": {"__data__": {"id_": "65152bff-bb56-4bc0-bf63-87deb9454799", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "original_text": "Appreciate you joining us for our call today. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "627aeba7-8346-44b2-8167-78afae96be7f", "node_type": "1", "metadata": {"window": "The presentation slides also include a summary of our results for the quarter and guidance assumptions.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "original_text": "Thank you, Nicole, and\u202fgood afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69fcd78c61adcf3de12145f3bd80fad3b69ddab305dcb3fe770304f5ed1f2cf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a31819f2-e2ec-42e9-a1d3-980aa273be52", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "original_text": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. "}, "hash": "7d6ec5e7ac491ffeba2d86db757289b969d89f661cf923a1a454792e89f86625", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate you joining us for our call today. ", "start_char_idx": 2384, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a31819f2-e2ec-42e9-a1d3-980aa273be52": {"__data__": {"id_": "a31819f2-e2ec-42e9-a1d3-980aa273be52", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "original_text": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65152bff-bb56-4bc0-bf63-87deb9454799", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "original_text": "Appreciate you joining us for our call today. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0e8ea3a1efd6184ac10f269d9b7738f3260ae1f2cc82da8d6e04c2c1af1fe55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a5228a-61a7-48a2-9be9-51282d40e6b8", "node_type": "1", "metadata": {"window": "Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "original_text": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. "}, "hash": "f2645f58acaebe8c06c6810a0b5cb0cf1e763a64c7a7cf4653f3bfab68a7cfda", "class_name": "RelatedNodeInfo"}}, "text": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "start_char_idx": 2430, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a5228a-61a7-48a2-9be9-51282d40e6b8": {"__data__": {"id_": "94a5228a-61a7-48a2-9be9-51282d40e6b8", "embedding": null, "metadata": {"window": "Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "original_text": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a31819f2-e2ec-42e9-a1d3-980aa273be52", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "original_text": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06416b617512305d58a9de2b24872dcdb09e5d632e9aa705a0f9fbc9a0c4f734", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0652f7be-cedd-4275-8f93-a3ed3695b3f7", "node_type": "1", "metadata": {"window": "Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "original_text": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n"}, "hash": "857da24391bb52880f9227567bcdcd578a3d87fd46d893d14cea64c95aca9439", "class_name": "RelatedNodeInfo"}}, "text": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "start_char_idx": 2525, "end_char_idx": 2625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0652f7be-cedd-4275-8f93-a3ed3695b3f7": {"__data__": {"id_": "0652f7be-cedd-4275-8f93-a3ed3695b3f7", "embedding": null, "metadata": {"window": "Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "original_text": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a5228a-61a7-48a2-9be9-51282d40e6b8", "node_type": "1", "metadata": {"window": "Thank you, Nicole, and\u202fgood afternoon, everyone.  Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "original_text": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fefb682faf148f981d1867d377ce5a7484f9d3e1885f5c0d4886f3c36b58d436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5235bf2-3eb0-4756-bdb5-dff3544827d0", "node_type": "1", "metadata": {"window": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "original_text": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. "}, "hash": "034c9f2846f4a4e21f443b726050dbc9b1264667102e0a642fe8a884e332ab68", "class_name": "RelatedNodeInfo"}}, "text": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "start_char_idx": 2625, "end_char_idx": 2776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5235bf2-3eb0-4756-bdb5-dff3544827d0": {"__data__": {"id_": "b5235bf2-3eb0-4756-bdb5-dff3544827d0", "embedding": null, "metadata": {"window": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "original_text": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0652f7be-cedd-4275-8f93-a3ed3695b3f7", "node_type": "1", "metadata": {"window": "Appreciate you joining us for our call today.  Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "original_text": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9883681fbb50c2bdabb10a72501c637310352343911b5c5eadc2794fd89df5e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d4a76bf-6023-4422-976d-482ba97746b3", "node_type": "1", "metadata": {"window": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "original_text": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. "}, "hash": "c9d6f09e33cce9591f014698c31632bcf45f24160f8990558d41d1f6eba87efa", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "start_char_idx": 2776, "end_char_idx": 2939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d4a76bf-6023-4422-976d-482ba97746b3": {"__data__": {"id_": "4d4a76bf-6023-4422-976d-482ba97746b3", "embedding": null, "metadata": {"window": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "original_text": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5235bf2-3eb0-4756-bdb5-dff3544827d0", "node_type": "1", "metadata": {"window": "Earlier today, we \nannounced fourth quarter results closing out a very successful fiscal 2023.  We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "original_text": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44e36854253fd329f81796dbaf62a9abfbd67522dcb9a330bd37499188d156f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40f2c965-d037-4aa8-99cd-0969d54098de", "node_type": "1", "metadata": {"window": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n"}, "hash": "1f126f4ab487c5f76c8dfd08ce4b91bf70fa0e3c461b710b60846bc9c4dcf20f", "class_name": "RelatedNodeInfo"}}, "text": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "start_char_idx": 2939, "end_char_idx": 3070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40f2c965-d037-4aa8-99cd-0969d54098de": {"__data__": {"id_": "40f2c965-d037-4aa8-99cd-0969d54098de", "embedding": null, "metadata": {"window": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d4a76bf-6023-4422-976d-482ba97746b3", "node_type": "1", "metadata": {"window": "We delivered full year revenues of \n$277 billion and adjusted earnings per diluted share of $25.94.  When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "original_text": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments. ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "163b54a26700c84e4af60b936ce2ac648a3946037359fa1ecde983f6c81f73a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27450ae1-ad61-4202-a937-ae82cdda5a31", "node_type": "1", "metadata": {"window": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n"}, "hash": "04355ea006a8f7f5ebedf7eefd623bffc6df8b8389cd8dcf85763bd5adcc9197", "class_name": "RelatedNodeInfo"}}, "text": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "start_char_idx": 3070, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27450ae1-ad61-4202-a937-ae82cdda5a31": {"__data__": {"id_": "27450ae1-ad61-4202-a937-ae82cdda5a31", "embedding": null, "metadata": {"window": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40f2c965-d037-4aa8-99cd-0969d54098de", "node_type": "1", "metadata": {"window": "When excluding certain items, adjusted earn ings \nper diluted share grew 15% from the prior year, driven by momentum across all business segments.  \n \n In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e5e4af88f7a43ea22a2ab16ca2be7f6eabbe65a920334905b147b36b1d60ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b90f5fe-ce16-4873-bede-877ff9c73b8f", "node_type": "1", "metadata": {"window": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n"}, "hash": "fbc06da24cee9a141213ac0dbb4ecabb690b3b7e44f260a2fa6e2949a53eb871", "class_name": "RelatedNodeInfo"}}, "text": "As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "start_char_idx": 3254, "end_char_idx": 3478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b90f5fe-ce16-4873-bede-877ff9c73b8f": {"__data__": {"id_": "2b90f5fe-ce16-4873-bede-877ff9c73b8f", "embedding": null, "metadata": {"window": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27450ae1-ad61-4202-a937-ae82cdda5a31", "node_type": "1", "metadata": {"window": "In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our \nposition as a diversified healthcare services company.  We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8e703a8b848c77c6e8ae6c60c170724d31cf6b334c4ba482cb25f028b5cc5d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edb7a043-364c-41b8-a5b4-f7137e47683b", "node_type": "1", "metadata": {"window": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n "}, "hash": "81de4010b98c6bd8660bc262c8f598b21263ee2a096537f788eb6871e6efa1af", "class_name": "RelatedNodeInfo"}}, "text": "This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "start_char_idx": 3478, "end_char_idx": 3592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edb7a043-364c-41b8-a5b4-f7137e47683b": {"__data__": {"id_": "edb7a043-364c-41b8-a5b4-f7137e47683b", "embedding": null, "metadata": {"window": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8160c9848a43695a422250d75fb6f0bf9e986350aa33793e3817568cbfd458dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b90f5fe-ce16-4873-bede-877ff9c73b8f", "node_type": "1", "metadata": {"window": "We grew our biopharma and oncology platforms through a \nbalance of strategic partnerships, acquisitions, and\u202finternal investments.  We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4179cceabfcac266f37fef56453b849c0db542e287da581cd6777b70f6955858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6918ef20-e896-423a-87eb-ae76410fa314", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n", "original_text": "McKesson Corp.  "}, "hash": "5de3cff43661b6f7c5cf18a7734ba09b33e0c1f9b67d5a2e4200a7794a54da49", "class_name": "RelatedNodeInfo"}}, "text": "Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "start_char_idx": 3592, "end_char_idx": 3735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6918ef20-e896-423a-87eb-ae76410fa314": {"__data__": {"id_": "6918ef20-e896-423a-87eb-ae76410fa314", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edb7a043-364c-41b8-a5b4-f7137e47683b", "node_type": "1", "metadata": {"window": "We delivered growth in the core \ndistribution businesses, and we divested the majority of the operations in Europe, fu rthering our goal to streamline \nand optimize the portfolio.  \n \n As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum \nforward, and we're excited to update and increase our\u202flong -term\u202fadjusted segment operatin g profit growth targets. \n This is a testament to our strategic focus, consistent execution, and\u202fconfidence in the outlook of the business. \n Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "original_text": "Building off our differentiated assets and capabilities, we are well -positioned to deliver strong, sustainable growth \nin the years ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81589295a50e9a950cbeb6396fbb7b4f01ae9fd01a72cd3e9be1a14aebabdf2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228e41f1-a67e-46a4-a63e-702b22916cee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets. "}, "hash": "d98b923ff816fd6f020c9cc11aa5c7d1691508a949f43fff6733fcef15418ef0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228e41f1-a67e-46a4-a63e-702b22916cee": {"__data__": {"id_": "228e41f1-a67e-46a4-a63e-702b22916cee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6918ef20-e896-423a-87eb-ae76410fa314", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fab06ff094f3048fd58ec27bdffed9229184b60e02e897dda01bcfb28904641a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "original_text": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture. "}, "hash": "69c01232aef2e1b08c2ddfd38a427d99424e8a9cc8dbba092efbe8ecd0b62ecb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets. ", "start_char_idx": 16, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd": {"__data__": {"id_": "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "original_text": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228e41f1-a67e-46a4-a63e-702b22916cee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "085b41b490811c575de01de8e1fcc46c7979178c0536c951e798444f77caefae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e0315a0-0248-4aeb-9719-e429e28bcaf6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "original_text": "Our talent is critical to everything that we do at McKesson. \n"}, "hash": "4c2c70de72abec3101287460d5bbabfcd8fb9b060e77dd3cfa1a43dde7753ab0", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture. ", "start_char_idx": 327, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e0315a0-0248-4aeb-9719-e429e28bcaf6": {"__data__": {"id_": "7e0315a0-0248-4aeb-9719-e429e28bcaf6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "original_text": "Our talent is critical to everything that we do at McKesson. \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "original_text": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a99ffa5cd6ec377cf8d95138f68020976961909806b783f26d3f9d4fd8cbae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62df6be1-f2c5-4880-b661-ee42241c93b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "original_text": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. "}, "hash": "9f19f01da8a9883e2460a6c558d62961532ed1eafbbec591ef7c107692ccb288", "class_name": "RelatedNodeInfo"}}, "text": "Our talent is critical to everything that we do at McKesson. \n", "start_char_idx": 458, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62df6be1-f2c5-4880-b661-ee42241c93b8": {"__data__": {"id_": "62df6be1-f2c5-4880-b661-ee42241c93b8", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "original_text": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e0315a0-0248-4aeb-9719-e429e28bcaf6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "original_text": "Our talent is critical to everything that we do at McKesson. \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "addab38dd9621dc85a2e304837edb4788bfb6bf99e24e50f6a3791cb8ca31ee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a", "node_type": "1", "metadata": {"window": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "original_text": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. "}, "hash": "c77c8a828b3a61472b76549a8a52205e97a533589f252c236985857ff0b1b302", "class_name": "RelatedNodeInfo"}}, "text": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "start_char_idx": 520, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a": {"__data__": {"id_": "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a", "embedding": null, "metadata": {"window": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "original_text": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62df6be1-f2c5-4880-b661-ee42241c93b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "original_text": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29d21a9add47b9a998af2391ce4e2c6d636241e588e31a6fef9feb46997a75a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0", "node_type": "1", "metadata": {"window": "Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "original_text": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n"}, "hash": "0887c76715a9ea4bb1f8d07a6b2f27aa03ca96d1cad7df20967624736b1c56d9", "class_name": "RelatedNodeInfo"}}, "text": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "start_char_idx": 828, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0": {"__data__": {"id_": "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0", "embedding": null, "metadata": {"window": "Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "original_text": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a", "node_type": "1", "metadata": {"window": "I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "original_text": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce8f78ff7330b484987ff9cb0db70e8aff41ef3b840c5f71461a3f182bb9ea6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f3c6574-597f-4bd8-af3b-2e07a7a58723", "node_type": "1", "metadata": {"window": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "original_text": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. "}, "hash": "5148e1526fb990337ef46cf4665805b95eabbaffff87a51c975f2ceb50adf4ef", "class_name": "RelatedNodeInfo"}}, "text": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "start_char_idx": 990, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f3c6574-597f-4bd8-af3b-2e07a7a58723": {"__data__": {"id_": "7f3c6574-597f-4bd8-af3b-2e07a7a58723", "embedding": null, "metadata": {"window": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "original_text": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0", "node_type": "1", "metadata": {"window": "Our talent is critical to everything that we do at McKesson. \n We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "original_text": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fe070928ab178fc1bcfabc709880f044625689e020a302576744f4cce36aca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0", "node_type": "1", "metadata": {"window": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth. ", "original_text": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. "}, "hash": "57fa8434d2de30b5eb993ecf99cf97710ddea4db4d25f96f69de3fe171251348", "class_name": "RelatedNodeInfo"}}, "text": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "start_char_idx": 1218, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0": {"__data__": {"id_": "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0", "embedding": null, "metadata": {"window": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth. ", "original_text": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f3c6574-597f-4bd8-af3b-2e07a7a58723", "node_type": "1", "metadata": {"window": "We strive to be the best place to work in\u202fhealthcare,\u202fand we're building a culture that not only unites the team but \nempowers them to innovate and succee d. \n \nOne of the important commitments we have to our employees is to create a workspace, where everyone can be \ncomfortable to work at their very best.  In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "original_text": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d699171c9ead0b122b73b5b7f08ba7bbb374d6f1122480dbbf552cb089f9157f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5984bdb5-6632-41c8-87da-0a5d1713ac7f", "node_type": "1", "metadata": {"window": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S. ", "original_text": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. "}, "hash": "6c9ec9a70d4d33a3ce402fb21c6e7059c349a635e2874016165fbeb39876693e", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "start_char_idx": 1348, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5984bdb5-6632-41c8-87da-0a5d1713ac7f": {"__data__": {"id_": "5984bdb5-6632-41c8-87da-0a5d1713ac7f", "embedding": null, "metadata": {"window": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S. ", "original_text": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0", "node_type": "1", "metadata": {"window": "In the past quarter, at McKesson, we celebrated Black History Month in \nFebruary and Women's History Month in March, with many great, great employee -led events.  I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth. ", "original_text": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2eb04ab3e90c23a34f775b2de70a1ca9379dc0f5b01ae00b709338e1c896bf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e238d4e0-e4c6-4095-8981-4838fb97d06e", "node_type": "1", "metadata": {"window": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "original_text": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n"}, "hash": "464a495a0250f1d214e2c8bbdc5650d90f46da3f7404ca29a5b5493a2ae1afb4", "class_name": "RelatedNodeInfo"}}, "text": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "start_char_idx": 1489, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e238d4e0-e4c6-4095-8981-4838fb97d06e": {"__data__": {"id_": "e238d4e0-e4c6-4095-8981-4838fb97d06e", "embedding": null, "metadata": {"window": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "original_text": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5984bdb5-6632-41c8-87da-0a5d1713ac7f", "node_type": "1", "metadata": {"window": "I had the \nopportunity to participate in many of these, and I'm energized by the dedication and passion our employees have \ndemonstrated towards promoting awareness and listening and supporting each other  as Team McKesson.  \n \n We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S. ", "original_text": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cae571426bd06ccfad385bf6f62c0977aab72935393c1ab1fa8132bcab33a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60ffea83-639d-49e5-a23b-53dafd9d09a2", "node_type": "1", "metadata": {"window": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "original_text": "Our second company priority is to drive sustainable core growth. "}, "hash": "2996b71669900ed38c031b4aaeaddaea61a3193332194964548943e003ced804", "class_name": "RelatedNodeInfo"}}, "text": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "start_char_idx": 1632, "end_char_idx": 1721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60ffea83-639d-49e5-a23b-53dafd9d09a2": {"__data__": {"id_": "60ffea83-639d-49e5-a23b-53dafd9d09a2", "embedding": null, "metadata": {"window": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "original_text": "Our second company priority is to drive sustainable core growth. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e238d4e0-e4c6-4095-8981-4838fb97d06e", "node_type": "1", "metadata": {"window": "We have a strong employee value proposition, and our progress in creating the best place to work is being \nrecognized externally.  Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "original_text": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dd58748b83b894586e02e744484c55a576540835a1319a9fd2cd642ddab9746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0968846-5bce-4202-9d30-0e8335e393ba", "node_type": "1", "metadata": {"window": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "original_text": "In U.S. "}, "hash": "f35f3b30446fa80cf4b24922c06f51ce0e8fab8a0abc63297bcab69fbb8c5007", "class_name": "RelatedNodeInfo"}}, "text": "Our second company priority is to drive sustainable core growth. ", "start_char_idx": 1721, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0968846-5bce-4202-9d30-0e8335e393ba": {"__data__": {"id_": "a0968846-5bce-4202-9d30-0e8335e393ba", "embedding": null, "metadata": {"window": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "original_text": "In U.S. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60ffea83-639d-49e5-a23b-53dafd9d09a2", "node_type": "1", "metadata": {"window": "Recently, we were pleased to be named by Forbes as one of America's Best Large \nEmployers, earning the third  highest ranking in\u202fhealthcare.  We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "original_text": "Our second company priority is to drive sustainable core growth. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4bd30faffa4b776aa2b707f3d529d02a59d1a5a22af5a26f04a08bb52bdb51b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f452736-1311-478d-8ab7-83e3e1056de6", "node_type": "1", "metadata": {"window": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "original_text": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. "}, "hash": "aa688d44393894a64cf794dc449fee7d361a8f5b905d5613a18e3a15899b3a25", "class_name": "RelatedNodeInfo"}}, "text": "In U.S. ", "start_char_idx": 1786, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f452736-1311-478d-8ab7-83e3e1056de6": {"__data__": {"id_": "4f452736-1311-478d-8ab7-83e3e1056de6", "embedding": null, "metadata": {"window": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "original_text": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0968846-5bce-4202-9d30-0e8335e393ba", "node_type": "1", "metadata": {"window": "We were also named by Newsweek as one of \nAmerica's Greatest Places for Work (sic) [Workplaces] for Women, among many, many more recognitions.  I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "original_text": "In U.S. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ddb5c878ffc1a142d14b7e4cd20eed243cd9bf025ffc287083576cf405dad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a640af6-aa1d-470a-9947-d2fbf09b54aa", "node_type": "1", "metadata": {"window": "Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "original_text": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n"}, "hash": "c17eb96b983b77b7af906d2e1e426a58356fbc1381141e1163e25b101058062f", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "start_char_idx": 1794, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a640af6-aa1d-470a-9947-d2fbf09b54aa": {"__data__": {"id_": "8a640af6-aa1d-470a-9947-d2fbf09b54aa", "embedding": null, "metadata": {"window": "Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "original_text": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f452736-1311-478d-8ab7-83e3e1056de6", "node_type": "1", "metadata": {"window": "I'm \nvery proud of the accomplishments, togetherness, and the alignment of our team . \n \n Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "original_text": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eaa13f3fa6c5636dc0afa321e94b112c7d452a687f36a92dc5c9e69fd9b4db99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b5197bc-302e-484c-a90b-5bee7b0a59fb", "node_type": "1", "metadata": {"window": "In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "original_text": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. "}, "hash": "526ca726d69fe1bb20cffa7f453b0715d13da6527f5d5b4d04eb16b9460e5cb5", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "start_char_idx": 1914, "end_char_idx": 2134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b5197bc-302e-484c-a90b-5bee7b0a59fb": {"__data__": {"id_": "7b5197bc-302e-484c-a90b-5bee7b0a59fb", "embedding": null, "metadata": {"window": "In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "original_text": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a640af6-aa1d-470a-9947-d2fbf09b54aa", "node_type": "1", "metadata": {"window": "Our second company priority is to drive sustainable core growth.  In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "original_text": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "715e2b7a4e8d74e0c7a492fefc428b09baff61383608bf21bd31dd92c816cb54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "181259de-5580-4db7-9d2e-a870fada2970", "node_type": "1", "metadata": {"window": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities. ", "original_text": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. "}, "hash": "3a69264b347199a756eafad66fcee96aa27a2b18583c739fbe032de51427a278", "class_name": "RelatedNodeInfo"}}, "text": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "start_char_idx": 2134, "end_char_idx": 2340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "181259de-5580-4db7-9d2e-a870fada2970": {"__data__": {"id_": "181259de-5580-4db7-9d2e-a870fada2970", "embedding": null, "metadata": {"window": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities. ", "original_text": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b5197bc-302e-484c-a90b-5bee7b0a59fb", "node_type": "1", "metadata": {"window": "In U.S.  Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "original_text": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84f11179e8f6ba51459d4457872686be060d6dcf60796581447c01dc70f4d6db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17bf866b-cb77-4af2-93e0-7ef2184d81a2", "node_type": "1", "metadata": {"window": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "original_text": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n"}, "hash": "ea8ee501c1254902ab44733619d96c24b96be641631a19117839a8cff0f3bd01", "class_name": "RelatedNodeInfo"}}, "text": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "start_char_idx": 2340, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17bf866b-cb77-4af2-93e0-7ef2184d81a2": {"__data__": {"id_": "17bf866b-cb77-4af2-93e0-7ef2184d81a2", "embedding": null, "metadata": {"window": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "original_text": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "181259de-5580-4db7-9d2e-a870fada2970", "node_type": "1", "metadata": {"window": "Pharmaceutical, the core pharmaceutical \ndistribution business continues to support the growth momentum of the segment.  In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities. ", "original_text": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e1136cfd756f968107dd45f6bcd2f2a517f308139e0d76e64f06a71badc50c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfd1f5a1-b771-4161-8e67-3ab607dc6208", "node_type": "1", "metadata": {"window": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "original_text": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. "}, "hash": "f1cea42e8ea054984684d008ceeaf30a73aec5fdb4ac4df3bb2baf31abf66ac4", "class_name": "RelatedNodeInfo"}}, "text": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "start_char_idx": 2497, "end_char_idx": 2652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfd1f5a1-b771-4161-8e67-3ab607dc6208": {"__data__": {"id_": "cfd1f5a1-b771-4161-8e67-3ab607dc6208", "embedding": null, "metadata": {"window": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "original_text": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17bf866b-cb77-4af2-93e0-7ef2184d81a2", "node_type": "1", "metadata": {"window": "In fiscal 2023, the segment \nrevenue increased 13%, and adjust ed operating profit, excluding COVID -19-related contributions, increased 8%, \nrepresenting the highest profit growth rate since we formed this segment.  \n \n We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "original_text": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc4cf67684c2a8cf7a061fbf688b3db0d7b97fa5dca26a468fb3759b20f5b652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9435e7f5-a537-4f93-8657-f5ba9e90e8bb", "node_type": "1", "metadata": {"window": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n", "original_text": "This is one of  our \nmost technologically advanced facilities. "}, "hash": "15c3a849d3e854ed627e18a8d7747544a93846a3f6246057b328a58a61b47599", "class_name": "RelatedNodeInfo"}}, "text": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "start_char_idx": 2652, "end_char_idx": 2747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9435e7f5-a537-4f93-8657-f5ba9e90e8bb": {"__data__": {"id_": "9435e7f5-a537-4f93-8657-f5ba9e90e8bb", "embedding": null, "metadata": {"window": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n", "original_text": "This is one of  our \nmost technologically advanced facilities. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfd1f5a1-b771-4161-8e67-3ab607dc6208", "node_type": "1", "metadata": {"window": "We renewed our\u202flongstanding\u202frelationship with CVS and delivered strong value propositions to support cus tomers \nacross all channels, partnering with them to help solve their most immediate business needs.  Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "original_text": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbfe30505321d0e2081a5f9417488a41ae081829712a17cabd3f5ea78ac8a245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02168467-21fa-464e-960a-789472c1c77d", "node_type": "1", "metadata": {"window": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "original_text": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. "}, "hash": "62df4fb11a45a55314811e382ea0160953a8e4d93b699bd73c188ba0c973a699", "class_name": "RelatedNodeInfo"}}, "text": "This is one of  our \nmost technologically advanced facilities. ", "start_char_idx": 2747, "end_char_idx": 2810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02168467-21fa-464e-960a-789472c1c77d": {"__data__": {"id_": "02168467-21fa-464e-960a-789472c1c77d", "embedding": null, "metadata": {"window": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "original_text": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9435e7f5-a537-4f93-8657-f5ba9e90e8bb", "node_type": "1", "metadata": {"window": "Our ability to \nconsistently deliver high -quality services is supported by our deep expertise in pharmaceutical distribution and \nscaled network of assets.  We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n", "original_text": "This is one of  our \nmost technologically advanced facilities. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9597225c6df9b1c8a3681ba50f2d8a9352acf32e9cdbcd8bd6a339d8b975efd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8", "node_type": "1", "metadata": {"window": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "original_text": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. "}, "hash": "1b670a05e0957ba664838a3e67e4141425668feccc81ca4a06e67d24c1ce85c9", "class_name": "RelatedNodeInfo"}}, "text": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "start_char_idx": 2810, "end_char_idx": 2918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8": {"__data__": {"id_": "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8", "embedding": null, "metadata": {"window": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "original_text": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02168467-21fa-464e-960a-789472c1c77d", "node_type": "1", "metadata": {"window": "We  continue to invest in the infrastructure to improve efficiency and modernize the \nnetwork in support of our growth and in pursuit of efficiencies.  \n \n In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "original_text": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35f1a49de809522721204327c776311076d41dea54d66de93485444c8b506e46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65ad2d6-1a18-460b-8bc5-15903611d928", "node_type": "1", "metadata": {"window": "This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "original_text": "Both government contracts are scheduled to expire in July of 2023.  \n \n"}, "hash": "a9528d42b3b3372ce01d44a15a551c61fe1251cc174eddcc10ab45628e755ea3", "class_name": "RelatedNodeInfo"}}, "text": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "start_char_idx": 2918, "end_char_idx": 3126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65ad2d6-1a18-460b-8bc5-15903611d928": {"__data__": {"id_": "e65ad2d6-1a18-460b-8bc5-15903611d928", "embedding": null, "metadata": {"window": "This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "original_text": "Both government contracts are scheduled to expire in July of 2023.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8", "node_type": "1", "metadata": {"window": "In October 2022, we opened a new state -of-the-art pharmaceutical distribution center in Ohio.  This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "original_text": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ef969034c55fb8ad2e979c0b44496211ee2509e676dd3c1c317274e67efa0fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "557175d0-2055-4c69-977f-f1fa81c309d5", "node_type": "1", "metadata": {"window": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "original_text": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n"}, "hash": "5e9cb46d4303fb5d6ffd52fb51ff363c3bd0b3eb2e45116cbe7854f42723f1e3", "class_name": "RelatedNodeInfo"}}, "text": "Both government contracts are scheduled to expire in July of 2023.  \n \n", "start_char_idx": 3126, "end_char_idx": 3197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "557175d0-2055-4c69-977f-f1fa81c309d5": {"__data__": {"id_": "557175d0-2055-4c69-977f-f1fa81c309d5", "embedding": null, "metadata": {"window": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "original_text": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e65ad2d6-1a18-460b-8bc5-15903611d928", "node_type": "1", "metadata": {"window": "This is one of  our \nmost technologically advanced facilities.  It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "original_text": "Both government contracts are scheduled to expire in July of 2023.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb15864bff0d6c74973ef604fb2cb99a2b25da9c8e6108ab1f76a047f58de4e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4216193f-eedc-41fc-af5b-52924477e536", "node_type": "1", "metadata": {"window": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform. ", "original_text": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n"}, "hash": "4df3ae9b8bdbe27f234a0aaa32d99baa92b61be8fe876b382383bdc70f76a7c1", "class_name": "RelatedNodeInfo"}}, "text": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "start_char_idx": 3197, "end_char_idx": 3414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4216193f-eedc-41fc-af5b-52924477e536": {"__data__": {"id_": "4216193f-eedc-41fc-af5b-52924477e536", "embedding": null, "metadata": {"window": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform. ", "original_text": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "557175d0-2055-4c69-977f-f1fa81c309d5", "node_type": "1", "metadata": {"window": "It leverages automation to increase efficiency, increase productivity \nand\u202fenhance the employee experience.  Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "original_text": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8ba69cd54ebd0164de512cad28b6c24659f50d263103edeb8213c3d96e03b71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd96697c-ff88-49df-92b0-add2c7886adc", "node_type": "1", "metadata": {"window": "Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability. ", "original_text": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. "}, "hash": "6d72fb42b975330637b519d7dc9e66fdc244637a993d1b5e87ebe791f5be76a9", "class_name": "RelatedNodeInfo"}}, "text": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "start_char_idx": 3414, "end_char_idx": 3557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd96697c-ff88-49df-92b0-add2c7886adc": {"__data__": {"id_": "bd96697c-ff88-49df-92b0-add2c7886adc", "embedding": null, "metadata": {"window": "Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability. ", "original_text": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4216193f-eedc-41fc-af5b-52924477e536", "node_type": "1", "metadata": {"window": "Leveraging our scaled distribution network and logistics expertise, we \nhave supported the US governmen t in its initiatives of distributing COVID -19 vaccines and the kitting and storage \nof ancillary kits.  Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform. ", "original_text": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe119bc797d3e7cc431c76e13a142d3793f66abf99aca98c7f2e26135e6ca29a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7", "node_type": "1", "metadata": {"window": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "original_text": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n"}, "hash": "db0ad183be0d7cd125de63ea72356f187ce30d81f4c79fb402534b6bc80157db", "class_name": "RelatedNodeInfo"}}, "text": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "start_char_idx": 3557, "end_char_idx": 3660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7": {"__data__": {"id_": "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7", "embedding": null, "metadata": {"window": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "original_text": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd96697c-ff88-49df-92b0-add2c7886adc", "node_type": "1", "metadata": {"window": "Both government contracts are scheduled to expire in July of 2023.  \n \n Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability. ", "original_text": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cc60b4d2ba84d152fab614087dfe21e8c1509672915f4d7b8248167b5aea13e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e847ad1-047b-4cca-8a71-94fb1bf058cc", "node_type": "1", "metadata": {"window": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "I'll start with the oncology platform. "}, "hash": "e1dfa8461735049617cc2952da753d8fa9f7de754323dfd2e9a1d0749cddf26c", "class_name": "RelatedNodeInfo"}}, "text": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "start_char_idx": 3660, "end_char_idx": 3899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e847ad1-047b-4cca-8a71-94fb1bf058cc": {"__data__": {"id_": "2e847ad1-047b-4cca-8a71-94fb1bf058cc", "embedding": null, "metadata": {"window": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "I'll start with the oncology platform. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7", "node_type": "1", "metadata": {"window": "Looking back at the past two years, Team McKesson has demonstrated incredible agility,  dedication and \ncommitment in standing up the operation and in distributing millions of lifesaving vaccines across the country. \n We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "original_text": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37e970109c412133c3a266a387d4054561677bcd71d659a9832a08e55c628815", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f", "node_type": "1", "metadata": {"window": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "One of the pillars of our oncology platform is the distribution capability. "}, "hash": "25d77773335c9739a74f7518b1854c2da9ef89cc83f9a2f8623980967af108b0", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with the oncology platform. ", "start_char_idx": 3899, "end_char_idx": 3938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f": {"__data__": {"id_": "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f", "embedding": null, "metadata": {"window": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "One of the pillars of our oncology platform is the distribution capability. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e847ad1-047b-4cca-8a71-94fb1bf058cc", "node_type": "1", "metadata": {"window": "We've gained invaluable experience, deepened our relationship with government partners and\u202fproven our value, \ncapabilities and ex pertise.  \n \n The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "I'll start with the oncology platform. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bcddd3f69d56a8c717dd98c10a749584b6f5e0c04992199680febed61c154dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cae42834-fc81-40f6-9489-797b67e767e5", "node_type": "1", "metadata": {"window": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. "}, "hash": "63bbd2ccaf2cc387e46302f9cda1de9a8887beb1f030dba15d67f0e5ce3f227c", "class_name": "RelatedNodeInfo"}}, "text": "One of the pillars of our oncology platform is the distribution capability. ", "start_char_idx": 3938, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cae42834-fc81-40f6-9489-797b67e767e5": {"__data__": {"id_": "cae42834-fc81-40f6-9489-797b67e767e5", "embedding": null, "metadata": {"window": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f", "node_type": "1", "metadata": {"window": "The next priority I want to talk about is our priority to expand the oncology and biopharma platforms.  Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "One of the pillars of our oncology platform is the distribution capability. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9b310855e84404583f6fc72e0bcc6dc9f8374a929cc758c821c16f9c8efdbdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "092feeaf-cc82-4de4-bc96-608278b8f1a9", "node_type": "1", "metadata": {"window": "I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  "}, "hash": "e683981be30f1110eb6fe7740d0e52589603dce55a4c4a470c571c665095502b", "class_name": "RelatedNodeInfo"}}, "text": "We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "start_char_idx": 4014, "end_char_idx": 4141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "092feeaf-cc82-4de4-bc96-608278b8f1a9": {"__data__": {"id_": "092feeaf-cc82-4de4-bc96-608278b8f1a9", "embedding": null, "metadata": {"window": "I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20331b5a2332843f6b837294287140f57159c54ea804bb1bc3b0705be3e38ab6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cae42834-fc81-40f6-9489-797b67e767e5", "node_type": "1", "metadata": {"window": "Through \nyears of focused investment and execution, we have built differentiated assets and capabilities in oncology and in \nbiopharma services, and we've strengthened our market positions in these high -growth and high -margin areas.  \n \n I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting. ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a0403538a0576593da1a80c07cf1654e5d576bb888581d096ebaa40362701a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "original_text": "McKesson Corp.  "}, "hash": "2b3a8566c0f5f8bfa9f207a1fc9eacf777ec4d74ab339303bcddfeeab44eb128", "class_name": "RelatedNodeInfo"}}, "text": "Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "start_char_idx": 4141, "end_char_idx": 4271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2": {"__data__": {"id_": "2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "092feeaf-cc82-4de4-bc96-608278b8f1a9", "node_type": "1", "metadata": {"window": "I'll start with the oncology platform.  One of the pillars of our oncology platform is the distribution capability.  We are \nthe leading distributor in the community onco logy market, with a scaled reach to providers in the community \nsetting.  Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "original_text": "Biologics, our specialty pharmacy, supports more than 3,500 specialty practices with cancer and other \nrare disease medications.  ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13e3df9682bfd8665ca79fb74f417e7a7c3f844a424b989c93f7eadaed87619d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78845abe-dc1b-4812-9704-b35c7bd30319", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n"}, "hash": "5dfd14b94fe56b95cb82daaabf62409a9f3d1d91b3ef61fa7a75c701f48f46c2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78845abe-dc1b-4812-9704-b35c7bd30319": {"__data__": {"id_": "78845abe-dc1b-4812-9704-b35c7bd30319", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92ddd50f556a57cf75738a391b9efd91e4b78f712ae0fdb6a2420975e5f9e698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5eaac5e-edc4-49ee-aa05-0cf339ea772c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "original_text": "Fiscal 2023 has been a year of significant growth for our practice management business. "}, "hash": "72e466544e1625dab72e0ee809e7d8f4b2e9114a0cb04c761b4b87802adaf763", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n", "start_char_idx": 16, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5eaac5e-edc4-49ee-aa05-0cf339ea772c": {"__data__": {"id_": "a5eaac5e-edc4-49ee-aa05-0cf339ea772c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "original_text": "Fiscal 2023 has been a year of significant growth for our practice management business. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78845abe-dc1b-4812-9704-b35c7bd30319", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d28ac1b2f041b27c2d41ca4503f93a62836aa5372ba71bbe6647055fe2c13f29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82fa50ee-628b-4188-a9bd-fe967bcb105b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "original_text": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. "}, "hash": "9577d612e8e95e11af7393d2059b489b92abbf5ab56b9a43f20613c53d774779", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2023 has been a year of significant growth for our practice management business. ", "start_char_idx": 422, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82fa50ee-628b-4188-a9bd-fe967bcb105b": {"__data__": {"id_": "82fa50ee-628b-4188-a9bd-fe967bcb105b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "original_text": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5eaac5e-edc4-49ee-aa05-0cf339ea772c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "original_text": "Fiscal 2023 has been a year of significant growth for our practice management business. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "908d3d0ec5a2b7001c365d32f8620baa7dd6c5455a266e364652649b33c04544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d10916-699a-43d7-9f75-3af9cc9866a8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "original_text": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. "}, "hash": "c6a7615006a49c9dc4edf99cbd6e1a33b54f1b4e9cd293401253e55db18ecb51", "class_name": "RelatedNodeInfo"}}, "text": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "start_char_idx": 510, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d10916-699a-43d7-9f75-3af9cc9866a8": {"__data__": {"id_": "93d10916-699a-43d7-9f75-3af9cc9866a8", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "original_text": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82fa50ee-628b-4188-a9bd-fe967bcb105b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "original_text": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1695ec2505096e123f988d4310b3853d168cb5db90cf03520245dd12a4a74f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b588da2-86e3-4c95-86a0-4086b5aede87", "node_type": "1", "metadata": {"window": "Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "original_text": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. "}, "hash": "74015e8d56f6d527d674ceb7f43c1ab540a34dce88d0113c8de2250a990579bf", "class_name": "RelatedNodeInfo"}}, "text": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "start_char_idx": 680, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b588da2-86e3-4c95-86a0-4086b5aede87": {"__data__": {"id_": "0b588da2-86e3-4c95-86a0-4086b5aede87", "embedding": null, "metadata": {"window": "Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "original_text": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d10916-699a-43d7-9f75-3af9cc9866a8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "original_text": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3944012141872a1c221f1c027fe9ad1dbcf661d925e86fd20f7b07e1f1dcad32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88a4eac-2aca-4d74-a7fc-36a15fe81328", "node_type": "1", "metadata": {"window": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "original_text": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n"}, "hash": "83b61d8e94ca64161def01477e539629fb8b75b51b2b380ac64ad55a6ec51081", "class_name": "RelatedNodeInfo"}}, "text": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "start_char_idx": 783, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88a4eac-2aca-4d74-a7fc-36a15fe81328": {"__data__": {"id_": "a88a4eac-2aca-4d74-a7fc-36a15fe81328", "embedding": null, "metadata": {"window": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "original_text": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b588da2-86e3-4c95-86a0-4086b5aede87", "node_type": "1", "metadata": {"window": "Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "original_text": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77269b9aa5f176446f18254096d70535903492925e2039f9e759fd8911d1ba16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4ac6a45-75fa-4792-8099-0ca35eb21e33", "node_type": "1", "metadata": {"window": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "original_text": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. "}, "hash": "4fc43d254e8579602b2d0a4473439551eaa9394bade44be365a67d70ddd404cf", "class_name": "RelatedNodeInfo"}}, "text": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "start_char_idx": 877, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4ac6a45-75fa-4792-8099-0ca35eb21e33": {"__data__": {"id_": "a4ac6a45-75fa-4792-8099-0ca35eb21e33", "embedding": null, "metadata": {"window": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "original_text": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88a4eac-2aca-4d74-a7fc-36a15fe81328", "node_type": "1", "metadata": {"window": "The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023.  With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "original_text": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f5b38672e0ed7c624241ec91b4ee5e079385e8e387b43a755a19dae08132930", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d36c965-4c59-4819-859f-daa1ee2fdb33", "node_type": "1", "metadata": {"window": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "original_text": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. "}, "hash": "4daf394d57bf838ea7b70e4085a2a1f12f3a0909654789cdcbbe6ab8b688e93e", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "start_char_idx": 1029, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d36c965-4c59-4819-859f-daa1ee2fdb33": {"__data__": {"id_": "7d36c965-4c59-4819-859f-daa1ee2fdb33", "embedding": null, "metadata": {"window": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "original_text": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4ac6a45-75fa-4792-8099-0ca35eb21e33", "node_type": "1", "metadata": {"window": "With these additions, the number of providers grew by more than 450 \nto a total  exceeding over 2,300.  This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "original_text": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "035d8de9057a2bb5744bba9217e510c6ce9656c0af5b9a26fa2086c2a42e8abe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e", "node_type": "1", "metadata": {"window": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "original_text": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n"}, "hash": "950bb4ea161425cc6f9bfa62fda6c6a410a8125a3ec59a127b21d1f5b8f78ef2", "class_name": "RelatedNodeInfo"}}, "text": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "start_char_idx": 1194, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e": {"__data__": {"id_": "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e", "embedding": null, "metadata": {"window": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "original_text": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d36c965-4c59-4819-859f-daa1ee2fdb33", "node_type": "1", "metadata": {"window": "This represents the fastest growth period since we acquired The US Oncology \nNetwork in 2010.  These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "original_text": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a8235ba8418757b67903ac2af00bb8751cf790cd20a410aa1bbe17ce54ced61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6116bf6a-379f-4f00-aafe-f438eb1208a2", "node_type": "1", "metadata": {"window": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "original_text": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. "}, "hash": "97f8d08254e95c0c7e0f9c7f052c9cbf4f88a9d3cba0799b579e5194f166c703", "class_name": "RelatedNodeInfo"}}, "text": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "start_char_idx": 1353, "end_char_idx": 1496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6116bf6a-379f-4f00-aafe-f438eb1208a2": {"__data__": {"id_": "6116bf6a-379f-4f00-aafe-f438eb1208a2", "embedding": null, "metadata": {"window": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "original_text": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e", "node_type": "1", "metadata": {"window": "These new practices expand the reach of the network into new geographies and enhance its \ncommitment to providing high -quality care close to home.  \n \n In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "original_text": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecf4339e9cc1330984f593e9b28d64a7bbd8b2c6c25a677bea9ce16683a38c57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eb60e54-e63a-4605-80fa-1a591695ef29", "node_type": "1", "metadata": {"window": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "original_text": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n"}, "hash": "24b271809b71a8dc383d6994c37d0aa15d0a6fcc3447507c4df3339ec49e0f68", "class_name": "RelatedNodeInfo"}}, "text": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "start_char_idx": 1496, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eb60e54-e63a-4605-80fa-1a591695ef29": {"__data__": {"id_": "3eb60e54-e63a-4605-80fa-1a591695ef29", "embedding": null, "metadata": {"window": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "original_text": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6116bf6a-379f-4f00-aafe-f438eb1208a2", "node_type": "1", "metadata": {"window": "In addition to the expansion in footprint, we continue to empower the growth of individual oncology practices to \nensure that they are the forefront of cancer care.  Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "original_text": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a85bfac754e4144a275d553eaea57dc2bf74679894ea4b31a003e0f371646b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b", "node_type": "1", "metadata": {"window": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "original_text": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n"}, "hash": "3742ae79eddecda41f6ca04077f233c648905a43195215456090285b620adb1d", "class_name": "RelatedNodeInfo"}}, "text": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "start_char_idx": 1661, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b": {"__data__": {"id_": "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b", "embedding": null, "metadata": {"window": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "original_text": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eb60e54-e63a-4605-80fa-1a591695ef29", "node_type": "1", "metadata": {"window": "Physicians in the network stand out as thought leaders in the \nindustry, with particip ation in leading publications and leadership roles within the industry.  The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "original_text": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "941005fd8b463aa2c8c4b21fb194c0df16778897ae0026bcfd113b2fb1bf7949", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72225bd9-0034-4e10-9839-872f9e70c5c9", "node_type": "1", "metadata": {"window": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n", "original_text": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. "}, "hash": "fb5975f9964db54dca69abc5d04ce9964a691afd93bbe0d6d8539e587af1fbb8", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "start_char_idx": 1866, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72225bd9-0034-4e10-9839-872f9e70c5c9": {"__data__": {"id_": "72225bd9-0034-4e10-9839-872f9e70c5c9", "embedding": null, "metadata": {"window": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n", "original_text": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b", "node_type": "1", "metadata": {"window": "The network also plays \na leading role in the transformation to value -based care, including its participation in the Oncology Care Model.  \n \n In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "original_text": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ed42a09cc30abcb277476df4a4d041f0d44763582196fbd12857c501c92a6c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1679835e-3214-4a4a-9ad5-01ad9177923f", "node_type": "1", "metadata": {"window": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "original_text": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n"}, "hash": "de5863bfb877820b6756ff10f9c96547a05bfc38f3c6dc00a2b92482bd08f00f", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "start_char_idx": 2071, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1679835e-3214-4a4a-9ad5-01ad9177923f": {"__data__": {"id_": "1679835e-3214-4a4a-9ad5-01ad9177923f", "embedding": null, "metadata": {"window": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "original_text": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72225bd9-0034-4e10-9839-872f9e70c5c9", "node_type": "1", "metadata": {"window": "In October 2022, US\u202fOncology Research formed a  joint venture with HCA Sarah Cannon Research Institute, \ncreating a fully integrated oncology research organization.  We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n", "original_text": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "612a35794c7a6cec29c03f2654b77811c54cb62554c219f779b84d6747e1da9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d13b939f-c700-4bf7-9fe8-b518b216bd7c", "node_type": "1", "metadata": {"window": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "original_text": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. "}, "hash": "b780c05b54dab6203cb0ed43effdf9564dc5ceb8691fcc56feb01e07717fc9a0", "class_name": "RelatedNodeInfo"}}, "text": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "start_char_idx": 2231, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d13b939f-c700-4bf7-9fe8-b518b216bd7c": {"__data__": {"id_": "d13b939f-c700-4bf7-9fe8-b518b216bd7c", "embedding": null, "metadata": {"window": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "original_text": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1679835e-3214-4a4a-9ad5-01ad9177923f", "node_type": "1", "metadata": {"window": "We expect this transaction to accelerate our oncology \nstrategy, expand clinical research and increase access to clinical trials for communi ty oncology providers \nand,\u202fmore importantly, for patients.  \n \n We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "original_text": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e268da1d7bfc8d68bf2c655cfb03de89612c065ee56bc4c1503801d904bc49ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4caab501-3ff3-4ab7-afe7-74d83b29275c", "node_type": "1", "metadata": {"window": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "original_text": "This helped patients get access to medicine more than 78 million times.  \n \n"}, "hash": "8fd0eff786a887f3f767a531d509cf4f3f037473e730349d33f19b9652718209", "class_name": "RelatedNodeInfo"}}, "text": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "start_char_idx": 2377, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4caab501-3ff3-4ab7-afe7-74d83b29275c": {"__data__": {"id_": "4caab501-3ff3-4ab7-afe7-74d83b29275c", "embedding": null, "metadata": {"window": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "original_text": "This helped patients get access to medicine more than 78 million times.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d13b939f-c700-4bf7-9fe8-b518b216bd7c", "node_type": "1", "metadata": {"window": "We're pleased with the performance across the oncology platform, and we believe our differentiated set of assets \nallows us to be a key partner of choice across both providers and biopharma compani es. \n \n In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "original_text": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "801f43c5acfbce1c33266c969391c685dc54608002f9af6107d86b5c1f74f868", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a7e9e09-9124-4919-b196-a206d205fb46", "node_type": "1", "metadata": {"window": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "original_text": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. "}, "hash": "66d1654336cdb84c3ae7b5c3ec8bff0d0f4667b80eab6e53f91ed289dc348ea1", "class_name": "RelatedNodeInfo"}}, "text": "This helped patients get access to medicine more than 78 million times.  \n \n", "start_char_idx": 2612, "end_char_idx": 2688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a7e9e09-9124-4919-b196-a206d205fb46": {"__data__": {"id_": "4a7e9e09-9124-4919-b196-a206d205fb46", "embedding": null, "metadata": {"window": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "original_text": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4caab501-3ff3-4ab7-afe7-74d83b29275c", "node_type": "1", "metadata": {"window": "In addition to the momentum in the oncology platform, we're also making significant progress in growing our \nassets and capabilities in the biopharma platform.  We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "original_text": "This helped patients get access to medicine more than 78 million times.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fee5a14f334a6adbb2a50aec0935baf970c8d263cb0cd5dab83ea18e4fc5b5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f84532-ee5d-4c20-9902-92337a845d2d", "node_type": "1", "metadata": {"window": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "original_text": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n"}, "hash": "d781416ece6f778ac34822f7bb742efbb2415e78afd5e8cc0ee0fe2c1fcff616", "class_name": "RelatedNodeInfo"}}, "text": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "start_char_idx": 2688, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f84532-ee5d-4c20-9902-92337a845d2d": {"__data__": {"id_": "64f84532-ee5d-4c20-9902-92337a845d2d", "embedding": null, "metadata": {"window": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "original_text": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a7e9e09-9124-4919-b196-a206d205fb46", "node_type": "1", "metadata": {"window": "We continue to enhance the ways patients get their \nmedications by improving access, affordability and adherence to prescription medications.  \n \n In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "original_text": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baba64aeb27b1ab9705b683cc4d7df1937bac5abab55a3539f11f7e883c12974", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24a79bd1-96d0-4229-aca4-de4fa5d7d34f", "node_type": "1", "metadata": {"window": "This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "original_text": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. "}, "hash": "e783b31c2e55e1fc40c5ae8e9fa8882b483c11d8a3558aba752894c43af924fa", "class_name": "RelatedNodeInfo"}}, "text": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "start_char_idx": 2827, "end_char_idx": 3017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24a79bd1-96d0-4229-aca4-de4fa5d7d34f": {"__data__": {"id_": "24a79bd1-96d0-4229-aca4-de4fa5d7d34f", "embedding": null, "metadata": {"window": "This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "original_text": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f84532-ee5d-4c20-9902-92337a845d2d", "node_type": "1", "metadata": {"window": "In this past year, we managed programs that helped patients save more than $8 billion on branded and specialty \nmedications, and prevented approximately 9.9 million prescriptions from being abandoned  due to affordability \nchallenges.  This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "original_text": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fd408e68dcfb66659fd88834cc445c06c05a45815242e200393c19f00595d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5", "node_type": "1", "metadata": {"window": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "original_text": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. "}, "hash": "1abf06eace5d12ebc22f50b1024bbf041132b06b1c30fe5604a1b989a0e9c96c", "class_name": "RelatedNodeInfo"}}, "text": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "start_char_idx": 3017, "end_char_idx": 3191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5": {"__data__": {"id_": "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5", "embedding": null, "metadata": {"window": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "original_text": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24a79bd1-96d0-4229-aca4-de4fa5d7d34f", "node_type": "1", "metadata": {"window": "This helped patients get access to medicine more than 78 million times.  \n \n In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "original_text": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9732fd9a9af5c6bc40d70da319f615ae2d44c350a453b1faa5a713d2965a6344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06d6b076-1b11-4d53-b232-54fa1393f8eb", "node_type": "1", "metadata": {"window": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n"}, "hash": "4ec93f7073c11a3b86d10df1f81032b7713e54725d2a60bc50a1885ffa30a15d", "class_name": "RelatedNodeInfo"}}, "text": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "start_char_idx": 3191, "end_char_idx": 3328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06d6b076-1b11-4d53-b232-54fa1393f8eb": {"__data__": {"id_": "06d6b076-1b11-4d53-b232-54fa1393f8eb", "embedding": null, "metadata": {"window": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5", "node_type": "1", "metadata": {"window": "In November of 2022, we completed the acquisition of Rx Savings Solutions, a prescription price transparency \nand benefit insight company.  The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "original_text": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "590bbe588c5f1de9d9fb24f3c66fed01aa0b354d32bff3ad2a478c8c17339b36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8", "node_type": "1", "metadata": {"window": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. "}, "hash": "c4aae173508bb802ee469a629320057b5c304ccefc6b39bf9633536d1bcb149c", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "start_char_idx": 3328, "end_char_idx": 3467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8": {"__data__": {"id_": "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8", "embedding": null, "metadata": {"window": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06d6b076-1b11-4d53-b232-54fa1393f8eb", "node_type": "1", "metadata": {"window": "The acquisi tion expands our affordability and adherence capabilities and sets the \nfoundation for the expansion of outcomes management and evidence -based biopharma and payer services.  \n \n For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e40b75c42718cf5965d83569fedddeb37cebec6cec0e435572673986e796ef07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc75d76-13e3-4daf-83ff-8ffb66a0f755", "node_type": "1", "metadata": {"window": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. "}, "hash": "24df5bf9aa7f25ea3894568d17f71e3d45b8151fa49bbc8d5dc4c0e683d59cf1", "class_name": "RelatedNodeInfo"}}, "text": "While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "start_char_idx": 3467, "end_char_idx": 3633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc75d76-13e3-4daf-83ff-8ffb66a0f755": {"__data__": {"id_": "ddc75d76-13e3-4daf-83ff-8ffb66a0f755", "embedding": null, "metadata": {"window": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8", "node_type": "1", "metadata": {"window": "For the Prescription Technology Solutions segment, our fiscal fourth quarter is usu ally the busiest quarter of the \nyear, driven by customer annual verification activities.  Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1e97faac1a21efeb5de956a64e65a77f4e5eac0f3ca698d5f65792689ab7c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65", "node_type": "1", "metadata": {"window": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n "}, "hash": "8ac2c924fe845808aa2775ce46cd99c0c8d82ae16f27dc8807430411befa46ec", "class_name": "RelatedNodeInfo"}}, "text": "We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "start_char_idx": 3633, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65": {"__data__": {"id_": "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65", "embedding": null, "metadata": {"window": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303b834ddaee55aba0433100b0d7b30ee73b61c50fe3fd51fdf71d76ad9c1598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc75d76-13e3-4daf-83ff-8ffb66a0f755", "node_type": "1", "metadata": {"window": "Our employees had a particularly busy season this past \nquarter, assisting the highest volume of patients in the history of the segment.  We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority. ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdde7b7d1e91cc3d30169b8ad40dda30b64178797a9566e7d1f33fa3e89c44a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "636324d9-bb96-4295-98a9-80180d01a5a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "467339a60400b1578d24c7c2b112d138066caa973c0f5934b3f0ff91fa16808d", "class_name": "RelatedNodeInfo"}}, "text": "In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "start_char_idx": 3755, "end_char_idx": 4007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "636324d9-bb96-4295-98a9-80180d01a5a5": {"__data__": {"id_": "636324d9-bb96-4295-98a9-80180d01a5a5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65", "node_type": "1", "metadata": {"window": "We continue to see strong marke t \ndemand for the products and services we provide, which supports the growth outlook of this segment.  \n \n While we're committed to grow the biopharma platform, we're also continually looking for opportunities to optimize \nthe portfolio of products and services  we offer.  We have a disciplined review process to ensure that our resources \nare aligned with the areas of most strategic priority.  In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "original_text": "In this past quarter, we made the decision to re -prioritize \ninvestments of products within the Prescription Technology Solut ions segment that we believe have reached the \nend of their lifecycle and are no longer essential to the growth strategy.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0ab88ae0d9f80eb0060035094573a817fc9a402d315d5a6e279f701d5159fc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "051eae26-5f0b-4dc6-bc06-9ca2875e82ed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n"}, "hash": "1b0026d076dd79aa8314d6d88fa005c17b0a3101306cf29d30293c46fda78156", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "051eae26-5f0b-4dc6-bc06-9ca2875e82ed": {"__data__": {"id_": "051eae26-5f0b-4dc6-bc06-9ca2875e82ed", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "636324d9-bb96-4295-98a9-80180d01a5a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae655f90475d86f5fbe3b39aaf5bd50eded43d6795bd081b2932a18a0ec49f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "original_text": "These types of decisions are always difficult, and it had a direct impact on some of our employees. "}, "hash": "a664cc06be02da9c7055f212d52f9dd551e85137730992f54293a514227b9d03", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n", "start_char_idx": 16, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2": {"__data__": {"id_": "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "original_text": "These types of decisions are always difficult, and it had a direct impact on some of our employees. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "051eae26-5f0b-4dc6-bc06-9ca2875e82ed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d65937a2307b3383df540ddef66ca6a1c50247c127e43add3fb0992605434bce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses. ", "original_text": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n"}, "hash": "1e205d1878b5419e343ebf0aceba01aec326cc8f8b684e71c2734884665624a4", "class_name": "RelatedNodeInfo"}}, "text": "These types of decisions are always difficult, and it had a direct impact on some of our employees. ", "start_char_idx": 380, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1": {"__data__": {"id_": "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses. ", "original_text": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "original_text": "These types of decisions are always difficult, and it had a direct impact on some of our employees. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f25f5eb0620e7ce7bf2bcecc4bf98dd32efeed4593f46bb5ac2e3daec210fea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bdd8744-ed24-4553-973f-71c2c95b2b68", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "original_text": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. "}, "hash": "ed3a3ef61e36aaa81dffc22dbe16ecba10ee6a9ea82334bff2e17acf74cd78e0", "class_name": "RelatedNodeInfo"}}, "text": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "start_char_idx": 480, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bdd8744-ed24-4553-973f-71c2c95b2b68": {"__data__": {"id_": "4bdd8744-ed24-4553-973f-71c2c95b2b68", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "original_text": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses. ", "original_text": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c27264f9be79e0be47818fe902bad20acb3c63a49c603bface73dd825ab86ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9a9777d-f577-4354-a787-8c41caa3cb73", "node_type": "1", "metadata": {"window": "These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "original_text": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n"}, "hash": "b0c0853153b7eee0848ab4ab1df1541a0e54a84f640bedc2baa02ff07edbc266", "class_name": "RelatedNodeInfo"}}, "text": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "start_char_idx": 696, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9a9777d-f577-4354-a787-8c41caa3cb73": {"__data__": {"id_": "d9a9777d-f577-4354-a787-8c41caa3cb73", "embedding": null, "metadata": {"window": "These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "original_text": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bdd8744-ed24-4553-973f-71c2c95b2b68", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "original_text": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d30c1eaa502ae7a4a85bf67337d449df37252cf31d19a26403e2a87349e9d7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a3caa5a-74e9-4690-a07d-77c1a1dce07f", "node_type": "1", "metadata": {"window": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "original_text": "Another important portfolio action we are executing is the divestiture of our European businesses. "}, "hash": "835fc7fe4b22f432a7e64b73a3e1f4650d2f1be8f414b500725627585cef3c88", "class_name": "RelatedNodeInfo"}}, "text": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "start_char_idx": 819, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a3caa5a-74e9-4690-a07d-77c1a1dce07f": {"__data__": {"id_": "3a3caa5a-74e9-4690-a07d-77c1a1dce07f", "embedding": null, "metadata": {"window": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "original_text": "Another important portfolio action we are executing is the divestiture of our European businesses. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9a9777d-f577-4354-a787-8c41caa3cb73", "node_type": "1", "metadata": {"window": "These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "original_text": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5f57bd95f8703b3363eb960a347802204561066d25dfb46016773cd8adde8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde", "node_type": "1", "metadata": {"window": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "original_text": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n"}, "hash": "dba8aba8a43b22b5f869647a20424d361f634096acb418d8af7ab54a1052089f", "class_name": "RelatedNodeInfo"}}, "text": "Another important portfolio action we are executing is the divestiture of our European businesses. ", "start_char_idx": 980, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde": {"__data__": {"id_": "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde", "embedding": null, "metadata": {"window": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "original_text": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a3caa5a-74e9-4690-a07d-77c1a1dce07f", "node_type": "1", "metadata": {"window": "I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "original_text": "Another important portfolio action we are executing is the divestiture of our European businesses. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fea11d871159650d862b6281c992b7bd4f5cc2e744d52ba0673da04a0016e0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3", "node_type": "1", "metadata": {"window": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "original_text": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. "}, "hash": "b3c13fb2edfbfed642a7c43c3a891d8cf4f63f07191e3a32fcd9d3e02b1d98e6", "class_name": "RelatedNodeInfo"}}, "text": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "start_char_idx": 1079, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3": {"__data__": {"id_": "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3", "embedding": null, "metadata": {"window": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "original_text": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde", "node_type": "1", "metadata": {"window": "As part of this initiative, we're also streamlining the real estate assets supporting more flexibility for our \nemployees.  We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "original_text": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f643441ba2df744e338b1fa437ba9abfce86db2dcf5a43585ac08799d890ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea9859e-3688-49c4-99c8-58624c225565", "node_type": "1", "metadata": {"window": "Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "original_text": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. "}, "hash": "b355f335002123e8ac54805c0b61d0db20d0e8e20d60ec67ff119a5bd9e28369", "class_name": "RelatedNodeInfo"}}, "text": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "start_char_idx": 1238, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea9859e-3688-49c4-99c8-58624c225565": {"__data__": {"id_": "dea9859e-3688-49c4-99c8-58624c225565", "embedding": null, "metadata": {"window": "Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "original_text": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3", "node_type": "1", "metadata": {"window": "We remain confident  about our differentiated capabilities, the market opportunity and\u202four ability to \nachieve the\u202flong -term\u202fgrowth target of this segment.  \n \n Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "original_text": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9826ea2f19a57ddb545752f999679158c231b957d35e96a35519bd8d3ffe6837", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af8cf404-4acf-4227-b820-381da79088c2", "node_type": "1", "metadata": {"window": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "original_text": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n"}, "hash": "37cb47fc68d72f44119020c565fba92bbe16fc38111e1029e0be779300a63f96", "class_name": "RelatedNodeInfo"}}, "text": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "start_char_idx": 1389, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af8cf404-4acf-4227-b820-381da79088c2": {"__data__": {"id_": "af8cf404-4acf-4227-b820-381da79088c2", "embedding": null, "metadata": {"window": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "original_text": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea9859e-3688-49c4-99c8-58624c225565", "node_type": "1", "metadata": {"window": "Another important portfolio action we are executing is the divestiture of our European businesses.  We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "original_text": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6497f6f46d9e2e125270de7dae235e12223e4b46bb0d72aa8252942ca7ecfb39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c01806a-3194-46e5-b58f-ad13d777bd34", "node_type": "1", "metadata": {"window": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together. ", "original_text": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. "}, "hash": "44efa9a7c713c751c7ca1683bac9d168023c23c534b2d7d2371c4965ccf15af0", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "start_char_idx": 1642, "end_char_idx": 1757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c01806a-3194-46e5-b58f-ad13d777bd34": {"__data__": {"id_": "6c01806a-3194-46e5-b58f-ad13d777bd34", "embedding": null, "metadata": {"window": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together. ", "original_text": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af8cf404-4acf-4227-b820-381da79088c2", "node_type": "1", "metadata": {"window": "We've now \nsuccessfull y divested businesses in 11 of the 12 countries, with Norway being the only country for which we are \nstill exploring alternatives.  \n \n As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "original_text": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f60696476d388f30668ba9d8101a8d097fd3a91620777b8ea1172d854aacd3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1213a41-d7b5-452f-aa94-3a2deee7ee8f", "node_type": "1", "metadata": {"window": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results. ", "original_text": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. "}, "hash": "d49f8b0cc5c22ddb8827a19bb0e4012e061ddfb254962867c4d65f09e8629b36", "class_name": "RelatedNodeInfo"}}, "text": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "start_char_idx": 1757, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1213a41-d7b5-452f-aa94-3a2deee7ee8f": {"__data__": {"id_": "e1213a41-d7b5-452f-aa94-3a2deee7ee8f", "embedding": null, "metadata": {"window": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results. ", "original_text": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c01806a-3194-46e5-b58f-ad13d777bd34", "node_type": "1", "metadata": {"window": "As we make significant progress in expanding the strategic growth areas, we are doing so in a way that allows us \nto deliver for all our stakeholders.  We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together. ", "original_text": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "506a34d9af5525f5a2c8e67eb27f10e033eee5cc444b92974a82f4bafdf69a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d32921e-bc4a-4977-a427-500949454b1d", "node_type": "1", "metadata": {"window": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "original_text": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n"}, "hash": "61f0657c62a94bb97c67447e1d3d8cd92269e3f84e86044cd9e87fc26fd97652", "class_name": "RelatedNodeInfo"}}, "text": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "start_char_idx": 1905, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d32921e-bc4a-4977-a427-500949454b1d": {"__data__": {"id_": "2d32921e-bc4a-4977-a427-500949454b1d", "embedding": null, "metadata": {"window": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "original_text": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1213a41-d7b5-452f-aa94-3a2deee7ee8f", "node_type": "1", "metadata": {"window": "We're committed to drive sustainability and to execute on initiatives that are \naligned to our business strategy, support our growth, and\u202fcontribute to measurable and enduring positive impacts \nand health outcomes for our stakeholde rs and communities.  We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results. ", "original_text": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ea085865a25cb03ca851c26f9aa29a7125da8125e4f5e1ef001a78064637a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b", "node_type": "1", "metadata": {"window": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication. ", "original_text": "So let me pull everything together. "}, "hash": "44186d421f063d6c38ffb77ee52710172d6e223ebc619e331c75432c8ce1a717", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "start_char_idx": 2048, "end_char_idx": 2258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b": {"__data__": {"id_": "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b", "embedding": null, "metadata": {"window": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication. ", "original_text": "So let me pull everything together. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d32921e-bc4a-4977-a427-500949454b1d", "node_type": "1", "metadata": {"window": "We look forward to publishing our Impact Report in \nJune to share our progress on these important initiatives.  \n \n Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "original_text": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e96b4c6f82f211cd0d0b70474bdc479a1a14a840174fc048c32b66cb7ecb8a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2710b7db-d8f0-45c2-9751-53a679e46d8d", "node_type": "1", "metadata": {"window": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth. ", "original_text": "McKesson reported a strong fourth quarter and full year results. "}, "hash": "ca1bb6f716b56d0adf13374bf7aa8ad6f9282944029c26328b73acdba4bd8663", "class_name": "RelatedNodeInfo"}}, "text": "So let me pull everything together. ", "start_char_idx": 2258, "end_char_idx": 2294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2710b7db-d8f0-45c2-9751-53a679e46d8d": {"__data__": {"id_": "2710b7db-d8f0-45c2-9751-53a679e46d8d", "embedding": null, "metadata": {"window": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth. ", "original_text": "McKesson reported a strong fourth quarter and full year results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b", "node_type": "1", "metadata": {"window": "Earlier this year, our\u202fnear -term\u202fscience -based greenhouse gas emissions reduction targets were approved by the \nScience Based Targets initiative.  Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication. ", "original_text": "So let me pull everything together. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e8225baf8c5b32eb18569ef269aec2e04a3cc01aea08e0c04474c74f9ac21b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564dba20-9fc7-45b0-85a1-9397dbf738e0", "node_type": "1", "metadata": {"window": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "original_text": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. "}, "hash": "33e56e855df457312a035a7d393b8437bd0cf1374ea85f0da79718254eef53e3", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported a strong fourth quarter and full year results. ", "start_char_idx": 2294, "end_char_idx": 2359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564dba20-9fc7-45b0-85a1-9397dbf738e0": {"__data__": {"id_": "564dba20-9fc7-45b0-85a1-9397dbf738e0", "embedding": null, "metadata": {"window": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "original_text": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2710b7db-d8f0-45c2-9751-53a679e46d8d", "node_type": "1", "metadata": {"window": "Focused on energy, transportation and real estate, our teams are taking \nmeaningful actions to achieve these targets and improve the business.  Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth. ", "original_text": "McKesson reported a strong fourth quarter and full year results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fbc0827d38204d00a1ef43790d153cac7d821886eaecd1e64d976725a42e839", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9", "node_type": "1", "metadata": {"window": "So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "original_text": "We executed on our strategy \nwith focus and dedication. "}, "hash": "da4db807f677d5f65a7272eec6465d9bc6d0ae17a756dbfe3db6697a946f8d71", "class_name": "RelatedNodeInfo"}}, "text": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "start_char_idx": 2359, "end_char_idx": 2456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9": {"__data__": {"id_": "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9", "embedding": null, "metadata": {"window": "So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "original_text": "We executed on our strategy \nwith focus and dedication. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564dba20-9fc7-45b0-85a1-9397dbf738e0", "node_type": "1", "metadata": {"window": "Recently, we were included in \nSustainalytics 2023 Industry Top -Rated ESG Company list, recogni zing our comprehensive commitment and \nachievements in environmental, social and\u202fgovernance -related issues.  \n \n So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "original_text": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51389978abc22317635f4d9ca2d4f3968ee55e4541204c95fccde4655c2d7d2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da74db55-b97b-47c0-80d7-0d04740f1276", "node_type": "1", "metadata": {"window": "McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n ", "original_text": "We invested in our businesses and our people for future growth. "}, "hash": "fdd10c893b3065aa902c1d028b3f7fbe9979af4c78d21f45e740f5bda1da62a0", "class_name": "RelatedNodeInfo"}}, "text": "We executed on our strategy \nwith focus and dedication. ", "start_char_idx": 2456, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da74db55-b97b-47c0-80d7-0d04740f1276": {"__data__": {"id_": "da74db55-b97b-47c0-80d7-0d04740f1276", "embedding": null, "metadata": {"window": "McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n ", "original_text": "We invested in our businesses and our people for future growth. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9", "node_type": "1", "metadata": {"window": "So let me pull everything together.  McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "original_text": "We executed on our strategy \nwith focus and dedication. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1d5c816e5be773edcfdc687bffc0b6d7f2c5892dc69fbd7c09c2601018b88b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f588c957-a005-4f0d-9730-65b607bd5825", "node_type": "1", "metadata": {"window": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n"}, "hash": "7c48530b7f5a484a3c3d28af77be15ce570483c60dd605a404d6ff35329a271d", "class_name": "RelatedNodeInfo"}}, "text": "We invested in our businesses and our people for future growth. ", "start_char_idx": 2512, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f588c957-a005-4f0d-9730-65b607bd5825": {"__data__": {"id_": "f588c957-a005-4f0d-9730-65b607bd5825", "embedding": null, "metadata": {"window": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da74db55-b97b-47c0-80d7-0d04740f1276", "node_type": "1", "metadata": {"window": "McKesson reported a strong fourth quarter and full year results.  Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n ", "original_text": "We invested in our businesses and our people for future growth. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3eac2820f5324aee530d43ed256eb503705b41e4a5bab495586a17acf4e9c6f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7731c38c-72e3-49a9-b8b8-defcdc0a23c9", "node_type": "1", "metadata": {"window": "We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian. ", "original_text": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n"}, "hash": "0d2b99950ea4c1cc7c4e38deba96633aac7f08bbe578cca21c122e6d1dcdcac2", "class_name": "RelatedNodeInfo"}}, "text": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "start_char_idx": 2576, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7731c38c-72e3-49a9-b8b8-defcdc0a23c9": {"__data__": {"id_": "7731c38c-72e3-49a9-b8b8-defcdc0a23c9", "embedding": null, "metadata": {"window": "We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian. ", "original_text": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f588c957-a005-4f0d-9730-65b607bd5825", "node_type": "1", "metadata": {"window": "Looking back \nto fiscal 2023, we made significan t progress in advancing our company priorities.  We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3847a58323196db569494c54cbb4745aab22d45d265432aa8843de76618a41eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7c1884a-0a15-4410-a60d-eaf635d102f0", "node_type": "1", "metadata": {"window": "We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "original_text": "With that,  Britt, I'll hand it over to you for additional comments.  \n "}, "hash": "471cc958a4101dd0f5ed33651d83999645b5468b92507a9f5a28b9cfa0dc3ebe", "class_name": "RelatedNodeInfo"}}, "text": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "start_char_idx": 2707, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7c1884a-0a15-4410-a60d-eaf635d102f0": {"__data__": {"id_": "e7c1884a-0a15-4410-a60d-eaf635d102f0", "embedding": null, "metadata": {"window": "We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "original_text": "With that,  Britt, I'll hand it over to you for additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7731c38c-72e3-49a9-b8b8-defcdc0a23c9", "node_type": "1", "metadata": {"window": "We executed on our strategy \nwith focus and dedication.  We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian. ", "original_text": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71d6163cd4d98e37b904ea962a4af0a8db3e7d6d03a4c9b84aeb7a3eb33234be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d9b5a6d-1a6a-479e-be96-8756c259c65c", "node_type": "1", "metadata": {"window": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "36d5c1f80e83a10fe1cad2d896ecf768c1cc5ef743ee8e190c61fbb366b43239", "class_name": "RelatedNodeInfo"}}, "text": "With that,  Britt, I'll hand it over to you for additional comments.  \n ", "start_char_idx": 2922, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d9b5a6d-1a6a-479e-be96-8756c259c65c": {"__data__": {"id_": "2d9b5a6d-1a6a-479e-be96-8756c259c65c", "embedding": null, "metadata": {"window": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7c1884a-0a15-4410-a60d-eaf635d102f0", "node_type": "1", "metadata": {"window": "We invested in our businesses and our people for future growth.  And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "original_text": "With that,  Britt, I'll hand it over to you for additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b48c36c9e40a95bc3f7feb2e8e0473c4ed2c69f58d1377c5cd11efa2f42669e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94493ee2-3dde-4eec-a88c-707f717ef766", "node_type": "1", "metadata": {"window": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "original_text": "Well, thank you, Brian. "}, "hash": "f1c9e5f8ebee40fddd13dfe1eda5afdecae39dd8ab1593b1c50fa5e8e70c66b7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 2994, "end_char_idx": 3340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94493ee2-3dde-4eec-a88c-707f717ef766": {"__data__": {"id_": "94493ee2-3dde-4eec-a88c-707f717ef766", "embedding": null, "metadata": {"window": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "original_text": "Well, thank you, Brian. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d9b5a6d-1a6a-479e-be96-8756c259c65c", "node_type": "1", "metadata": {"window": "And as a \ndiversified\u202fhealthcare\u202fservice company, we enacted positive changes to our custo mers, partners and\u202ftheir \npatients.  \n \n I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bed6528b493da6d4c1c28754467b8f5b1ebfb12a8a7689e22cc74bcd68650ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cfd2274-b6d5-4e39-9534-b68a0feb1093", "node_type": "1", "metadata": {"window": "With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results. ", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results. "}, "hash": "18c49657a8011324602f98160daedd2259d96b6bf1c220cefa0363d268de29b6", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, Brian. ", "start_char_idx": 3340, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cfd2274-b6d5-4e39-9534-b68a0feb1093": {"__data__": {"id_": "8cfd2274-b6d5-4e39-9534-b68a0feb1093", "embedding": null, "metadata": {"window": "With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results. ", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94493ee2-3dde-4eec-a88c-707f717ef766", "node_type": "1", "metadata": {"window": "I'm incredibly proud of what we have achieved as a team, and I'm confident in our ability to continue the \nmomentum and deliver sustainable growth, as reflected in our updated\u202flong -term\u202fsegment growth targets.  \n \n With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "original_text": "Well, thank you, Brian. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2f857f0085afe7888e30fa7bdab78ea38aba6ad2ebb182ffaa47a712dec4d14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38a1473a-44ad-47f6-a725-4ab84720fd12", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "original_text": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n"}, "hash": "0bc8a43156bd8e935e6ece8b4336907cadfc7f52d6e79a84c5d37d51d14ea091", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "start_char_idx": 3364, "end_char_idx": 3438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38a1473a-44ad-47f6-a725-4ab84720fd12": {"__data__": {"id_": "38a1473a-44ad-47f6-a725-4ab84720fd12", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "original_text": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cfd2274-b6d5-4e39-9534-b68a0feb1093", "node_type": "1", "metadata": {"window": "With that,  Britt, I'll hand it over to you for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results. ", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51959bf0fa87b539aa3faa54db7955b1370f1bd63f0b760b10638748fbf31758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31c3988f-137f-478b-9263-5aa7253f5b8d", "node_type": "1", "metadata": {"window": "Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. "}, "hash": "c112ad3a95f441d8c7380f29baba7486eb614dfb1613d2f6ead12fa12dd25a09", "class_name": "RelatedNodeInfo"}}, "text": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "start_char_idx": 3438, "end_char_idx": 3586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31c3988f-137f-478b-9263-5aa7253f5b8d": {"__data__": {"id_": "31c3988f-137f-478b-9263-5aa7253f5b8d", "embedding": null, "metadata": {"window": "Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38a1473a-44ad-47f6-a725-4ab84720fd12", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "original_text": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d4ba26681bcdfde9deda5091ad536827f0db97d1266c6fd4b6662bddff1108b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29803a04-6a6e-48f5-877f-8e929a1c1989", "node_type": "1", "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "We delivered strong \nfourth quarte r results. "}, "hash": "bbd3ffd613abe5a22d2ad9501334e9d5f9c0d51b707a7ed8c18eb3a682044e92", "class_name": "RelatedNodeInfo"}}, "text": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "start_char_idx": 3586, "end_char_idx": 3678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29803a04-6a6e-48f5-877f-8e929a1c1989": {"__data__": {"id_": "29803a04-6a6e-48f5-877f-8e929a1c1989", "embedding": null, "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "We delivered strong \nfourth quarte r results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31c3988f-137f-478b-9263-5aa7253f5b8d", "node_type": "1", "metadata": {"window": "Well, thank you, Brian.  Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08008ec0e7f3924f37fb0facde8e7ed820d30bb99996bb48e751f3850160f96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a61d568-a5b7-49d0-a6e1-5e31f0f47841", "node_type": "1", "metadata": {"window": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n"}, "hash": "2febd13aae395974ad0548b8c45a421057a0b584211943643344352a17ad5f0a", "class_name": "RelatedNodeInfo"}}, "text": "We delivered strong \nfourth quarte r results. ", "start_char_idx": 3678, "end_char_idx": 3724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a61d568-a5b7-49d0-a6e1-5e31f0f47841": {"__data__": {"id_": "0a61d568-a5b7-49d0-a6e1-5e31f0f47841", "embedding": null, "metadata": {"window": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29803a04-6a6e-48f5-877f-8e929a1c1989", "node_type": "1", "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2023 results.  Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "We delivered strong \nfourth quarte r results. ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44a4646d50e1cff336c3622b2db0b45a806b398e90ce90718793a6bbe75b97b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bc956e2-2a1a-4e48-9556-b1555532c449", "node_type": "1", "metadata": {"window": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "These results were right in line with the guidance we provided on our third quarter earnings call.  \n "}, "hash": "8d31c1d9106c05fdbd00a9c158feca1bdb1b91a6acb9bd6c2241244f1e625c29", "class_name": "RelatedNodeInfo"}}, "text": "Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "start_char_idx": 3724, "end_char_idx": 3810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bc956e2-2a1a-4e48-9556-b1555532c449": {"__data__": {"id_": "0bc956e2-2a1a-4e48-9556-b1555532c449", "embedding": null, "metadata": {"window": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8b0a3079d9fe561e4b51fde9f78cb2e577d602703fc992c3c484d9bd8fe696", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a61d568-a5b7-49d0-a6e1-5e31f0f47841", "node_type": "1", "metadata": {"window": "Then, I'll provide an \noverview of our fiscal 2024 outlook, including our updated\u202flong -term\u202fadjusted segment operating profit growth \ntargets.  \n \n My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ce3fb53415a1ce35e3b0a28cbf2593ae603bae1805324ecdec088687909c2c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a14dced-028b-41a8-8b26-d04712256ac8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "028bebf868e133fa0ae2e0fe25439a4e4f1752b0cf0394b659bb4f8fc07484eb", "class_name": "RelatedNodeInfo"}}, "text": "These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "start_char_idx": 3810, "end_char_idx": 3912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a14dced-028b-41a8-8b26-d04712256ac8": {"__data__": {"id_": "7a14dced-028b-41a8-8b26-d04712256ac8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bc956e2-2a1a-4e48-9556-b1555532c449", "node_type": "1", "metadata": {"window": "My comments today will refer to our fiscal 2023 adjusted results, unless I state otherwise.  We delivered strong \nfourth quarte r results.  Earnings per diluted share was $7.19, an increase of 23% compared to the prior year. \n These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "original_text": "These results were right in line with the guidance we provided on our third quarter earnings call.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4be3bcff828a03948d1cbd9444221314968c11f2bedf8fb2de118c19848b67d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b661bbfa-65b5-48d1-ac31-da705a07f4ed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses. "}, "hash": "b637e2a3227ad0c9627874150ea020c715f268e1cc1375c7354d320b7492ded1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b661bbfa-65b5-48d1-ac31-da705a07f4ed": {"__data__": {"id_": "b661bbfa-65b5-48d1-ac31-da705a07f4ed", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a14dced-028b-41a8-8b26-d04712256ac8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdb499bbc26a88ec9f3319fb9c93e4d02ed1129e5072804273fe36ad9198fff8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "original_text": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S. "}, "hash": "6614eb7ff68a87e668a3cf97da2ce71df8d658b4ea511dee29867683a3c5d112", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses. ", "start_char_idx": 16, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad": {"__data__": {"id_": "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "original_text": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b661bbfa-65b5-48d1-ac31-da705a07f4ed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bab654cc6bb13cbd0131dc9acf58ed763804ee563c7b67db7aabaa9346a52b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15affcf5-8a0b-4f6e-b28a-b7b9146899f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "original_text": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n"}, "hash": "cb09ecf686cee4045030b83837a864c480a48e42d58784e04f45820a5c5061ce", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S. ", "start_char_idx": 372, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15affcf5-8a0b-4f6e-b28a-b7b9146899f2": {"__data__": {"id_": "15affcf5-8a0b-4f6e-b28a-b7b9146899f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "original_text": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "original_text": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60dcdf7ef4f32c595815183bf12993d7bb401ca8aa2a682fe93ba21c2bc832ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "original_text": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n"}, "hash": "ad7a46916d4bc9697afbd153ccc23dbbd58faabaf6b0167cfee09a10f2fc258e", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "start_char_idx": 513, "end_char_idx": 688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7": {"__data__": {"id_": "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "original_text": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15affcf5-8a0b-4f6e-b28a-b7b9146899f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "original_text": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0f9e82c68c4a6f7c5a439013ff5390a305ec6e5b20ff87c0a3d9475ad99d00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "637ba99a-6164-4307-9a75-5789a5065ba7", "node_type": "1", "metadata": {"window": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "original_text": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. "}, "hash": "e52f3e7626454a0484af401177e2c59b1e0d2dc1d93d55ec6366f17766cd9bcb", "class_name": "RelatedNodeInfo"}}, "text": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "start_char_idx": 688, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "637ba99a-6164-4307-9a75-5789a5065ba7": {"__data__": {"id_": "637ba99a-6164-4307-9a75-5789a5065ba7", "embedding": null, "metadata": {"window": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "original_text": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "original_text": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75f4a237d4120f9f7d4616cab2bcb5a92e10193a50ae8dd1c0837230f074588a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "original_text": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n"}, "hash": "301c893f733d3e78f25e77e8ee74d1cf7c7c815cf08c83dc811c10de06b127e6", "class_name": "RelatedNodeInfo"}}, "text": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "start_char_idx": 1278, "end_char_idx": 1434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04": {"__data__": {"id_": "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04", "embedding": null, "metadata": {"window": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "original_text": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "637ba99a-6164-4307-9a75-5789a5065ba7", "node_type": "1", "metadata": {"window": "For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "original_text": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fe260e35cfe537263c140dda6c307e5d497e1b1a4d87324793a60e6f13b152b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b91f60f2-8f86-47de-83cc-b04cbaf7433e", "node_type": "1", "metadata": {"window": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. "}, "hash": "64bfa4f64cb99b726d5a639cb035c079b91d4af43748f631975444a5ec67c85d", "class_name": "RelatedNodeInfo"}}, "text": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "start_char_idx": 1434, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b91f60f2-8f86-47de-83cc-b04cbaf7433e": {"__data__": {"id_": "b91f60f2-8f86-47de-83cc-b04cbaf7433e", "embedding": null, "metadata": {"window": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "original_text": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6084e3bf5948b1bdcdcb74133afe20a9e0009a1c2df732138fcc64110eac62ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3205d079-3a59-4ca6-9a52-a224ed73b1cf", "node_type": "1", "metadata": {"window": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "original_text": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. "}, "hash": "1297c7dcc7eab0517d99a65ef9d46853676c28be366655809fd64cb71887d356", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "start_char_idx": 1584, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3205d079-3a59-4ca6-9a52-a224ed73b1cf": {"__data__": {"id_": "3205d079-3a59-4ca6-9a52-a224ed73b1cf", "embedding": null, "metadata": {"window": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "original_text": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b91f60f2-8f86-47de-83cc-b04cbaf7433e", "node_type": "1", "metadata": {"window": "Full year earnings per diluted share also included $2.36 related to the f ollowing certain items, which can also be \nfound on slide 23 in the appendix to our earnings presentation: $0.78 related to the US government's centralized \nCOVID -19 vaccine distribution program; $1.12 related to COVID -19 tests and the kitting, storage, and distribution \nof ancillary supplies for the US government; $0.65 related to the early termination of the tax receivable \nagreement, or TRA, with Change\u202fHealthcare; and $0.19 related to net losses associated with McKesson \nVentures' equity investments.  \n \n Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69faf90ea777d455ab1bf985e912045b18e1698b7401b18909bf7e2de37a4869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128bc1b8-c42c-483e-8a7f-b580f0fc606b", "node_type": "1", "metadata": {"window": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate. ", "original_text": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. "}, "hash": "2f28e4e2e48e5bffe4731dd05b6e0bde703bc73343a5a674be2364ad7fcf3a3a", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "start_char_idx": 1710, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128bc1b8-c42c-483e-8a7f-b580f0fc606b": {"__data__": {"id_": "128bc1b8-c42c-483e-8a7f-b580f0fc606b", "embedding": null, "metadata": {"window": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate. ", "original_text": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3205d079-3a59-4ca6-9a52-a224ed73b1cf", "node_type": "1", "metadata": {"window": "Exclud ing these certain items, earnings per diluted share increased 15% year -over-year, above our previously \ncommunicated\u202flong -term\u202fgrowth rate target.  Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "original_text": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20be1a4a4e7cf4a5906fa429ff94f36f21ed37a7beb0c9ace830f99e0b93e6b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccebdaad-0390-4a9e-8259-573c30d0c708", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "original_text": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n"}, "hash": "c0bc43027163c53c8213e366d569cb01193126c8b6f28e3f42c1e82aecc9457e", "class_name": "RelatedNodeInfo"}}, "text": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "start_char_idx": 1867, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccebdaad-0390-4a9e-8259-573c30d0c708": {"__data__": {"id_": "ccebdaad-0390-4a9e-8259-573c30d0c708", "embedding": null, "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "original_text": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128bc1b8-c42c-483e-8a7f-b580f0fc606b", "node_type": "1", "metadata": {"window": "Our strong full year results are broad -based and reflect our ongoing \ncommitment to deliver sustainable growth and\u202flong -term\u202fshareholder value.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate. ", "original_text": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20c2fbc8fd816c1f10984e3088e52b821e3c59bcab7aae31a0fcd7e824f36e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1234179c-76f7-4e14-9441-48f9ff3ffc7d", "node_type": "1", "metadata": {"window": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "original_text": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. "}, "hash": "eee5342b94f8c854f13523def9fbbfb4d725b3f226e9fc1d7d287432639e36ab", "class_name": "RelatedNodeInfo"}}, "text": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "start_char_idx": 2112, "end_char_idx": 2215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1234179c-76f7-4e14-9441-48f9ff3ffc7d": {"__data__": {"id_": "1234179c-76f7-4e14-9441-48f9ff3ffc7d", "embedding": null, "metadata": {"window": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "original_text": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccebdaad-0390-4a9e-8259-573c30d0c708", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our fourth quarter GAAP -only \nresults.  We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "original_text": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eadedaafcba356d6b3cfb968f0fccd9a7969a171c9e347248d020f0f0617364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f188298-307b-4ca2-9ec3-ee581049d5ca", "node_type": "1", "metadata": {"window": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "original_text": "Pharmaceutical segment, \nand real estate charges within Co rporate. "}, "hash": "4fbbc60d2a32dcd8a4a33783205ec806ff55f45a3cb06ddd5c4e023a6ffef29b", "class_name": "RelatedNodeInfo"}}, "text": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "start_char_idx": 2215, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f188298-307b-4ca2-9ec3-ee581049d5ca": {"__data__": {"id_": "9f188298-307b-4ca2-9ec3-ee581049d5ca", "embedding": null, "metadata": {"window": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "original_text": "Pharmaceutical segment, \nand real estate charges within Co rporate. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1234179c-76f7-4e14-9441-48f9ff3ffc7d", "node_type": "1", "metadata": {"window": "We remain focused on strategically managing\u202fthe company\u202fto deliver differentiated customer value, as \nwell as\u202flong -term\u202ffinancial growth and profitability.  In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "original_text": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b82d92c1762ddba926b581b1b8753eb008cce280bfe23bcc49df4a443b1542bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98f41714-191a-470b-9346-10cc6e68509d", "node_type": "1", "metadata": {"window": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "original_text": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. "}, "hash": "d0577721b3670771b2e55983d3f7fb482193a7c3f972db7ea03c5f564c584acf", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, \nand real estate charges within Co rporate. ", "start_char_idx": 2532, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98f41714-191a-470b-9346-10cc6e68509d": {"__data__": {"id_": "98f41714-191a-470b-9346-10cc6e68509d", "embedding": null, "metadata": {"window": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "original_text": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f188298-307b-4ca2-9ec3-ee581049d5ca", "node_type": "1", "metadata": {"window": "In support of delivering sustainable value, innovation, and \ngrowth, during the fourth quarter fiscal 2023, we announced a broad set of initiatives: simplify our infrastructure, \ndrive operational effi ciencies, and increased cost optimization.  These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "original_text": "Pharmaceutical segment, \nand real estate charges within Co rporate. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3a54b0c21cb458c03a34f949ef784efd78fcc6ac65575dff4400da82fcfa792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee5c80c0-bbfc-4e46-a2d5-1095f632c533", "node_type": "1", "metadata": {"window": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "original_text": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n"}, "hash": "43b9344d9a016c2b4c03a02588c51ba0dbd541a1cd9ed473f75031efaa274aa4", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "start_char_idx": 2600, "end_char_idx": 2713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee5c80c0-bbfc-4e46-a2d5-1095f632c533": {"__data__": {"id_": "ee5c80c0-bbfc-4e46-a2d5-1095f632c533", "embedding": null, "metadata": {"window": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "original_text": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98f41714-191a-470b-9346-10cc6e68509d", "node_type": "1", "metadata": {"window": "These initiatives include head count reductions \nand the exit or downsizing of certain facilities.  \n \n During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "original_text": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a5b360e5108a6066c24d66f5f2679a286028548b676594c0e71c9ce3014402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8482b4c5-87b3-4daf-8783-69fd0dbd74f8", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "original_text": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. "}, "hash": "bc3083a57ab4ddf46843c7950df9c7be4dab16e8bde4ae91a17e8a1e947d902d", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "start_char_idx": 2713, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8482b4c5-87b3-4daf-8783-69fd0dbd74f8": {"__data__": {"id_": "8482b4c5-87b3-4daf-8783-69fd0dbd74f8", "embedding": null, "metadata": {"window": "Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "original_text": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee5c80c0-bbfc-4e46-a2d5-1095f632c533", "node_type": "1", "metadata": {"window": "During the fourth quarter, we recorded charges of $60 million related to these initiatives, which include severanc e \nand other employee -related costs within our Prescription Technology Solutions segment, asset impairments and \naccelerated depreciation, including certain asset impairments primarily within our U.S.  Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "original_text": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf1a3cf021bd0c92267343a31ab3269e2c3d9781d55a244cb599c92461e6e4ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dcfe75a-fbdb-48b4-b753-1f21a22ba637", "node_type": "1", "metadata": {"window": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "original_text": "Fourth quarter and full year results were driven by \ngrowth in the U.S. "}, "hash": "b065de29f41ff7e7032c1292ee6816d08ac37a6ccc57f0cdcc99b2bb61844d85", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "start_char_idx": 2822, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dcfe75a-fbdb-48b4-b753-1f21a22ba637": {"__data__": {"id_": "3dcfe75a-fbdb-48b4-b753-1f21a22ba637", "embedding": null, "metadata": {"window": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "original_text": "Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8482b4c5-87b3-4daf-8783-69fd0dbd74f8", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, \nand real estate charges within Co rporate.  We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "original_text": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "824494cce2447cfb4826941e0a306ed750ccdf9eb5e6b2867fa4fb7d8e4e9aa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c", "node_type": "1", "metadata": {"window": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "original_text": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. "}, "hash": "56c847d111bf6125c8f11e9637d8ff2f9f12c701a39466222b14f7272c162301", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "start_char_idx": 2997, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c": {"__data__": {"id_": "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c", "embedding": null, "metadata": {"window": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "original_text": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dcfe75a-fbdb-48b4-b753-1f21a22ba637", "node_type": "1", "metadata": {"window": "We anticipate total charges of approximately $125 million within our \nPrescription Technology Solutions and U.S.  Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "original_text": "Fourth quarter and full year results were driven by \ngrowth in the U.S. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40e429154bda3a4ff71c8d5f5aa3bdecbeb248e2bb2ab936b010e2debe93819a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4293ea53-97a1-4b13-a226-52122ae33d9e", "node_type": "1", "metadata": {"window": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "original_text": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n"}, "hash": "cd9b8ae6154efac3af432ba6c5dc876bbb2fc871b0df1171effc02627a6daa43", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "start_char_idx": 3069, "end_char_idx": 3323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4293ea53-97a1-4b13-a226-52122ae33d9e": {"__data__": {"id_": "4293ea53-97a1-4b13-a226-52122ae33d9e", "embedding": null, "metadata": {"window": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "original_text": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c", "node_type": "1", "metadata": {"window": "Pharmaceutical segments, as well as Corporate, to be substantially \ncompleted by the end of fiscal 2024.  \n \n Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "original_text": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b52c18d2788b702084c14533402254663d6889206cdae6c71c29f09344f0307d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcff898f-4b96-4a96-80ed-298d9cce1c37", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 8%. "}, "hash": "e3a7ff8caf492e2085024d477ce08d2ccdca7f44951850c31fceaee64194bf94", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "start_char_idx": 3323, "end_char_idx": 3528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcff898f-4b96-4a96-80ed-298d9cce1c37": {"__data__": {"id_": "dcff898f-4b96-4a96-80ed-298d9cce1c37", "embedding": null, "metadata": {"window": "Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4293ea53-97a1-4b13-a226-52122ae33d9e", "node_type": "1", "metadata": {"window": "Moving now to our consolidated  results, our consolidated revenues increased 4% to $68.9 billion in the fourth \nquarter, and for the full year increased 5% to $276.7 billion.  Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "original_text": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94242e4ebf343d30be269739e3ee8ccec58df1bd7a865ad547bd3e7abf9716bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f87522a8-b7bf-4dcc-955b-86555692da50", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "original_text": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. "}, "hash": "ba9de1d17ef4cd87c17edcf7f1401ae664001e38221e284c4ffe6796c48f433f", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "start_char_idx": 3528, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f87522a8-b7bf-4dcc-955b-86555692da50": {"__data__": {"id_": "f87522a8-b7bf-4dcc-955b-86555692da50", "embedding": null, "metadata": {"window": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "original_text": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcff898f-4b96-4a96-80ed-298d9cce1c37", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results were driven by \ngrowth in the U.S.  Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 8%. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5832a7646be5e5b5ecefbbb0d200307a3266bc4762c5ebbba03352f788ece64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cdbd904-155c-46e6-93d9-dd1bdda28da2", "node_type": "1", "metadata": {"window": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n"}, "hash": "a5f3702338554f5ea03990882193f663f4161d5395cb9f53acfbd1134af6b18b", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "start_char_idx": 3593, "end_char_idx": 3664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cdbd904-155c-46e6-93d9-dd1bdda28da2": {"__data__": {"id_": "3cdbd904-155c-46e6-93d9-dd1bdda28da2", "embedding": null, "metadata": {"window": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f87522a8-b7bf-4dcc-955b-86555692da50", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, including increase d specialty product volumes from retail national \naccount customers, partially offset by lower revenues in the International segment as a result of the completed \ndivestitures of McKesson's European businesses.  Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "original_text": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88227ffb578938d686853c1d813f51ce1e624332f50ae59052d0a79da04ade04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b43dbae-6f3f-4113-8f68-4be701fedff4", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Pharmaceutical and Presc ription Technology Solutions segments.  \n \n"}, "hash": "c9e378006200fe708c72fd2ad8843ee8b4a6e70cacd09bc486f7d87fe793907f", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "start_char_idx": 3664, "end_char_idx": 3868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b43dbae-6f3f-4113-8f68-4be701fedff4": {"__data__": {"id_": "9b43dbae-6f3f-4113-8f68-4be701fedff4", "embedding": null, "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cdbd904-155c-46e6-93d9-dd1bdda28da2", "node_type": "1", "metadata": {"window": "Excluding the impact of the European business o perations, \nincluding these completed divestitures, revenues increased 13% in the fourth quarter and 12% in the full year \nwhen compared to fiscal 2022.  \n \n Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b47ecb3fc3d3b7246451fd9f8a39a774ceb28f025e96d12b1c9fbc5ac569bfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32", "node_type": "1", "metadata": {"window": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. "}, "hash": "18d1a42367521d85ebee1e6368f6678ff3f6dc3638f6005b2a0d0f7734ff13d0", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "start_char_idx": 3868, "end_char_idx": 3936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32": {"__data__": {"id_": "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32", "embedding": null, "metadata": {"window": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b43dbae-6f3f-4113-8f68-4be701fedff4", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 8%.  For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Pharmaceutical and Presc ription Technology Solutions segments.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "058af22ae02e03dde37b35f76942c8db46ee0d487fbd1c29ddbef1ea84392d59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e26ffd4-e3cd-4955-97f4-46f271009d04", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  "}, "hash": "92f76fb362b9b22d3807ffd1185500d2bea90080c3b2f2b7769bff19bf62e585", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "start_char_idx": 3936, "end_char_idx": 4126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e26ffd4-e3cd-4955-97f4-46f271009d04": {"__data__": {"id_": "3e26ffd4-e3cd-4955-97f4-46f271009d04", "embedding": null, "metadata": {"window": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fc4d5318739e73bd58875857c3979c4b7aa703083749deec5670035097ca19", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32", "node_type": "1", "metadata": {"window": "For the full year, gross profit was $12 .2 billion, a \ndecrease of 7%.  Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs. ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb3a111f86cd243c6e93751b7a0e57babe6899d8d9b767499eb1ceac7273546d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faae7809-63f6-4171-8a91-0709b652a05d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "76b969eeb280b987b33d96ece0be1bed76a611e4437f578262eac16ca902c68e", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "start_char_idx": 4126, "end_char_idx": 4297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faae7809-63f6-4171-8a91-0709b652a05d": {"__data__": {"id_": "faae7809-63f6-4171-8a91-0709b652a05d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e26ffd4-e3cd-4955-97f4-46f271009d04", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations and completed divestitures, gross \nprofit increased 9% in the fourth quarter and 8% in the full year, primarily as a result of growth in the U.S. \n Pharmaceutical and Presc ription Technology Solutions segments.  \n \n Operating expenses decreased 14% in the quarter and 13% for the full year, largely driven by completed \nEuropean divestitures in our International segment and lower opioid litigation costs.  Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "original_text": "Excluding the impact of our  \nEuropean business operations and the completed divestitures, operating expenses increased 8% in both the \nfourth quarter and the full year.  ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9f1e5217a73e230a7189c8b87c046a754dbb78aa51ad31a7199fe7e1c227d35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff472c87-e2d7-4302-95e9-1af87557e88c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S. "}, "hash": "c2da12de1ac4ffff1f1f69a72a87977040a12fd335a9ee8333626bba915a3714", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff472c87-e2d7-4302-95e9-1af87557e88c": {"__data__": {"id_": "ff472c87-e2d7-4302-95e9-1af87557e88c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faae7809-63f6-4171-8a91-0709b652a05d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a64c7e6a73ba452d28fcdfa6717b687b530731e4ca08550c869f3c8b3270a4f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3f294dd-acd0-4969-be87-ba346f69d43f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "original_text": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n"}, "hash": "08df0f7008e8086d4c426730cdb7856dbc4dfb53780def3787435a2071955a44", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S. ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3f294dd-acd0-4969-be87-ba346f69d43f": {"__data__": {"id_": "c3f294dd-acd0-4969-be87-ba346f69d43f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "original_text": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff472c87-e2d7-4302-95e9-1af87557e88c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "801116445f53fdde09f7de82750d4020e6af45369a1f29d1641e83b33051760a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b109cca8-4ebf-48a4-9448-ba59d729df71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates. ", "original_text": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n"}, "hash": "519ee119f2be154b42210ead186106a96cd01f8e28b674db894c4c22bbf2c614", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n", "start_char_idx": 269, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b109cca8-4ebf-48a4-9448-ba59d729df71": {"__data__": {"id_": "b109cca8-4ebf-48a4-9448-ba59d729df71", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates. ", "original_text": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3f294dd-acd0-4969-be87-ba346f69d43f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "original_text": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d33fa35d8647f600f6151fa98922e0dbe463244a4920018255b0242030b02f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a885cb9-0a6f-4270-be69-5b3c8d0f9650", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "original_text": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n"}, "hash": "f43de0501c05d0e4ebe729632380668cf81fe7dfc195b46cec118414ddc2ec64", "class_name": "RelatedNodeInfo"}}, "text": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "start_char_idx": 490, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a885cb9-0a6f-4270-be69-5b3c8d0f9650": {"__data__": {"id_": "5a885cb9-0a6f-4270-be69-5b3c8d0f9650", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "original_text": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b109cca8-4ebf-48a4-9448-ba59d729df71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates. ", "original_text": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75a28dfd2f11930fd9b48d8597d7f686ec525ea4ec4f8b3c2ce7a6724d7e27dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62db3ddf-98fb-4ea0-8dee-6cc268529848", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "original_text": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. "}, "hash": "d63883d0a16bcfd9901773bb071367de3d7cb696db8125dd4aeb855d1de65d8b", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "start_char_idx": 758, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62db3ddf-98fb-4ea0-8dee-6cc268529848": {"__data__": {"id_": "62db3ddf-98fb-4ea0-8dee-6cc268529848", "embedding": null, "metadata": {"window": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "original_text": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a885cb9-0a6f-4270-be69-5b3c8d0f9650", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "original_text": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e72a855e36495579382141c5cff4488310a77f91fb7570933bd61ce93b9ae3f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a919e8f8-740a-42fa-a8ae-9d863df726b8", "node_type": "1", "metadata": {"window": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "original_text": "The \nincrease was primarily due to impacts from higher interest rates. "}, "hash": "c92bea02d8ab9854a8aea537f2f32814229a09af430cb74de5ccda4ed4b72244", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "start_char_idx": 1161, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a919e8f8-740a-42fa-a8ae-9d863df726b8": {"__data__": {"id_": "a919e8f8-740a-42fa-a8ae-9d863df726b8", "embedding": null, "metadata": {"window": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "original_text": "The \nincrease was primarily due to impacts from higher interest rates. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62db3ddf-98fb-4ea0-8dee-6cc268529848", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "original_text": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aebf50ad39bb1db68aca3466ea2376cb48100f0bda21f14f58e35940e0b1e9e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52", "node_type": "1", "metadata": {"window": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "original_text": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. "}, "hash": "c16cd43e57dcf58f527ade86ed3e4c9484931b16a345a8d3020dc84c0a243b66", "class_name": "RelatedNodeInfo"}}, "text": "The \nincrease was primarily due to impacts from higher interest rates. ", "start_char_idx": 1268, "end_char_idx": 1339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52": {"__data__": {"id_": "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52", "embedding": null, "metadata": {"window": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "original_text": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a919e8f8-740a-42fa-a8ae-9d863df726b8", "node_type": "1", "metadata": {"window": "Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "original_text": "The \nincrease was primarily due to impacts from higher interest rates. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a89847d4909dadd0a257b0d552177a3f0337e8dd9ba62d2e7be33c3918a3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d24cafa8-d2ca-473d-9268-0a83bc80c1cf", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical. ", "original_text": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. "}, "hash": "0aa4b31132ba25a0e76eb2ccf7911d3da017d8603eaf3bf1f13b46fd8b070c9e", "class_name": "RelatedNodeInfo"}}, "text": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "start_char_idx": 1339, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d24cafa8-d2ca-473d-9268-0a83bc80c1cf": {"__data__": {"id_": "d24cafa8-d2ca-473d-9268-0a83bc80c1cf", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical. ", "original_text": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52", "node_type": "1", "metadata": {"window": "When excluding the impact related to the distribution of COVID -19-related products, a\u202fpre -tax\u202fbenefit of $126 \nmillion related to the early termination of the TRA with Change\u202fHealthcare\u202fin the third quarter, and net gains or \nlosses associated with McKesson Ventures' equity investments, operating profit increased 9% in t he fourth \nquarter and 8% for the full year when compared to fiscal 2022.  \n \n Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "original_text": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce9afa037fb6dc75719616aea66763c469244109bdfc13dd52d229f7169feac5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c", "node_type": "1", "metadata": {"window": "The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S. ", "original_text": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n"}, "hash": "b174d5a3c1a398143eca0a7c6ccbedff678a2b67b69525ed23d5fa650c875b9d", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "start_char_idx": 1451, "end_char_idx": 1586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c": {"__data__": {"id_": "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c", "embedding": null, "metadata": {"window": "The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S. ", "original_text": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d24cafa8-d2ca-473d-9268-0a83bc80c1cf", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $70 million in the quarter and $239 million for the full year.  The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical. ", "original_text": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c46ff17b457a74a6a4a2e5a50fb97e4e4ed70091ef6e0520b09e4b7086b315c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f4a293-d8fc-4961-8aab-9b54f6922da8", "node_type": "1", "metadata": {"window": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "original_text": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. "}, "hash": "14b50fde202ba15b37ea681c5a859bf0d00052c5057a1744f0c9585da090dd3b", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "start_char_idx": 1586, "end_char_idx": 1738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f4a293-d8fc-4961-8aab-9b54f6922da8": {"__data__": {"id_": "c5f4a293-d8fc-4961-8aab-9b54f6922da8", "embedding": null, "metadata": {"window": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "original_text": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c", "node_type": "1", "metadata": {"window": "The \nincrease was primarily due to impacts from higher interest rates.  Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S. ", "original_text": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cabb71f97cbe0d7e6d1220f7db1cb35b3ab3ae1f83a65a75575780b609a4a20b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "original_text": "Ph armaceutical. "}, "hash": "3ddc6df1d0cfe488b67b88ee55d15f8a07d02a2bb3bc677f4f0df0cbfa8538be", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "start_char_idx": 1738, "end_char_idx": 1865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c": {"__data__": {"id_": "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c", "embedding": null, "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "original_text": "Ph armaceutical. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f4a293-d8fc-4961-8aab-9b54f6922da8", "node_type": "1", "metadata": {"window": "Effec tive tax rate was 12.9% for the quarter and \n18.8% for the full year, in line with our original guidance.  As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "original_text": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1583f28b74cda0e3d506602d7f6c1bc85b0f028fd05f699cdbf23d6c27fef2e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3", "node_type": "1", "metadata": {"window": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "original_text": "Our U.S. "}, "hash": "86c79ccca73a342a1968111c2b580fa23db2ac3a2adae527bf44d6cb6366adb8", "class_name": "RelatedNodeInfo"}}, "text": "Ph armaceutical. ", "start_char_idx": 1865, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3": {"__data__": {"id_": "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3", "embedding": null, "metadata": {"window": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "original_text": "Our U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-\nquarter, driven by our mix of income and the timing of discrete tax items.  Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "original_text": "Ph armaceutical. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "387e18028ff6b14bca153a367edcc639e5e881029326a08bb2bbbcb22c8186f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7098cabe-2265-4004-a516-fe68c98cf7a1", "node_type": "1", "metadata": {"window": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "original_text": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n"}, "hash": "c9129943fe26f3421da85e5e7bab452c818b5c9e09d52672c48c161b784bd8e7", "class_name": "RelatedNodeInfo"}}, "text": "Our U.S. ", "start_char_idx": 1882, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7098cabe-2265-4004-a516-fe68c98cf7a1": {"__data__": {"id_": "7098cabe-2265-4004-a516-fe68c98cf7a1", "embedding": null, "metadata": {"window": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "original_text": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3", "node_type": "1", "metadata": {"window": "Wrapping up our co nsolidated results, \nfourth quarter diluted weighted average shares outstanding was 138 million, decrease of 8% year -over-year.  \n \n Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "original_text": "Our U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a59b0ebf5debc5f20f4a033fcb8fcabc9554ded55516b491ca0098420eae888a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "712ecf80-1177-4df9-9a34-9c6bfa766c54", "node_type": "1", "metadata": {"window": "Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "original_text": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n"}, "hash": "fdb47a07544dadf080c358bd1b90d1e9fb657ab845fbfb48b0f81b4d43c7446c", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "start_char_idx": 1891, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "712ecf80-1177-4df9-9a34-9c6bfa766c54": {"__data__": {"id_": "712ecf80-1177-4df9-9a34-9c6bfa766c54", "embedding": null, "metadata": {"window": "Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "original_text": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7098cabe-2265-4004-a516-fe68c98cf7a1", "node_type": "1", "metadata": {"window": "Turning to our fourth quarter and full year segment results, which can be found on slides 7 through 12 and starting \nwith U.S.  Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "original_text": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbf8d9ec80811c730c2b6b14be86e5e159b6dd32575249a9a3c79fde8b0e1f44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca783919-9d1b-42d2-821b-f033bf99c7f8", "node_type": "1", "metadata": {"window": "Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "original_text": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. "}, "hash": "6573bc44507350fd1d11eee300510bc2ae4031a56e06329cbcb960caf28e50cd", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "start_char_idx": 2112, "end_char_idx": 2432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca783919-9d1b-42d2-821b-f033bf99c7f8": {"__data__": {"id_": "ca783919-9d1b-42d2-821b-f033bf99c7f8", "embedding": null, "metadata": {"window": "Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "original_text": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "712ecf80-1177-4df9-9a34-9c6bfa766c54", "node_type": "1", "metadata": {"window": "Ph armaceutical.  Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "original_text": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11ac844647f39da79ef829b674e1393ec62d85a6c07773ff51df94595e6fdbe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1003a391-2243-4913-8654-8e3edd5d8983", "node_type": "1", "metadata": {"window": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "original_text": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. "}, "hash": "d11f7d01a66e0049dbd17dd652297ce056ed76b1fa1aedbbdcdbe1416dd31f34", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "start_char_idx": 2432, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1003a391-2243-4913-8654-8e3edd5d8983": {"__data__": {"id_": "1003a391-2243-4913-8654-8e3edd5d8983", "embedding": null, "metadata": {"window": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "original_text": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca783919-9d1b-42d2-821b-f033bf99c7f8", "node_type": "1", "metadata": {"window": "Our U.S.  Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "original_text": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24e794be411a4f344f423f58682fa251991b9f3e46fb2a86ebfa1bc4bc807127", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23f4456e-12f4-45d4-b794-dd7c3bdfe57e", "node_type": "1", "metadata": {"window": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "original_text": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n"}, "hash": "0d45aa3eb2884539624ee15cae93fe6c2c38d6d28efd2aebf89e6649fb2b89ce", "class_name": "RelatedNodeInfo"}}, "text": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "start_char_idx": 2696, "end_char_idx": 2840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23f4456e-12f4-45d4-b794-dd7c3bdfe57e": {"__data__": {"id_": "23f4456e-12f4-45d4-b794-dd7c3bdfe57e", "embedding": null, "metadata": {"window": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "original_text": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1003a391-2243-4913-8654-8e3edd5d8983", "node_type": "1", "metadata": {"window": "Pharmaceutical business is a scaled efficient business and comprises the \nbreadth and depth of services and capabilities, including our growing oncology platform, and we're pleased with \nthe momentum in this segment.  \n \n Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "original_text": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d1e48ef7bbe97ec7e27e6245bde3de0809f1af5ab622ce85c244fbb5f196087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2407983-05c4-4922-a0d6-cea00fecf7b2", "node_type": "1", "metadata": {"window": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "original_text": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. "}, "hash": "4680d6a4e6125f449f711e741acc05193ef98d9540d6e201e9fcbe36fd8198c5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "start_char_idx": 2840, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2407983-05c4-4922-a0d6-cea00fecf7b2": {"__data__": {"id_": "f2407983-05c4-4922-a0d6-cea00fecf7b2", "embedding": null, "metadata": {"window": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "original_text": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23f4456e-12f4-45d4-b794-dd7c3bdfe57e", "node_type": "1", "metadata": {"window": "Fourth quarter re venues were $61.7 billion, an increase of 15% year -over-year, driven by growth across all \ncustomer segments, including increased volume of specialty products, higher volumes from retail national account \ncustomers, and market growth, which is partially offs et by branded to generic conversions.  \n \n Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "original_text": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63a7cd1c0cfcee73a29400faebe60c10939626ff5a5895905eb51186c580ef73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1", "node_type": "1", "metadata": {"window": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "original_text": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n"}, "hash": "d54cb5c8abed83fed6647824e14f43c53bb09cd37ba2496df638630e26d51836", "class_name": "RelatedNodeInfo"}}, "text": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "start_char_idx": 2952, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1": {"__data__": {"id_": "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1", "embedding": null, "metadata": {"window": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "original_text": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2407983-05c4-4922-a0d6-cea00fecf7b2", "node_type": "1", "metadata": {"window": "Fourth quarter operating profit increased 10% to $861 million and for the full year increased 6% to $3.1 billion, \ndriven by growth in the distribution of specialty products to providers and health systems and increase d \ncontributions from our generics programs.  We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "original_text": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ee1d943b9797de7d6dee96c09c0133b7fce7200278f2af051eccfcf8dfa7ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e1442da-f7de-47cc-ace7-3222254d2f72", "node_type": "1", "metadata": {"window": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "When excluding the impact of COVID -19 vaccine distribution, the U.S. "}, "hash": "4419519e49ca090981fe7ba72ac37fa09017ea7c59296174770b23cde3f37114", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "start_char_idx": 3214, "end_char_idx": 3366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e1442da-f7de-47cc-ace7-3222254d2f72": {"__data__": {"id_": "4e1442da-f7de-47cc-ace7-3222254d2f72", "embedding": null, "metadata": {"window": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1", "node_type": "1", "metadata": {"window": "We remain pleased with the performance of our generics program lead \nby stable market fundamentals and the strength of our sourcing operations.  We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "original_text": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "211dbe3715604ba13ec5fe8d8b59096ea9a437b6b0901eaf8e914cfe317dc020", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b91caa3-6ebe-468a-834e-9b234e582d3e", "node_type": "1", "metadata": {"window": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n"}, "hash": "28bbffeba141cb7c298b202e9e1dac38c841d275ac56fc5571f29d6d1deb9a4a", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "start_char_idx": 3366, "end_char_idx": 3436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b91caa3-6ebe-468a-834e-9b234e582d3e": {"__data__": {"id_": "4b91caa3-6ebe-468a-834e-9b234e582d3e", "embedding": null, "metadata": {"window": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e1442da-f7de-47cc-ace7-3222254d2f72", "node_type": "1", "metadata": {"window": "We continue to provide solid value to \nour customers and partners, del ivering low -cost and stable supply.  \n \n Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "When excluding the impact of COVID -19 vaccine distribution, the U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8607529e17b15b87667d4f1e858c317ccd34a96f8b75415bec986293d2b0a056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33b8a16-bf16-4821-965e-aa36b4c209eb", "node_type": "1", "metadata": {"window": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. "}, "hash": "3354145e7b1320b2c81c32c63882110e29144344334c6fd81b423351906548f1", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "start_char_idx": 3436, "end_char_idx": 3646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c33b8a16-bf16-4821-965e-aa36b4c209eb": {"__data__": {"id_": "c33b8a16-bf16-4821-965e-aa36b4c209eb", "embedding": null, "metadata": {"window": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b91caa3-6ebe-468a-834e-9b234e582d3e", "node_type": "1", "metadata": {"window": "Our contract with the US government for COVID -19 vaccine distribution provided an operating profit benefit of \napproximately $21 million or $0.11 per share in the fourth quarter compared to $12 million or $0.06 per share  in \nthe fourth quarter the prior year.  For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e25aac06ad844abed2ee75f94b6108a62dab5ff1a3d2b540936d171ea275ef55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5b25399-fb22-46f1-9a89-fccc5aa03dcc", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  "}, "hash": "2a7b6d7cdf7e84c5c2fbee5df59c961c985a356ff7f056fddcb788d1c73d4e5c", "class_name": "RelatedNodeInfo"}}, "text": "For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "start_char_idx": 3646, "end_char_idx": 3915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5b25399-fb22-46f1-9a89-fccc5aa03dcc": {"__data__": {"id_": "b5b25399-fb22-46f1-9a89-fccc5aa03dcc", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca9973e85be608561a47ad6395a1d324e0f971d873fdccda244c2d96eab5925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33b8a16-bf16-4821-965e-aa36b4c209eb", "node_type": "1", "metadata": {"window": "For the full year, this contract provided a benefit of $149 million or $0.78 per \nshare compared to $186 million or $0.89 per share in fiscal 2022.  \n \n When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes. ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8dc690d1b86725d1a9364569bdafb7c1033aa68e5ae815e47e796b542c26031", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94645c12-4d12-4f5a-a952-202b259fbb0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "2c5e6eabcce4b0cd973f202bd81b05403f924d0d628a65f534e930cc23ada8b2", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "start_char_idx": 3915, "end_char_idx": 4097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94645c12-4d12-4f5a-a952-202b259fbb0b": {"__data__": {"id_": "94645c12-4d12-4f5a-a952-202b259fbb0b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5b25399-fb22-46f1-9a89-fccc5aa03dcc", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19 vaccine distribution, the U.S.  Pharmaceutical segment delivered \noperating profit growth of 9% in the fourth quarter and 8% for the full year, compared to fiscal 2022 results, which \nwere ahead of the segment's long -term growth target.  \n \n For the Prescription Technology Solutions segment, f ourth quarter revenues were $1.2 billion, an increase of 16% \nyear-over-year, driven by growth in prescription volumes in our third -party logistics business, and access and \nadherence solutions transaction volumes.  Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "original_text": "Fourth quarter operating profit increased 3 5% to $218 million and full \nyear operating profit increased 15% to $679 million driven by growth in access and affordability solutions.  ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfa464c63c6c81399c8901abfdb4b50e82e84e2efa572f8807b9d11608af9b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve. "}, "hash": "de2c36bdf24aa51d6ed459afd4bc96b72a75c99c6a602c6d621dfc55c1db44c8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4": {"__data__": {"id_": "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94645c12-4d12-4f5a-a952-202b259fbb0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74c93a276c2ce9d47b9b8188dfc1b84b0d96bd59e760583b020088b4444bbd7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "original_text": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history. "}, "hash": "4359b7fa0026d46f94cb6d9effcc5a65cb05d4b7fa513920aa854a1853763036", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve. ", "start_char_idx": 16, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2": {"__data__": {"id_": "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "original_text": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10d947c4bf0e10515ea393f9d54ebead8dcd3cae7ab57ab096f90a37b3d432fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25357344-adb5-474c-96b6-138914b1b45a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "original_text": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n"}, "hash": "e6379751d5035ad110f8785c0f4137fb01ecf26b34bdef05c9a54a997f6abc0b", "class_name": "RelatedNodeInfo"}}, "text": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history. ", "start_char_idx": 388, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25357344-adb5-474c-96b6-138914b1b45a": {"__data__": {"id_": "25357344-adb5-474c-96b6-138914b1b45a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "original_text": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "original_text": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adea7b61f5e7a6882b3d308e849f07d0d852eabde89788ee8f032bf0063704b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c436f45a-11f4-4dad-a857-ce7acbc4d22e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "7cc9885272f129745a57ed3306ee5f6957281279b69be31ded33bdc9f6b48aa3", "class_name": "RelatedNodeInfo"}}, "text": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "start_char_idx": 607, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c436f45a-11f4-4dad-a857-ce7acbc4d22e": {"__data__": {"id_": "c436f45a-11f4-4dad-a857-ce7acbc4d22e", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25357344-adb5-474c-96b6-138914b1b45a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "original_text": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "761d6d96ab83a9655af68b88080032eb9ea075c0c2e50478eed46f8cf4e8d43a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3893858a-3120-4057-bdc3-88966abeee39", "node_type": "1", "metadata": {"window": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "original_text": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. "}, "hash": "3d3a49f73651e2cedefcfa9ab17347fa8350c5e063b5800d6e9fd88239108b07", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 731, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3893858a-3120-4057-bdc3-88966abeee39": {"__data__": {"id_": "3893858a-3120-4057-bdc3-88966abeee39", "embedding": null, "metadata": {"window": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "original_text": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c436f45a-11f4-4dad-a857-ce7acbc4d22e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48f417f69b6cde22dc0fe96caca0bf4d216e72cc260f5069b7363527cab00573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c5ff63-5724-4444-861a-753376dd38e0", "node_type": "1", "metadata": {"window": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "original_text": "For the full year, operating profit \ndeclined 4% to $1.2 billion. "}, "hash": "0e14f4102bcdb443fc9319717f5c4313a12cf65bb8aa64fa51d492a7d702d40f", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "start_char_idx": 774, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77c5ff63-5724-4444-861a-753376dd38e0": {"__data__": {"id_": "77c5ff63-5724-4444-861a-753376dd38e0", "embedding": null, "metadata": {"window": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "original_text": "For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3893858a-3120-4057-bdc3-88966abeee39", "node_type": "1", "metadata": {"window": "Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "original_text": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61becca2620369b8c84d62cb9309fa1000f8c73a5fa6621a71d6d057e944a85b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80171b71-a837-4e65-a89f-5e05cb65b183", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "original_text": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n"}, "hash": "696eb293146a0904345770fbda04d317120c0dc583913f324169c1c53880c221", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "start_char_idx": 917, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80171b71-a837-4e65-a89f-5e05cb65b183": {"__data__": {"id_": "80171b71-a837-4e65-a89f-5e05cb65b183", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "original_text": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c5ff63-5724-4444-861a-753376dd38e0", "node_type": "1", "metadata": {"window": "This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "original_text": "For the full year, operating profit \ndeclined 4% to $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ac3eabacb64aebb6fa29e75abd0e5dd85be00852cadb46285079dcfcf10a9b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e16973f7-ea2f-4bd0-b598-4ab477601868", "node_type": "1", "metadata": {"window": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results. ", "original_text": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n"}, "hash": "56dc7f70ad5cd01015e9cf6eb193756ae6f1bcad49ba0c52e32bfc37a76f6cfe", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "start_char_idx": 983, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e16973f7-ea2f-4bd0-b598-4ab477601868": {"__data__": {"id_": "e16973f7-ea2f-4bd0-b598-4ab477601868", "embedding": null, "metadata": {"window": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results. ", "original_text": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80171b71-a837-4e65-a89f-5e05cb65b183", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "original_text": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dfe192524a720d1dd173b81432a18dfdcdb7ac6915837a970a9c872f049bf78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97de9c4-0736-4b11-ac28-1f24be980455", "node_type": "1", "metadata": {"window": "For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "original_text": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. "}, "hash": "ec5623c447bff77780fd4bb9bdcd813064ba73550802019eb1c61022579e42d6", "class_name": "RelatedNodeInfo"}}, "text": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "start_char_idx": 1356, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97de9c4-0736-4b11-ac28-1f24be980455": {"__data__": {"id_": "a97de9c4-0736-4b11-ac28-1f24be980455", "embedding": null, "metadata": {"window": "For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "original_text": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e16973f7-ea2f-4bd0-b598-4ab477601868", "node_type": "1", "metadata": {"window": "In the fourth quarter, revenues were $2.7 billi on, a decrease of 6% \nyear-over-year, and operating profit was $248 million a decrease of 17%.  For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results. ", "original_text": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae04e324190b0a3100957c0119469e4c0a09994d1cac527a693926211514d231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2837749-2b2e-4621-a6d6-5502d0e29414", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "original_text": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n"}, "hash": "df6d0667b41c17d616eb4073c0d75aedb947fc289b1fb619daa5003ce1ec5ecb", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "start_char_idx": 1662, "end_char_idx": 1822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2837749-2b2e-4621-a6d6-5502d0e29414": {"__data__": {"id_": "f2837749-2b2e-4621-a6d6-5502d0e29414", "embedding": null, "metadata": {"window": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "original_text": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97de9c4-0736-4b11-ac28-1f24be980455", "node_type": "1", "metadata": {"window": "For the full year, operating profit \ndeclined 4% to $1.2 billion.  Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "original_text": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a51eb871c6a6479ace6c71ca674fb94b589a040e589b4cb94a54c8abd8ccec04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2102243e-1528-4d9d-8cf3-ab07f11a89b8", "node_type": "1", "metadata": {"window": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "original_text": "Next, we'll address our Internationa l results. "}, "hash": "e592f79d268b7a34ed3e1a0534e36f74c887fa8e815e32d75985e82241c5fa24", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "start_char_idx": 1822, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2102243e-1528-4d9d-8cf3-ab07f11a89b8": {"__data__": {"id_": "2102243e-1528-4d9d-8cf3-ab07f11a89b8", "embedding": null, "metadata": {"window": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "original_text": "Next, we'll address our Internationa l results. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2837749-2b2e-4621-a6d6-5502d0e29414", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results were impacted by lower sales of COVID -19 tests \nand lower con tribution from kitting, storage, and distribution of ancillary supplies to the US government's COVID -\n19 program, partially offset by growth in the primary care business, including favorable sourcing activities and \nillness season testing compared to the pri or year.  \n \n Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "original_text": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03562036886b98c4732f9094d3f70ca1ac0bcf11d370618e8f86325a5958e0b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f52c1806-9b7b-4ecd-8916-7950f69c416a", "node_type": "1", "metadata": {"window": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "original_text": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. "}, "hash": "94f5976d9ba97479b4269810d7897abcc18d3881633c1ecfaa4dfbb27abaeeb0", "class_name": "RelatedNodeInfo"}}, "text": "Next, we'll address our Internationa l results. ", "start_char_idx": 2093, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f52c1806-9b7b-4ecd-8916-7950f69c416a": {"__data__": {"id_": "f52c1806-9b7b-4ecd-8916-7950f69c416a", "embedding": null, "metadata": {"window": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "original_text": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2102243e-1528-4d9d-8cf3-ab07f11a89b8", "node_type": "1", "metadata": {"window": "Contributions for COVID -19 tests in our contract with the US government for the kitting, storage, and distribution \nof ancillary supplies provided a total benefit of $31 million or $0.16 per share in the fourth quarter compared to \n$85 million or $0.42 per share in the fourth quarter of fiscal 2022.  \n \n For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "original_text": "Next, we'll address our Internationa l results. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77d76e4ac8bc9b73b5029e76787b83c0065fce3b80dd2d599f32273d2672c4ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef3549d0-70ac-460b-bc74-aa4c743274d6", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. "}, "hash": "e1708c25155510047f56aa7f946932579658e076b495b9658670681a4c652296", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "start_char_idx": 2141, "end_char_idx": 2282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef3549d0-70ac-460b-bc74-aa4c743274d6": {"__data__": {"id_": "ef3549d0-70ac-460b-bc74-aa4c743274d6", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f52c1806-9b7b-4ecd-8916-7950f69c416a", "node_type": "1", "metadata": {"window": "For the full year, COVID -19-related items provided a benefit of $216 million, or $1.12 per -share compared to $371 \nmillion or $1.78 per share in fiscal 2022.  When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "original_text": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e89fbbdc74a912e15a2997941767a39e7244fb04362ac16f7b90860e126a17a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "466d3e8d-ea0c-4230-817d-fa6354400dec", "node_type": "1", "metadata": {"window": "Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "original_text": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. "}, "hash": "03ac0bf9a24bb4b178d2b33e48e67fc12768d2e9c66afc60f1a7fbab1a704bf0", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "start_char_idx": 2282, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "466d3e8d-ea0c-4230-817d-fa6354400dec": {"__data__": {"id_": "466d3e8d-ea0c-4230-817d-fa6354400dec", "embedding": null, "metadata": {"window": "Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "original_text": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef3549d0-70ac-460b-bc74-aa4c743274d6", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-relate d items, this segment \ndelivered operating profit growth of 2% in the fourth quarter and 13% for the full year compared to fiscal 2022 \nresults, which was at the upper end of the original guidance range that we provided.  \n \n Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "original_text": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcf7620afd7ec601555b1e94f13ce566c495f6ba88808ce2db6d1c4e72c68da1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31632b48-c4c7-4f37-88f2-4268edfd5c2b", "node_type": "1", "metadata": {"window": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "original_text": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n"}, "hash": "a054d5c87848a087d44db7e4eb2bef8679088d60506aea06acf22d2ef6742632", "class_name": "RelatedNodeInfo"}}, "text": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "start_char_idx": 2429, "end_char_idx": 2509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31632b48-c4c7-4f37-88f2-4268edfd5c2b": {"__data__": {"id_": "31632b48-c4c7-4f37-88f2-4268edfd5c2b", "embedding": null, "metadata": {"window": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "original_text": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "466d3e8d-ea0c-4230-817d-fa6354400dec", "node_type": "1", "metadata": {"window": "Next, we'll address our Internationa l results.  Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "original_text": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65ba086a023e52d05d71291ba1e8b674a3b2fcc166b18d4018aad89cf1bb2738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "original_text": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. "}, "hash": "85979d9471367b6fdf6949b9f3d94973f9ab8ab8cc040a660c26d51ed6051427", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "start_char_idx": 2509, "end_char_idx": 2650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce": {"__data__": {"id_": "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "original_text": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31632b48-c4c7-4f37-88f2-4268edfd5c2b", "node_type": "1", "metadata": {"window": "Revenues in the fourth quarter were $3.4 billion, a decrease of 61% \nyear-over-year and operating profit was $80 million, a decrease of 46%.  On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "original_text": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19b347f73d50dbb8d97828806f77d1d8c2fb18f1eed783b802c4961f0f478b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "905de93d-d934-4102-813c-968ae4c63937", "node_type": "1", "metadata": {"window": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "original_text": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n"}, "hash": "b0e95ba6f1b6d7f1c23fee55c094aad4ce36c3d23f57c331083fa480af57102e", "class_name": "RelatedNodeInfo"}}, "text": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "start_char_idx": 2650, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "905de93d-d934-4102-813c-968ae4c63937": {"__data__": {"id_": "905de93d-d934-4102-813c-968ae4c63937", "embedding": null, "metadata": {"window": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "original_text": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, fourth quarter \nrevenues were $3.6 billion, a decrease of 58%; and operating prof it was $88 million, a decrease of 40%.  For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "original_text": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df10fb5698a94422e5a0e27ff2e36be313b11eeecc40a269d3d74391a75f2152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702eecf8-6dcf-4a18-9952-f19e3d033ce1", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "original_text": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. "}, "hash": "25c85303314f0793a5e4adb2debf1ecf777799c87494ca3a82987f0ffc2fef16", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "start_char_idx": 2774, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702eecf8-6dcf-4a18-9952-f19e3d033ce1": {"__data__": {"id_": "702eecf8-6dcf-4a18-9952-f19e3d033ce1", "embedding": null, "metadata": {"window": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "original_text": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "905de93d-d934-4102-813c-968ae4c63937", "node_type": "1", "metadata": {"window": "For the \nfull year, operating profit on an FX -adjusted basis decreased by 22%.  Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "original_text": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d42f828b27f09394f67e081e7908ae714ea438aa053473f2b0db835d7a8f7696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cde3b73-0d39-4fda-9da9-20528b5ca45e", "node_type": "1", "metadata": {"window": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "original_text": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n"}, "hash": "eaf95bcd3ec999f8c57aa96879407d2a57f01e5796bdd450752fad363c890aa2", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "start_char_idx": 3024, "end_char_idx": 3167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cde3b73-0d39-4fda-9da9-20528b5ca45e": {"__data__": {"id_": "4cde3b73-0d39-4fda-9da9-20528b5ca45e", "embedding": null, "metadata": {"window": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "original_text": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702eecf8-6dcf-4a18-9952-f19e3d033ce1", "node_type": "1", "metadata": {"window": "Fourth quarter and full year results reflect \nthe year -over-year effects and the completed divestitures within our European businesses.  \n \n And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "original_text": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d34aea372a385e9b26d7b2ae91ce18ecf070044d6b4ce7975b87624fa256a26a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c0b15cb-8f3d-41d8-9638-1bb400097188", "node_type": "1", "metadata": {"window": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. "}, "hash": "6a10b4b6a815eacceede62b2b6438a795c50c5f4022fbc2c7bdd517d3167d09a", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "start_char_idx": 3167, "end_char_idx": 3426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c0b15cb-8f3d-41d8-9638-1bb400097188": {"__data__": {"id_": "9c0b15cb-8f3d-41d8-9638-1bb400097188", "embedding": null, "metadata": {"window": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cde3b73-0d39-4fda-9da9-20528b5ca45e", "node_type": "1", "metadata": {"window": "And wrapping up our segment review, corporate expenses were $149 million in the quarter, a decrease of 19% \nyear-over-year.  For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "original_text": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27a45eb99c81dc6dca5946a0f4fe74a631d00216dce6de8aa868fcfc013cae82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f88ffc8d-3966-425d-bfcf-921bd7f630e0", "node_type": "1", "metadata": {"window": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n"}, "hash": "54171bea83f5548e96df20d0d760c5735a994d1d6058ecd4e1eb733fc9063553", "class_name": "RelatedNodeInfo"}}, "text": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "start_char_idx": 3426, "end_char_idx": 3588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f88ffc8d-3966-425d-bfcf-921bd7f630e0": {"__data__": {"id_": "f88ffc8d-3966-425d-bfcf-921bd7f630e0", "embedding": null, "metadata": {"window": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c0b15cb-8f3d-41d8-9638-1bb400097188", "node_type": "1", "metadata": {"window": "For the full year, corporate expenses were $457 million, a decrease of 21%, which included a pre -\ntax benefit of $126 million related to the early termination of the tax receivable agreement or TRA, with Change \nHealthcare in the third quarter.  \n \n Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8714bf624c2ceb4fc64bd84b4028dabf423cb25566c17dc771ce5fa8af4f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f403fae-976c-4721-9fd6-d5974ba630dd", "node_type": "1", "metadata": {"window": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n"}, "hash": "ec659102f98e7e66d03c4c52bce90437bc35bc7703e9189316ede9acf69dae89", "class_name": "RelatedNodeInfo"}}, "text": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "start_char_idx": 3588, "end_char_idx": 3701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f403fae-976c-4721-9fd6-d5974ba630dd": {"__data__": {"id_": "0f403fae-976c-4721-9fd6-d5974ba630dd", "embedding": null, "metadata": {"window": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f88ffc8d-3966-425d-bfcf-921bd7f630e0", "node_type": "1", "metadata": {"window": "Corporate expenses in the fourth quarter and full year were positively impacted by lower opioid -related expenses \ncompared to the prior year.  During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b717f8f951ac8f0b3ef59f91678eebba20a44e88f81bd6c992b573f85659e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb88f6db-13ac-451b-9baa-47a75c6808ed", "node_type": "1", "metadata": {"window": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. "}, "hash": "32a8b06cf7d9c1ff4b90a76cadfbb06233fd43c039c6fa7223efebf706084e2a", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "start_char_idx": 3701, "end_char_idx": 3930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb88f6db-13ac-451b-9baa-47a75c6808ed": {"__data__": {"id_": "bb88f6db-13ac-451b-9baa-47a75c6808ed", "embedding": null, "metadata": {"window": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f403fae-976c-4721-9fd6-d5974ba630dd", "node_type": "1", "metadata": {"window": "During the quarter, we had net losses of $12 million, or $0.06 per share, related to \nequity investments within the McKesson Ventures portfolio compared to net losses of approximately $6 billion, or \n$0.03 per share, in the fourth quarter of fiscal 2022.  \n \n For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea68c288f85444de5af625b852da942a868431decc728e865816fa14802e1924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd", "node_type": "1", "metadata": {"window": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "Excluding the benefi t from the early termination of the TRA and "}, "hash": "1bb289e53f0fa94986e5e1e9fbaca4940c95f50fd93160c543f35782535b32b3", "class_name": "RelatedNodeInfo"}}, "text": "The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "start_char_idx": 3930, "end_char_idx": 4195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd": {"__data__": {"id_": "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd", "embedding": null, "metadata": {"window": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "Excluding the benefi t from the early termination of the TRA and ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76cf59b21ae4fa0a4cb70517b03472a8b698803133f0f2c58b77340c03803e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb88f6db-13ac-451b-9baa-47a75c6808ed", "node_type": "1", "metadata": {"window": "For the f ull year, McKesson had net losses related to equity investments with our McKesson Ventures portfolio of \napproximately $36 million, or $0.19 per share.  This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "701f1dc8ef3c3ff652d858da5a73cf64eb94516cd0a6da7f586420042bc77310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "416b568b-61d5-429b-8616-2a10f39abff4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "original_text": "McKesson Corp.  "}, "hash": "5c1b5bf195459a684cfc3609c48ac5516a76d4f0da07291663829be840477910", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the benefi t from the early termination of the TRA and ", "start_char_idx": 4195, "end_char_idx": 4260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "416b568b-61d5-429b-8616-2a10f39abff4": {"__data__": {"id_": "416b568b-61d5-429b-8616-2a10f39abff4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd", "node_type": "1", "metadata": {"window": "This compares to net gains of approximately $98 million, or $0.47 \nper share, for the full year fiscal 202 2. \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies, and we're pleased with the insights and the results that we've obtained through this portfolio. \n The impacts on consolidat ed financials can be influenced by the performance of each individual investment \nquarter -to-quarter; and as a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  Excluding the benefi t from the early termination of the TRA and ", "original_text": "Excluding the benefi t from the early termination of the TRA and ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cbba0952af91c88139fa50358c6cf695018736d2c62959a6ea09e93e079cbda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "044fb551-27d3-4bd6-abed-d6b4fce0dd40", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n"}, "hash": "91c6f3c0e3ef383a09eaf2be74b115918f2e7b786622136d2b4d61989360a25e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "044fb551-27d3-4bd6-abed-d6b4fce0dd40": {"__data__": {"id_": "044fb551-27d3-4bd6-abed-d6b4fce0dd40", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "416b568b-61d5-429b-8616-2a10f39abff4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "928e92b6301d79b7c0391d6fce9855bbc924533c3304ad500c5e71fc8fea0322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f7e3747-680a-4cf1-a81b-c05fab7aa183", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "original_text": "Turning now to our cash position and capital deployment, w hich can be found on slide 13. "}, "hash": "35b70b291d960097f71736f46ed312ba69ce6984cbcdd426c02591f639ee9f96", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n", "start_char_idx": 16, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f7e3747-680a-4cf1-a81b-c05fab7aa183": {"__data__": {"id_": "5f7e3747-680a-4cf1-a81b-c05fab7aa183", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "original_text": "Turning now to our cash position and capital deployment, w hich can be found on slide 13. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "044fb551-27d3-4bd6-abed-d6b4fce0dd40", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff1cd7d5eb6a3549f40775846146a9e7c7ca692c2dd971196cdc35b449a37ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea26b8e9-dc4f-4ace-9df0-a94dd604340e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "original_text": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. "}, "hash": "1e53f7fee4ea241dcc26087147e7e007de0bff8b2ad428fcd7ee63c775e16691", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our cash position and capital deployment, w hich can be found on slide 13. ", "start_char_idx": 339, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea26b8e9-dc4f-4ace-9df0-a94dd604340e": {"__data__": {"id_": "ea26b8e9-dc4f-4ace-9df0-a94dd604340e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "original_text": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f7e3747-680a-4cf1-a81b-c05fab7aa183", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "original_text": "Turning now to our cash position and capital deployment, w hich can be found on slide 13. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "715107bdb1e81fcab34a83c1e32aa23640143a5b56b249e6300916cebf332521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d12a2a-6cec-447e-b8e8-1db96442a6d1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "original_text": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n"}, "hash": "f582c07e51d153d35e78975f4e3ca51b7245e54ec7a3d77fe0b82c97f5f904bb", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "start_char_idx": 429, "end_char_idx": 615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d12a2a-6cec-447e-b8e8-1db96442a6d1": {"__data__": {"id_": "c7d12a2a-6cec-447e-b8e8-1db96442a6d1", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "original_text": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea26b8e9-dc4f-4ace-9df0-a94dd604340e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "original_text": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5453a11e9e05d77d9907042a5fd56281a632e676fa168c440956ff33923236d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b787712-4d66-488a-b626-c47a66bc9f82", "node_type": "1", "metadata": {"window": "Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "original_text": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. "}, "hash": "0162617029e2af83f2e59e3fb08b93126ccc31520b1019e52af0f9a11226f0f6", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "start_char_idx": 615, "end_char_idx": 882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b787712-4d66-488a-b626-c47a66bc9f82": {"__data__": {"id_": "7b787712-4d66-488a-b626-c47a66bc9f82", "embedding": null, "metadata": {"window": "Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "original_text": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d12a2a-6cec-447e-b8e8-1db96442a6d1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "original_text": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84452b71394b254e6de57b19c3071bdae40abcd101e37d5c3d8afd3a434007bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d", "node_type": "1", "metadata": {"window": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "original_text": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. "}, "hash": "9cf1d8b0e0be3b159ed361e2720a4579b6e5c035c2d7eef2d2aedb3f055e5929", "class_name": "RelatedNodeInfo"}}, "text": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "start_char_idx": 882, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d": {"__data__": {"id_": "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d", "embedding": null, "metadata": {"window": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "original_text": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b787712-4d66-488a-b626-c47a66bc9f82", "node_type": "1", "metadata": {"window": "Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "original_text": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34511a6e1babd8325b48b350bb503d082490403011786fadd512eec21191fdd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "779547e4-1f3c-4a4a-9358-0ea09f5a9f07", "node_type": "1", "metadata": {"window": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "original_text": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n"}, "hash": "3d252b7f91eb03b5267062cca75fbcf5e115ccdd6463704afb67b7c802b095d0", "class_name": "RelatedNodeInfo"}}, "text": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "start_char_idx": 1029, "end_char_idx": 1139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "779547e4-1f3c-4a4a-9358-0ea09f5a9f07": {"__data__": {"id_": "779547e4-1f3c-4a4a-9358-0ea09f5a9f07", "embedding": null, "metadata": {"window": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "original_text": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d", "node_type": "1", "metadata": {"window": "For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment.  For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "original_text": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a1751814858b05a9a1996dda7caaf7d11be323cd2852f4ff67fd136ca6d7aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00240f1f-444c-4681-9334-631c17f9a6e9", "node_type": "1", "metadata": {"window": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "original_text": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. "}, "hash": "08428d78bcddf6797a0e50fe53f7902c95f5b5a314da5088e2661990b7e38761", "class_name": "RelatedNodeInfo"}}, "text": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "start_char_idx": 1139, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00240f1f-444c-4681-9334-631c17f9a6e9": {"__data__": {"id_": "00240f1f-444c-4681-9334-631c17f9a6e9", "embedding": null, "metadata": {"window": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "original_text": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "779547e4-1f3c-4a4a-9358-0ea09f5a9f07", "node_type": "1", "metadata": {"window": "For the full year, we generated $4.6 billi on in free cash flow, \nincluding $558 million of capital expenditures, which included investments to support our strategic pillars of \noncology and biopharma services, as well as investments in our distribution centers.  \n \n We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "original_text": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce33d83f25f15d41859597a10089e2990aa023f96bf5da26833055bc7445df9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "393e0ac3-3f3f-4b62-937f-28b38cc890b6", "node_type": "1", "metadata": {"window": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "original_text": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. "}, "hash": "0cee98236f9a009079aa314a8c062c04e270ef12fbc3829cf1e221319b3db309", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "start_char_idx": 1225, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "393e0ac3-3f3f-4b62-937f-28b38cc890b6": {"__data__": {"id_": "393e0ac3-3f3f-4b62-937f-28b38cc890b6", "embedding": null, "metadata": {"window": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "original_text": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00240f1f-444c-4681-9334-631c17f9a6e9", "node_type": "1", "metadata": {"window": "We used our strong balance sheet to r eturn $3.6 billion to shareholders through share repurchases, including \n$138 million in the fourth quarter.  During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "original_text": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adccaab30852a6fa3745517540d1eae7701fad82ae3db4f54fd0c050ca65d5e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "967fc5e3-99e7-4970-8edf-1b8d99808c76", "node_type": "1", "metadata": {"window": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "original_text": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n"}, "hash": "5cbd2c504c8498768efd488948130d71ba30d6f1f5fd4360ae7d2d85b87a95f3", "class_name": "RelatedNodeInfo"}}, "text": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "start_char_idx": 1371, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967fc5e3-99e7-4970-8edf-1b8d99808c76": {"__data__": {"id_": "967fc5e3-99e7-4970-8edf-1b8d99808c76", "embedding": null, "metadata": {"window": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "original_text": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "393e0ac3-3f3f-4b62-937f-28b38cc890b6", "node_type": "1", "metadata": {"window": "During quarter, we entered a new share repurchase program, which allows up \nto $1 billion of new repurchases.  I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "original_text": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b16b33d9ff8b9b6ee0684c913152543d5ba02e03e2f3a0d18c541ac0a565ef40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f2797f-b1dc-4330-87a8-94ab36e56d1a", "node_type": "1", "metadata": {"window": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "original_text": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. "}, "hash": "2451eb7941d3d09276fda2c0cc2484c2aca7ea7e28ae01e6442b29df20891bdf", "class_name": "RelatedNodeInfo"}}, "text": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "start_char_idx": 1507, "end_char_idx": 1603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8f2797f-b1dc-4330-87a8-94ab36e56d1a": {"__data__": {"id_": "f8f2797f-b1dc-4330-87a8-94ab36e56d1a", "embedding": null, "metadata": {"window": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "original_text": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "967fc5e3-99e7-4970-8edf-1b8d99808c76", "node_type": "1", "metadata": {"window": "I'll speak about our share repurchase g uidance for fiscal 2024 in a few minutes.  \n \n Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "original_text": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddccf0b7b3dcc1b83278fd1e0ae06ba2033194bcecf9355e5152382387bdc9da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61884e42-d0ea-478f-aa11-cdd67994d994", "node_type": "1", "metadata": {"window": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "original_text": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. "}, "hash": "c322583bf702bdfe7fd4141a3e30df33277197a1e962f9999e2a247dddb84077", "class_name": "RelatedNodeInfo"}}, "text": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "start_char_idx": 1603, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61884e42-d0ea-478f-aa11-cdd67994d994": {"__data__": {"id_": "61884e42-d0ea-478f-aa11-cdd67994d994", "embedding": null, "metadata": {"window": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "original_text": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8f2797f-b1dc-4330-87a8-94ab36e56d1a", "node_type": "1", "metadata": {"window": "Additionally, we paid dividends of $292 million for the full year, and we remain committed to growing the dividend \nin line with earnings growth.  When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "original_text": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "854543767213c29d04586ff465b47f2e33db53c2dfac36acd8fcc960bf685d42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5052f34-9e58-46b0-a55e-8b402ef991d9", "node_type": "1", "metadata": {"window": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "original_text": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n"}, "hash": "2b0e65654fb68c3e3ee25860688fd43aacfaa05752c06943981363c2ec25f5d8", "class_name": "RelatedNodeInfo"}}, "text": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "start_char_idx": 1732, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5052f34-9e58-46b0-a55e-8b402ef991d9": {"__data__": {"id_": "d5052f34-9e58-46b0-a55e-8b402ef991d9", "embedding": null, "metadata": {"window": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "original_text": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61884e42-d0ea-478f-aa11-cdd67994d994", "node_type": "1", "metadata": {"window": "When combining share repurchases with dividends paid, we returned ap proximately \n85% of free cash flow to shareholders in fiscal 2023.  We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "original_text": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a1d0e98c1ed4a485b09d3a907eeb53da7287bd2382c6a735e8753c10ada0e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c7e5a7-70f8-488c-92ae-2795f8775d60", "node_type": "1", "metadata": {"window": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "original_text": "Now, let me spend a few minutes discussing our outlook for fiscal 2024. "}, "hash": "25f60dbaea077dbfe92b2acda47afbb228ba9615a14d84e104401bb8ea85b589", "class_name": "RelatedNodeInfo"}}, "text": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "start_char_idx": 1882, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c7e5a7-70f8-488c-92ae-2795f8775d60": {"__data__": {"id_": "65c7e5a7-70f8-488c-92ae-2795f8775d60", "embedding": null, "metadata": {"window": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "original_text": "Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5052f34-9e58-46b0-a55e-8b402ef991d9", "node_type": "1", "metadata": {"window": "We continue to utilize capital deployment as a method to \ndrive value for our shareholders.  \n \n Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "original_text": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19a89d46bf1e546ad238a9fc45d416fbb93493a27dfc9496e7c4cff2ba9e5100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92117f62-79fd-44b1-ae12-3a271847f6bd", "node_type": "1", "metadata": {"window": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "original_text": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. "}, "hash": "108bffe8761f81b694924846bf875f6f9de9f2c50ab8ad24c39d72a011575386", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "start_char_idx": 2031, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92117f62-79fd-44b1-ae12-3a271847f6bd": {"__data__": {"id_": "92117f62-79fd-44b1-ae12-3a271847f6bd", "embedding": null, "metadata": {"window": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "original_text": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c7e5a7-70f8-488c-92ae-2795f8775d60", "node_type": "1", "metadata": {"window": "Since the beginning of fiscal 2019, we returned $12.9 billion of cash to shareholders through shar e repurchases \nand dividends.  Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "original_text": "Now, let me spend a few minutes discussing our outlook for fiscal 2024. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a8fff7dcea6ee8c5efbc7283c046389644255a3ecdad38726224e8c98ab5466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c", "node_type": "1", "metadata": {"window": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. "}, "hash": "471facce285ad07b1c498628887e992708b90c5b0d68ab64c73a607bfbcd4f02", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "start_char_idx": 2103, "end_char_idx": 2252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c": {"__data__": {"id_": "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c", "embedding": null, "metadata": {"window": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92117f62-79fd-44b1-ae12-3a271847f6bd", "node_type": "1", "metadata": {"window": "Of this amount, approximately $11.5 billion has been returned through share repurchases, \nreducing our total shares outstanding by approximately 33%.  Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "original_text": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dd557822aa8a0b65fd2dd9929e9bb3c086698b0ec4066d95b5b5ba1c3cacce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c983f10-f288-4368-8fa1-f89966c7aa98", "node_type": "1", "metadata": {"window": "Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "original_text": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n"}, "hash": "282653dd63ba3b7cca1c609c6ad1d51e4cb176f3a705b025ed4c0bbaf2918ae7", "class_name": "RelatedNodeInfo"}}, "text": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "start_char_idx": 2252, "end_char_idx": 2408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c983f10-f288-4368-8fa1-f89966c7aa98": {"__data__": {"id_": "7c983f10-f288-4368-8fa1-f89966c7aa98", "embedding": null, "metadata": {"window": "Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "original_text": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c", "node_type": "1", "metadata": {"window": "Our strong operating performance, combined with \nour return of capital to share holders, reinforces our commitment to driving shareholder value.  \n \n Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ed23bd61597f6932ed5835450416eac0adc4812509b030100b9a84f6a796ce0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c52326ab-d146-4097-a806-7948a66b47a1", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "original_text": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. "}, "hash": "abf5910e5ce50302781c0e9a5276f0699c301360c892225a9e40208baa104037", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "start_char_idx": 2408, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c52326ab-d146-4097-a806-7948a66b47a1": {"__data__": {"id_": "c52326ab-d146-4097-a806-7948a66b47a1", "embedding": null, "metadata": {"window": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "original_text": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c983f10-f288-4368-8fa1-f89966c7aa98", "node_type": "1", "metadata": {"window": "Now, let me spend a few minutes discussing our outlook for fiscal 2024.  As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "original_text": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63742eaaeb5130265d97540424c3b646f2494c3f5d268da7cee97d2e25d4d23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc6b678-47b1-410c-9c8f-aaafb1c58028", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "original_text": "These results have increased our confidence and our \noutlook. "}, "hash": "f59b4d1112ea9aa291c2fdb3d46d1aa8bba2a271e6153e13fda771fbfc45d16e", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "start_char_idx": 2521, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc6b678-47b1-410c-9c8f-aaafb1c58028": {"__data__": {"id_": "acc6b678-47b1-410c-9c8f-aaafb1c58028", "embedding": null, "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "original_text": "These results have increased our confidence and our \noutlook. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c52326ab-d146-4097-a806-7948a66b47a1", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide \nforward -looking guidance on a GAAP basis, so the following metrics are provided on an  adjusted non -GAAP \nbasis.  Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "original_text": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cf8bc1f855b8ec33c79507d0f278655be2093642747675957e86db70e5775f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aa29aba-baf8-4b13-be16-a56ee5913c43", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "original_text": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n"}, "hash": "85d4896c1ccd70acb3f0daf272765e77abba74792111d72302909b90c300961f", "class_name": "RelatedNodeInfo"}}, "text": "These results have increased our confidence and our \noutlook. ", "start_char_idx": 2696, "end_char_idx": 2758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aa29aba-baf8-4b13-be16-a56ee5913c43": {"__data__": {"id_": "6aa29aba-baf8-4b13-be16-a56ee5913c43", "embedding": null, "metadata": {"window": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "original_text": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc6b678-47b1-410c-9c8f-aaafb1c58028", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items beginning with additional \ndetails of fiscal 2024 consolidated guidance.  A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "original_text": "These results have increased our confidence and our \noutlook. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d6bcd1e885b0701981250a8e96f7c1a0f8f8844bbff6f1d2b0ac4b6eabbb5ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba", "node_type": "1", "metadata": {"window": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n"}, "hash": "e6265c4094f0bfdcc8d4ecc36b0288d62dbee182296f6b67f700d0f240b102ea", "class_name": "RelatedNodeInfo"}}, "text": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "start_char_idx": 2758, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba": {"__data__": {"id_": "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba", "embedding": null, "metadata": {"window": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aa29aba-baf8-4b13-be16-a56ee5913c43", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found in slides 14 through 19 in \nour supplemental slide presentation.  \n \n Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "original_text": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "066f3218a1e4c4bef9b6511f282188fffdf7eeb6c85bbe21766e29a59ad27511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599c6f49-6e07-43c4-bff2-15988d9dcca0", "node_type": "1", "metadata": {"window": "These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n"}, "hash": "c79ba8c58c128733d84a2522898d5ff4bd6008e7f16c6469c3f5c28e2761cba5", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "start_char_idx": 2960, "end_char_idx": 3222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599c6f49-6e07-43c4-bff2-15988d9dcca0": {"__data__": {"id_": "599c6f49-6e07-43c4-bff2-15988d9dcca0", "embedding": null, "metadata": {"window": "These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba", "node_type": "1", "metadata": {"window": "Fiscal 2023 was a strong year where we exceeded our full year operating profit, earnings per share and cash flow \nguidance that we laid out at the beginning of May last year.  These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8402461408f41c360a0f8c154062650df16bfe27b1b7176670bf5734bda142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f34c969b-8e40-42ca-87c0-28012ec18396", "node_type": "1", "metadata": {"window": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. "}, "hash": "791d65bdb83e0279c8b617697b85199d3ca8366c1cb966ea8145bf72b1e0477c", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "start_char_idx": 3222, "end_char_idx": 3540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f34c969b-8e40-42ca-87c0-28012ec18396": {"__data__": {"id_": "f34c969b-8e40-42ca-87c0-28012ec18396", "embedding": null, "metadata": {"window": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599c6f49-6e07-43c4-bff2-15988d9dcca0", "node_type": "1", "metadata": {"window": "These results have increased our confidence and our \noutlook.  Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "107860bc0dc5d0c044f6328e2f4ade2beb178601938268041b8b37da8f337b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0c620c-643c-49af-827c-6f49257066c1", "node_type": "1", "metadata": {"window": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n "}, "hash": "360aea91345a4626a39844afcc3e25e678d2d90ed963e54165da505e039a128b", "class_name": "RelatedNodeInfo"}}, "text": "Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "start_char_idx": 3540, "end_char_idx": 3635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0c620c-643c-49af-827c-6f49257066c1": {"__data__": {"id_": "5f0c620c-643c-49af-827c-6f49257066c1", "embedding": null, "metadata": {"window": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5c25936-2a88-4915-8f7c-297444d457b0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55a6201883d393ceca8c325d7413410bb4b589674bee410df0415f0e9c6eb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f34c969b-8e40-42ca-87c0-28012ec18396", "node_type": "1", "metadata": {"window": "Strategies that we've discussed today are delivering, and we expect that they will continue to deliver \nstrong levels of operating profit, earnings per share growth and robust cash flow generation.  \n \n We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook. ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6a65ffb37495d153c6a1a885f37123bd6ec9f1dc71114b6fd3c8bdc115ed5de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92f551f0-4a27-4b47-88ff-83551bcdaeec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments. ", "original_text": "McKesson Corp.  "}, "hash": "71b49ee8c8c651dd2b481131e60bc1240a4c6d27b15f2b48c93a5824d6b48d95", "class_name": "RelatedNodeInfo"}}, "text": "Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "start_char_idx": 3635, "end_char_idx": 3929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92f551f0-4a27-4b47-88ff-83551bcdaeec": {"__data__": {"id_": "92f551f0-4a27-4b47-88ff-83551bcdaeec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0c620c-643c-49af-827c-6f49257066c1", "node_type": "1", "metadata": {"window": "We anticipate earnings per diluted share of $ 26.10 to $26.90 for fiscal 2024, which contemplates operating profit \ngrowth across each of our core operating businesses, when excluding COVID -19-related items, supplemented by \ndisciplined capital deployment.  \n \n We anticipate earnings per diluted share to increase 11% to 14% in fiscal 2024 when excluding $1.90 related to \nCOVID -19-related items, $0.19 of net losses associated with McKesson Ventures equity investments, and $0.65 \nbenefit related to the early termination of the TRA with Change Healthcare in fis cal 2023.  \n \n Let me start by discussing our approach to COVID -19-related items in our fiscal 2024 outlook.  Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "original_text": "Since the onset of \nthe pandemic, McKesson has played a central role in providing support for the US government's distribution of \nCOVID -19 vaccines and the kitting, storage and distribution of ancillary supplies, as well as providing the \ndistribution of COVID -19 tests to our customers.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1658c794b7c2103324f32288732ada317c33eb57fda12cb4460c71e3d3887c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "415a3188-13a7-450b-af36-c0dfdb02ae9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results. "}, "hash": "d04b0a77d230f622f6a841ffd9e9b03324d84163c4535cfa57f3f5cb5e3b4ee2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "415a3188-13a7-450b-af36-c0dfdb02ae9e": {"__data__": {"id_": "415a3188-13a7-450b-af36-c0dfdb02ae9e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92f551f0-4a27-4b47-88ff-83551bcdaeec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98cf43c72c6187055b1823335a9046a1f0e2a5bf0e70f1789491f20dc2929c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790bdb3e-df9a-43a5-8a78-1b2683df513b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment. ", "original_text": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n"}, "hash": "c6014bc72fcd6cae4f39d36c89edea8415d32fa4c0b5bebe4efd3e33d06f58cb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results. ", "start_char_idx": 16, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790bdb3e-df9a-43a5-8a78-1b2683df513b": {"__data__": {"id_": "790bdb3e-df9a-43a5-8a78-1b2683df513b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment. ", "original_text": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "415a3188-13a7-450b-af36-c0dfdb02ae9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9523163c7fa53202077872d73bc6e418b27ee2985c2a41188529ff6979358c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "original_text": "Let m e discuss the outlook for our segments. "}, "hash": "6748de4b33e1dbc5acbdd954526c42df4bdb692199694aebcf6e1b9f609b80ad", "class_name": "RelatedNodeInfo"}}, "text": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n", "start_char_idx": 439, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14": {"__data__": {"id_": "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "original_text": "Let m e discuss the outlook for our segments. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790bdb3e-df9a-43a5-8a78-1b2683df513b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment. ", "original_text": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "204aca1ca6884673544926da59dfa52e45cc9b2093434a4d7b0c0a46099c5d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01dfebfa-c31c-4806-860f-c3b94b63ece2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform. ", "original_text": "We continue to be pleased with the growth we're seeing in the U.S. \n"}, "hash": "a604c4776ef819fdd20a73977f0cd96ad19f116b91335fea35e6112dfe914d59", "class_name": "RelatedNodeInfo"}}, "text": "Let m e discuss the outlook for our segments. ", "start_char_idx": 562, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01dfebfa-c31c-4806-860f-c3b94b63ece2": {"__data__": {"id_": "01dfebfa-c31c-4806-860f-c3b94b63ece2", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform. ", "original_text": "We continue to be pleased with the growth we're seeing in the U.S. \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "original_text": "Let m e discuss the outlook for our segments. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb54077ad66440647ceb76fd6197e9c9ad7b6e522b62bdc32819e2c67689bdfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c66b039-5b97-4638-8b3c-ce9a1915dab3", "node_type": "1", "metadata": {"window": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "original_text": "Pharmaceutical segment. "}, "hash": "3df88a84805d0309a767f36397ec26187ca85ddcb969f91bd25bb5333c34c52f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be pleased with the growth we're seeing in the U.S. \n", "start_char_idx": 608, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c66b039-5b97-4638-8b3c-ce9a1915dab3": {"__data__": {"id_": "1c66b039-5b97-4638-8b3c-ce9a1915dab3", "embedding": null, "metadata": {"window": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "original_text": "Pharmaceutical segment. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01dfebfa-c31c-4806-860f-c3b94b63ece2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform. ", "original_text": "We continue to be pleased with the growth we're seeing in the U.S. \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79f9354493e5468bcee2c0e18d081754a7fd4090affcf3a5609584095e329d7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26f842d5-61d7-4b3d-a5e1-60c2b149de37", "node_type": "1", "metadata": {"window": "Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "original_text": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n"}, "hash": "f642ce5daadb6fca2af899ca5f40035b09116b6d17155f11abb93b7f9c337695", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment. ", "start_char_idx": 676, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26f842d5-61d7-4b3d-a5e1-60c2b149de37": {"__data__": {"id_": "26f842d5-61d7-4b3d-a5e1-60c2b149de37", "embedding": null, "metadata": {"window": "Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "original_text": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c66b039-5b97-4638-8b3c-ce9a1915dab3", "node_type": "1", "metadata": {"window": "As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "original_text": "Pharmaceutical segment. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19fcb6f8b82d1c43b08747155aea1fe66d49cbff4d7d92f3d5367548b066a801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01abe337-acf0-44be-8e7e-1961bc501261", "node_type": "1", "metadata": {"window": "We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "original_text": "We also anticipate further growth in oncology platform. "}, "hash": "7f71a85c3f0f0a49d7d03ef6d426f6b9567907fc0e33d42d7543857f790bfc42", "class_name": "RelatedNodeInfo"}}, "text": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "start_char_idx": 700, "end_char_idx": 884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01abe337-acf0-44be-8e7e-1961bc501261": {"__data__": {"id_": "01abe337-acf0-44be-8e7e-1961bc501261", "embedding": null, "metadata": {"window": "We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "original_text": "We also anticipate further growth in oncology platform. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26f842d5-61d7-4b3d-a5e1-60c2b149de37", "node_type": "1", "metadata": {"window": "Let m e discuss the outlook for our segments.  We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "original_text": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c3a8b9a8b6eb606e3eff5f2c41f5610802925affac5ddc7c1ac27326a52ec44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "559bbad6-295f-466a-8db3-711fb864ac03", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "original_text": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. "}, "hash": "a2213841b9c3b3abe8b5e3b14797465133c7dbe95e7c2aa9e568b1ade72a2247", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate further growth in oncology platform. ", "start_char_idx": 884, "end_char_idx": 940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "559bbad6-295f-466a-8db3-711fb864ac03": {"__data__": {"id_": "559bbad6-295f-466a-8db3-711fb864ac03", "embedding": null, "metadata": {"window": "Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "original_text": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01abe337-acf0-44be-8e7e-1961bc501261", "node_type": "1", "metadata": {"window": "We continue to be pleased with the growth we're seeing in the U.S. \n Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "original_text": "We also anticipate further growth in oncology platform. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "572022409803e50ca76f0b0f1343ae42c0ada1adce11423498cd841971ae95a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c26f760c-f46d-4ce8-85d0-08972a3cb796", "node_type": "1", "metadata": {"window": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "original_text": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n"}, "hash": "39dffd97433804306572a08e532715d50077da452eadab62d5c75b4504ac3ca3", "class_name": "RelatedNodeInfo"}}, "text": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "start_char_idx": 940, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c26f760c-f46d-4ce8-85d0-08972a3cb796": {"__data__": {"id_": "c26f760c-f46d-4ce8-85d0-08972a3cb796", "embedding": null, "metadata": {"window": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "original_text": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "559bbad6-295f-466a-8db3-711fb864ac03", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "original_text": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47fbc6440447fd5e761b554217617fd5199c728882eff7c37d085f654a1592ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbf92855-9042-4152-8eca-07bc9328b14a", "node_type": "1", "metadata": {"window": "We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "original_text": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. "}, "hash": "4b00a6e97520557a1d0ebb72aeb64f0d8517986c07e7677734cb6c68415be13e", "class_name": "RelatedNodeInfo"}}, "text": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "start_char_idx": 1196, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbf92855-9042-4152-8eca-07bc9328b14a": {"__data__": {"id_": "cbf92855-9042-4152-8eca-07bc9328b14a", "embedding": null, "metadata": {"window": "We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "original_text": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c26f760c-f46d-4ce8-85d0-08972a3cb796", "node_type": "1", "metadata": {"window": "The value proposition of our core distribution platform resonates across retail, health \nsystems and provider settings, and we  anticipate growth across several customer channels.  \n \n We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "original_text": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "143ec8c38636ae2af2fcb1492435b85f77e5308153ba05526e138b2da788d2fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6a1db03-433d-4a1c-a836-417a0d141303", "node_type": "1", "metadata": {"window": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S. ", "original_text": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n"}, "hash": "641010f4d78e77e0b6528c94877c8144759319f01159a693da86663b11212f10", "class_name": "RelatedNodeInfo"}}, "text": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "start_char_idx": 1286, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a1db03-433d-4a1c-a836-417a0d141303": {"__data__": {"id_": "c6a1db03-433d-4a1c-a836-417a0d141303", "embedding": null, "metadata": {"window": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S. ", "original_text": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbf92855-9042-4152-8eca-07bc9328b14a", "node_type": "1", "metadata": {"window": "We also anticipate further growth in oncology platform.  US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "original_text": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b03bc9e1f9a47d4f0b2e3189a63d8f799c1f784b4bc005378f07d3101ce589d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08a19543-a8db-4b93-90e9-6ea05281c89f", "node_type": "1", "metadata": {"window": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "original_text": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. "}, "hash": "71ffb3e98ab0f29adf6f21abdff7c35a5d385e7bc8f6c5619cef76e1a6cbf0c8", "class_name": "RelatedNodeInfo"}}, "text": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "start_char_idx": 1370, "end_char_idx": 1535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08a19543-a8db-4b93-90e9-6ea05281c89f": {"__data__": {"id_": "08a19543-a8db-4b93-90e9-6ea05281c89f", "embedding": null, "metadata": {"window": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "original_text": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6a1db03-433d-4a1c-a836-417a0d141303", "node_type": "1", "metadata": {"window": "US Oncology Network (sic) [The US Oncology Network], \nthe largest oncology practice management organization in the US, has continued to expand its footprint into local \ncommunities to increase the availability of advanced care and better patient outcomes.  We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S. ", "original_text": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a3c6c8679ca3a59068c56f6721585586bf5ff9be0bc41e80f2197df27165157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d19147d-638d-4ac4-9c84-d41de07d8979", "node_type": "1", "metadata": {"window": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "original_text": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n"}, "hash": "a66054d4cea3060ec08b380a303ef9bbd9ceb0a26220e4b4214a90a6265058b0", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "start_char_idx": 1535, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d19147d-638d-4ac4-9c84-d41de07d8979": {"__data__": {"id_": "3d19147d-638d-4ac4-9c84-d41de07d8979", "embedding": null, "metadata": {"window": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "original_text": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08a19543-a8db-4b93-90e9-6ea05281c89f", "node_type": "1", "metadata": {"window": "We continue to grow the \nprovider footprint with over 2,300 providers in the network.  \n \n We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "original_text": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "017a3a1fb99a7026e210595298b8d4628ecd119ff1e8232b2fa0814920be04f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24239bbe-7e3c-4802-b0a9-a50d879f9c61", "node_type": "1", "metadata": {"window": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "original_text": "Wrapping up the U.S. "}, "hash": "7cf3934cda5519476b3db92485e18b522e18a911d4c0ce9dded55ee02f38c39a", "class_name": "RelatedNodeInfo"}}, "text": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "start_char_idx": 1784, "end_char_idx": 1948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24239bbe-7e3c-4802-b0a9-a50d879f9c61": {"__data__": {"id_": "24239bbe-7e3c-4802-b0a9-a50d879f9c61", "embedding": null, "metadata": {"window": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "original_text": "Wrapping up the U.S. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d19147d-638d-4ac4-9c84-d41de07d8979", "node_type": "1", "metadata": {"window": "We formed a joint venture with the Sarah Cannon Research Insti tute in fiscal 2023.  This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "original_text": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbff41b4fc58d8b7040522accf12399599a703f9f27db0183171873af38869af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "198403cb-266e-421b-b548-54139c57676c", "node_type": "1", "metadata": {"window": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "original_text": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. "}, "hash": "859a46cdafb9f64f0483c76a4d896b3647da78146c504dd6d7feb46f6eddcd9c", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up the U.S. ", "start_char_idx": 1948, "end_char_idx": 1969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "198403cb-266e-421b-b548-54139c57676c": {"__data__": {"id_": "198403cb-266e-421b-b548-54139c57676c", "embedding": null, "metadata": {"window": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "original_text": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24239bbe-7e3c-4802-b0a9-a50d879f9c61", "node_type": "1", "metadata": {"window": "This partnership enhances \nour proposition to biopharma companies and further advances our differentiated offerings across the entire \npharmaceutical lifecycle.  \n \n Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "original_text": "Wrapping up the U.S. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b99ebe06f5d1fd1285320affac758db34f989e77560613fe7ee5c0fad23f395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9859b5bd-c140-4436-9624-70ec66b55261", "node_type": "1", "metadata": {"window": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "original_text": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n"}, "hash": "0541deec8eaef94a6178510dd468474e14102dc5a5bb655c0590b99cf1464d3b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "start_char_idx": 1969, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9859b5bd-c140-4436-9624-70ec66b55261": {"__data__": {"id_": "9859b5bd-c140-4436-9624-70ec66b55261", "embedding": null, "metadata": {"window": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "original_text": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "198403cb-266e-421b-b548-54139c57676c", "node_type": "1", "metadata": {"window": "Additionally, in fiscal 2024, we anticipate branded pharmaceutical price in creases to be in line with the increases \nexperienced in fiscal 2022, and do not anticipate the higher price increases that we saw in fiscal 2023 to repeat in \nfiscal 2024.  Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "original_text": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0c9533094ed390c5faac45ba5a024123df6b6eb4a8c9dde6384a9f2c4b01019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29c38176-50dd-4d33-92f6-06c3e323dcf1", "node_type": "1", "metadata": {"window": "Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n"}, "hash": "cfbeef3f8d4b1500cf56f7e9cee8fc62de0b6afa3ec16549fd24b311e52286f1", "class_name": "RelatedNodeInfo"}}, "text": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "start_char_idx": 2131, "end_char_idx": 2268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29c38176-50dd-4d33-92f6-06c3e323dcf1": {"__data__": {"id_": "29c38176-50dd-4d33-92f6-06c3e323dcf1", "embedding": null, "metadata": {"window": "Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9859b5bd-c140-4436-9624-70ec66b55261", "node_type": "1", "metadata": {"window": "Within our generics business, the fundamentals remain competitive yet stable, with ou r strong \nsourcing program continuing to provide value for our customers.  \n \n Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "original_text": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dabb607b22bd6a0d7f0e27b75b5219ab19d2818585d287cd89e6fd7ebc95e2fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "260a2a4d-0482-4955-b369-18c907223048", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "original_text": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. "}, "hash": "a04cdc0b26b412ea8abc547965cbb83a5946e97cb7c56625ab58e240d00dc82a", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "start_char_idx": 2268, "end_char_idx": 2537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "260a2a4d-0482-4955-b369-18c907223048": {"__data__": {"id_": "260a2a4d-0482-4955-b369-18c907223048", "embedding": null, "metadata": {"window": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "original_text": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29c38176-50dd-4d33-92f6-06c3e323dcf1", "node_type": "1", "metadata": {"window": "Wrapping up the U.S.  Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a48a3f7bab22f8bed5bb7e2aefb24f78ebc6a6cf1dbb4b8c42cf93df9bc1306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0757958a-8072-41f2-a200-33320e595ccb", "node_type": "1", "metadata": {"window": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "original_text": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. "}, "hash": "a9bb8b17b0e94f5784a98ed75c626e654f4c85f716b896d97d77d0e62924d2e8", "class_name": "RelatedNodeInfo"}}, "text": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "start_char_idx": 2537, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0757958a-8072-41f2-a200-33320e595ccb": {"__data__": {"id_": "0757958a-8072-41f2-a200-33320e595ccb", "embedding": null, "metadata": {"window": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "original_text": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "260a2a4d-0482-4955-b369-18c907223048", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, for fiscal 2024, we anticipate revenue to increase 9% to 11% and \noperating profit to be approximately flat to 3% growth year -over-year.  W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "original_text": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "408d3d10e2c3c287a8625f1be2543e14fbf33adae12b5694c01ebe957165e692", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "756caf27-8a3b-4965-851e-c7974081aa46", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "original_text": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n"}, "hash": "758a5441fa35adc604af2b036a1d600f7e6a882f4fd445dbe13f179f23dd864d", "class_name": "RelatedNodeInfo"}}, "text": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "start_char_idx": 2818, "end_char_idx": 2911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "756caf27-8a3b-4965-851e-c7974081aa46": {"__data__": {"id_": "756caf27-8a3b-4965-851e-c7974081aa46", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "original_text": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0757958a-8072-41f2-a200-33320e595ccb", "node_type": "1", "metadata": {"window": "W hen excluding the impact of COVID -19 \nvaccine distribution from fiscal 2023, we anticipate operating profit to increase 5% to 8%.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "original_text": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78f1ad68fa55e1a3ac9c34cc3458e5b85b2512d50c02b2fd33001430a6cb6d32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0328e6d9-106f-4e95-a23d-470654d5f33b", "node_type": "1", "metadata": {"window": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "original_text": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. "}, "hash": "049fef00718d7af92d091a3c666fcd9b62a8b1cd8e535e81c143a2ad97ac7811", "class_name": "RelatedNodeInfo"}}, "text": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "start_char_idx": 2911, "end_char_idx": 3045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0328e6d9-106f-4e95-a23d-470654d5f33b": {"__data__": {"id_": "0328e6d9-106f-4e95-a23d-470654d5f33b", "embedding": null, "metadata": {"window": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "original_text": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "756caf27-8a3b-4965-851e-c7974081aa46", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13% and operating \nprofit growth of 11%  to 15%, reflecting continued organic growth and higher transaction volumes across our \naccess and affordability solutions and services.  \n \n Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "original_text": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a215be2150ec9a6f51b768ff53712cf0462a6f1d282c3c64f8b5edb4caf1a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85d270d0-9b87-4c94-98de-fd844609d0a5", "node_type": "1", "metadata": {"window": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "original_text": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n"}, "hash": "f5d105db9acc4dc3d459f2817869c4dbb09bfeb91a181bfb97e11a0bf51cb966", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "start_char_idx": 3045, "end_char_idx": 3223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85d270d0-9b87-4c94-98de-fd844609d0a5": {"__data__": {"id_": "85d270d0-9b87-4c94-98de-fd844609d0a5", "embedding": null, "metadata": {"window": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "original_text": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0328e6d9-106f-4e95-a23d-470654d5f33b", "node_type": "1", "metadata": {"window": "Within the Prescription Technology Solutions segment, our 3PL services typically represent slightly more than half \nof full year revenues, [indiscernible] (00:34:09) services represented less than 10% of full year operating profit on \naverage over the previous three fiscal years.  As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "original_text": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bafa33b8eb72c43fa25331d920530fff272ef83d547938b930cebdf4cdf73bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db5a4442-5fdd-4d10-8635-bb58d4da98f6", "node_type": "1", "metadata": {"window": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. "}, "hash": "eee7386acad6932107274282b81321fb320b8ff178660ab01cf0ced350105c5d", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "start_char_idx": 3223, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db5a4442-5fdd-4d10-8635-bb58d4da98f6": {"__data__": {"id_": "db5a4442-5fdd-4d10-8635-bb58d4da98f6", "embedding": null, "metadata": {"window": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85d270d0-9b87-4c94-98de-fd844609d0a5", "node_type": "1", "metadata": {"window": "As I've stated previously, the mix of revenue in this segment can \nvary quarter -to-quarter.  Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "original_text": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "344693c92e6ccb35645c7c5b0dd9e00f0e76f03a3110c3c8bd88d724bba2fc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "755b61f6-b2cf-489c-b8e7-b59b213c6fa1", "node_type": "1", "metadata": {"window": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n"}, "hash": "f0d0f4710b62f46255cc11ef322bbefb40452e1e454c3e252d71ceb98d707b4e", "class_name": "RelatedNodeInfo"}}, "text": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "start_char_idx": 3382, "end_char_idx": 3521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "755b61f6-b2cf-489c-b8e7-b59b213c6fa1": {"__data__": {"id_": "755b61f6-b2cf-489c-b8e7-b59b213c6fa1", "embedding": null, "metadata": {"window": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db5a4442-5fdd-4d10-8635-bb58d4da98f6", "node_type": "1", "metadata": {"window": "Howev er, over the balance of a full year, we anticipate full year product mix in fiscal 2024 \nto be consistent with prior years.  \n \n In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfbe57476b6c7125be8a5028395addffab29b6a1d62e239c37d6ad249a115821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fea1b57f-c7bf-486a-b9f4-04be3c18004b", "node_type": "1", "metadata": {"window": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. "}, "hash": "8788de4b8276e39b1889a32e0dd168ea27a7957ec448a4a68bf0b12910b9ee55", "class_name": "RelatedNodeInfo"}}, "text": "The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "start_char_idx": 3521, "end_char_idx": 3820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fea1b57f-c7bf-486a-b9f4-04be3c18004b": {"__data__": {"id_": "fea1b57f-c7bf-486a-b9f4-04be3c18004b", "embedding": null, "metadata": {"window": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "755b61f6-b2cf-489c-b8e7-b59b213c6fa1", "node_type": "1", "metadata": {"window": "In fiscal 2023, we also acquired Rx Savings Solutions, which helps employers and health plans reduce \nprescription drug costs, by uti lizing its advanced analytics capabilities.  We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c515f10a3f28d94af804fcaef4c08b06241f16d64bacbb2bb51c2f92431dfb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9129f271-8da6-4259-a51e-247efeec32bb", "node_type": "1", "metadata": {"window": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The Medical -Surgical business remains well -positioned "}, "hash": "f6a675394d04e0c8d044009aab0e1f6ef638841e6fc5e17e68aab27a1c171e4e", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "start_char_idx": 3820, "end_char_idx": 3989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9129f271-8da6-4259-a51e-247efeec32bb": {"__data__": {"id_": "9129f271-8da6-4259-a51e-247efeec32bb", "embedding": null, "metadata": {"window": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The Medical -Surgical business remains well -positioned ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "994e5fa8-eb2b-488b-804e-b30505caf461", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950461e65e5ee906cc0db7b8d2024e93e051b1d1f816715bc967e0686d31e744", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fea1b57f-c7bf-486a-b9f4-04be3c18004b", "node_type": "1", "metadata": {"window": "We're pleased with this acquisition's \nprogress, and will continue its integration during fiscal 2024 as we begin to realize the value from the synergies.  \n \n This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%. ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "231e0e837a6ad67f4ea0125b08edff22374380aa312286e1d712768c60772e99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da7d4778-0086-4262-8fe2-88ddbbe88256", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "original_text": "McKesson Corp.  "}, "hash": "930094a426c5b5cd0b45b9d3848aa795941e471b80e1be5a18285261db833701", "class_name": "RelatedNodeInfo"}}, "text": "The Medical -Surgical business remains well -positioned ", "start_char_idx": 3989, "end_char_idx": 4045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da7d4778-0086-4262-8fe2-88ddbbe88256": {"__data__": {"id_": "da7d4778-0086-4262-8fe2-88ddbbe88256", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9129f271-8da6-4259-a51e-247efeec32bb", "node_type": "1", "metadata": {"window": "This segment continues to perform well with higher revenu e and margin opportunities that leverage our scale and \ntechnology capabilities.  The strong growth profile, over the last few years, reflects our ongoing strategic \ninvestments to grow and expand our suite of products and solutions to provide next generation  patient access, \naffordability and adherence solutions that are automated and integrated in the provider workflows.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to be approximately a 1% decline to \n3% growth, and operating pro fit to decrease 5% to 11%.  The Medical -Surgical business remains well -positioned ", "original_text": "The Medical -Surgical business remains well -positioned ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3300db1e0b81b2123e9d811873a6e78fbd514a1361de724fe284b8df5ad4f7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4699b10f-b75c-4022-b270-069300a28ce5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions. "}, "hash": "240cbd8e1df68123b6235b7732ffc367e98ae0862fe9c32321ec17a8a7aa79a7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4699b10f-b75c-4022-b270-069300a28ce5": {"__data__": {"id_": "4699b10f-b75c-4022-b270-069300a28ce5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da7d4778-0086-4262-8fe2-88ddbbe88256", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dd84680f177ee9589d40f8adb750fdaba263ad54b7c36d57eabffd99dbee7eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e32e259-f695-4d18-bbcc-6e3efe6347f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "original_text": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n"}, "hash": "2e3da06bd89a973ba24e83144ed31915b7738a370f8082116cef0efb893224da", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions. ", "start_char_idx": 16, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e32e259-f695-4d18-bbcc-6e3efe6347f7": {"__data__": {"id_": "5e32e259-f695-4d18-bbcc-6e3efe6347f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "original_text": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4699b10f-b75c-4022-b270-069300a28ce5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a7f4161cf916c6a0d457370d9d5363c50480c52753b42f1f3677020d63a61fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c15e358-fcb7-4fbc-8083-9480c7cb63b0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "original_text": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. "}, "hash": "38ca33817eafe76e118c9a3736bd565d4fde415dc83f5217ac083f7f92b7ccc2", "class_name": "RelatedNodeInfo"}}, "text": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n", "start_char_idx": 335, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c15e358-fcb7-4fbc-8083-9480c7cb63b0": {"__data__": {"id_": "1c15e358-fcb7-4fbc-8083-9480c7cb63b0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "original_text": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e32e259-f695-4d18-bbcc-6e3efe6347f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "original_text": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6eda0665906ac62772f36bdf6855156ca28ab71be4ff40c308c80d729e7e7ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a755ed57-e4dc-4866-a803-ae2f37375342", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "original_text": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n"}, "hash": "a503825641aa80f9229401270b28f2aa0124bde851932537b0b62557bd9ae74a", "class_name": "RelatedNodeInfo"}}, "text": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "start_char_idx": 557, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a755ed57-e4dc-4866-a803-ae2f37375342": {"__data__": {"id_": "a755ed57-e4dc-4866-a803-ae2f37375342", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "original_text": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c15e358-fcb7-4fbc-8083-9480c7cb63b0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "original_text": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afd9aa39dcb5de7597b39a0c6ccf0f8849d160636552c54b994d8fc67ec913d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "346b9384-789c-40c0-94b3-bff05bd61afd", "node_type": "1", "metadata": {"window": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. "}, "hash": "a387db3b8d45d656f41894b8d2fd648131b6f1bd1f57cc3914abc356d4c67128", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "start_char_idx": 758, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "346b9384-789c-40c0-94b3-bff05bd61afd": {"__data__": {"id_": "346b9384-789c-40c0-94b3-bff05bd61afd", "embedding": null, "metadata": {"window": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a755ed57-e4dc-4866-a803-ae2f37375342", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "original_text": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1af99665bf7e93e53311553b128b4fc47c1a16dd3168c66a13e666e75fbb5daf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c23383f9-fde4-48e5-a096-c2558b09deef", "node_type": "1", "metadata": {"window": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. "}, "hash": "fb0c870c530e7cb49eafe099e23ff932951637efc0126202832773c4d0bf961b", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "start_char_idx": 915, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c23383f9-fde4-48e5-a096-c2558b09deef": {"__data__": {"id_": "c23383f9-fde4-48e5-a096-c2558b09deef", "embedding": null, "metadata": {"window": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "346b9384-789c-40c0-94b3-bff05bd61afd", "node_type": "1", "metadata": {"window": "Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "befc15ea578a2573f6b62c617551e5c954207e56a5d51b9f913768a71e765743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e8e8851-1325-4b97-8bd1-133daf38dae2", "node_type": "1", "metadata": {"window": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "original_text": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. "}, "hash": "836ef1a8f0aa30cfe93ed67fcb82e289bcb398de3c394587cd44a9ae737e5a3f", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "start_char_idx": 1051, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e8e8851-1325-4b97-8bd1-133daf38dae2": {"__data__": {"id_": "0e8e8851-1325-4b97-8bd1-133daf38dae2", "embedding": null, "metadata": {"window": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "original_text": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c23383f9-fde4-48e5-a096-c2558b09deef", "node_type": "1", "metadata": {"window": "And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results.  Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffc35a3431ab9244ac81fff1f6370b054f84aa56728f4360dff32c6137cd2ad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6492f1-17e6-4924-a9d9-a27f97e42f3f", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "original_text": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n"}, "hash": "65b0f87957a2cbce3061309c38da0998b4baf7899800748993381a361247ce90", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "start_char_idx": 1235, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6492f1-17e6-4924-a9d9-a27f97e42f3f": {"__data__": {"id_": "cf6492f1-17e6-4924-a9d9-a27f97e42f3f", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "original_text": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e8e8851-1325-4b97-8bd1-133daf38dae2", "node_type": "1", "metadata": {"window": "Excluding the impact of \nthese COVID -19-related items from fiscal 2023 results, we anticipate operating profit to incre ase 11% to 15% \nyear-over-year.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "original_text": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a997a8e1c1188d18a1a8e4d7ac130c25875987b92e1e5e9d2f0a517e97d64948", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d246e36e-8d86-4b99-881d-82444d917ee2", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "original_text": "Now, turning to cash flow and capital deployment. "}, "hash": "798a1fcd8ebc453b84a5c1d55af9451416ce7e092bc31af20103600787074ec5", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "start_char_idx": 1326, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d246e36e-8d86-4b99-881d-82444d917ee2": {"__data__": {"id_": "d246e36e-8d86-4b99-881d-82444d917ee2", "embedding": null, "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "original_text": "Now, turning to cash flow and capital deployment. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6492f1-17e6-4924-a9d9-a27f97e42f3f", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34%, and operating profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "original_text": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fefcb83964cc719aa7339062d72b223cc96392b96b58b6f62d564cc080c0e897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd2090e1-ca4f-4d70-a900-715397a32fde", "node_type": "1", "metadata": {"window": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "original_text": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. "}, "hash": "f7dbf439c84f6bfe03d652d7f848d22c7b012efea455d9f2693496a20a10ff0d", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to cash flow and capital deployment. ", "start_char_idx": 1506, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd2090e1-ca4f-4d70-a900-715397a32fde": {"__data__": {"id_": "fd2090e1-ca4f-4d70-a900-715397a32fde", "embedding": null, "metadata": {"window": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "original_text": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d246e36e-8d86-4b99-881d-82444d917ee2", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nbusine sses and transactions we've closed to -date and that we expect to close during fiscal 2024.  We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "original_text": "Now, turning to cash flow and capital deployment. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f99463be4753f9270a444fe5b3894dacc5a1ceecba2ceaff02618895b1dfd945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "433dd75f-febf-40f1-b0fe-fa27e386e1e2", "node_type": "1", "metadata": {"window": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities. ", "original_text": "We continue to be focused on profitable \ngrowth and efficient deployment of capital. "}, "hash": "64feac5b3001c14db633e243f6dd3b6028325eade4482dc3709712b8cb9c7341", "class_name": "RelatedNodeInfo"}}, "text": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "start_char_idx": 1556, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433dd75f-febf-40f1-b0fe-fa27e386e1e2": {"__data__": {"id_": "433dd75f-febf-40f1-b0fe-fa27e386e1e2", "embedding": null, "metadata": {"window": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities. ", "original_text": "We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd2090e1-ca4f-4d70-a900-715397a32fde", "node_type": "1", "metadata": {"window": "We continue to \nexplore strategic alternatives to exit our remaining operations in Norway.  And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "original_text": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c14bfe7200ebd416aa00028034a0b4edf526b81f5835ee4941ecd8eab300cdcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "752b4725-a5a8-4de5-bc76-8765348f3fcb", "node_type": "1", "metadata": {"window": "Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "original_text": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n"}, "hash": "7169d7c4a517e5a3fa9447be5049f9c96a442565ea2f1ad1a71f8b973b1dd561", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "start_char_idx": 1686, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "752b4725-a5a8-4de5-bc76-8765348f3fcb": {"__data__": {"id_": "752b4725-a5a8-4de5-bc76-8765348f3fcb", "embedding": null, "metadata": {"window": "Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "original_text": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433dd75f-febf-40f1-b0fe-fa27e386e1e2", "node_type": "1", "metadata": {"window": "And as I mentioned on our third quarter \nearnings call, we intend to deploy capital through share repurchases to offset any dilution resulting from the \nEuropean divestitures.  \n \n Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities. ", "original_text": "We continue to be focused on profitable \ngrowth and efficient deployment of capital. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0d29a8e967a395fbf6036d724d56b51e779c31ad743c6cb7a29a33020e144e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f86e4d-c969-413e-bf96-ce62ccb2ed7b", "node_type": "1", "metadata": {"window": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "original_text": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. "}, "hash": "1df035b0a2f6cb679b78883309d526787f177333213f3b89c0a140ff4f374d78", "class_name": "RelatedNodeInfo"}}, "text": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "start_char_idx": 1771, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f86e4d-c969-413e-bf96-ce62ccb2ed7b": {"__data__": {"id_": "50f86e4d-c969-413e-bf96-ce62ccb2ed7b", "embedding": null, "metadata": {"window": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "original_text": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "752b4725-a5a8-4de5-bc76-8765348f3fcb", "node_type": "1", "metadata": {"window": "Now, turning to cash flow and capital deployment.  Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "original_text": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dbe298d00b044416d86d7ed214685b3fdb1e06c5affcdf8af78cb60a59d0f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce85eb3c-30a7-4020-b2e6-dda88f73a611", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders. ", "original_text": "We \nwill continue to prioritize growth through organic opportunities. "}, "hash": "99066329fae875aedbc925ba6fa4cd11acb558ae9f2dfa9ee1dd05b0d125de54", "class_name": "RelatedNodeInfo"}}, "text": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "start_char_idx": 1864, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce85eb3c-30a7-4020-b2e6-dda88f73a611": {"__data__": {"id_": "ce85eb3c-30a7-4020-b2e6-dda88f73a611", "embedding": null, "metadata": {"window": "We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders. ", "original_text": "We \nwill continue to prioritize growth through organic opportunities. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f86e4d-c969-413e-bf96-ce62ccb2ed7b", "node_type": "1", "metadata": {"window": "Our North American businesses continue to generate strong \nfree cash flow and our capital allocation priorities remain unchanged.  We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "original_text": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b155e86ac55d6176413a9430641e2e84c2ed6f154879bcd394c009541804e254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95477e9d-f023-416d-8bac-edf0ec65db16", "node_type": "1", "metadata": {"window": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "original_text": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. "}, "hash": "fc7b61cbaf1108fc338a63d99cea3f5a4dbf1e871ded00af647b5beeb11f9072", "class_name": "RelatedNodeInfo"}}, "text": "We \nwill continue to prioritize growth through organic opportunities. ", "start_char_idx": 1981, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95477e9d-f023-416d-8bac-edf0ec65db16": {"__data__": {"id_": "95477e9d-f023-416d-8bac-edf0ec65db16", "embedding": null, "metadata": {"window": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "original_text": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce85eb3c-30a7-4020-b2e6-dda88f73a611", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable \ngrowth and efficient deployment of capital.  Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders. ", "original_text": "We \nwill continue to prioritize growth through organic opportunities. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9452cf29b5b6ed19ca6dc29e3a4b2a30a12a23e88405e4d7a2c555dcdef00b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea97f61-6383-4854-8814-95b4eaba3c29", "node_type": "1", "metadata": {"window": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "original_text": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n"}, "hash": "8ca52ef06cebf3ff4bfb602a69d9161b8d4147f0a6024408942643669970df2c", "class_name": "RelatedNodeInfo"}}, "text": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "start_char_idx": 2051, "end_char_idx": 2139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea97f61-6383-4854-8814-95b4eaba3c29": {"__data__": {"id_": "dea97f61-6383-4854-8814-95b4eaba3c29", "embedding": null, "metadata": {"window": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "original_text": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95477e9d-f023-416d-8bac-edf0ec65db16", "node_type": "1", "metadata": {"window": "Our 24% return on invested capital illustrates our focus on shareholder \nvalue creation.  \n \n Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "original_text": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c24f64cc87165c2151b142e7ac22e8d01d4c69bc3c7838ffda6f89b0ac04de57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95dc488a-afe7-4269-899d-494b76a0d980", "node_type": "1", "metadata": {"window": "We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "original_text": "We also remain committed to returning capital to our shareholders. "}, "hash": "28811dd76cb9cb19bbef305cf2fa6ca6b545d41dbeea6107b14eeaeec4fe3e04", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "start_char_idx": 2139, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95dc488a-afe7-4269-899d-494b76a0d980": {"__data__": {"id_": "95dc488a-afe7-4269-899d-494b76a0d980", "embedding": null, "metadata": {"window": "We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "original_text": "We also remain committed to returning capital to our shareholders. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea97f61-6383-4854-8814-95b4eaba3c29", "node_type": "1", "metadata": {"window": "Our strong balance sheet provides us the flexibility t o pursue multiple capital allocation priorities concurrently.  We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "original_text": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0dc917646ebfac16f6d04a7b5f134fe3460fb0f11b6d057d4008e01447bfb07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcb4dabb-9219-47bc-8b33-f0de55acf5db", "node_type": "1", "metadata": {"window": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "original_text": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. "}, "hash": "e69a94e8262c312b1504e7de5a571a06b454c9baf384ac2326eb396744d38f27", "class_name": "RelatedNodeInfo"}}, "text": "We also remain committed to returning capital to our shareholders. ", "start_char_idx": 2302, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcb4dabb-9219-47bc-8b33-f0de55acf5db": {"__data__": {"id_": "fcb4dabb-9219-47bc-8b33-f0de55acf5db", "embedding": null, "metadata": {"window": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "original_text": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95dc488a-afe7-4269-899d-494b76a0d980", "node_type": "1", "metadata": {"window": "We \nwill continue to prioritize growth through organic opportunities.  However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "original_text": "We also remain committed to returning capital to our shareholders. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79f98fec521cf692998a1d500292ea1b29f52de42fb98f47de131d4caf5c067a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7", "node_type": "1", "metadata": {"window": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework. ", "original_text": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n"}, "hash": "b38469f22495e7d1635ef8b20fd2f400cb14b8c608bb69cb300d2b4b69471b9e", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "start_char_idx": 2369, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7": {"__data__": {"id_": "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7", "embedding": null, "metadata": {"window": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework. ", "original_text": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcb4dabb-9219-47bc-8b33-f0de55acf5db", "node_type": "1", "metadata": {"window": "However, increasingly, through acquisitions and on \nstrategy and appropriate multiples.  For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "original_text": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "773545191c66f9d248fe99cb60ad6102c8c65f39ce9485d935c74360728484c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4da918c6-f822-45bc-9aae-51ba4e785e2b", "node_type": "1", "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "original_text": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. "}, "hash": "a08161c1455f8ec27d64f75788c249ee6c25773f9dbf84e66d3bce9ee76e9226", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "start_char_idx": 2468, "end_char_idx": 2656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4da918c6-f822-45bc-9aae-51ba4e785e2b": {"__data__": {"id_": "4da918c6-f822-45bc-9aae-51ba4e785e2b", "embedding": null, "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "original_text": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7", "node_type": "1", "metadata": {"window": "For fiscal 2024, we anticipate free ca sh flow of approximately $3.7 billion to \n$4.1 billion net of property, acquisitions and capitalized software expenses.  \n \n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework. ", "original_text": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f66dd2823bf8d58d07a2837aac07780c0b3bdd408ff16b35a0bb5cb70e9a180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "original_text": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. "}, "hash": "7c213745c8f3654bf62e59da0a9bf97866c6f12b4c104d5157cd59d47a55b401", "class_name": "RelatedNodeInfo"}}, "text": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "start_char_idx": 2656, "end_char_idx": 2743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8": {"__data__": {"id_": "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8", "embedding": null, "metadata": {"window": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "original_text": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4da918c6-f822-45bc-9aae-51ba4e785e2b", "node_type": "1", "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "original_text": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a65aa93fbd4b964173815fe7ca5498c8ef804fd2205b4ad9c395fcecdcaaf73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2a944f-daba-4432-9324-d782cbdc7025", "node_type": "1", "metadata": {"window": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "original_text": "The strong outlook further demonstrates our shareholder value creation \nframework. "}, "hash": "1f3720ad72ba2bcc8029d6476ebd25359b24509b57a33f09af3a425898167b5f", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "start_char_idx": 2743, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2a944f-daba-4432-9324-d782cbdc7025": {"__data__": {"id_": "5b2a944f-daba-4432-9324-d782cbdc7025", "embedding": null, "metadata": {"window": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "original_text": "The strong outlook further demonstrates our shareholder value creation \nframework. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase \napproximately $3.5 billion of shares in fiscal 2024.  As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "original_text": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c0da61eb182a7a2f242271c6ed43a1d44c667b9c7862d815fe3dfa06da8e428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8be28f5c-2919-4085-912b-39f3f3bae2a7", "node_type": "1", "metadata": {"window": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets. ", "original_text": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n"}, "hash": "0a81adbcfeb0e4ce49da0132a7708ee3ab20b451917917c28433604ac8cbda78", "class_name": "RelatedNodeInfo"}}, "text": "The strong outlook further demonstrates our shareholder value creation \nframework. ", "start_char_idx": 3024, "end_char_idx": 3107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8be28f5c-2919-4085-912b-39f3f3bae2a7": {"__data__": {"id_": "8be28f5c-2919-4085-912b-39f3f3bae2a7", "embedding": null, "metadata": {"window": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets. ", "original_text": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2a944f-daba-4432-9324-d782cbdc7025", "node_type": "1", "metadata": {"window": "As a result of the share repurchase activity, we estimate \nweighted average diluted shares outstanding for fiscal 2024 to be in the range of approximately 133 million to 134 \nmillion.  \n \n Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "original_text": "The strong outlook further demonstrates our shareholder value creation \nframework. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed4da098f399a3b230c39250d4ff958edb92a05954fc7401cd5c8e27ae033536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64bdfb51-7eda-4c64-8bc3-1ce594d5af22", "node_type": "1", "metadata": {"window": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "original_text": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. "}, "hash": "d426237dea2eb784208cb8629e11b12fcfcd67d95548ad09df8b6ddc7bd159fa", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "start_char_idx": 3107, "end_char_idx": 3195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64bdfb51-7eda-4c64-8bc3-1ce594d5af22": {"__data__": {"id_": "64bdfb51-7eda-4c64-8bc3-1ce594d5af22", "embedding": null, "metadata": {"window": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "original_text": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8be28f5c-2919-4085-912b-39f3f3bae2a7", "node_type": "1", "metadata": {"window": "Combining all these elements, we've sug gested earnings per share of $26.10 to $26.90.  Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets. ", "original_text": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d47eab13b8a1ef53fd5cfcd1cb9a62e05a231ead8454582b69e0dfa219379710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaa9db80-d6dd-400d-b3fa-b61667335ffe", "node_type": "1", "metadata": {"window": "The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S. ", "original_text": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. "}, "hash": "476f33a36ca516a9c49c833eaef3b0206910e56b81eb87b2d5e269afb2c643c7", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "start_char_idx": 3195, "end_char_idx": 3306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaa9db80-d6dd-400d-b3fa-b61667335ffe": {"__data__": {"id_": "aaa9db80-d6dd-400d-b3fa-b61667335ffe", "embedding": null, "metadata": {"window": "The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S. ", "original_text": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64bdfb51-7eda-4c64-8bc3-1ce594d5af22", "node_type": "1", "metadata": {"window": "Excluding the impact of \nCOVID -19-related items and the contribution from our remaining European operations in Norway, we anticipate \nearnings per diluted share growth of approximately 14% to 18%% in fiscal 2024  which is above the long -term \ntarget rate we previously provided.  The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "original_text": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83803e7e662b81d3c9cf4f92fcc080fade0b44fc03b629b33069fc6ca8ee6f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb3d78b-79c2-460c-8d60-6303948f4c7a", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "original_text": "As a result, we're pleased to be raising our long -term growth \ntargets. "}, "hash": "3cfe47ac55789bff436a3506bce7811998bb45e9e37f38ccff2e0292a229586e", "class_name": "RelatedNodeInfo"}}, "text": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "start_char_idx": 3306, "end_char_idx": 3591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb3d78b-79c2-460c-8d60-6303948f4c7a": {"__data__": {"id_": "dbb3d78b-79c2-460c-8d60-6303948f4c7a", "embedding": null, "metadata": {"window": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "original_text": "As a result, we're pleased to be raising our long -term growth \ntargets. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaa9db80-d6dd-400d-b3fa-b61667335ffe", "node_type": "1", "metadata": {"window": "The strong outlook further demonstrates our shareholder value creation \nframework.  We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S. ", "original_text": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66ae5f1ec4ac078f0ea32647a64f83813b2b35385a71f037902f0313fe0c506a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b838b745-9b31-4039-b4d7-5b516ccd6b13", "node_type": "1", "metadata": {"window": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "original_text": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n"}, "hash": "17fa36b90b690592dbed07f53312347aba2b118936a364697bffd91d5105a656", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we're pleased to be raising our long -term growth \ntargets. ", "start_char_idx": 3591, "end_char_idx": 3664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b838b745-9b31-4039-b4d7-5b516ccd6b13": {"__data__": {"id_": "b838b745-9b31-4039-b4d7-5b516ccd6b13", "embedding": null, "metadata": {"window": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "original_text": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb3d78b-79c2-460c-8d60-6303948f4c7a", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable growth and efficient deployment of capital.  \n \n Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "original_text": "As a result, we're pleased to be raising our long -term growth \ntargets. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0321c08b4c8cd2744b3a0d973c95a8fadf607a548fa587fa7a8831b4c439d64a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e26a07f6-0990-4858-9820-4e92118a14a5", "node_type": "1", "metadata": {"window": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "original_text": "For U.S. "}, "hash": "5388f779a0cddd85abf9efc67031c2aac86894efdcf880dbd001b06a3c2629c4", "class_name": "RelatedNodeInfo"}}, "text": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "start_char_idx": 3664, "end_char_idx": 3788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e26a07f6-0990-4858-9820-4e92118a14a5": {"__data__": {"id_": "e26a07f6-0990-4858-9820-4e92118a14a5", "embedding": null, "metadata": {"window": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "original_text": "For U.S. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b838b745-9b31-4039-b4d7-5b516ccd6b13", "node_type": "1", "metadata": {"window": "Turning now to our long -term adjusted segment operating profit growth targets which can be found on slide 19.  As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "original_text": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08b2a8cbbe7ead5650c97fba1e4905e41a6ddc6a79b2724386c32da6ccc19b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ee070b-7c63-4fca-96bb-4afbb99cd9f0", "node_type": "1", "metadata": {"window": "As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. "}, "hash": "fe84445135ec79f711514fdae7d7c3f1638c1a5988f9e8abbea3b263735a2f53", "class_name": "RelatedNodeInfo"}}, "text": "For U.S. ", "start_char_idx": 3788, "end_char_idx": 3797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ee070b-7c63-4fca-96bb-4afbb99cd9f0": {"__data__": {"id_": "38ee070b-7c63-4fca-96bb-4afbb99cd9f0", "embedding": null, "metadata": {"window": "As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e26a07f6-0990-4858-9820-4e92118a14a5", "node_type": "1", "metadata": {"window": "As \nCOVID -19-related contracts with US government are scheduled to end in July of 2023, and the contribution from \nEurope continues to run -off as guided, we remain committ ed to executing against our strategic initiatives and \nbuilding on our differentiated assets and capabilities.  As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "original_text": "For U.S. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2e59b3cb23ec2c771055a564e4d25d8580dff8823131f553306a7796cb9c180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbb34f94-f934-4ccf-ad0b-a314ab773b24", "node_type": "1", "metadata": {"window": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. "}, "hash": "c79827905ef9d5c63afc8e11e3a4b310332b35b699c3f5890dcd62cd0353373f", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "start_char_idx": 3797, "end_char_idx": 3876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbb34f94-f934-4ccf-ad0b-a314ab773b24": {"__data__": {"id_": "fbb34f94-f934-4ccf-ad0b-a314ab773b24", "embedding": null, "metadata": {"window": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ee070b-7c63-4fca-96bb-4afbb99cd9f0", "node_type": "1", "metadata": {"window": "As a result, we're pleased to be raising our long -term growth \ntargets.  It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eac445555c97c29a7f082bd2640816ea1784b23f27bb9aa161784f3fe09ffd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7067eefb-ddc5-44c9-a0fa-071052365ba8", "node_type": "1", "metadata": {"window": "For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. "}, "hash": "80c6f774e1e2c9b4a13f0aef797a608345b365b2e2edaea8b4494b3d1b8411a8", "class_name": "RelatedNodeInfo"}}, "text": "For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "start_char_idx": 3876, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7067eefb-ddc5-44c9-a0fa-071052365ba8": {"__data__": {"id_": "7067eefb-ddc5-44c9-a0fa-071052365ba8", "embedding": null, "metadata": {"window": "For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbb34f94-f934-4ccf-ad0b-a314ab773b24", "node_type": "1", "metadata": {"window": "It's a demonstration of the execution of our strategies, our leading market  positions, and strong financial \nposition.  \n \n For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1153ff58f6ca7ddb284ab164b2a86f9c21203b6a03b9c06589e70ad2ed460ad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed2e75d4-db62-41fb-a25a-7508ca08d60a", "node_type": "1", "metadata": {"window": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "With our strong underlying momentum and our aligned focus on the many "}, "hash": "05ca2a314e3a7309de89f3dd46f663d4aae2c6b247f36d095c258256e90d58f3", "class_name": "RelatedNodeInfo"}}, "text": "And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "start_char_idx": 3959, "end_char_idx": 4039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed2e75d4-db62-41fb-a25a-7508ca08d60a": {"__data__": {"id_": "ed2e75d4-db62-41fb-a25a-7508ca08d60a", "embedding": null, "metadata": {"window": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "With our strong underlying momentum and our aligned focus on the many ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7497161c-fadf-4981-a08d-334af63c9750", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2089315745c1c5b12ff8195d1804783c2694595780b182129a91d5322e2a5dc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7067eefb-ddc5-44c9-a0fa-071052365ba8", "node_type": "1", "metadata": {"window": "For U.S.  Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%. ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0a08b85b025b82399d9da89d980d68cac093e458adb59776f04e4ee5ee3a2f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d01d53c-0c5d-4d79-8312-30c8faad46d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "original_text": "McKesson Corp.  "}, "hash": "8b19f7f04e45597d4e5019cc22e5ed0bcbdf9632a3e9c53c0394fc65a6e3be75", "class_name": "RelatedNodeInfo"}}, "text": "With our strong underlying momentum and our aligned focus on the many ", "start_char_idx": 4039, "end_char_idx": 4109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d01d53c-0c5d-4d79-8312-30c8faad46d9": {"__data__": {"id_": "9d01d53c-0c5d-4d79-8312-30c8faad46d9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed2e75d4-db62-41fb-a25a-7508ca08d60a", "node_type": "1", "metadata": {"window": "Pharmaceutical, we anticipate 5% to 7% long -term growth, which is up from 4%.  For Prescription \nTechnology Solutions, 11% to 12% long -term growth, up from 11%.  And in Medical -Surgical Solutions, 10% to \n12% long -term growth, up from 10%.  With our strong underlying momentum and our aligned focus on the many ", "original_text": "With our strong underlying momentum and our aligned focus on the many ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab2a3eab7184ae877e05bcdf9577d32d5330bf3d25d76f185a4f01e59d1ef80e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03deac2f-2345-44d0-8051-98562c50ebcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n"}, "hash": "1c9f6958d050c4699ae97c95938b9f168bb305c8f28d03dd78963fba9d7f7cfd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03deac2f-2345-44d0-8051-98562c50ebcd": {"__data__": {"id_": "03deac2f-2345-44d0-8051-98562c50ebcd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d01d53c-0c5d-4d79-8312-30c8faad46d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00ab9d183c533f48e33c264fc3b1ab8bffad58274b289be4e2b82c4fc5357f6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b63b072-f58c-4c82-80a9-ad293690ad24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "original_text": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide. "}, "hash": "93bdc9c13bb558ab776446db795773cf1acfb52e1a504f7f84f9043494764036", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n", "start_char_idx": 16, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b63b072-f58c-4c82-80a9-ad293690ad24": {"__data__": {"id_": "2b63b072-f58c-4c82-80a9-ad293690ad24", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "original_text": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03deac2f-2345-44d0-8051-98562c50ebcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "433e94510dfb08d6837ab7496a58b07326e3177ee68fa41ddabc6186963d7cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b26ce2d9-c767-4d36-9fd1-a4239ff329e1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "original_text": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. "}, "hash": "542d90b82d1239099707138c0c2e05d7fbe5eae0cfc5b972224556794602e374", "class_name": "RelatedNodeInfo"}}, "text": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide. ", "start_char_idx": 382, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b26ce2d9-c767-4d36-9fd1-a4239ff329e1": {"__data__": {"id_": "b26ce2d9-c767-4d36-9fd1-a4239ff329e1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "original_text": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b63b072-f58c-4c82-80a9-ad293690ad24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "original_text": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "819cd7c5d1a1cca4b48898487a4f48ac29e61f09087350b46787d2decb6e3bb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ca53e5-c379-4295-a3ea-6873a5e91692", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n ", "original_text": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. "}, "hash": "d486bd94eed1a3e5efbe07c1024590be97bdaaa69c250d62d3f3fbaf1ee76ee0", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "start_char_idx": 499, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ca53e5-c379-4295-a3ea-6873a5e91692": {"__data__": {"id_": "10ca53e5-c379-4295-a3ea-6873a5e91692", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n ", "original_text": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b26ce2d9-c767-4d36-9fd1-a4239ff329e1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "original_text": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cfe3e4b8412c5f9a72b39eb306a156000802e2f1ce7d74e5565a856d6642fc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "236222f3-7587-4e7a-8d2d-60f368b19c60", "node_type": "1", "metadata": {"window": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "original_text": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. "}, "hash": "9b484c52dee45f8e95e428f2dd941179ac982a6ead09c94b235601e28d2703be", "class_name": "RelatedNodeInfo"}}, "text": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "start_char_idx": 627, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "236222f3-7587-4e7a-8d2d-60f368b19c60": {"__data__": {"id_": "236222f3-7587-4e7a-8d2d-60f368b19c60", "embedding": null, "metadata": {"window": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "original_text": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ca53e5-c379-4295-a3ea-6873a5e91692", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n ", "original_text": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec60ddaefd7a50a2d66a9c2d07e7ce5edf6201a6395db3d667798cf78cbd4536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45793a9c-f655-43c8-960b-3fe2c7614b5b", "node_type": "1", "metadata": {"window": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "original_text": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n"}, "hash": "934f134d3bfe32df019797b85af26ebc897b7d84d5fdeb698307903d89b459f8", "class_name": "RelatedNodeInfo"}}, "text": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "start_char_idx": 723, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45793a9c-f655-43c8-960b-3fe2c7614b5b": {"__data__": {"id_": "45793a9c-f655-43c8-960b-3fe2c7614b5b", "embedding": null, "metadata": {"window": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "original_text": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "236222f3-7587-4e7a-8d2d-60f368b19c60", "node_type": "1", "metadata": {"window": "In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "original_text": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77a114b66ad1999725414e5c5c10a900255b424600f00d8f3fd55ae8249d3202", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1458d380-febe-466e-bf19-54bbe43d3138", "node_type": "1", "metadata": {"window": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you. ", "original_text": "With that, let me now turn it back over to the operator for your questions.  \n "}, "hash": "9e1e539d0629a7f491bfcbbb3968e7f52747cf298c4b81ad7401b96f4a6f2945", "class_name": "RelatedNodeInfo"}}, "text": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "start_char_idx": 938, "end_char_idx": 1033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1458d380-febe-466e-bf19-54bbe43d3138": {"__data__": {"id_": "1458d380-febe-466e-bf19-54bbe43d3138", "embedding": null, "metadata": {"window": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you. ", "original_text": "With that, let me now turn it back over to the operator for your questions.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45793a9c-f655-43c8-960b-3fe2c7614b5b", "node_type": "1", "metadata": {"window": "We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform.  As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "original_text": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba7d4e659b5836572ac3808cc8470bf650b07e54f8ddfb2b35838596ca7d030b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa65cf3-49f9-4707-a68f-6dc98568c77a", "node_type": "1", "metadata": {"window": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n "}, "hash": "65e12fb78ad68071374e4b05bc294b08c79d31e64d7a4fb8859b67d0d3cb49ab", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me now turn it back over to the operator for your questions.  \n ", "start_char_idx": 1033, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa65cf3-49f9-4707-a68f-6dc98568c77a": {"__data__": {"id_": "6fa65cf3-49f9-4707-a68f-6dc98568c77a", "embedding": null, "metadata": {"window": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1458d380-febe-466e-bf19-54bbe43d3138", "node_type": "1", "metadata": {"window": "As fiscal 2023 demonstrated, our strategies are working, producing value for all \nstakeholders.  We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you. ", "original_text": "With that, let me now turn it back over to the operator for your questions.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49e3e908301d54761e0b579c0741b7f55df40a4a7a001fa347c7022efc489dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127", "node_type": "1", "metadata": {"window": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. "}, "hash": "94ed348cc0b71092fcaf29acb7ab9787cb7e77ee9d79c461cee7f84b9337bbae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "start_char_idx": 1112, "end_char_idx": 1512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127": {"__data__": {"id_": "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127", "embedding": null, "metadata": {"window": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa65cf3-49f9-4707-a68f-6dc98568c77a", "node_type": "1", "metadata": {"window": "We have tremendous momentum across the business, a strong financial outlook; and our financial \nframework and execution position us to  deliver sustainable profit growth, cash flows and shareholder value \ncreation.  We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c7d3b5cc0f70c2590abe47dd01c0b8accd17a3015299633f1a3649415a71c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65e68038-40ba-486a-ab85-e18b6d424330", "node_type": "1", "metadata": {"window": "With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you. "}, "hash": "c36bf1bea28d1af021d06bca24546c5f69557d158f121da341fb4e202fdf56fe", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "start_char_idx": 1512, "end_char_idx": 1848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65e68038-40ba-486a-ab85-e18b6d424330": {"__data__": {"id_": "65e68038-40ba-486a-ab85-e18b6d424330", "embedding": null, "metadata": {"window": "With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127", "node_type": "1", "metadata": {"window": "We have great confidence in our teams, and our products and services, and in our strategy.  \n \n With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9d80d77ef3e0d243513f2a13b8330cff7f650a96e3377206bb97f94403bdb93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "428d6dca-fecc-4774-b41f-c915386fc249", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. "}, "hash": "795157917e9999ea8f0e8423fc10c99ab47fa056209723755d03b9b5c57e2633", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 1848, "end_char_idx": 1859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "428d6dca-fecc-4774-b41f-c915386fc249": {"__data__": {"id_": "428d6dca-fecc-4774-b41f-c915386fc249", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65e68038-40ba-486a-ab85-e18b6d424330", "node_type": "1", "metadata": {"window": "With that, let me now turn it back over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0740f1c313a04721413786f6a7d0df183d66b3ce588c53ab5d16aeb2d654d8fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d996166-b393-4fa6-a88a-128ecf50d32a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "original_text": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n "}, "hash": "4c0fb01bcfff6d9c87b905fb6a8dfa708b2879fb6e7607b369217d9f5844971e", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "start_char_idx": 1859, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d996166-b393-4fa6-a88a-128ecf50d32a": {"__data__": {"id_": "4d996166-b393-4fa6-a88a-128ecf50d32a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "original_text": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "428d6dca-fecc-4774-b41f-c915386fc249", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTI ON AND ANSWER SECTION  \n  \nOperator : [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f53e7463ebbf180703f0299027fa2008033687ea6ba811453fe45108e023937f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8956faf7-3f97-4896-bfef-48c5fddd9251", "node_type": "1", "metadata": {"window": "Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "1b6b85d87d13d07209672eda21b198525182a24bfe8ceac8399d88e8228397f8", "class_name": "RelatedNodeInfo"}}, "text": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "start_char_idx": 2093, "end_char_idx": 2276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8956faf7-3f97-4896-bfef-48c5fddd9251": {"__data__": {"id_": "8956faf7-3f97-4896-bfef-48c5fddd9251", "embedding": null, "metadata": {"window": "Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d996166-b393-4fa6-a88a-128ecf50d32a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThanks for all of the detail.  Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "original_text": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "175178e6a7774e5623886f2509f2256b9aa5aad31c88c255f2a741e7521b307f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c", "node_type": "1", "metadata": {"window": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization. ", "original_text": "A \nThanks for the question, Eric. "}, "hash": "474a43df6fd21e22ea410fbec81425782b19d1e1405c5bbf5d77c713d422365d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2276, "end_char_idx": 2621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c": {"__data__": {"id_": "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c", "embedding": null, "metadata": {"window": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8956faf7-3f97-4896-bfef-48c5fddd9251", "node_type": "1", "metadata": {"window": "Thank you.  I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27c47794e11178944713ffb069f72ee5526e9d4a7fd082924f4cb10c08d4e69a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddf23c14-600e-4502-a026-997dd76c7e4a", "node_type": "1", "metadata": {"window": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "original_text": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. "}, "hash": "5614178f1ba232dd5335cd11a6db440f0f2c01f0e6eda978251118bcb35f8c62", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Eric. ", "start_char_idx": 2621, "end_char_idx": 2655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddf23c14-600e-4502-a026-997dd76c7e4a": {"__data__": {"id_": "ddf23c14-600e-4502-a026-997dd76c7e4a", "embedding": null, "metadata": {"window": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "original_text": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c", "node_type": "1", "metadata": {"window": "I'd like to dig into the increase in long-term profit growth targets and \nspecifically, pharma, and it's a massive absolute number at the high -end of the new range; and for 2024, that \nrange comes with needing to lap brand benefits.  So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12e053a4d917409fb04e41228b232f0beb2bbf619cf07d4c3492a9982a4ff176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "original_text": "I think there are a \nnumber of factors that are a part of that.  \n \n"}, "hash": "42d378dafa971771ab485bb47ffe98a85107d74dc3ab769b0d9d6f78adb9cfad", "class_name": "RelatedNodeInfo"}}, "text": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "start_char_idx": 2655, "end_char_idx": 2835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5": {"__data__": {"id_": "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "original_text": "I think there are a \nnumber of factors that are a part of that.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddf23c14-600e-4502-a026-997dd76c7e4a", "node_type": "1", "metadata": {"window": "So I'd love to hear what gets you to the high -end of the range , \nfactors within the year, and what drives the long -term guidance, macro trend versus strategy versus investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "original_text": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86137d61b6c608480fbf72a3776ef43a68fb78855fe5fda946126e661b99e2ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f9dded8-ac86-469d-95e2-ee924980b7c8", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n", "original_text": "First of all, we've seen strong uti lization. "}, "hash": "f7608f6025d5bec2f575d944bc563bedaded7ad2ecf2e1411f0615be006ef1d2", "class_name": "RelatedNodeInfo"}}, "text": "I think there are a \nnumber of factors that are a part of that.  \n \n", "start_char_idx": 2835, "end_char_idx": 2903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f9dded8-ac86-469d-95e2-ee924980b7c8": {"__data__": {"id_": "1f9dded8-ac86-469d-95e2-ee924980b7c8", "embedding": null, "metadata": {"window": "A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n", "original_text": "First of all, we've seen strong uti lization. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "original_text": "I think there are a \nnumber of factors that are a part of that.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a634ff4e0d03e6927148faf76a2c4cdef784dc616028cc151b11ae87cad8716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a598e007-9758-46ad-b460-975f34a01ba4", "node_type": "1", "metadata": {"window": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "original_text": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. "}, "hash": "d5d3c2a13ada4672159b2aa479c61ad48864da60bdf512fb5264e1b2cd71d1d2", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we've seen strong uti lization. ", "start_char_idx": 2903, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a598e007-9758-46ad-b460-975f34a01ba4": {"__data__": {"id_": "a598e007-9758-46ad-b460-975f34a01ba4", "embedding": null, "metadata": {"window": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "original_text": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f9dded8-ac86-469d-95e2-ee924980b7c8", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n", "original_text": "First of all, we've seen strong uti lization. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b069714e93482198049a765b3c4ed4269483f87e37921dabd3293180a6da713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d76302-a108-4c0b-917c-356ddf21e875", "node_type": "1", "metadata": {"window": "I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "original_text": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. "}, "hash": "8209e587f66dd00e9b710a982ddf008ad1b81c384bc5151500e30103717bc14a", "class_name": "RelatedNodeInfo"}}, "text": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "start_char_idx": 2949, "end_char_idx": 3098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d76302-a108-4c0b-917c-356ddf21e875": {"__data__": {"id_": "c6d76302-a108-4c0b-917c-356ddf21e875", "embedding": null, "metadata": {"window": "I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "original_text": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a598e007-9758-46ad-b460-975f34a01ba4", "node_type": "1", "metadata": {"window": "I think what \u2013 as we look at the business, we've already previously indicated that we \nthought we could grow the business faster than the originally indicated long -term guidance.  I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "original_text": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dc1caf81911a6e67ba5881c4684f60aedd7bc147d85af004dc3cfa4711d0cde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f", "node_type": "1", "metadata": {"window": "First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "You heard Brian and I both reference the number of providers that we've added. \n"}, "hash": "da05d74b8df0e8b856f21d1fe9491cfc7e93593848dcd2ad1d40dec874d9e406", "class_name": "RelatedNodeInfo"}}, "text": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "start_char_idx": 3098, "end_char_idx": 3284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f": {"__data__": {"id_": "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f", "embedding": null, "metadata": {"window": "First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "You heard Brian and I both reference the number of providers that we've added. \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6d76302-a108-4c0b-917c-356ddf21e875", "node_type": "1", "metadata": {"window": "I think there are a \nnumber of factors that are a part of that.  \n \n First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "original_text": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40541d6ac895f9dc997a40fba0c1f04d49f58821c500180d597c342c06a5b9a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a1be49-b0fc-4bc4-bc08-ea857cf8576d", "node_type": "1", "metadata": {"window": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. "}, "hash": "fc555822c3c84531ce01b42647dadcf9e233486317e520495b3b483ff7e10da3", "class_name": "RelatedNodeInfo"}}, "text": "You heard Brian and I both reference the number of providers that we've added. \n", "start_char_idx": 3284, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a1be49-b0fc-4bc4-bc08-ea857cf8576d": {"__data__": {"id_": "33a1be49-b0fc-4bc4-bc08-ea857cf8576d", "embedding": null, "metadata": {"window": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f", "node_type": "1", "metadata": {"window": "First of all, we've seen strong uti lization.  I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "You heard Brian and I both reference the number of providers that we've added. \n", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9705f5164c8eeaa2464839dce6136c0f1ceac5c4c3c4c4d3fa8b8d277239119f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d10026-b658-4fa0-8412-60a126799d1a", "node_type": "1", "metadata": {"window": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n "}, "hash": "703ae00bd6790121da29b1f820be66bf1bdd839df1bb46c5c06e171da8699642", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "start_char_idx": 3364, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d10026-b658-4fa0-8412-60a126799d1a": {"__data__": {"id_": "68d10026-b658-4fa0-8412-60a126799d1a", "embedding": null, "metadata": {"window": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a1be49-b0fc-4bc4-bc08-ea857cf8576d", "node_type": "1", "metadata": {"window": "I think that, as a baseline, we've seen that actually increase throughout \nthe year, and we expect that utilization will remain solid going forward.  We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations. ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2b045ee8f03618fcf40c84a110e9673915a136be9d1512dbcbac87f0627ae0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf00b7b6-49b9-4915-8d78-14fc526b9b7f", "node_type": "1", "metadata": {"window": "You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "d647caf1bf18d6b97792bd6ffceb935f785399b9c8ee158427fc023df8df424a", "class_name": "RelatedNodeInfo"}}, "text": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "start_char_idx": 3827, "end_char_idx": 3985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf00b7b6-49b9-4915-8d78-14fc526b9b7f": {"__data__": {"id_": "cf00b7b6-49b9-4915-8d78-14fc526b9b7f", "embedding": null, "metadata": {"window": "You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d10026-b658-4fa0-8412-60a126799d1a", "node_type": "1", "metadata": {"window": "We've built a lot of momentum across our \nhealth systems business, our retail pharmacy network, and  the value that we're providing there, and we've been \ngrowing our oncology platform.  You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b4d95d673bb09c347a3153ef81b7d52cbaab72602b48b455b14fbe9b362078c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca7b391d-8d1a-4319-be3e-9069e764c668", "node_type": "1", "metadata": {"window": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "A \nNext question, please.  \n "}, "hash": "eb04d274e90a6c5603c0e7e9e2e51e0ac472151ed5ab885230ce50ad523a1d90", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 3985, "end_char_idx": 4303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca7b391d-8d1a-4319-be3e-9069e764c668": {"__data__": {"id_": "ca7b391d-8d1a-4319-be3e-9069e764c668", "embedding": null, "metadata": {"window": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf00b7b6-49b9-4915-8d78-14fc526b9b7f", "node_type": "1", "metadata": {"window": "You heard Brian and I both reference the number of providers that we've added. \n Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a0a5dc8382eb6284d6d1de85cf5f6108e21a217273c7bf7a70d158b5888f7db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a05de6-a422-44e0-8782-5a479af92a3d", "node_type": "1", "metadata": {"window": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  "}, "hash": "7dbb47c0b358cea721253dccac82a785b77a71813c1beb432f39bee77e0c85aa", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 4303, "end_char_idx": 4332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a05de6-a422-44e0-8782-5a479af92a3d": {"__data__": {"id_": "d2a05de6-a422-44e0-8782-5a479af92a3d", "embedding": null, "metadata": {"window": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a9da58e948742f30131e7cfa03e2cf5ab16aa60e7d6b98b6f28b74850ade1b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca7b391d-8d1a-4319-be3e-9069e764c668", "node_type": "1", "metadata": {"window": "Certainly, if you think about the value that we provide not only as a distributor but GPO se rvices, and now the \nadded capabilities with Ontada and Sarah Cannon Research, and the opportunities going forward as it relates to \nbiosimilars, all of these things really point to the opportunities for us to grow faster in the future than the original \nlong-term target rate; and the business continues to generate good cash and efficiency through scaled \noperations.  So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bda4e279060f528d5dc973a7b2314dff233752c53845b69856c72a594ca6c823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide. ", "original_text": "McKesson Corp.  "}, "hash": "b0fd43f723df8ba8afff47a34e656367df7dc09d5f3e7651a267cc6f0406bf83", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "start_char_idx": 4332, "end_char_idx": 4661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c": {"__data__": {"id_": "1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a05de6-a422-44e0-8782-5a479af92a3d", "node_type": "1", "metadata": {"window": "So, I think all of those things and the momentum that we've showed now over a number of years lead \nus to have some confidence in a higher growth t arget.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next will be Michael Cherny with Bank of America.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "679d8fc9f01947f1cd3c57f739ad79c6b8aeb1cb4f1bd053a7b18d19da7999c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a3a88b-9c47-4a05-b5ef-6563cc0003be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "b28d98c4c397fdd6d51ecdc53b6b5430ccf987f5992d5a3cee44923d811d17f4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a3a88b-9c47-4a05-b5ef-6563cc0003be": {"__data__": {"id_": "61a3a88b-9c47-4a05-b5ef-6563cc0003be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2ef9b1d76f7a399cf48229468d64fda2298e303223ec7e3e19376f5b6568a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd13addd-b9cb-47fe-8bc0-0ac916f8201f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "original_text": "Q \nGood afternoon, and thanks for taking the question. "}, "hash": "f78659d708f7821559b8cbfe05048fa1a9b7d3c9e5f102f01ccc216c7a95e07a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 16, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd13addd-b9cb-47fe-8bc0-0ac916f8201f": {"__data__": {"id_": "fd13addd-b9cb-47fe-8bc0-0ac916f8201f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "original_text": "Q \nGood afternoon, and thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a3a88b-9c47-4a05-b5ef-6563cc0003be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e1e2171f692690e2ff45fedff5b3e41d1dc13db2521422329aad97a52a5e70e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03badf40-fdbc-4ebe-bc43-3c520a42fe05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "original_text": "Congratulations on a really strong guide. "}, "hash": "0869d35ed2eb8c2deae494361bfca168fce0644919e0ee18b4fd595c4fef14d6", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon, and thanks for taking the question. ", "start_char_idx": 230, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03badf40-fdbc-4ebe-bc43-3c520a42fe05": {"__data__": {"id_": "03badf40-fdbc-4ebe-bc43-3c520a42fe05", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "original_text": "Congratulations on a really strong guide. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd13addd-b9cb-47fe-8bc0-0ac916f8201f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "original_text": "Q \nGood afternoon, and thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d1712299f7a496b6f7b2a38dd65d1920dce4faea3d8f98efe9d89867bf801a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a369bf5e-e6bf-4a05-aa93-22680bd10c5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "original_text": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. "}, "hash": "acf598ed94270b378690dba80acf20e41445992d06672e2f8be334e8bf7bd662", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations on a really strong guide. ", "start_char_idx": 285, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a369bf5e-e6bf-4a05-aa93-22680bd10c5f": {"__data__": {"id_": "a369bf5e-e6bf-4a05-aa93-22680bd10c5f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "original_text": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03badf40-fdbc-4ebe-bc43-3c520a42fe05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "original_text": "Congratulations on a really strong guide. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81c87abadaf0b32857daacda7340abba1e8c039950d20bf4543b0dc736299140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e87ced3-476c-4f71-844f-8fc08f4b8350", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah. ", "original_text": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. "}, "hash": "aa92d426a399a51da45f5ad80f0ff42e42c06c350016f6dab6bc21e7fcb76fd4", "class_name": "RelatedNodeInfo"}}, "text": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "start_char_idx": 327, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e87ced3-476c-4f71-844f-8fc08f4b8350": {"__data__": {"id_": "6e87ced3-476c-4f71-844f-8fc08f4b8350", "embedding": null, "metadata": {"window": "Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah. ", "original_text": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a369bf5e-e6bf-4a05-aa93-22680bd10c5f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "original_text": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "963385a591c43f61f295adb276b7cf003ddc2a7d673c0d49408946271008ce86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c57e4331-7708-4ea6-a17e-0dc97770fbfd", "node_type": "1", "metadata": {"window": "Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael. ", "original_text": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n "}, "hash": "e4d87a2357a48f6723e7c6cc9391c6e8c81ba7f428f0d88eb82fb3d8b8b1bd9d", "class_name": "RelatedNodeInfo"}}, "text": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "start_char_idx": 404, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c57e4331-7708-4ea6-a17e-0dc97770fbfd": {"__data__": {"id_": "c57e4331-7708-4ea6-a17e-0dc97770fbfd", "embedding": null, "metadata": {"window": "Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael. ", "original_text": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e87ced3-476c-4f71-844f-8fc08f4b8350", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah. ", "original_text": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e41eb6af2b2c0f4bcf3f0b3cafe44552fa38de59a1c2c6f8fbbd42fe2e1dd03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "712b00e6-2aa0-4578-83ea-2638810dc5d6", "node_type": "1", "metadata": {"window": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  "}, "hash": "159c0780174abe4dba2b33fe96fb82cf2873c2e05cb1454399f9e63b38aa57ee", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "start_char_idx": 560, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "712b00e6-2aa0-4578-83ea-2638810dc5d6": {"__data__": {"id_": "712b00e6-2aa0-4578-83ea-2638810dc5d6", "embedding": null, "metadata": {"window": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c57e4331-7708-4ea6-a17e-0dc97770fbfd", "node_type": "1", "metadata": {"window": "Congratulations on a really strong guide.  Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael. ", "original_text": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ba67e7e93bc531813027444bae376f1b7fa663d08b3901b2856b5b35d48ab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ffed0fa-5963-43b0-aacf-87e5e33edc59", "node_type": "1", "metadata": {"window": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse. ", "original_text": "A \nYeah. "}, "hash": "2403ecb638d4fb0e5414a68c265e4c8c0080e493faa321da87c8e38b059b4780", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "start_char_idx": 1003, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ffed0fa-5963-43b0-aacf-87e5e33edc59": {"__data__": {"id_": "1ffed0fa-5963-43b0-aacf-87e5e33edc59", "embedding": null, "metadata": {"window": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "712b00e6-2aa0-4578-83ea-2638810dc5d6", "node_type": "1", "metadata": {"window": "Maybe to take Eric's \nquestion, but pivot it a bit on to the Med -Surg side.  It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5ffc2ab1993437448b7c194aa61834d7d350f1d6ab724caaeecf730fd537452", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0edaf59-bca1-459c-a49f-67bbd79631ec", "node_type": "1", "metadata": {"window": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "original_text": "Thanks, Michael. "}, "hash": "c3faa56054d68c4e30fa7d18abeca0aadaee9b2b5274a9ae9ee38b52f47f9d98", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1333, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0edaf59-bca1-459c-a49f-67bbd79631ec": {"__data__": {"id_": "f0edaf59-bca1-459c-a49f-67bbd79631ec", "embedding": null, "metadata": {"window": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "original_text": "Thanks, Michael. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ffed0fa-5963-43b0-aacf-87e5e33edc59", "node_type": "1", "metadata": {"window": "It seems like the multitude of factors, even backing out COVID, \nhas continued to help you, strong market positioning, site of car e, volumes, you name it.  As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21744bde5b6c619a9cf04fff93e6041f93ddc8467a367c83581bbef71783dc72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "original_text": "I'll take that one, and give Britt a minute of relief. "}, "hash": "d8eede891cb81c1ebfb86b86ac19f6785fa16f426503440734c5b58345575e46", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Michael. ", "start_char_idx": 1342, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a": {"__data__": {"id_": "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "original_text": "I'll take that one, and give Britt a minute of relief. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0edaf59-bca1-459c-a49f-67bbd79631ec", "node_type": "1", "metadata": {"window": "As you think about the \nbuild, because you did take up that guidance as well, what do you think the steady state looks like in terms of \nwhere we have been pre -COVID versus going forward among all those different metrics, among share  gain, \namong site of care, among private label, that allows you to build to that higher and consistent double -digit growth \nrate within what already is a pretty sizable segment from an EBIT perspective?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "original_text": "Thanks, Michael. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc51ebc08bc03b63ac1385d9b91d72e0d835b892d3c7f077bc83ddbb0187da5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db26373-b309-4960-8a4e-4fcb12e88827", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products. ", "original_text": "So, our Medical business is incredibly \ndiverse. "}, "hash": "957490956ef0ace63586bd1a6951a196747bb53ec7a3f55c824e97bc33e9b0b9", "class_name": "RelatedNodeInfo"}}, "text": "I'll take that one, and give Britt a minute of relief. ", "start_char_idx": 1359, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db26373-b309-4960-8a4e-4fcb12e88827": {"__data__": {"id_": "7db26373-b309-4960-8a4e-4fcb12e88827", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products. ", "original_text": "So, our Medical business is incredibly \ndiverse. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director , McKesson Corp.   A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "original_text": "I'll take that one, and give Britt a minute of relief. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce39d07327ba88dc8971a1fa2e698933bb28fcffd94ddd8984ac53f4ca08309e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87c04c69-da61-4622-9eb3-f19ec7e49832", "node_type": "1", "metadata": {"window": "Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "original_text": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. "}, "hash": "b7ef52c80b7e2605718a7733980ef53a3f04d70eab2e9f2b7e01c5c1ba6f0984", "class_name": "RelatedNodeInfo"}}, "text": "So, our Medical business is incredibly \ndiverse. ", "start_char_idx": 1414, "end_char_idx": 1463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87c04c69-da61-4622-9eb3-f19ec7e49832": {"__data__": {"id_": "87c04c69-da61-4622-9eb3-f19ec7e49832", "embedding": null, "metadata": {"window": "Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "original_text": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db26373-b309-4960-8a4e-4fcb12e88827", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products. ", "original_text": "So, our Medical business is incredibly \ndiverse. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a24022269226d1cc62b54386975fdab12d81a76bbcaaf39edc1986df021af7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29884a5a-d553-4626-a20f-571f12f1d835", "node_type": "1", "metadata": {"window": "I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah. ", "original_text": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. "}, "hash": "74780b9d33418874770c36a20bcda99cbd50b42c23190e89ed7bc1e52a7713af", "class_name": "RelatedNodeInfo"}}, "text": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "start_char_idx": 1463, "end_char_idx": 1586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29884a5a-d553-4626-a20f-571f12f1d835": {"__data__": {"id_": "29884a5a-d553-4626-a20f-571f12f1d835", "embedding": null, "metadata": {"window": "I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah. ", "original_text": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87c04c69-da61-4622-9eb3-f19ec7e49832", "node_type": "1", "metadata": {"window": "Thanks, Michael.  I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "original_text": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5309d904a11172635d12fc9fa188dbb4651d516d87cab7399837a379991b9d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc762b21-d49f-4506-b8d4-c1391eda1e4c", "node_type": "1", "metadata": {"window": "So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "original_text": "It's not just commodity \nmedical products. "}, "hash": "ecbb928ea77af8d2896202048b673ccaaa8c85b0e076cfbfd18e8d00b1a3473d", "class_name": "RelatedNodeInfo"}}, "text": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "start_char_idx": 1586, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc762b21-d49f-4506-b8d4-c1391eda1e4c": {"__data__": {"id_": "cc762b21-d49f-4506-b8d4-c1391eda1e4c", "embedding": null, "metadata": {"window": "So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "original_text": "It's not just commodity \nmedical products. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29884a5a-d553-4626-a20f-571f12f1d835", "node_type": "1", "metadata": {"window": "I'll take that one, and give Britt a minute of relief.  So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah. ", "original_text": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3176ab6d25db5a6e1b2e78d33b3b5dbba8a56e86efa1edfb24f0a968231b16ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac9006e-2f8f-4bed-ab61-58818e67ad9c", "node_type": "1", "metadata": {"window": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback. ", "original_text": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. "}, "hash": "e18c38cafe5375d9c6f9ef8460c67daa9aeda61ffc48222762cc7bfe1636c3a6", "class_name": "RelatedNodeInfo"}}, "text": "It's not just commodity \nmedical products. ", "start_char_idx": 1777, "end_char_idx": 1820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac9006e-2f8f-4bed-ab61-58818e67ad9c": {"__data__": {"id_": "6ac9006e-2f8f-4bed-ab61-58818e67ad9c", "embedding": null, "metadata": {"window": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback. ", "original_text": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc762b21-d49f-4506-b8d4-c1391eda1e4c", "node_type": "1", "metadata": {"window": "So, our Medical business is incredibly \ndiverse.  Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "original_text": "It's not just commodity \nmedical products. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2929179a12c0dfbc498e37214051c96104246c55673bff5471fcfcdfb6617f0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7e4a91-0b0a-42d3-8453-382301f395be", "node_type": "1", "metadata": {"window": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back. ", "original_text": "Yeah. "}, "hash": "5a8a2ac26c88de7dfae12a227f5d891960e6137427175ea81202183315abda74", "class_name": "RelatedNodeInfo"}}, "text": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "start_char_idx": 1820, "end_char_idx": 1899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7e4a91-0b0a-42d3-8453-382301f395be": {"__data__": {"id_": "7f7e4a91-0b0a-42d3-8453-382301f395be", "embedding": null, "metadata": {"window": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back. ", "original_text": "Yeah. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac9006e-2f8f-4bed-ab61-58818e67ad9c", "node_type": "1", "metadata": {"window": "Across, it's really shows up in all of the alternate sites, or everywhere that's not a hospital setting, to be  \ntruthful.  And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback. ", "original_text": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ad1203e1e6f7e32cb23421d625d3fc9b788bb56ddb2e347ea4656698c3d21cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b580475-9361-4483-919d-1527d2307475", "node_type": "1", "metadata": {"window": "It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "original_text": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back. "}, "hash": "c7225885ee21385de210aae4009907e704a02145e514dfa9337ae6dc2618a387", "class_name": "RelatedNodeInfo"}}, "text": "Yeah. ", "start_char_idx": 1336, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b580475-9361-4483-919d-1527d2307475": {"__data__": {"id_": "1b580475-9361-4483-919d-1527d2307475", "embedding": null, "metadata": {"window": "It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "original_text": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7e4a91-0b0a-42d3-8453-382301f395be", "node_type": "1", "metadata": {"window": "And even amongst hospitals, we tend to serve all of their community, not all, but we do serve their \ncommunity -based locations, and it's also diverse from a sense of multiple product lines.  It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back. ", "original_text": "Yeah. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "532faf84627b4a1e20ce767c2910606ca1d7b58a23eae59f659e72b0e176453e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b4dcef4-69e5-4425-9e06-3787f2d669d6", "node_type": "1", "metadata": {"window": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business. ", "original_text": "We've seen prescriptions come \nback. "}, "hash": "d137334a9ca97b0a31f3384cf6df2553d64f74a65dd9fa0b52b14295269efeed", "class_name": "RelatedNodeInfo"}}, "text": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "start_char_idx": 1905, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b4dcef4-69e5-4425-9e06-3787f2d669d6": {"__data__": {"id_": "1b4dcef4-69e5-4425-9e06-3787f2d669d6", "embedding": null, "metadata": {"window": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business. ", "original_text": "We've seen prescriptions come \nback. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b580475-9361-4483-919d-1527d2307475", "node_type": "1", "metadata": {"window": "It's not just commodity \nmedical products.  It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "original_text": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f861d4ce9a798080f7062ebc57779db8b772a4dacbc1f7d372159319eb926d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd", "node_type": "1", "metadata": {"window": "Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate. ", "original_text": "Oncology visits come back. "}, "hash": "114a4bf460d4ec6633c69b3a452c17384cd64f7a2c78bb6af57f4b22ad6114e2", "class_name": "RelatedNodeInfo"}}, "text": "We've seen prescriptions come \nback. ", "start_char_idx": 2003, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd": {"__data__": {"id_": "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd", "embedding": null, "metadata": {"window": "Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate. ", "original_text": "Oncology visits come back. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b4dcef4-69e5-4425-9e06-3787f2d669d6", "node_type": "1", "metadata": {"window": "It's equipment , it's lab, it's pharmaceutical, it's specialty pharmaceutical.  Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business. ", "original_text": "We've seen prescriptions come \nback. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0859812fa4d478603b96f69fb4e44d6ab28a8969c6ef32765ba919ea4bc6f40e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c72de8fd-85ec-4184-a7f4-cba16c167b7f", "node_type": "1", "metadata": {"window": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us. ", "original_text": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n"}, "hash": "1e2dc5a5fe7fc4c28d0bce7782d321b220a932949480d30d703f1e8e2b8e0c4a", "class_name": "RelatedNodeInfo"}}, "text": "Oncology visits come back. ", "start_char_idx": 2040, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c72de8fd-85ec-4184-a7f4-cba16c167b7f": {"__data__": {"id_": "c72de8fd-85ec-4184-a7f4-cba16c167b7f", "embedding": null, "metadata": {"window": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us. ", "original_text": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd", "node_type": "1", "metadata": {"window": "Yeah.  When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate. ", "original_text": "Oncology visits come back. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d98c312c9faa07b0e8381755d57bd4c5cf9ba0378a2a7d06b9982552cd9931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f769c54c-6242-45a9-bab9-a77496b5f480", "node_type": "1", "metadata": {"window": "We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio. ", "original_text": "So, I think there's a big utilization that we think continues to under lie this business. "}, "hash": "1efa8878fae67817cce67896f6792799b7cddb9fa5835ef10a83f80751620f51", "class_name": "RelatedNodeInfo"}}, "text": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "start_char_idx": 2067, "end_char_idx": 2254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f769c54c-6242-45a9-bab9-a77496b5f480": {"__data__": {"id_": "f769c54c-6242-45a9-bab9-a77496b5f480", "embedding": null, "metadata": {"window": "We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio. ", "original_text": "So, I think there's a big utilization that we think continues to under lie this business. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c72de8fd-85ec-4184-a7f4-cba16c167b7f", "node_type": "1", "metadata": {"window": "When we look at \nutilization broadly across the industry, we've been pleased to see it come back.  We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us. ", "original_text": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00de53b02c20d484767a0b67974864de290d3b0ba8205522291803b1399d741a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72abebe3-d288-4c2c-9436-ebee7d2b4754", "node_type": "1", "metadata": {"window": "Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "original_text": "There's the diversity of the \nproducts and the new segments that we can penetrate. "}, "hash": "f40e3b7b31f9599bbf75cf3719d10ae6a0a6dc3f63bd62eb43828859a828b44a", "class_name": "RelatedNodeInfo"}}, "text": "So, I think there's a big utilization that we think continues to under lie this business. ", "start_char_idx": 2254, "end_char_idx": 2344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72abebe3-d288-4c2c-9436-ebee7d2b4754": {"__data__": {"id_": "72abebe3-d288-4c2c-9436-ebee7d2b4754", "embedding": null, "metadata": {"window": "Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "original_text": "There's the diversity of the \nproducts and the new segments that we can penetrate. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f769c54c-6242-45a9-bab9-a77496b5f480", "node_type": "1", "metadata": {"window": "We've seen prescriptions come \nback.  Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio. ", "original_text": "So, I think there's a big utilization that we think continues to under lie this business. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7f3be03cb5241fa44dcdfd5d161ca974591f50271f4dd7e91757bd9346265f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a25775-2c55-4c55-8bae-46c44e7eb07e", "node_type": "1", "metadata": {"window": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "There's opportunities for us. "}, "hash": "e5fe20a3161df0d51bcef092744e5c3edbba276fa39d5e4b6883941e73582296", "class_name": "RelatedNodeInfo"}}, "text": "There's the diversity of the \nproducts and the new segments that we can penetrate. ", "start_char_idx": 2344, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a25775-2c55-4c55-8bae-46c44e7eb07e": {"__data__": {"id_": "03a25775-2c55-4c55-8bae-46c44e7eb07e", "embedding": null, "metadata": {"window": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "There's opportunities for us. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72abebe3-d288-4c2c-9436-ebee7d2b4754", "node_type": "1", "metadata": {"window": "Oncology visits come back.  Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "original_text": "There's the diversity of the \nproducts and the new segments that we can penetrate. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e8089d836de4a3a8736f5a490c46c180a37f1f75f0c4ad2ea51ee9fc00b624f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a79b90e6-c0dc-41e9-b369-a556b7b5c93e", "node_type": "1", "metadata": {"window": "So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We continue to believe in our \nprivate brand portfolio. "}, "hash": "d681628b41f4cf230486626f3066ad6edbef83eb25794714780c41dcc4f2abe5", "class_name": "RelatedNodeInfo"}}, "text": "There's opportunities for us. ", "start_char_idx": 2427, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a79b90e6-c0dc-41e9-b369-a556b7b5c93e": {"__data__": {"id_": "a79b90e6-c0dc-41e9-b369-a556b7b5c93e", "embedding": null, "metadata": {"window": "So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We continue to believe in our \nprivate brand portfolio. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a25775-2c55-4c55-8bae-46c44e7eb07e", "node_type": "1", "metadata": {"window": "Medical is probably recove red a bit over the course of the last year, but we \nwere encouraged by recent commentary and stats on the recovery and ambulatory surgery centers for example. \n So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "There's opportunities for us. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aa82eff23320ffbcd8320e4650f8538ac84a4471bbfb4ded311cc4bf8612239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1379ecc1-7d8b-487c-9712-30113dc7d09b", "node_type": "1", "metadata": {"window": "There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So, I'd say it's the confluence of all those things that give us the confidence.  \n "}, "hash": "b494a996762a1ce23422cb422081e80aceed780fa5173b906474bee7060b98fc", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe in our \nprivate brand portfolio. ", "start_char_idx": 2457, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1379ecc1-7d8b-487c-9712-30113dc7d09b": {"__data__": {"id_": "1379ecc1-7d8b-487c-9712-30113dc7d09b", "embedding": null, "metadata": {"window": "There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a79b90e6-c0dc-41e9-b369-a556b7b5c93e", "node_type": "1", "metadata": {"window": "So, I think there's a big utilization that we think continues to under lie this business.  There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We continue to believe in our \nprivate brand portfolio. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30557de7d4164c0c5cbf8d6f4162cabcb4484a1e2599d3656bb3408bc89079a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20ea64ae-5994-4ce1-aa52-a4b96625f1da", "node_type": "1", "metadata": {"window": "There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "d542f583bee1c7be9e4fa6083205dd4c563b906a5a50b77c042cedbf96cba645", "class_name": "RelatedNodeInfo"}}, "text": "So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "start_char_idx": 2513, "end_char_idx": 2597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20ea64ae-5994-4ce1-aa52-a4b96625f1da": {"__data__": {"id_": "20ea64ae-5994-4ce1-aa52-a4b96625f1da", "embedding": null, "metadata": {"window": "There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1379ecc1-7d8b-487c-9712-30113dc7d09b", "node_type": "1", "metadata": {"window": "There's the diversity of the \nproducts and the new segments that we can penetrate.  There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So, I'd say it's the confluence of all those things that give us the confidence.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "488758908faa6d1bed28f97931d4b94255eaa15c5cc1b93f085530fb95642f29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f85e01b-1695-4ebc-a60c-aca3f021723c", "node_type": "1", "metadata": {"window": "We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon. ", "original_text": "A \nNext question, please.  \n "}, "hash": "0a4b844318159bacc4c61c0dcf514d2f35f3610cc4db1ae287a8baa6a558b85f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 2597, "end_char_idx": 2915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f85e01b-1695-4ebc-a60c-aca3f021723c": {"__data__": {"id_": "2f85e01b-1695-4ebc-a60c-aca3f021723c", "embedding": null, "metadata": {"window": "We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20ea64ae-5994-4ce1-aa52-a4b96625f1da", "node_type": "1", "metadata": {"window": "There's opportunities for us.  We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17f3f4565d313f272b6445b56ed72908143f8a56dda677b0ed04e5c71aca1a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1410bf2d-c4dd-467e-a3d5-99e8374d3deb", "node_type": "1", "metadata": {"window": "So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n "}, "hash": "2e5dbd742be1e4f26a050d6738c9775b9f5a183d19e77aaee97e074a15590c63", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2915, "end_char_idx": 2944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1410bf2d-c4dd-467e-a3d5-99e8374d3deb": {"__data__": {"id_": "1410bf2d-c4dd-467e-a3d5-99e8374d3deb", "embedding": null, "metadata": {"window": "So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f85e01b-1695-4ebc-a60c-aca3f021723c", "node_type": "1", "metadata": {"window": "We continue to believe in our \nprivate brand portfolio.  So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9485ff1e5c12802a0e729f0a70853ed3494bbc061f1c2e5ffda6a44fef4b84a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "481de532-1905-4ffd-b849-ca7f42467bc6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "d100c60be493862815b0bea83b7fcbfdd3e10fa7f27d4be4cf73ccc0204c3ca2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "start_char_idx": 2944, "end_char_idx": 3259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "481de532-1905-4ffd-b849-ca7f42467bc6": {"__data__": {"id_": "481de532-1905-4ffd-b849-ca7f42467bc6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1410bf2d-c4dd-467e-a3d5-99e8374d3deb", "node_type": "1", "metadata": {"window": "So, I'd say it's the confluence of all those things that give us the confidence.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e34f5fc6fdc9207e10961f4cfd09a8bf49dfebd131ba43894a24bf9cf6a3eea1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5659e253-ebdd-413d-8045-ba6d349ab210", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "original_text": "Good afternoon. "}, "hash": "bfc3028cbd2ac12ab6e982e131f847a4a318434d82cfbac09a3eb8de89cde34e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 3259, "end_char_idx": 3586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5659e253-ebdd-413d-8045-ba6d349ab210": {"__data__": {"id_": "5659e253-ebdd-413d-8045-ba6d349ab210", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "original_text": "Good afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "481de532-1905-4ffd-b849-ca7f42467bc6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51a6b381c344fe19151c4a44d587936d35543b86f30c5525f7b3ecd5aff2bae9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "original_text": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. "}, "hash": "d4b18d88d1f706373fa4faa03ac102cc054fd889ec742e830c5a3683d5fade56", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 3586, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3": {"__data__": {"id_": "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "original_text": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5659e253-ebdd-413d-8045-ba6d349ab210", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "original_text": "Good afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90b6550d07dcba312aa7717b984527f36f052bd30059eeaf18fb583b34a00d37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30745b78-025e-428a-b86f-b09d8094b779", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? "}, "hash": "203e300c152bb290f45672640a851170fb4298c1a7bdc6463d436e25c56b7af6", "class_name": "RelatedNodeInfo"}}, "text": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "start_char_idx": 3602, "end_char_idx": 3776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30745b78-025e-428a-b86f-b09d8094b779": {"__data__": {"id_": "30745b78-025e-428a-b86f-b09d8094b779", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "original_text": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba95b885d17f688051f73ab0e6b1de4bee1153129c1133ffcceb9a3e518db647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e53604f-0714-47eb-9505-41a1f80a4558", "node_type": "1", "metadata": {"window": "Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa. ", "original_text": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. "}, "hash": "6d1b4270027d64606f81bb46c40378be002ab1ce71a0c56f904a78846f7f332c", "class_name": "RelatedNodeInfo"}}, "text": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "start_char_idx": 3776, "end_char_idx": 3981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e53604f-0714-47eb-9505-41a1f80a4558": {"__data__": {"id_": "8e53604f-0714-47eb-9505-41a1f80a4558", "embedding": null, "metadata": {"window": "Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa. ", "original_text": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30745b78-025e-428a-b86f-b09d8094b779", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin? ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b86fd0050a0060b7c7bc8bbc11ac50130001fb9e3916c386143fd240f507a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "706c98d1-f7c3-4d68-b857-7aa3adfbee57", "node_type": "1", "metadata": {"window": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there. ", "original_text": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n "}, "hash": "d0060f08a8375ae077466e95241d4f0da94db53686aede4c572055f816f3f237", "class_name": "RelatedNodeInfo"}}, "text": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "start_char_idx": 3981, "end_char_idx": 4194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "706c98d1-f7c3-4d68-b857-7aa3adfbee57": {"__data__": {"id_": "706c98d1-f7c3-4d68-b857-7aa3adfbee57", "embedding": null, "metadata": {"window": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there. ", "original_text": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e53604f-0714-47eb-9505-41a1f80a4558", "node_type": "1", "metadata": {"window": "Good afternoon.  Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa. ", "original_text": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26eee0d1541d3afd4cc4daebfb80d08d641fc5d0f55fac9439075b4a3bdce94a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cfd3f0f-e0d3-47a7-866f-16838d906239", "node_type": "1", "metadata": {"window": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "fc8b62a51bb22a2d2db4ce2c5188d6318a2f7b592ca69336ef28be579b197f57", "class_name": "RelatedNodeInfo"}}, "text": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "start_char_idx": 4194, "end_char_idx": 4289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cfd3f0f-e0d3-47a7-866f-16838d906239": {"__data__": {"id_": "3cfd3f0f-e0d3-47a7-866f-16838d906239", "embedding": null, "metadata": {"window": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "706c98d1-f7c3-4d68-b857-7aa3adfbee57", "node_type": "1", "metadata": {"window": "Just, Britt, I first wanted to follow up on the  $0.40 range as we think of the \nguidance and just understand some of the puts and takes and the upper end and the lower end.  And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there. ", "original_text": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "756bbe9d9c6dba9d1b37548053f2af61001cd84f2bf2c840f6c288f37ed2ade4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee", "node_type": "1", "metadata": {"window": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me. ", "original_text": "A \nThanks for the question, Lisa. "}, "hash": "7ac613c37bdb3f95b7449ff5fd62196eafe4d203f6ff4974b08c65f6965a7721", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 4289, "end_char_idx": 4634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee": {"__data__": {"id_": "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee", "embedding": null, "metadata": {"window": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me. ", "original_text": "A \nThanks for the question, Lisa. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cfd3f0f-e0d3-47a7-866f-16838d906239", "node_type": "1", "metadata": {"window": "And more \nimportantly, as we think about, for example, the changes in insulin pricing and how drug distributors make money; \nso, one,  can you maybe just walk us through how we should think about insulin?  And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2331d15e16e2cc062b2a14d60fa46c56ce011858bec4bc2ae7cb84e55e1c91ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72764918-f315-4bcc-ac28-9b577d46f12e", "node_type": "1", "metadata": {"window": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "original_text": "So, a lot there. "}, "hash": "8e3d1f1865e23efa9220b3a9242514cd507c85215fb9e004fd65fb669ddf1c23", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Lisa. ", "start_char_idx": 4634, "end_char_idx": 4668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72764918-f315-4bcc-ac28-9b577d46f12e": {"__data__": {"id_": "72764918-f315-4bcc-ac28-9b577d46f12e", "embedding": null, "metadata": {"window": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "original_text": "So, a lot there. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee", "node_type": "1", "metadata": {"window": "And then, secondly, in the \nanswer to an earlier question, you talked about lapping the brand benefit, but I'm also curious as to how you and \nBrian are thinking about new products that a re coming to the market.  I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me. ", "original_text": "A \nThanks for the question, Lisa. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60d79a2a71ce20e1df821de5d816adc4724e872d8286f05a284e892a658c3fc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25ff13c5-a1f2-47a0-b624-5d29887a5117", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "Let  me just see if I can kind of tick through it. "}, "hash": "831c47c67b63b6538773e6cf1472424df70afe34084ca044705cd7763d223c16", "class_name": "RelatedNodeInfo"}}, "text": "So, a lot there. ", "start_char_idx": 4668, "end_char_idx": 4685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25ff13c5-a1f2-47a0-b624-5d29887a5117": {"__data__": {"id_": "25ff13c5-a1f2-47a0-b624-5d29887a5117", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "Let  me just see if I can kind of tick through it. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72764918-f315-4bcc-ac28-9b577d46f12e", "node_type": "1", "metadata": {"window": "I think things like GLP -1 and other really \nexpensive drugs that will have a big top line.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "original_text": "So, a lot there. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a76807b3ad899be349af3cb31a0587e423d0dc8b6a721dcbc0a62e5b89aafa2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e27d416-2bcb-492b-b853-723ce702b695", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "If I miss something, \nplease remind me. "}, "hash": "a7ecbcb7d06823f0c5c87e609e78a32145ec4c48525eea53f143d95f14daa93d", "class_name": "RelatedNodeInfo"}}, "text": "Let  me just see if I can kind of tick through it. ", "start_char_idx": 4685, "end_char_idx": 4736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e27d416-2bcb-492b-b853-723ce702b695": {"__data__": {"id_": "5e27d416-2bcb-492b-b853-723ce702b695", "embedding": null, "metadata": {"window": "A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "If I miss something, \nplease remind me. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25ff13c5-a1f2-47a0-b624-5d29887a5117", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "Let  me just see if I can kind of tick through it. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf7ea06e6f85cfee0f1ecc2282f9c5cc06c82e065f6e76249b5bc13684a2d9c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7cda1d6-5519-4c72-aeef-2a4a6b91a557", "node_type": "1", "metadata": {"window": "So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. "}, "hash": "bce5a937fc0b5f3a75b36684b1911130314610d4acd0ebbd257f009a9142f91f", "class_name": "RelatedNodeInfo"}}, "text": "If I miss something, \nplease remind me. ", "start_char_idx": 4736, "end_char_idx": 4776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7cda1d6-5519-4c72-aeef-2a4a6b91a557": {"__data__": {"id_": "a7cda1d6-5519-4c72-aeef-2a4a6b91a557", "embedding": null, "metadata": {"window": "So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e27d416-2bcb-492b-b853-723ce702b695", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Lisa.  So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "If I miss something, \nplease remind me. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f0ca152c80b9af7a922a0015009fb308f1965150b24833bd50d62eba967cf3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3", "node_type": "1", "metadata": {"window": "Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "And when we do that, we work to establish a "}, "hash": "cab520ce94a8eacb39888fbecae8083bbe29af6ffd3475e4e78eefa2f3603ca3", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "start_char_idx": 4776, "end_char_idx": 5053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3": {"__data__": {"id_": "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3", "embedding": null, "metadata": {"window": "Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "And when we do that, we work to establish a ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ec2d02e17b3a6648d7e799ee5b7e8423e8edfe6fb87a76529d998394c3ba1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7cda1d6-5519-4c72-aeef-2a4a6b91a557", "node_type": "1", "metadata": {"window": "So, a lot there.  Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products. ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b6daa4228b56280eec176be0a882de39ca14cf4efc85d56390225a9fa6b1c97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "509d0ac6-3d31-4ca3-b505-9ae41a8a651c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "7ae8d6de975bbbfe07370e454ea9e244c58db014b97e1fd62c481fe5b046d84b", "class_name": "RelatedNodeInfo"}}, "text": "And when we do that, we work to establish a ", "start_char_idx": 5053, "end_char_idx": 5097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "509d0ac6-3d31-4ca3-b505-9ae41a8a651c": {"__data__": {"id_": "509d0ac6-3d31-4ca3-b505-9ae41a8a651c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3", "node_type": "1", "metadata": {"window": "Let  me just see if I can kind of tick through it.  If I miss something, \nplease remind me.  As we think about the products that we serve across our biopharma partners, our first job there \nis to think about what is it that our customers need, and then work with a  biopharma partners to determine the \nservices that they need us to provide on behalf of those products.  And when we do that, we work to establish a ", "original_text": "And when we do that, we work to establish a ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "584b87e9cbef902c2f5f47e0fec9addeca7bb692534434fdbf77913799c858cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "998a721d-9f31-47ca-9631-ec0ddc0947ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is. "}, "hash": "ef34913e151163f12d49b11ba1a9a850d90d174b39c4b6cc745ebe10370e8daf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "998a721d-9f31-47ca-9631-ec0ddc0947ab": {"__data__": {"id_": "998a721d-9f31-47ca-9631-ec0ddc0947ab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "509d0ac6-3d31-4ca3-b505-9ae41a8a651c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "122b02e7c7674609255b01fd70cf5b6798c227cbcef3ef2c93289ec2e6ef5f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9598c7c4-2528-4348-98a0-13ac33164059", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "original_text": "That's what we do on a con stant \nbasis, working with our manufacturers. "}, "hash": "290719f58e05a4b66301a5061430a592df389827d0af35062d523d0b8dcba983", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is. ", "start_char_idx": 16, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9598c7c4-2528-4348-98a0-13ac33164059": {"__data__": {"id_": "9598c7c4-2528-4348-98a0-13ac33164059", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "original_text": "That's what we do on a con stant \nbasis, working with our manufacturers. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "998a721d-9f31-47ca-9631-ec0ddc0947ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8172ac9da84ed1cd122ed7720bb98902f0b73b06f87c5791d6186093a1dbc79c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e612020-f16c-4656-b9bc-c460c7b1b7a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "original_text": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n"}, "hash": "a1dda46a256882bbc0f75f962e5ff03a0b352ac89c76b1cb185943816877d81f", "class_name": "RelatedNodeInfo"}}, "text": "That's what we do on a con stant \nbasis, working with our manufacturers. ", "start_char_idx": 263, "end_char_idx": 336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e612020-f16c-4656-b9bc-c460c7b1b7a2": {"__data__": {"id_": "8e612020-f16c-4656-b9bc-c460c7b1b7a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "original_text": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9598c7c4-2528-4348-98a0-13ac33164059", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "original_text": "That's what we do on a con stant \nbasis, working with our manufacturers. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a10bc98f71a9105ac1c077fae1d878bbb5f578ea0ae22b4183e7b2c41dccb9d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94800faa-960f-4344-bab4-61585a9b8f19", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n ", "original_text": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. "}, "hash": "c7fe46ed17f107f8faad6c141eceaf9b86496c904efdc1185b9e134b07bcf1a8", "class_name": "RelatedNodeInfo"}}, "text": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "start_char_idx": 336, "end_char_idx": 697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94800faa-960f-4344-bab4-61585a9b8f19": {"__data__": {"id_": "94800faa-960f-4344-bab4-61585a9b8f19", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n ", "original_text": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e612020-f16c-4656-b9bc-c460c7b1b7a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "original_text": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "519c9adef7719d930d0b454df8e6fa0e658e9adf5ee500f597054d0aa9d71b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564d02c4-3b8a-4e0c-864b-6f61ce7554df", "node_type": "1", "metadata": {"window": "That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "original_text": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. "}, "hash": "c2a8fb0ba75a0fafc6ed2f56f80b5bc13f38ad6ec8a1bdaf997275ff02ac3afe", "class_name": "RelatedNodeInfo"}}, "text": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "start_char_idx": 697, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564d02c4-3b8a-4e0c-864b-6f61ce7554df": {"__data__": {"id_": "564d02c4-3b8a-4e0c-864b-6f61ce7554df", "embedding": null, "metadata": {"window": "That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "original_text": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94800faa-960f-4344-bab4-61585a9b8f19", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n ", "original_text": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "490d7c6d8c63c391b95bd31c8ae488cb363a570b34a5820a579d48e3b58e4742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d43bdec-d331-4601-a886-9f4f7d510f58", "node_type": "1", "metadata": {"window": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done. ", "original_text": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n"}, "hash": "d17366421fa27d11687267bec1a13474cade85dae173f6e834f47de90a4e6df4", "class_name": "RelatedNodeInfo"}}, "text": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "start_char_idx": 827, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d43bdec-d331-4601-a886-9f4f7d510f58": {"__data__": {"id_": "9d43bdec-d331-4601-a886-9f4f7d510f58", "embedding": null, "metadata": {"window": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done. ", "original_text": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564d02c4-3b8a-4e0c-864b-6f61ce7554df", "node_type": "1", "metadata": {"window": "That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "original_text": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b33d9b27564e8b240782d1253f9dccc48497112931e40a36892632243c0684b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "848b740c-de4e-420c-bebf-55d6eb6f92f7", "node_type": "1", "metadata": {"window": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "original_text": "Brian, if you would \u2013 there's anything you would add to that?  \n "}, "hash": "81cfcfbf82574559fe85daab1f8d21a416f2564dac47d3d34e084d7e18f6522f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "start_char_idx": 1125, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "848b740c-de4e-420c-bebf-55d6eb6f92f7": {"__data__": {"id_": "848b740c-de4e-420c-bebf-55d6eb6f92f7", "embedding": null, "metadata": {"window": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "original_text": "Brian, if you would \u2013 there's anything you would add to that?  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d43bdec-d331-4601-a886-9f4f7d510f58", "node_type": "1", "metadata": {"window": "So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done. ", "original_text": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "585bba70c0921803b6f8e126fa2c7e35a945a1ebd9f2dbe15a404ad9b21f19a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1337df31-8a45-4236-87ff-78e8a4ba73f5", "node_type": "1", "metadata": {"window": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  "}, "hash": "e48acf85d178d88ac6c18ff44ab7570956871afaaad8cbb710ae7cc798bf7582", "class_name": "RelatedNodeInfo"}}, "text": "Brian, if you would \u2013 there's anything you would add to that?  \n ", "start_char_idx": 1227, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1337df31-8a45-4236-87ff-78e8a4ba73f5": {"__data__": {"id_": "1337df31-8a45-4236-87ff-78e8a4ba73f5", "embedding": null, "metadata": {"window": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "848b740c-de4e-420c-bebf-55d6eb6f92f7", "node_type": "1", "metadata": {"window": "In terms of GLP -1, again it's part of the broad set of products that we distribute on behalf of manufacturers to our \ncustomers.  One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "original_text": "Brian, if you would \u2013 there's anything you would add to that?  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa08d10af3a8220ea9c2aac4285b696b1eefe25f5f05d121aef3b07c3468073a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b", "node_type": "1", "metadata": {"window": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nI think that's well -done. "}, "hash": "90b06790d624ebb6779d71f2e17cf902ee4a44f4fe08288cfbeb2d8acf64dadd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "start_char_idx": 1292, "end_char_idx": 1622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b": {"__data__": {"id_": "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b", "embedding": null, "metadata": {"window": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nI think that's well -done. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1337df31-8a45-4236-87ff-78e8a4ba73f5", "node_type": "1", "metadata": {"window": "One of the other things I would remind you of is over the last several years, we've been on a journey \nto ensure that all products, regardless of the category, individually, are reflective of the economics that we receive \nin terms of how we p rice those back with our customers, so we're on that.  We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f304e64fc42985d280f6add838b7242c019e01230d6b997d4e6eadc8d56342c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d5d66e-b127-4da1-a27b-c38bc1b23624", "node_type": "1", "metadata": {"window": "Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. "}, "hash": "84a0f3e440da297e3a3ffb078202013b4f91b3ff9a0e48bbb2edd35f7cfb91e0", "class_name": "RelatedNodeInfo"}}, "text": "A \nI think that's well -done. ", "start_char_idx": 1622, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d5d66e-b127-4da1-a27b-c38bc1b23624": {"__data__": {"id_": "d5d5d66e-b127-4da1-a27b-c38bc1b23624", "embedding": null, "metadata": {"window": "Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b", "node_type": "1", "metadata": {"window": "We continue to be on that focus, and I \nthink we're well -positioned to do that as we go forward.  \n \n Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nI think that's well -done. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fcfd1b1d3d174258f1cb16ef4798ff88adb0018f593e3091f5b33b71b4161a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501d9f40-cf0d-4324-826c-4e8a763758ce", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n "}, "hash": "8ef167323e27c4866aff282ea8dc2086068bddbaf79a1dfb0a9ca0dd5e41fdba", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "start_char_idx": 1652, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501d9f40-cf0d-4324-826c-4e8a763758ce": {"__data__": {"id_": "501d9f40-cf0d-4324-826c-4e8a763758ce", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d5d66e-b127-4da1-a27b-c38bc1b23624", "node_type": "1", "metadata": {"window": "Brian, if you would \u2013 there's anything you would add to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eeef1e007860e69480aabff1818dafa199bba8ed861060eeba891661ae4a9f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92", "node_type": "1", "metadata": {"window": "A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "723eb0d86831bca7b1d74d4062daa5f136f28e2dc9ac4b14d68376b55205fd22", "class_name": "RelatedNodeInfo"}}, "text": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "start_char_idx": 1771, "end_char_idx": 1893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92": {"__data__": {"id_": "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92", "embedding": null, "metadata": {"window": "A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501d9f40-cf0d-4324-826c-4e8a763758ce", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer  & Director, McKesson Corp.   A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "119788b798142e4e4eb06b85cb0487f056c0c20daf3416301a275bc52747b0f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca3b5f2-c800-40d4-91c8-e6efccf5720f", "node_type": "1", "metadata": {"window": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide. ", "original_text": "A \nNext question, please.  \n "}, "hash": "3cde4d6c67a85a71b2bf5384770d473fd2644dbf86c4397b506e2f5bba24b501", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 1893, "end_char_idx": 2211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca3b5f2-c800-40d4-91c8-e6efccf5720f": {"__data__": {"id_": "6ca3b5f2-c800-40d4-91c8-e6efccf5720f", "embedding": null, "metadata": {"window": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92", "node_type": "1", "metadata": {"window": "A \nI think that's well -done.  Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f172c81ae81addcf483e617ab0c5e831b05f6d4fece6b05f3c5419a0f2d99b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca08383a-2d43-40a8-849e-bf87b1a4b3f9", "node_type": "1", "metadata": {"window": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n "}, "hash": "53909c4a4e0a400224089c56a8bf943f95c407b0756ba72c3ca14f60832cd437", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 2211, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca08383a-2d43-40a8-849e-bf87b1a4b3f9": {"__data__": {"id_": "ca08383a-2d43-40a8-849e-bf87b1a4b3f9", "embedding": null, "metadata": {"window": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca3b5f2-c800-40d4-91c8-e6efccf5720f", "node_type": "1", "metadata": {"window": "Obviously, it's hard to go anywhere these days without talking about GLP -1s, and I'd just \ncharacterize it generally.  I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a3ffbcddcf65e9849983cac76c1b76e8d485d9cf8e3752ce60eca60d0d242e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37158d28-6d09-4447-8f77-8129b3d4a7fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. "}, "hash": "e3923484e3ea59ab4c629fb8e4d42b43628e296e3a9e04dd45c382f497ea4c95", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 2240, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37158d28-6d09-4447-8f77-8129b3d4a7fd": {"__data__": {"id_": "37158d28-6d09-4447-8f77-8129b3d4a7fd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca08383a-2d43-40a8-849e-bf87b1a4b3f9", "node_type": "1", "metadata": {"window": "I think their growth will be positive for us and have a big impact on, hopefully, patients \nand health of the country.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "444629b02a3a1e88246f2571820e99cf1fc08917eee70b0c1d6a60a820f29369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4faa5c13-e364-4a85-ad62-271c3b1b676d", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n ", "original_text": "Good afternoon, guys, and  congrats again also on the guide. "}, "hash": "d1d93cd6469729a56e563229adc41fd8e2cbbdd45035a3b0bce5b9ec54f11338", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "start_char_idx": 2562, "end_char_idx": 2868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4faa5c13-e364-4a85-ad62-271c3b1b676d": {"__data__": {"id_": "4faa5c13-e364-4a85-ad62-271c3b1b676d", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n ", "original_text": "Good afternoon, guys, and  congrats again also on the guide. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37158d28-6d09-4447-8f77-8129b3d4a7fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "952a05e8d41a7f26a70e5829553a7eb490f694ac06c9233d28cb427f5d189091", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c4ed57e-6a2c-47f2-aa64-80555ddb6963", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. "}, "hash": "d000eb942a96c35d36eae04e081c6df55768565517a2c0ffb2c0d0a5f431a89a", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys, and  congrats again also on the guide. ", "start_char_idx": 2868, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c4ed57e-6a2c-47f2-aa64-80555ddb6963": {"__data__": {"id_": "6c4ed57e-6a2c-47f2-aa64-80555ddb6963", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4faa5c13-e364-4a85-ad62-271c3b1b676d", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n ", "original_text": "Good afternoon, guys, and  congrats again also on the guide. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62928dd8cd19d6af15353abe28f77907729a70093220d3594128495d7fed574", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba58546-5100-45b6-b6ba-ef4ee917d4b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? "}, "hash": "1d166db703fde35b62378de111444c1b41b97edfdd5548794fbfc2439c74d9bc", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "start_char_idx": 2929, "end_char_idx": 3120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba58546-5100-45b6-b6ba-ef4ee917d4b8": {"__data__": {"id_": "aba58546-5100-45b6-b6ba-ef4ee917d4b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c4ed57e-6a2c-47f2-aa64-80555ddb6963", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb5bfd880b5a702c7ef6af3c7d333031d746651371fe5faefe254ffb1ce69d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6ccaf2b-5030-4a3e-bf78-b91886ec2236", "node_type": "1", "metadata": {"window": "Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion. ", "original_text": "Thanks.  \n "}, "hash": "3abdeca0094ff48b890a868ac3fd4b6641e7e84e0e5b8e28e5700fc2e518bb9d", "class_name": "RelatedNodeInfo"}}, "text": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "start_char_idx": 3120, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6ccaf2b-5030-4a3e-bf78-b91886ec2236": {"__data__": {"id_": "a6ccaf2b-5030-4a3e-bf78-b91886ec2236", "embedding": null, "metadata": {"window": "Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba58546-5100-45b6-b6ba-ef4ee917d4b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi.  Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth? ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30f99cbde4a79fed00d8e27c51f6da2fcb1236da31fc277a59ac2a5c5153bf8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27", "node_type": "1", "metadata": {"window": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "9a925f4be3b458725a2bcd5a1b9474b85a33b8c66c683c972958400140b21a94", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3279, "end_char_idx": 3290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27": {"__data__": {"id_": "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27", "embedding": null, "metadata": {"window": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6ccaf2b-5030-4a3e-bf78-b91886ec2236", "node_type": "1", "metadata": {"window": "Good afternoon, guys, and  congrats again also on the guide.  I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44cb1cb716ab960b0ac23820ca3fb9fed581b455860bdfbe907782f3a95fb089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69d3b9c5-bd6c-4485-968a-e7093b0dd8be", "node_type": "1", "metadata": {"window": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS. ", "original_text": "A \nYeah. "}, "hash": "ca8513df2363cfdac0506b003bb3e5f8a3e51e82e2f3472bd676af47703ea641", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3290, "end_char_idx": 3635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69d3b9c5-bd6c-4485-968a-e7093b0dd8be": {"__data__": {"id_": "69d3b9c5-bd6c-4485-968a-e7093b0dd8be", "embedding": null, "metadata": {"window": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27", "node_type": "1", "metadata": {"window": "I guess, Britt, as I think about the guidance, \nobviously raising your operating income target, you don't have an EPS growth target here in like the last time \nwhen you did the Investor Day.  So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3514eeb87f0a25fb079108c760bebac1e7918055e0219c651a83d55a002cde9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee1de9c4-f928-41d7-8ff1-a3d68180f126", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "original_text": "Brian, thanks for that ques tion. "}, "hash": "9bfe02d9571582d7e8ff1d5f60133b05e3a0b274a133d5d2fae7ccb8c10fcef1", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3635, "end_char_idx": 3644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee1de9c4-f928-41d7-8ff1-a3d68180f126": {"__data__": {"id_": "ee1de9c4-f928-41d7-8ff1-a3d68180f126", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "original_text": "Brian, thanks for that ques tion. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69d3b9c5-bd6c-4485-968a-e7093b0dd8be", "node_type": "1", "metadata": {"window": "So, just curious if the bridge t o EPS has changed from the operating income \ntarget that you've laid out or maybe how should we be thinking about EPS growth?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48d2e3cdf9b4e33c3d8793dbcd4b00af85d5b0359f4d127c500cdf0ba83528a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8efbaa18-809f-454c-b06f-aef9cac23628", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "original_text": "I think what we've done here is we've updated the segments. "}, "hash": "9618fdac35c2dc6e68fd6d17fe0df5c280b1f0462ca7778f722cb5370cf7ada1", "class_name": "RelatedNodeInfo"}}, "text": "Brian, thanks for that ques tion. ", "start_char_idx": 3644, "end_char_idx": 3678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8efbaa18-809f-454c-b06f-aef9cac23628": {"__data__": {"id_": "8efbaa18-809f-454c-b06f-aef9cac23628", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "original_text": "I think what we've done here is we've updated the segments. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee1de9c4-f928-41d7-8ff1-a3d68180f126", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "original_text": "Brian, thanks for that ques tion. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c43a8989657231d044c8cf38e87f3e99b8559d2df8d25dfc420b05a5f537f21f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a403b965-0ec7-4c82-9ba2-6c7459ebe082", "node_type": "1", "metadata": {"window": "A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "original_text": "There really is \nno change to the range that we provided for adjusted EPS. "}, "hash": "43293fa43e3a6f2eda00fc0ace31550b8f1297f522fdea30a3e9da053353b72f", "class_name": "RelatedNodeInfo"}}, "text": "I think what we've done here is we've updated the segments. ", "start_char_idx": 3678, "end_char_idx": 3738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a403b965-0ec7-4c82-9ba2-6c7459ebe082": {"__data__": {"id_": "a403b965-0ec7-4c82-9ba2-6c7459ebe082", "embedding": null, "metadata": {"window": "A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "original_text": "There really is \nno change to the range that we provided for adjusted EPS. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8efbaa18-809f-454c-b06f-aef9cac23628", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "original_text": "I think what we've done here is we've updated the segments. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "448be2be0cdb5176c53c5947174fb0827a42e36168dbc2d28170ff305eccf647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9564c03-5744-4d7a-ae2a-707f7768d2af", "node_type": "1", "metadata": {"window": "Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. "}, "hash": "715377831d61c25a12c6282f26efa638fbf814ad6be2bc58d2c383981509c96e", "class_name": "RelatedNodeInfo"}}, "text": "There really is \nno change to the range that we provided for adjusted EPS. ", "start_char_idx": 3738, "end_char_idx": 3813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9564c03-5744-4d7a-ae2a-707f7768d2af": {"__data__": {"id_": "b9564c03-5744-4d7a-ae2a-707f7768d2af", "embedding": null, "metadata": {"window": "Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a403b965-0ec7-4c82-9ba2-6c7459ebe082", "node_type": "1", "metadata": {"window": "A \nYeah.  Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "original_text": "There really is \nno change to the range that we provided for adjusted EPS. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7adb064f73d3d9fd9ab263cd6463fbdfe541e7cde2793bf450951b3fd1fc329b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88c2fb3e-523e-432e-a61f-f2a8b10bc965", "node_type": "1", "metadata": {"window": "I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. "}, "hash": "d555b548fd3c789e5fccb7b4b89613a29e9d8de9e4a5432a8660abfcc1a82777", "class_name": "RelatedNodeInfo"}}, "text": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "start_char_idx": 3813, "end_char_idx": 4054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88c2fb3e-523e-432e-a61f-f2a8b10bc965": {"__data__": {"id_": "88c2fb3e-523e-432e-a61f-f2a8b10bc965", "embedding": null, "metadata": {"window": "I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9564c03-5744-4d7a-ae2a-707f7768d2af", "node_type": "1", "metadata": {"window": "Brian, thanks for that ques tion.  I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a80732886e50bd33d4a36b0ce0f9a4dd5f786d7d7f7d5e5d4a24bb7b9e66220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d63111-b3a7-4b04-93bc-27e640940232", "node_type": "1", "metadata": {"window": "There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n"}, "hash": "2d17221017b606c67a2acc62b392c0c1dff60abe5f8d5ee90b8366eef1b1a265", "class_name": "RelatedNodeInfo"}}, "text": "You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "start_char_idx": 4054, "end_char_idx": 4238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d63111-b3a7-4b04-93bc-27e640940232": {"__data__": {"id_": "92d63111-b3a7-4b04-93bc-27e640940232", "embedding": null, "metadata": {"window": "There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88c2fb3e-523e-432e-a61f-f2a8b10bc965", "node_type": "1", "metadata": {"window": "I think what we've done here is we've updated the segments.  There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A. ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a1c719792626e02d6521f2f356fa33a4a18c93aa7efced80cac5e63b5199f33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "560efba9-eaf8-4e99-b067-87c5118c4120", "node_type": "1", "metadata": {"window": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  "}, "hash": "f1422672826f0ce038616eebba646929b4d5c7d8120fb201917d9ecb3b470384", "class_name": "RelatedNodeInfo"}}, "text": "We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "start_char_idx": 4238, "end_char_idx": 4449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "560efba9-eaf8-4e99-b067-87c5118c4120": {"__data__": {"id_": "560efba9-eaf8-4e99-b067-87c5118c4120", "embedding": null, "metadata": {"window": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "391de6b5-664c-4a54-944c-01444b060505", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1904a0ead7e8b4e402778a553eb56ea359a0cc2c9e60f4524b783e6c602e05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d63111-b3a7-4b04-93bc-27e640940232", "node_type": "1", "metadata": {"window": "There really is \nno change to the range that we provided for adjusted EPS.  In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fc5296eaf21e9524dbf5d43a11f7efaff7b296cfdbd3e321871adbffab47610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5383fb40-242a-4d6e-b200-b5eb563cd3ff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "original_text": "McKesson Corp.  "}, "hash": "0639639ec32e4ad6bb02e0ddd1405502243413a9c4b07baed1e597587d89c441", "class_name": "RelatedNodeInfo"}}, "text": "There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "start_char_idx": 4449, "end_char_idx": 4771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5383fb40-242a-4d6e-b200-b5eb563cd3ff": {"__data__": {"id_": "5383fb40-242a-4d6e-b200-b5eb563cd3ff", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "560efba9-eaf8-4e99-b067-87c5118c4120", "node_type": "1", "metadata": {"window": "In one of the comments that I made, as we think about \ncapital deployment, we're going to continue to focus on growin g the business, whether that be organically in the \ninvestments that we make in it or more as we go -forward, more on M&A.  You saw us do a couple of really key \nM&A transactions last year that were right on strategy and, as you know, it generally takes a few years to get the \nfull synergies from that M&A.  We expect that we'll continue to do M&A on strategy at the right multiples and that \neven with the increase in the operating segment guidance, that the overall EPS guidance would still be within the \nrange.  \n \n There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "original_text": "There's opportunities, obviously, for us if we're able to generate some more capital deployment and we're able to \nget some acquisitions here that we can realize the synergies in an earlier manner for us to be at the upper end of \nthe range that we provided you, but really no change to the overall range in this update.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f653aef1e86c29258541e714eb8e15a0eb792e3fe38bf8c1c88aa2fae84fae58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00405df2-e191-4d27-ab4c-41f24126e2ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "c19031a1274b92becd21a32a60a5115c704136515749f34042fbd2f6dac68068", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00405df2-e191-4d27-ab4c-41f24126e2ac": {"__data__": {"id_": "00405df2-e191-4d27-ab4c-41f24126e2ac", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5383fb40-242a-4d6e-b200-b5eb563cd3ff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb37171bfee6d503cd24a9a4a8f9e853e652242743409a10f541b0670d62ebb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58b251a2-cae6-461a-8cea-288e885c95ff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well. ", "original_text": "A \nNext question, please.  \n "}, "hash": "f79114273ff1eb32e1d275287c0404de019d2ebcae089fa7dc6f169d2982f0c9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58b251a2-cae6-461a-8cea-288e885c95ff": {"__data__": {"id_": "58b251a2-cae6-461a-8cea-288e885c95ff", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00405df2-e191-4d27-ab4c-41f24126e2ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18ac960803276f6b729aef040ffb42556515efa792da8b8452626f9bb26e42a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84cd8bec-746a-4d42-b509-7191a7f1c628", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n "}, "hash": "3351cb9542f142ed1839ac3b2e098c573f18637278ddc83e0169b7e95a11092b", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 242, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84cd8bec-746a-4d42-b509-7191a7f1c628": {"__data__": {"id_": "84cd8bec-746a-4d42-b509-7191a7f1c628", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58b251a2-cae6-461a-8cea-288e885c95ff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f8b3148a4b79b44e464cf734df4c1280729fd71a9f3a610530322ec9e07d803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a0c615-aed7-4354-8f54-58e77da6b251", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. "}, "hash": "49c926b4f7331b2c9459a374806d34b05901a00d6af6148878d4d3e35645dd82", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "start_char_idx": 271, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a0c615-aed7-4354-8f54-58e77da6b251": {"__data__": {"id_": "17a0c615-aed7-4354-8f54-58e77da6b251", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84cd8bec-746a-4d42-b509-7191a7f1c628", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f14f7d7fdbecddd8d8341976875fee23a425aa6ab0cbfe2ac74760905ab32c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "original_text": "Thanks f or taking the questions, and congrats as well. "}, "hash": "b5177a37a991e7f4bb4c4e0e0a4fc3b37a99c844ca878d96c6990af923e0654d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "start_char_idx": 590, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c": {"__data__": {"id_": "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "original_text": "Thanks f or taking the questions, and congrats as well. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a0c615-aed7-4354-8f54-58e77da6b251", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beaeaeabf784432438466967a4497acf21ac938bb8bf36d6d8805e0413bfdc40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "253cb390-bd54-4d38-b0fb-b4f50139a9a5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "original_text": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. "}, "hash": "35a7a8d321372271046eec9f5929821af5735b4c4b17e2724a530ef7312ea674", "class_name": "RelatedNodeInfo"}}, "text": "Thanks f or taking the questions, and congrats as well. ", "start_char_idx": 891, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "253cb390-bd54-4d38-b0fb-b4f50139a9a5": {"__data__": {"id_": "253cb390-bd54-4d38-b0fb-b4f50139a9a5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "original_text": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "original_text": "Thanks f or taking the questions, and congrats as well. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a032973a9179a2d437059531b475711d3e4baec3a531680406110ba416f0da51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49821383-27dc-4fd8-afc6-c381d3338dd0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there. ", "original_text": "Pharma segment. "}, "hash": "931c8c184d6fb609131402697a5c0359ccab7b74a31cf9ec9021c3438c871ef2", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "start_char_idx": 947, "end_char_idx": 1085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49821383-27dc-4fd8-afc6-c381d3338dd0": {"__data__": {"id_": "49821383-27dc-4fd8-afc6-c381d3338dd0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there. ", "original_text": "Pharma segment. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "253cb390-bd54-4d38-b0fb-b4f50139a9a5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "original_text": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57cd70c9f41fb79b21c72e2f26806cc63f07e02e25e1dce9ade18e9bc448700f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95b5f1eb-cc49-4a38-ba8a-2ef02f496261", "node_type": "1", "metadata": {"window": "Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "original_text": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? "}, "hash": "4aab072c507702d8ea1e8dadca3825f4350bee22b5f0da27eedfb6d19afce684", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment. ", "start_char_idx": 1085, "end_char_idx": 1101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95b5f1eb-cc49-4a38-ba8a-2ef02f496261": {"__data__": {"id_": "95b5f1eb-cc49-4a38-ba8a-2ef02f496261", "embedding": null, "metadata": {"window": "Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "original_text": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49821383-27dc-4fd8-afc6-c381d3338dd0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there. ", "original_text": "Pharma segment. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16d5f33f6348e98cb5944830641d02a385032170eeff7eb6c06908ccb0d83f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc524a7-a81d-4240-9331-4c3e0b90d25c", "node_type": "1", "metadata": {"window": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "original_text": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? "}, "hash": "d03955a0c0988bd21c65d83a6305d295b6898706a4e9369f85fcd9db6d78b131", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "start_char_idx": 1101, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc524a7-a81d-4240-9331-4c3e0b90d25c": {"__data__": {"id_": "adc524a7-a81d-4240-9331-4c3e0b90d25c", "embedding": null, "metadata": {"window": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "original_text": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95b5f1eb-cc49-4a38-ba8a-2ef02f496261", "node_type": "1", "metadata": {"window": "Thanks f or taking the questions, and congrats as well.  I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "original_text": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95afa635d8d82a10f8ee4324fb499a9bf25765bca0391b9754243e1856581540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41275ad5-65d1-49dd-af0a-56370f1ba440", "node_type": "1", "metadata": {"window": "Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And maybe talk a little bit more about what's been going on there. "}, "hash": "2d1fc518dc73e78a22a7527eb60cbc9898d14b03f71447e663d3c0ac7189d71c", "class_name": "RelatedNodeInfo"}}, "text": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "start_char_idx": 1191, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41275ad5-65d1-49dd-af0a-56370f1ba440": {"__data__": {"id_": "41275ad5-65d1-49dd-af0a-56370f1ba440", "embedding": null, "metadata": {"window": "Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And maybe talk a little bit more about what's been going on there. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc524a7-a81d-4240-9331-4c3e0b90d25c", "node_type": "1", "metadata": {"window": "I wanted to focus a little bit on within the \u2013 going \nback to an earlier question about the increase in the long -term guide for the U.S.  Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "original_text": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9db9876e6be43df2aaba8dc232f3b3b1b570d306ee9f3a40d0e58472e8f0eff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599180c8-61d9-4fda-bf9f-ccf875155d08", "node_type": "1", "metadata": {"window": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? "}, "hash": "7c2990a77dd111f4c511f044bdf3b9f2931cf56cbe0b3596cc9ced9ba2bc7b3f", "class_name": "RelatedNodeInfo"}}, "text": "And maybe talk a little bit more about what's been going on there. ", "start_char_idx": 1271, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599180c8-61d9-4fda-bf9f-ccf875155d08": {"__data__": {"id_": "599180c8-61d9-4fda-bf9f-ccf875155d08", "embedding": null, "metadata": {"window": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41275ad5-65d1-49dd-af0a-56370f1ba440", "node_type": "1", "metadata": {"window": "Pharma segment.  Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And maybe talk a little bit more about what's been going on there. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81e46c07d3ac3fffa37bcd1fc978156f6c2c9dd5d971f98e9adf37f6237aaaaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c804cb5e-0e21-4231-8d46-8246d0098a88", "node_type": "1", "metadata": {"window": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt. ", "original_text": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n "}, "hash": "5894c18cc1812d0b21fa1992fad475563b869ba44043f9485a9c769a818c0861", "class_name": "RelatedNodeInfo"}}, "text": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "start_char_idx": 1338, "end_char_idx": 1473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c804cb5e-0e21-4231-8d46-8246d0098a88": {"__data__": {"id_": "c804cb5e-0e21-4231-8d46-8246d0098a88", "embedding": null, "metadata": {"window": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt. ", "original_text": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599180c8-61d9-4fda-bf9f-ccf875155d08", "node_type": "1", "metadata": {"window": "Can you talk a \nlittle bit more about Ontada and sort of t he progress you've made there?  The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate? ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5b471a84176936aaf9b7804425f8740d2d5eaece1ba7d27a8f06f0e52d666f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939", "node_type": "1", "metadata": {"window": "And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "1f42b7fdbd95ed6c05cc66522a5572f5801156261802bce7f0429c3fe1f18583", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "start_char_idx": 1473, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939": {"__data__": {"id_": "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939", "embedding": null, "metadata": {"window": "And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c804cb5e-0e21-4231-8d46-8246d0098a88", "node_type": "1", "metadata": {"window": "The increase in guide \u2013 long-term guide, \nwould you expect to come from Ontada?  And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt. ", "original_text": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d314aedd60044ed839ec3bfb0435f2ecb8c186213ed9dc23920f0ba9af962f74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efac3c90-4a0a-4437-83e2-e2fd43117a27", "node_type": "1", "metadata": {"window": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "original_text": "A \nYeah. "}, "hash": "7241286f9b7c242d48a15c82e9bf05a53ac7ddc02291260d37329eb9097f51c7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1756, "end_char_idx": 2085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efac3c90-4a0a-4437-83e2-e2fd43117a27": {"__data__": {"id_": "efac3c90-4a0a-4437-83e2-e2fd43117a27", "embedding": null, "metadata": {"window": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939", "node_type": "1", "metadata": {"window": "And maybe talk a little bit more about what's been going on there.  And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4723fa011effc68804561fdeeac0d56c9458c147de3cdcc485457d4925fbdcf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb4f9142-6d95-46bb-87c5-068f3e8bd908", "node_type": "1", "metadata": {"window": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess. ", "original_text": "Let me jump in on this one, Britt. "}, "hash": "94f3e8fba4b7fd6ac6d58c7802eea6fdd36cfefd015da8623240dbdbcb9526ab", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2085, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb4f9142-6d95-46bb-87c5-068f3e8bd908": {"__data__": {"id_": "bb4f9142-6d95-46bb-87c5-068f3e8bd908", "embedding": null, "metadata": {"window": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess. ", "original_text": "Let me jump in on this one, Britt. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efac3c90-4a0a-4437-83e2-e2fd43117a27", "node_type": "1", "metadata": {"window": "And I \nguess the JV with HCA, the Sarah Cannon Cancer Institute, is that part of  the Ontada sort of partnership or is that \nseparate?  Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2ee9c1a30c456b6ec339a92526c56dd394a1c2900f0f53b459600efd7ebe494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78b083da-3550-4dd3-bf2e-31d0beefea0f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n", "original_text": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. "}, "hash": "06c19d80f7b9a323a4c4d0a18b0b94f588e7d68c7ed3cbe783379555fb1befd1", "class_name": "RelatedNodeInfo"}}, "text": "Let me jump in on this one, Britt. ", "start_char_idx": 2094, "end_char_idx": 2129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78b083da-3550-4dd3-bf2e-31d0beefea0f": {"__data__": {"id_": "78b083da-3550-4dd3-bf2e-31d0beefea0f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n", "original_text": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb4f9142-6d95-46bb-87c5-068f3e8bd908", "node_type": "1", "metadata": {"window": "Just trying to understand a little bit more where we've gotten to at this point because I know a couple of \nyears ago when you announced it at the Investor Day, you kind of suggested it was kind of immate rial in the near -\nterm, but just trying to see how far we've gone so far.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess. ", "original_text": "Let me jump in on this one, Britt. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5115d51ae564a50e3783cf424e5f58e051c76f564ef48b3153fafd95e5e1d127", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d5548e6-4f99-4d6e-8f98-df528b62ea93", "node_type": "1", "metadata": {"window": "A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "original_text": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. "}, "hash": "1c9a4639d0f3ed9bbcafa27113e72be6a5b70833df7e4be15e3fc65716b51b56", "class_name": "RelatedNodeInfo"}}, "text": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "start_char_idx": 2129, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d5548e6-4f99-4d6e-8f98-df528b62ea93": {"__data__": {"id_": "8d5548e6-4f99-4d6e-8f98-df528b62ea93", "embedding": null, "metadata": {"window": "A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "original_text": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78b083da-3550-4dd3-bf2e-31d0beefea0f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n", "original_text": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "678088eb12724a43f33057bcd71b67f1847cac80f29fe6a95491dd2af4a4bbce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffbf5785-dc8f-4b76-9889-084b1252baad", "node_type": "1", "metadata": {"window": "Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "original_text": "We've \nmade tremendous progr ess. "}, "hash": "e15058102c5f0dc8758016bb21705ebffcd7dd5fd93e6a9b95b3c3524b5e2602", "class_name": "RelatedNodeInfo"}}, "text": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "start_char_idx": 2310, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffbf5785-dc8f-4b76-9889-084b1252baad": {"__data__": {"id_": "ffbf5785-dc8f-4b76-9889-084b1252baad", "embedding": null, "metadata": {"window": "Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "original_text": "We've \nmade tremendous progr ess. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d5548e6-4f99-4d6e-8f98-df528b62ea93", "node_type": "1", "metadata": {"window": "A \nYeah.  Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "original_text": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9837072e05acbb5d05388c8e56950190fa67dea4deecf132fdcd08a127690655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccb8548e-6149-49c8-a095-d2cf590de326", "node_type": "1", "metadata": {"window": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "original_text": "Had a record year of adding providers to the network last year, and that's a piece. \n"}, "hash": "d999d9456be7e5883a7ba5aeea7e3f8cca4f4b7ef7a6fc92a290c6e8f7f21bcf", "class_name": "RelatedNodeInfo"}}, "text": "We've \nmade tremendous progr ess. ", "start_char_idx": 2429, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccb8548e-6149-49c8-a095-d2cf590de326": {"__data__": {"id_": "ccb8548e-6149-49c8-a095-d2cf590de326", "embedding": null, "metadata": {"window": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "original_text": "Had a record year of adding providers to the network last year, and that's a piece. \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffbf5785-dc8f-4b76-9889-084b1252baad", "node_type": "1", "metadata": {"window": "Let me jump in on this one, Britt.  So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "original_text": "We've \nmade tremendous progr ess. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5fb6c291519d414331cef465538cc3a30c9a6e6994eaf16237be3cd50e8a4d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d0715f7-aba2-41a8-802d-6c3c043e3d73", "node_type": "1", "metadata": {"window": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "original_text": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n"}, "hash": "17c73cbb94c8d8c040d37e792a97e1e61c1de83c19a93c9d76d2b063187e6959", "class_name": "RelatedNodeInfo"}}, "text": "Had a record year of adding providers to the network last year, and that's a piece. \n", "start_char_idx": 2463, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d0715f7-aba2-41a8-802d-6c3c043e3d73": {"__data__": {"id_": "1d0715f7-aba2-41a8-802d-6c3c043e3d73", "embedding": null, "metadata": {"window": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "original_text": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccb8548e-6149-49c8-a095-d2cf590de326", "node_type": "1", "metadata": {"window": "So we call it an oncology ecosystem because we really think there is  this \nvalue of all of the pieces together, and I'm really pleased with the progress that we're making overall.  You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "original_text": "Had a record year of adding providers to the network last year, and that's a piece. \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e3821ec216229caa1cac439dc7159f36b309616cb0bd3ff7f670ca3705a768f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ed7b1be-e946-43db-b212-6f37ca2e5a94", "node_type": "1", "metadata": {"window": "We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "original_text": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n"}, "hash": "444566a3e1040a818daeef5380c07d261bc0871ee6b75251685277a1f7a8f033", "class_name": "RelatedNodeInfo"}}, "text": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "start_char_idx": 2548, "end_char_idx": 2634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ed7b1be-e946-43db-b212-6f37ca2e5a94": {"__data__": {"id_": "1ed7b1be-e946-43db-b212-6f37ca2e5a94", "embedding": null, "metadata": {"window": "We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "original_text": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d0715f7-aba2-41a8-802d-6c3c043e3d73", "node_type": "1", "metadata": {"window": "You've seen \nthe growth that both Britt and I talked about in The US Oncology Network now scaled over 2,300 providers.  We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "original_text": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c97b8de526349f65681a265c8bb401d7b5d67c4545945c1528e6c787f270d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "363dee2b-577c-4095-be3d-9128db57e527", "node_type": "1", "metadata": {"window": "Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "original_text": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. "}, "hash": "12fd9350beb51a100d382477d57be3e917f83f16e34ef86dc72c57ad0c0d227c", "class_name": "RelatedNodeInfo"}}, "text": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "start_char_idx": 2634, "end_char_idx": 2913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "363dee2b-577c-4095-be3d-9128db57e527": {"__data__": {"id_": "363dee2b-577c-4095-be3d-9128db57e527", "embedding": null, "metadata": {"window": "Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "original_text": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ed7b1be-e946-43db-b212-6f37ca2e5a94", "node_type": "1", "metadata": {"window": "We've \nmade tremendous progr ess.  Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "original_text": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd49744e0a36e476c60972b04dcb2a6984ffbde562e306fd405dc73624fc95ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60285116-e264-44f0-a035-ef2283e38d3b", "node_type": "1", "metadata": {"window": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution. ", "original_text": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n"}, "hash": "80282b700f3b22e6ef43552f8eeafcd49818163116aa5547867db89c0d1b93d1", "class_name": "RelatedNodeInfo"}}, "text": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "start_char_idx": 2913, "end_char_idx": 3145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60285116-e264-44f0-a035-ef2283e38d3b": {"__data__": {"id_": "60285116-e264-44f0-a035-ef2283e38d3b", "embedding": null, "metadata": {"window": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution. ", "original_text": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "363dee2b-577c-4095-be3d-9128db57e527", "node_type": "1", "metadata": {"window": "Had a record year of adding providers to the network last year, and that's a piece. \n And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "original_text": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60d6c3bf2bc60f910d27af5971e6d917c89c2b4800431a991af2354e9d026636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd1f9cde-2634-4955-aaf5-f1e7a9c97326", "node_type": "1", "metadata": {"window": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "original_text": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. "}, "hash": "71b91f20e6214353c98f60a58113e495ae1c5289145540982e3939d1564b0349", "class_name": "RelatedNodeInfo"}}, "text": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "start_char_idx": 3145, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd1f9cde-2634-4955-aaf5-f1e7a9c97326": {"__data__": {"id_": "bd1f9cde-2634-4955-aaf5-f1e7a9c97326", "embedding": null, "metadata": {"window": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "original_text": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60285116-e264-44f0-a035-ef2283e38d3b", "node_type": "1", "metadata": {"window": "And as that grows, that obviously feeds more data, give us more provider insight.  \n \n That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution. ", "original_text": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e92554d386b09c0d62f266f855147541eb0deb529bb88b6c3f1a85d6e269e940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc", "node_type": "1", "metadata": {"window": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "original_text": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n"}, "hash": "b140187b5d1076f3b73089824b434497a620155587b4a32d1fe5acad31e773e4", "class_name": "RelatedNodeInfo"}}, "text": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "start_char_idx": 3364, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc": {"__data__": {"id_": "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc", "embedding": null, "metadata": {"window": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "original_text": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd1f9cde-2634-4955-aaf5-f1e7a9c97326", "node_type": "1", "metadata": {"window": "That allows Ontada to continue to work with our partners to create products and serv ices that help them develop, \ncommercialize and get their products to market, and understand how to most effectively go to market to have the \nutilization and patient impact that they want.  \n \n We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "original_text": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68d7a076fbde960c7627bacceed83948d40f07be7111ac3a9df10d3f4e6111a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88887736-bfcc-439c-aa69-e473809bd9ba", "node_type": "1", "metadata": {"window": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So each of the pieces is sort of additive to the overall solution. "}, "hash": "ff1db8ccb3d892c4e8fa9843f3f02fa5f54f7747a5203c506a7a741b1b4a7d08", "class_name": "RelatedNodeInfo"}}, "text": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "start_char_idx": 3533, "end_char_idx": 3674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88887736-bfcc-439c-aa69-e473809bd9ba": {"__data__": {"id_": "88887736-bfcc-439c-aa69-e473809bd9ba", "embedding": null, "metadata": {"window": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So each of the pieces is sort of additive to the overall solution. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc", "node_type": "1", "metadata": {"window": "We think that Ontada is in year three or four of its development, b uilding off some assets that we have long had, \nbut we continue to invest in new product development and we continue to see that business improve year -over-\nyear.  We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "original_text": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af1a11fce2b23605b0b2b54979e51b5df3878e6b88625ecd70d0d55b92b8a1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cb16cf7-c878-4528-bac5-ec2e2c72f307", "node_type": "1", "metadata": {"window": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. "}, "hash": "4b07a923d88f679b65ebad097e236fb9f599d3236e2919c9d5785fed7711ae0d", "class_name": "RelatedNodeInfo"}}, "text": "So each of the pieces is sort of additive to the overall solution. ", "start_char_idx": 3674, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cb16cf7-c878-4528-bac5-ec2e2c72f307": {"__data__": {"id_": "3cb16cf7-c878-4528-bac5-ec2e2c72f307", "embedding": null, "metadata": {"window": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88887736-bfcc-439c-aa69-e473809bd9ba", "node_type": "1", "metadata": {"window": "We think the partnership with the joint venture we did for the Sarah Cannon Research Institute brings \nadditional insights, moves us up stage in the clinical trials in a very prominent way in the community setting.  \n \n So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So each of the pieces is sort of additive to the overall solution. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fa32693c46eb784049693ccbbca4d5256bfa25cb5b3f2563c0b6fa86452d130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c3f30a3-3568-48b3-8a5b-89188e137bae", "node_type": "1", "metadata": {"window": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n "}, "hash": "fab1c9a5b3bc4539c604454de8b33bec1767a852a83ea1c9f00478f0b09e10af", "class_name": "RelatedNodeInfo"}}, "text": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "start_char_idx": 3741, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c3f30a3-3568-48b3-8a5b-89188e137bae": {"__data__": {"id_": "5c3f30a3-3568-48b3-8a5b-89188e137bae", "embedding": null, "metadata": {"window": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cb16cf7-c878-4528-bac5-ec2e2c72f307", "node_type": "1", "metadata": {"window": "So again, we think that trial, early insight business, that helps feed Ontada, that helps our providers navigate the \nclinical care that they have to provide every day.  The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have. ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "803cb810a365654f0b67a71ecb693d81a73d3ebeda2fa2d12043b808cd85c52c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d59eb3f-46a5-41dc-9afb-e836e6d92057", "node_type": "1", "metadata": {"window": "So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "b10beb3685fc8fcc400626cdb6f021dc690238a6ae1abb62c24ede75a743addb", "class_name": "RelatedNodeInfo"}}, "text": "Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "start_char_idx": 4014, "end_char_idx": 4114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d59eb3f-46a5-41dc-9afb-e836e6d92057": {"__data__": {"id_": "4d59eb3f-46a5-41dc-9afb-e836e6d92057", "embedding": null, "metadata": {"window": "So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c3f30a3-3568-48b3-8a5b-89188e137bae", "node_type": "1", "metadata": {"window": "The insights we get from that clinical care can feed back through \nsome of our data assets to provide information back to the biopharma.  \n \n So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "650cfd8eb16a9e5d7c3fffeabae0d0afb1320e1ee7df8f401f6ac5791d2db4ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69023623-501c-4dbf-b670-e9adb632fec7", "node_type": "1", "metadata": {"window": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "A \nNext question, please.  "}, "hash": "2ca6fdcc99ab0aa829726e1c135479a1cd0c22d5fa3746137e16d4d3b23cd99a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 4114, "end_char_idx": 4432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69023623-501c-4dbf-b670-e9adb632fec7": {"__data__": {"id_": "69023623-501c-4dbf-b670-e9adb632fec7", "embedding": null, "metadata": {"window": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "A \nNext question, please.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1cd35437b12565e9dfdd783f08ce6f13146e805dbe5c10399fc4b52650e8f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d59eb3f-46a5-41dc-9afb-e836e6d92057", "node_type": "1", "metadata": {"window": "So each of the pieces is sort of additive to the overall solution.  And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a74540331e904dc3979d29fd7604c1deb78b9c8acc16d8826bb18deb14e25bfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f2dfd10-4cf0-44c8-975c-42699ccf4aa3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "McKesson Corp.  "}, "hash": "5b28abc67a68356a66439e247316167d1cbb36fed622fa2fcf2f232706b0ba37", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  ", "start_char_idx": 242, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f2dfd10-4cf0-44c8-975c-42699ccf4aa3": {"__data__": {"id_": "7f2dfd10-4cf0-44c8-975c-42699ccf4aa3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69023623-501c-4dbf-b670-e9adb632fec7", "node_type": "1", "metadata": {"window": "And I'd just say tha t while we're probably, I would \ncharacterize it, it's still an investment phase in Ontada because we still believe there's opportunity and a big long -\nterm market out there and lots of space for us to be innovating in with the unique assets we have.  Overall , I think \nit was a \u2013 we're very pleased with where our oncology business has developed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  ", "original_text": "A \nNext question, please.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0384534ff162cb3191eb575fab1d870189e77008e9b297b612a034600b2ffaa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n "}, "hash": "616ee05e9d6d6cc40ba4d57ed32c873165dd5d2db7da28cd8d060e8a53190ee9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd": {"__data__": {"id_": "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f2dfd10-4cf0-44c8-975c-42699ccf4aa3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "341265fdbb95d5a1747ffd9ff93931a1d4529f492443437c6fe48ce96643fc98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "192c3eaa261283d16c2a92951a7f8c85d84e19d32da065e149dd7a30c3e50b2f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3": {"__data__": {"id_": "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80dd38a3c24fe540b323f53b4b47ba4692fd079fff7fee5d812704f3d127cb22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "original_text": "Q \nHi. "}, "hash": "b98b2a8713c9f6ffe8fa6d819463348ddd499a3e88e9561ec3c4783a98dbd2b5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 243, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce": {"__data__": {"id_": "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "original_text": "Q \nHi. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "931643c30f7a28a6b3dab3642ffda0c40e8f6977c02a81540fc96ab25ae03041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "165128bb-0f24-4e6f-88a0-f3c2333c8d44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "original_text": "Thanks for taking the question. "}, "hash": "b73a0192ccafac7784be6bfc4519a5d605816a96479fc52e9b891354e4e54b74", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHi. ", "start_char_idx": 561, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "165128bb-0f24-4e6f-88a0-f3c2333c8d44": {"__data__": {"id_": "165128bb-0f24-4e6f-88a0-f3c2333c8d44", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "original_text": "Thanks for taking the question. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "original_text": "Q \nHi. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fae844abac47bef0a0bc866ac90b6040133d6d98c3dc17cfe73ec903ddb33bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "original_text": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. "}, "hash": "cccd3c6a3cd1911b53223c56b9707da18726691ba3ea4ed9c00820dfdc8292ec", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 568, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c": {"__data__": {"id_": "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "original_text": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "165128bb-0f24-4e6f-88a0-f3c2333c8d44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "original_text": "Thanks for taking the question. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae7b4ac6cb5f1a8ab1158588a6b60d6728083208c9f39ae520478fd098d69f27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62d69da5-5c0b-4b98-932a-5a97c1b6dad5", "node_type": "1", "metadata": {"window": "Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition. ", "original_text": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n "}, "hash": "c18ff5838bbba1aaffa47b685fee2b3a2278f88afc96c2487cc6103167da0fd6", "class_name": "RelatedNodeInfo"}}, "text": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "start_char_idx": 600, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62d69da5-5c0b-4b98-932a-5a97c1b6dad5": {"__data__": {"id_": "62d69da5-5c0b-4b98-932a-5a97c1b6dad5", "embedding": null, "metadata": {"window": "Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition. ", "original_text": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "original_text": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "096c2a9467163ac690149d13998b08b628a441f36e1416ddea214df1de1440b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f932a6f4-da64-4196-84e1-bb45bb823862", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. "}, "hash": "12f08919355445e73a3fdd0d14d327119866e911ad77629e4cf8205ccfd2ccf7", "class_name": "RelatedNodeInfo"}}, "text": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "start_char_idx": 797, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f932a6f4-da64-4196-84e1-bb45bb823862": {"__data__": {"id_": "f932a6f4-da64-4196-84e1-bb45bb823862", "embedding": null, "metadata": {"window": "Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62d69da5-5c0b-4b98-932a-5a97c1b6dad5", "node_type": "1", "metadata": {"window": "Q \nHi.  Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition. ", "original_text": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bc47a87894cd85feab6f1a28e380614b56a4c1b305f7efd7b25c24a8d9b13df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8b20d32-b48a-42f4-93a4-0938cf926631", "node_type": "1", "metadata": {"window": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there. ", "original_text": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. "}, "hash": "1f7026868a82ad44622e92a01b1fba274cb3fe25ef131ebb7f098b79c5206fe1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "start_char_idx": 956, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8b20d32-b48a-42f4-93a4-0938cf926631": {"__data__": {"id_": "a8b20d32-b48a-42f4-93a4-0938cf926631", "embedding": null, "metadata": {"window": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there. ", "original_text": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f932a6f4-da64-4196-84e1-bb45bb823862", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9953bfbefff9c11256aef4e20a86404a58dd9028e523934e4afac76fb1f19bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5", "node_type": "1", "metadata": {"window": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets. ", "original_text": "We have a leading distribution \nposition. "}, "hash": "8a22e6a52714f1db1af257c8007e5b9d905e4557e930d050120935b7e6a425d7", "class_name": "RelatedNodeInfo"}}, "text": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "start_char_idx": 1386, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5": {"__data__": {"id_": "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5", "embedding": null, "metadata": {"window": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets. ", "original_text": "We have a leading distribution \nposition. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8b20d32-b48a-42f4-93a4-0938cf926631", "node_type": "1", "metadata": {"window": "If I back out the impact of divestitures from the International business, looks \nlike you're growing Canada around 8% to 10% or so depending on what the Norway contribution is as sumed this \nyear.  Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there. ", "original_text": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b9140d9e37179419b25ee452738a2ae5c02b339547679ac1c732e25af22194b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1909773d-f224-478d-ab8b-610790cefbea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "original_text": "We have a leadin g retail banner position. "}, "hash": "bd5ef94c33b920797b5070067e5c4ef1befc3e1cca204abcedb5ffafe3ad210b", "class_name": "RelatedNodeInfo"}}, "text": "We have a leading distribution \nposition. ", "start_char_idx": 1498, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1909773d-f224-478d-ab8b-610790cefbea": {"__data__": {"id_": "1909773d-f224-478d-ab8b-610790cefbea", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "original_text": "We have a leadin g retail banner position. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5", "node_type": "1", "metadata": {"window": "Curious what's driving the strength of the Canadian business in 2024 and if your International guidance \ncontemplates a full year contribution from Norway?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets. ", "original_text": "We have a leading distribution \nposition. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a48e0c7fbe9540411ac7e0555e8732c8813057c0aff2ac81479d9dd000ea7ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b", "node_type": "1", "metadata": {"window": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "original_text": "We've got a leading chain pharmacy position there. "}, "hash": "0ccf7a98b3a692723bd8a3af73c9e6078515cb0269fdd444addbf5ac89e7c183", "class_name": "RelatedNodeInfo"}}, "text": "We have a leadin g retail banner position. ", "start_char_idx": 1540, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b": {"__data__": {"id_": "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b", "embedding": null, "metadata": {"window": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "original_text": "We've got a leading chain pharmacy position there. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1909773d-f224-478d-ab8b-610790cefbea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Cor p. A \nWell, we don't really break out Norway and Canada and talk about them separately.  But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "original_text": "We have a leadin g retail banner position. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f01892ee2c9eaf27b0d1f6587d6bda3b3ed25576d323adc2f0db0cfa392d4e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3a841f5-a648-4813-9a17-2ef13f5f570b", "node_type": "1", "metadata": {"window": "We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale. ", "original_text": "We've got \nbiopharma and specialty assets. "}, "hash": "4bc7b74fed78ad0fbf6e7c2d03882cbf41e954d00e1d5572b8836f37db7c3bd5", "class_name": "RelatedNodeInfo"}}, "text": "We've got a leading chain pharmacy position there. ", "start_char_idx": 1583, "end_char_idx": 1634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3a841f5-a648-4813-9a17-2ef13f5f570b": {"__data__": {"id_": "d3a841f5-a648-4813-9a17-2ef13f5f570b", "embedding": null, "metadata": {"window": "We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale. ", "original_text": "We've got \nbiopharma and specialty assets. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b", "node_type": "1", "metadata": {"window": "But what I will say about our \nCanadian business is we have, again, a very diversified set of assets in Canada.  We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "original_text": "We've got a leading chain pharmacy position there. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49066cefa15524f789c57ea189ee8c50cf5f2b653b012eda2cf9d4174640ec2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3d35c8-0764-49cd-a173-97ea662dda1f", "node_type": "1", "metadata": {"window": "We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "original_text": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n"}, "hash": "5c4188b43f14229f93c48a13e7200a25a957f08856688a9afe7515bac9298ce7", "class_name": "RelatedNodeInfo"}}, "text": "We've got \nbiopharma and specialty assets. ", "start_char_idx": 1634, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3d35c8-0764-49cd-a173-97ea662dda1f": {"__data__": {"id_": "ee3d35c8-0764-49cd-a173-97ea662dda1f", "embedding": null, "metadata": {"window": "We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "original_text": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3a841f5-a648-4813-9a17-2ef13f5f570b", "node_type": "1", "metadata": {"window": "We have a leading distribution \nposition.  We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale. ", "original_text": "We've got \nbiopharma and specialty assets. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b651a401c91d7ccb83433d5df32d64d178e63ad1dbef1a171a2200a30ea62ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67eccf82-b02e-4d23-bb26-e355420ad3f8", "node_type": "1", "metadata": {"window": "We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. "}, "hash": "c68ae82532ea7ca1cd7b8cf79f18b8eeb25561cfcceae3960957433d123d7b98", "class_name": "RelatedNodeInfo"}}, "text": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "start_char_idx": 1677, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67eccf82-b02e-4d23-bb26-e355420ad3f8": {"__data__": {"id_": "67eccf82-b02e-4d23-bb26-e355420ad3f8", "embedding": null, "metadata": {"window": "We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3d35c8-0764-49cd-a173-97ea662dda1f", "node_type": "1", "metadata": {"window": "We have a leadin g retail banner position.  We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "original_text": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40917f88bfd59724820226aab6cee8e28c18358cc730773a328aee75af0a1e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab6f415b-5c58-4e0d-9882-e01654ea2832", "node_type": "1", "metadata": {"window": "We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "original_text": "And I \nthink we've been able to leverage that scale. "}, "hash": "607ce2cce3a2f7eb64c49d0609f7e6866ed91aef1b0cb9f1372aebe5b13d7d56", "class_name": "RelatedNodeInfo"}}, "text": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "start_char_idx": 1862, "end_char_idx": 1971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab6f415b-5c58-4e0d-9882-e01654ea2832": {"__data__": {"id_": "ab6f415b-5c58-4e0d-9882-e01654ea2832", "embedding": null, "metadata": {"window": "We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "original_text": "And I \nthink we've been able to leverage that scale. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67eccf82-b02e-4d23-bb26-e355420ad3f8", "node_type": "1", "metadata": {"window": "We've got a leading chain pharmacy position there.  We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4f375fcf0c3ad7923c533ccc9c599c9658b66a3f3ea110965b133a0eb4279db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf", "node_type": "1", "metadata": {"window": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024. ", "original_text": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n "}, "hash": "81377c51995273f402a6ff170fe2639f8d3707b7dbebdfebac41a4126ff0b988", "class_name": "RelatedNodeInfo"}}, "text": "And I \nthink we've been able to leverage that scale. ", "start_char_idx": 1971, "end_char_idx": 2024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf": {"__data__": {"id_": "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf", "embedding": null, "metadata": {"window": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024. ", "original_text": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab6f415b-5c58-4e0d-9882-e01654ea2832", "node_type": "1", "metadata": {"window": "We've got \nbiopharma and specialty assets.  Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "original_text": "And I \nthink we've been able to leverage that scale. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c75492b6995e6e069a98eb9cf84728ff60dc6d9f9696e019aefd6775668ce364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97", "node_type": "1", "metadata": {"window": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "2090ffb9df31de238c0983ccff5d25a824fbffa074ab019314155a680dcc913a", "class_name": "RelatedNodeInfo"}}, "text": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "start_char_idx": 2024, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97": {"__data__": {"id_": "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97", "embedding": null, "metadata": {"window": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf", "node_type": "1", "metadata": {"window": "Now, those work very differently than the ones that work in the\u202fUS, but really, in \nmany ways, getting at kind of the same overall need ju st in a very different healthcare system.  \n \n And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024. ", "original_text": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a24dbca8b85b97449e28c01871e36acdf9b38e7350d4410c84e7d8d068376ade", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "471118b1-c54c-488a-b737-3f92a31a4911", "node_type": "1", "metadata": {"window": "And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway. "}, "hash": "724586ea6751bc6ddbd43fa46d55f5e4ef7c78bc210b7288eab47fac9afcebdc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2146, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "471118b1-c54c-488a-b737-3f92a31a4911": {"__data__": {"id_": "471118b1-c54c-488a-b737-3f92a31a4911", "embedding": null, "metadata": {"window": "And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97", "node_type": "1", "metadata": {"window": "And so, on the basis of our scale and our breadth, we are a really important player in the health of Canada.  And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60db28ddbcc5908bfdc6ee7c1f6b989792b86d7f8df2f6e1e4b0eadb8adc5058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "332c711e-d8a0-48f8-8dda-12e8a8b6a759", "node_type": "1", "metadata": {"window": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We do have Norway included in our \nfull year FY 2024. "}, "hash": "19d2ae6805a8b4b3c4c7155cbcfcad6de07f13128e070ebd12f4f48177a9a7f3", "class_name": "RelatedNodeInfo"}}, "text": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "start_char_idx": 2491, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "332c711e-d8a0-48f8-8dda-12e8a8b6a759": {"__data__": {"id_": "332c711e-d8a0-48f8-8dda-12e8a8b6a759", "embedding": null, "metadata": {"window": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We do have Norway included in our \nfull year FY 2024. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "471118b1-c54c-488a-b737-3f92a31a4911", "node_type": "1", "metadata": {"window": "And I \nthink we've been able to leverage that scale.  We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33c053c5fb1adf4491c5f5ece36c69a6a3224314966ca37ef3a6ea300c05bbc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87851154-9bb3-4f66-835f-c372e0a5ff6c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "original_text": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n "}, "hash": "66c4b37caf234a42d38c001dcecca981da6710258d9b5a1d555cccb64beedc43", "class_name": "RelatedNodeInfo"}}, "text": "We do have Norway included in our \nfull year FY 2024. ", "start_char_idx": 2570, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87851154-9bb3-4f66-835f-c372e0a5ff6c": {"__data__": {"id_": "87851154-9bb3-4f66-835f-c372e0a5ff6c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "original_text": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "332c711e-d8a0-48f8-8dda-12e8a8b6a759", "node_type": "1", "metadata": {"window": "We've been able to find efficiencies across the busi ness to continue \nto support growth that we're very pleased with.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We do have Norway included in our \nfull year FY 2024. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "899d5b9cf97f855f4daf1f01ce853193b3a21df1d9fd4df53d441658735bde2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d388c10-b6b0-41d2-aefb-240da36ff804", "node_type": "1", "metadata": {"window": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "5d994884c0b7b2a4c6326df2bc825f161329d3ce9e8966906895e1add42b2ae8", "class_name": "RelatedNodeInfo"}}, "text": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "start_char_idx": 2624, "end_char_idx": 2849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d388c10-b6b0-41d2-aefb-240da36ff804": {"__data__": {"id_": "5d388c10-b6b0-41d2-aefb-240da36ff804", "embedding": null, "metadata": {"window": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87851154-9bb3-4f66-835f-c372e0a5ff6c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "original_text": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fedbae1c25be0561477d7a3f59ad7cfa9e4cd96a741cbb43179d37395d1f321", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99195272-6f4f-4938-bcbb-645aa8febbdf", "node_type": "1", "metadata": {"window": "We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "A \nNext question, please.  \n "}, "hash": "a1b1437ab09913edf3c2a987699f63f987544e0b8be9fda50eb8b9c6eaed2123", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 2849, "end_char_idx": 3167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99195272-6f4f-4938-bcbb-645aa8febbdf": {"__data__": {"id_": "99195272-6f4f-4938-bcbb-645aa8febbdf", "embedding": null, "metadata": {"window": "We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d388c10-b6b0-41d2-aefb-240da36ff804", "node_type": "1", "metadata": {"window": "A \nMaybe I'll just answer the one mechanical question as it relates to Norway.  We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23d205713700b6d56dc989e9024a93ca5c982decec9d1fb02f74bf033afdbfdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4", "node_type": "1", "metadata": {"window": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n "}, "hash": "52cc1a44067af25422e90c556961a5eb283c01c2681a6704b0a5d66732dd1338", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3167, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4": {"__data__": {"id_": "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4", "embedding": null, "metadata": {"window": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99195272-6f4f-4938-bcbb-645aa8febbdf", "node_type": "1", "metadata": {"window": "We do have Norway included in our \nfull year FY 2024.  Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6a6202b7f0d3bbda5168e7e472569aad6e33c2c140538baa4fc0684d33c023f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa71b54f-4105-4fac-b408-409bc89c7a8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "6f388ca852d3486bc91ea90922e2a3749803aabbfe90a2760ff74fca6d6b6c82", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "start_char_idx": 3196, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa71b54f-4105-4fac-b408-409bc89c7a8f": {"__data__": {"id_": "fa71b54f-4105-4fac-b408-409bc89c7a8f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4", "node_type": "1", "metadata": {"window": "Just to repeat, though, we continue to strategically look for an opportunity to exit the European \noperations completely, which would be Norway, but you should anticipate that there is full year of Norway in our \nnumbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "206a75ba8c55770ad7d3a64456106814a4687580d892083680e2cb4300b0759b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3f3c1f-3992-4e52-b07b-507a1149d857", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "original_text": "Q \nHey. "}, "hash": "697fe149014a2db2366de85090524bb8700c5f0bb1f3416ad89269d9eada5731", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 3518, "end_char_idx": 3830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3f3c1f-3992-4e52-b07b-507a1149d857": {"__data__": {"id_": "3d3f3c1f-3992-4e52-b07b-507a1149d857", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "original_text": "Q \nHey. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa71b54f-4105-4fac-b408-409bc89c7a8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36f7b450a294f686456968f25643f4cede4ab67187f13ec9ff465d1e6da9c753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51be610-4650-46c4-8164-f3fbebac4a67", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "original_text": "Good afternoon, guys, and thanks for taking the question. "}, "hash": "d3ccab882caf509ec257ef084322d188605670968ab57d5eb7bffd55794ba8af", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey. ", "start_char_idx": 3830, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51be610-4650-46c4-8164-f3fbebac4a67": {"__data__": {"id_": "c51be610-4650-46c4-8164-f3fbebac4a67", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "original_text": "Good afternoon, guys, and thanks for taking the question. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3f3c1f-3992-4e52-b07b-507a1149d857", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "original_text": "Q \nHey. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e702970dc18fbff387fa680070cedbcd17b0e051b72715969cb5a19dd9634b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "140ba22c-11a7-4618-a3f2-df3db6e04fb7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "original_text": "Brian, I kind of want to come back to one more on \noncology. "}, "hash": "edf88db7694e05443120dfd49939b3bc3cc6f345c6958ecc81500ce857477256", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys, and thanks for taking the question. ", "start_char_idx": 3838, "end_char_idx": 3896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "140ba22c-11a7-4618-a3f2-df3db6e04fb7": {"__data__": {"id_": "140ba22c-11a7-4618-a3f2-df3db6e04fb7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "original_text": "Brian, I kind of want to come back to one more on \noncology. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51be610-4650-46c4-8164-f3fbebac4a67", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : The next will be George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "original_text": "Good afternoon, guys, and thanks for taking the question. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3366839b0f579cb368a0313ea2a0ac007f70fd70d045a60cd505500c9ad54c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea922582-0fc3-47f4-87dc-fe0c9703663b", "node_type": "1", "metadata": {"window": "Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there. ", "original_text": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. "}, "hash": "e4ce68b846694e2933c119ac6549eb7910560e904c9056995100e938aa52c94b", "class_name": "RelatedNodeInfo"}}, "text": "Brian, I kind of want to come back to one more on \noncology. ", "start_char_idx": 3896, "end_char_idx": 3957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea922582-0fc3-47f4-87dc-fe0c9703663b": {"__data__": {"id_": "ea922582-0fc3-47f4-87dc-fe0c9703663b", "embedding": null, "metadata": {"window": "Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there. ", "original_text": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "140ba22c-11a7-4618-a3f2-df3db6e04fb7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "original_text": "Brian, I kind of want to come back to one more on \noncology. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23aeefb2f15d2dbfa4b7a59c5c07eb11678cdfaf5593fe39a8ed030232d2b8db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa64914-dbde-4b16-9761-4c729319553a", "node_type": "1", "metadata": {"window": "Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n ", "original_text": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n"}, "hash": "213f386ed4256af1b65655aaef9fa539f22bdf3251ea43b12b5cc6da28f676e8", "class_name": "RelatedNodeInfo"}}, "text": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "start_char_idx": 3957, "end_char_idx": 4098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa64914-dbde-4b16-9761-4c729319553a": {"__data__": {"id_": "cfa64914-dbde-4b16-9761-4c729319553a", "embedding": null, "metadata": {"window": "Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n ", "original_text": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea922582-0fc3-47f4-87dc-fe0c9703663b", "node_type": "1", "metadata": {"window": "Q \nHey.  Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there. ", "original_text": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1581368ad63e1537b157cf42522969dc546c28be9e3cef473da03b02cc2a83d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09", "node_type": "1", "metadata": {"window": "Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. "}, "hash": "d25e728ec7889aa037f3980393806dd935a58661546cf32fa71cddd3dad41aee", "class_name": "RelatedNodeInfo"}}, "text": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "start_char_idx": 4098, "end_char_idx": 4267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09": {"__data__": {"id_": "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09", "embedding": null, "metadata": {"window": "Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa64914-dbde-4b16-9761-4c729319553a", "node_type": "1", "metadata": {"window": "Good afternoon, guys, and thanks for taking the question.  Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n ", "original_text": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a738edcf7dde306a26ba6335970b81f14d6a49b2680dabfc078b97002b4d1bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c95cb270-e3f4-43b4-b864-2a411b85632e", "node_type": "1", "metadata": {"window": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to figure out what inning we're in there. "}, "hash": "cb561c5396bcb1e0f50dbb802011e27b4cffa75c1a480b835f86d0b9c422cc0a", "class_name": "RelatedNodeInfo"}}, "text": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "start_char_idx": 4267, "end_char_idx": 4547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c95cb270-e3f4-43b4-b864-2a411b85632e": {"__data__": {"id_": "c95cb270-e3f4-43b4-b864-2a411b85632e", "embedding": null, "metadata": {"window": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to figure out what inning we're in there. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09", "node_type": "1", "metadata": {"window": "Brian, I kind of want to come back to one more on \noncology.  You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34759a8d04fe87eafd9f5f5fb66a4bc68190a920de180697c3ca433a92939ccb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307", "node_type": "1", "metadata": {"window": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thank you.  \n "}, "hash": "40e667b845c0b2f4f08c338f2d9c81f1a6e15972f671d0176d6f0ba4609691e1", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to figure out what inning we're in there. ", "start_char_idx": 4547, "end_char_idx": 4601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307": {"__data__": {"id_": "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307", "embedding": null, "metadata": {"window": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c95cb270-e3f4-43b4-b864-2a411b85632e", "node_type": "1", "metadata": {"window": "You guys announced a couple of smaller transactions in the prepared commentary, and your friends in \nPhiladelphia recently announced a deal.  I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to figure out what inning we're in there. ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7d609af132a1c526c61db1726e93095dc108a3934f657e8b667a6d9db98548c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8", "node_type": "1", "metadata": {"window": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "95c8a91db859ae5c2a634b9507401a8a8798edee909316985d13bb12387d7f72", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 4601, "end_char_idx": 4615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8": {"__data__": {"id_": "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8", "embedding": null, "metadata": {"window": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3889549a359a624fa171f0a1f94d5cdd6f3175249c19d79671be86d0a94d86e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307", "node_type": "1", "metadata": {"window": "I guess, I would ask, as you guys look out fro m kind of the practice \nmanagement and partnership perspective, how much greenfield opportunity do you guys see left?  \n \n And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a40b02813365693861fdbeb6907668611aaa3b44ccd013323caae7198e975aaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf5297e-9e50-4bce-90e7-e560bb4db893", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  "}, "hash": "d9bfdb7199590b34dbda5de7a4fee9fbb2db52f9490fc7907a8a47e98c72f362", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 243, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf5297e-9e50-4bce-90e7-e560bb4db893": {"__data__": {"id_": "dcf5297e-9e50-4bce-90e7-e560bb4db893", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8", "node_type": "1", "metadata": {"window": "And I know that you have the Ontada business that's budding, but would just kind of love how you think about the \nrunway to continue to eit her work more tightly with practices or help them grow their business, which serves as an \nopportunity to grow McKesson's business as well.  Just trying to figure out what inning we're in there.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e621b322df3b2aa545ed7bba5e26871553ce5c87ab74a9b004df650f98a15e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8131d783-575e-4a65-97a5-7134d59978ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  "}, "hash": "147082f9b15e304ab9d848d5ef0aab91806ddd1e396aec19ad99c08a583270f7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8131d783-575e-4a65-97a5-7134d59978ce": {"__data__": {"id_": "8131d783-575e-4a65-97a5-7134d59978ce", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf5297e-9e50-4bce-90e7-e560bb4db893", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "744e5dae5e0dd7e83639b7d2d3776df88a25431509a0cfdcdd15c29724783f82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1262f8cd-5cda-4219-b732-0b44a5a6ee52", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time. ", "original_text": "A \nYeah. "}, "hash": "448fdd28d79cb6ff5fa48968768273b0acce9e7ceee7955b3f0348253b7f15f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1262f8cd-5cda-4219-b732-0b44a5a6ee52": {"__data__": {"id_": "1262f8cd-5cda-4219-b732-0b44a5a6ee52", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time. ", "original_text": "A \nYeah. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8131d783-575e-4a65-97a5-7134d59978ce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "330c862aaacb0dd46ffaf121b3e80f43566ce9488f8240e5640d60795784597d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "194e54bb-4ea2-459a-833e-b6568572cdf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "original_text": "Thanks, George. "}, "hash": "bf3104aa36cc5eb52336291565eab92bc1ec5a58cb4b06b80ac7ea0a0d8c0f57", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 254, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "194e54bb-4ea2-459a-833e-b6568572cdf3": {"__data__": {"id_": "194e54bb-4ea2-459a-833e-b6568572cdf3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "original_text": "Thanks, George. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1262f8cd-5cda-4219-b732-0b44a5a6ee52", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time. ", "original_text": "A \nYeah. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9c86647257c3554a79b4fcb43c117dd5856b8776f31c85f0d25c1fe6d25f86c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c8734a-3a0d-4296-9148-ab78939fee28", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience. ", "original_text": "Thanks for the question. "}, "hash": "368ca5b9fc88840e15bff35127e86c3098b12fd367a710ad707cb9a686865bae", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, George. ", "start_char_idx": 263, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c8734a-3a0d-4296-9148-ab78939fee28": {"__data__": {"id_": "f3c8734a-3a0d-4296-9148-ab78939fee28", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience. ", "original_text": "Thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "194e54bb-4ea2-459a-833e-b6568572cdf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "original_text": "Thanks, George. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b068fc4401b104f80d5552204e93f88dba458249eb6ff1dfeefdf73dd9a4fda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "200e8234-c2ab-4be5-b4b7-9484aeac310b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "original_text": "So we've been at this for a long time. "}, "hash": "34e0b9c013d8a1af7c69f81206fbd62d40e019df14b4dd68b29f6ccaf2414cef", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 279, "end_char_idx": 304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "200e8234-c2ab-4be5-b4b7-9484aeac310b": {"__data__": {"id_": "200e8234-c2ab-4be5-b4b7-9484aeac310b", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "original_text": "So we've been at this for a long time. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c8734a-3a0d-4296-9148-ab78939fee28", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience. ", "original_text": "Thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7578bae49b89aa66aed795f127269db953e8c7e4b04d273c1e003fb3ee1c5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49a5b280-49de-440b-8544-32123dd1fcf3", "node_type": "1", "metadata": {"window": "Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services. ", "original_text": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. "}, "hash": "5c0a003c6525cdd73da7fd1e9904e3aac03f354e1837922f0115b2b00eb3642a", "class_name": "RelatedNodeInfo"}}, "text": "So we've been at this for a long time. ", "start_char_idx": 304, "end_char_idx": 343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49a5b280-49de-440b-8544-32123dd1fcf3": {"__data__": {"id_": "49a5b280-49de-440b-8544-32123dd1fcf3", "embedding": null, "metadata": {"window": "Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services. ", "original_text": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "200e8234-c2ab-4be5-b4b7-9484aeac310b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "original_text": "So we've been at this for a long time. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35268bb62c0dbf6de63e6a6560dd6a243a241e7ec639a9155f48b269d5a09ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e981570-17bf-4ea1-8b59-1f3bdd1e934c", "node_type": "1", "metadata": {"window": "Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "original_text": "We've got a lot of experience. "}, "hash": "be2815988319435064189cd642cf0fd168402ee1e634815a7a146d7a89069cad", "class_name": "RelatedNodeInfo"}}, "text": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "start_char_idx": 343, "end_char_idx": 411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e981570-17bf-4ea1-8b59-1f3bdd1e934c": {"__data__": {"id_": "4e981570-17bf-4ea1-8b59-1f3bdd1e934c", "embedding": null, "metadata": {"window": "Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "original_text": "We've got a lot of experience. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49a5b280-49de-440b-8544-32123dd1fcf3", "node_type": "1", "metadata": {"window": "Thanks, George.  Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services. ", "original_text": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2980e2e6422fcf840bd595f640c74d419e88435189ddc3d140a7bc73eeb3145d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0965eb8-0f85-40f6-9584-50bd094f1843", "node_type": "1", "metadata": {"window": "So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "original_text": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. "}, "hash": "9934eab1d8267ec1e1c7cdc93087d61a20e3ef623813c25ea7da369a8cbc0f65", "class_name": "RelatedNodeInfo"}}, "text": "We've got a lot of experience. ", "start_char_idx": 411, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0965eb8-0f85-40f6-9584-50bd094f1843": {"__data__": {"id_": "f0965eb8-0f85-40f6-9584-50bd094f1843", "embedding": null, "metadata": {"window": "So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "original_text": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e981570-17bf-4ea1-8b59-1f3bdd1e934c", "node_type": "1", "metadata": {"window": "Thanks for the question.  So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "original_text": "We've got a lot of experience. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1affd6528fc5b5f91e04d135eac0f6da098c93c3558f9ef1277df79e8f0cdb53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d575ce9-55ac-4906-a191-efb1ddf65eb6", "node_type": "1", "metadata": {"window": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "original_text": "Then, you can add on distribution and our GPO services. "}, "hash": "518f659aa2f0c36d13d4403420cf64e159d5fa56bff62518de42a20119766175", "class_name": "RelatedNodeInfo"}}, "text": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "start_char_idx": 442, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d575ce9-55ac-4906-a191-efb1ddf65eb6": {"__data__": {"id_": "1d575ce9-55ac-4906-a191-efb1ddf65eb6", "embedding": null, "metadata": {"window": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "original_text": "Then, you can add on distribution and our GPO services. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0965eb8-0f85-40f6-9584-50bd094f1843", "node_type": "1", "metadata": {"window": "So we've been at this for a long time.  I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "original_text": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cef9b4c0a9dc2d2816f7b331b9bcb45842d78210fe65e782f8172d44cc54307", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f17a854f-71e5-4e1a-b7a1-a9d2d882109b", "node_type": "1", "metadata": {"window": "We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model. ", "original_text": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n"}, "hash": "c59057f350c0a0a058244641f63d209ee95722793d174970a58da5516d0957b5", "class_name": "RelatedNodeInfo"}}, "text": "Then, you can add on distribution and our GPO services. ", "start_char_idx": 614, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f17a854f-71e5-4e1a-b7a1-a9d2d882109b": {"__data__": {"id_": "f17a854f-71e5-4e1a-b7a1-a9d2d882109b", "embedding": null, "metadata": {"window": "We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model. ", "original_text": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d575ce9-55ac-4906-a191-efb1ddf65eb6", "node_type": "1", "metadata": {"window": "I think we \nacquired\u202fUS\u202fOncology in 2010, so it's been a long time.  We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "original_text": "Then, you can add on distribution and our GPO services. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "842b6853c74c7889f900996cb522b335890ecfdf3b2498ab99535d5f8118d541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99", "node_type": "1", "metadata": {"window": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "original_text": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. "}, "hash": "e8526aca7e2d94fb268b0e1547cbb84ba8c641c2650f4089e8d165d73050c353", "class_name": "RelatedNodeInfo"}}, "text": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "start_char_idx": 670, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99": {"__data__": {"id_": "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99", "embedding": null, "metadata": {"window": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "original_text": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f17a854f-71e5-4e1a-b7a1-a9d2d882109b", "node_type": "1", "metadata": {"window": "We've got a lot of experience.  And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model. ", "original_text": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd4f3cddbb127e7f46246b7d9f0e7c7d3de64f8d13e141be8792952412352cca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23891df2-7595-4982-8e7d-3a7ffa2607fa", "node_type": "1", "metadata": {"window": "Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n"}, "hash": "37c9351427e0c28f7915ff306438694bda2dfb05303688d74690942e39b40860", "class_name": "RelatedNodeInfo"}}, "text": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "start_char_idx": 761, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23891df2-7595-4982-8e7d-3a7ffa2607fa": {"__data__": {"id_": "23891df2-7595-4982-8e7d-3a7ffa2607fa", "embedding": null, "metadata": {"window": "Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99", "node_type": "1", "metadata": {"window": "And if you think about the \nbreadth of our solution s in the community oncology space, I mean, you can start your relationship with McKesson \nwith just basic distribution.  Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "original_text": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab7a7911409e5f7876be875d63e809f6d4779fda83d8572036341c947132bff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8", "node_type": "1", "metadata": {"window": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have a very disciplined model for the types of practices that we think fi t the USON model. "}, "hash": "5f182089f64057b83ac9c0de1b479982ae43b6fe0a3e0ac81f47590287fc74f9", "class_name": "RelatedNodeInfo"}}, "text": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "start_char_idx": 1038, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8": {"__data__": {"id_": "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8", "embedding": null, "metadata": {"window": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have a very disciplined model for the types of practices that we think fi t the USON model. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23891df2-7595-4982-8e7d-3a7ffa2607fa", "node_type": "1", "metadata": {"window": "Then, you can add on distribution and our GPO services.  And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b7649a6c9962181e432cd2dc3f5f1476ad51d6dded93aa72df75e6bfa9e2074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db7e5d4f-8ea3-4988-adc8-a300bd9516ac", "node_type": "1", "metadata": {"window": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n "}, "hash": "5f45200168256d8dcd0b38424151d296fbd0ff1201bd4517d69f426341c6e7bb", "class_name": "RelatedNodeInfo"}}, "text": "We have a very disciplined model for the types of practices that we think fi t the USON model. ", "start_char_idx": 1197, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db7e5d4f-8ea3-4988-adc8-a300bd9516ac": {"__data__": {"id_": "db7e5d4f-8ea3-4988-adc8-a300bd9516ac", "embedding": null, "metadata": {"window": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8", "node_type": "1", "metadata": {"window": "And then, we have \u00e0 la carte \nservices to support you in the running of your pract ice. \n \n And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We have a very disciplined model for the types of practices that we think fi t the USON model. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838cc13f71ddb2b207a4c6117777289ed30d9eea387e1a848dce98127d4edb26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68c11c06-5220-4b19-83de-5355dcdce32d", "node_type": "1", "metadata": {"window": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "920bd7ed727bcd422a6e410a0876b394e6a49103501f2d4d5d27525c57e8adf5", "class_name": "RelatedNodeInfo"}}, "text": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "start_char_idx": 1292, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68c11c06-5220-4b19-83de-5355dcdce32d": {"__data__": {"id_": "68c11c06-5220-4b19-83de-5355dcdce32d", "embedding": null, "metadata": {"window": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db7e5d4f-8ea3-4988-adc8-a300bd9516ac", "node_type": "1", "metadata": {"window": "And that gives us great relationships, great insight into the practices that are out there in the community and\u202fhelps \nus really identify who we consider to be the leaders, businesses that are run with similar clinical and operational \nphilosophies to The US Oncology Network.  So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0698773d330294128aa068fe7285e1590663ba2b25634b1cbe0c39f2f884d748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591650fc-244a-4306-bdec-a580dcf82f29", "node_type": "1", "metadata": {"window": "We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "A \nNext question, please.  \n "}, "hash": "d7f05f43a9fa4dde28dc30c51bf99c5a55d8b6b63fc90ed56e03435868b19e71", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 1417, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591650fc-244a-4306-bdec-a580dcf82f29": {"__data__": {"id_": "591650fc-244a-4306-bdec-a580dcf82f29", "embedding": null, "metadata": {"window": "We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68c11c06-5220-4b19-83de-5355dcdce32d", "node_type": "1", "metadata": {"window": "So it's not uncommon to see us start with just a very transactional \nrelationship, but then\u202fover time\u202fgrow that into inclusion in The US Oncology Network.  \n \n We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56d9af1a05bf78cfba09c6b2027713a4ebf285e5c5c2869269796832dfe91236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3aaefff-ec9c-4891-bc8e-26296b20f35e", "node_type": "1", "metadata": {"window": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n "}, "hash": "0c1fb67c8aee3c9193946117f0cd901272b80a672b88e3fd265ea839a5c907cc", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1735, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3aaefff-ec9c-4891-bc8e-26296b20f35e": {"__data__": {"id_": "a3aaefff-ec9c-4891-bc8e-26296b20f35e", "embedding": null, "metadata": {"window": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591650fc-244a-4306-bdec-a580dcf82f29", "node_type": "1", "metadata": {"window": "We have a very disciplined model for the types of practices that we think fi t the USON model.  And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c17e836458b3fe3962904e4ad30213f2c89fb3e860e2bcc76d7b6aac9b726a94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. "}, "hash": "bb63f1ee5c8099f2b3a60256102d0e74bced0561db640f73d62691256dceeb4b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "start_char_idx": 1764, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8": {"__data__": {"id_": "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3aaefff-ec9c-4891-bc8e-26296b20f35e", "node_type": "1", "metadata": {"window": "And I think over the \nlast couple of years, you've seen us pretty successfully attract them into The US Oncology Network.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0d3dab4eaf8729dd831b23493f05d78e0c2c240a3facfb77ddcc1fa1f95d32e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd996a72-d1ee-47ef-b0bb-9634659a800a", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "original_text": "Thanks for taking my question. "}, "hash": "7e2d42efa6aee7029b82c8a1cbfb79837e0d764643defa98a50ad3690c331754", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "start_char_idx": 2079, "end_char_idx": 2389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd996a72-d1ee-47ef-b0bb-9634659a800a": {"__data__": {"id_": "cd996a72-d1ee-47ef-b0bb-9634659a800a", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5274cb22169e0febb8f7dc7ad17bbe1fb842586c47d3c0794f4f9502f867c9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7d8adc5-5120-4448-b226-06663db47995", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else. ", "original_text": "It's about the long -range plan. "}, "hash": "0e4f9d84a0550f7ca6d2a0732696cad6d869112e559166c82feba069c76b42a4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 2389, "end_char_idx": 2420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7d8adc5-5120-4448-b226-06663db47995": {"__data__": {"id_": "b7d8adc5-5120-4448-b226-06663db47995", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else. ", "original_text": "It's about the long -range plan. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd996a72-d1ee-47ef-b0bb-9634659a800a", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1b584479a35ad510e32107b365245ef5f7219bf6b28dc4952ac2e3a5dbec1f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5e4dd2-53a4-4313-b332-4633a2c47daa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "original_text": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. "}, "hash": "034244417097c6457fed2947801e0b0a4df13ceace6497fab26d6f7e3fe3bb3a", "class_name": "RelatedNodeInfo"}}, "text": "It's about the long -range plan. ", "start_char_idx": 2420, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5e4dd2-53a4-4313-b332-4633a2c47daa": {"__data__": {"id_": "1a5e4dd2-53a4-4313-b332-4633a2c47daa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "original_text": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7d8adc5-5120-4448-b226-06663db47995", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else. ", "original_text": "It's about the long -range plan. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87e9aa9652dce8cbc08a84e56c9c84e7b46cf8ac484dbb36ed7c47753d0a9773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d3ee402-e0e4-4bdf-aeb3-565c85606176", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. "}, "hash": "1dd99088188f8e409c1bbbbef71d1662cdcada3e6b939dcf60c572f668167437", "class_name": "RelatedNodeInfo"}}, "text": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "start_char_idx": 2453, "end_char_idx": 2542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d3ee402-e0e4-4bdf-aeb3-565c85606176": {"__data__": {"id_": "2d3ee402-e0e4-4bdf-aeb3-565c85606176", "embedding": null, "metadata": {"window": "Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5e4dd2-53a4-4313-b332-4633a2c47daa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "original_text": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d3bfb866964ebcfaac9dfbdbb0d9d337db828653a4ab1fe832bdeb613770fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9409e604-380d-4d76-b4a9-c8a86e281f53", "node_type": "1", "metadata": {"window": "It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question. ", "original_text": "So I'm just \nwondering if that's insulin or something else. "}, "hash": "780fcb4b2090a85cbd9e29711cf870500c929737b01b543c2f2e22d1ca08a071", "class_name": "RelatedNodeInfo"}}, "text": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "start_char_idx": 2542, "end_char_idx": 2713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9409e604-380d-4d76-b4a9-c8a86e281f53": {"__data__": {"id_": "9409e604-380d-4d76-b4a9-c8a86e281f53", "embedding": null, "metadata": {"window": "It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question. ", "original_text": "So I'm just \nwondering if that's insulin or something else. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d3ee402-e0e4-4bdf-aeb3-565c85606176", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae0d38339fece145b46651275f0f3042bb16b0435ab5ca00b60a458c2763c740", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b41069-4160-49e5-bb5e-cac433ff9195", "node_type": "1", "metadata": {"window": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order. ", "original_text": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n "}, "hash": "dd767ba68f4148524fdf491a603e44dac20d7d30907181a9ed5a228bdfa116e5", "class_name": "RelatedNodeInfo"}}, "text": "So I'm just \nwondering if that's insulin or something else. ", "start_char_idx": 2713, "end_char_idx": 2773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b41069-4160-49e5-bb5e-cac433ff9195": {"__data__": {"id_": "72b41069-4160-49e5-bb5e-cac433ff9195", "embedding": null, "metadata": {"window": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order. ", "original_text": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9409e604-380d-4d76-b4a9-c8a86e281f53", "node_type": "1", "metadata": {"window": "It's about the long -range plan.  If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question. ", "original_text": "So I'm just \nwondering if that's insulin or something else. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "773d9b229785851a302f735f4f1c6ff87f83393ce5a124ecf5755899520e466c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "293b71db-e864-49b0-a5be-b5befa76036f", "node_type": "1", "metadata": {"window": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "cac78b5881d061af4e2015cfa4d4d4b6b6ac57f0ec7a59fe816bc112e08fa43c", "class_name": "RelatedNodeInfo"}}, "text": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "start_char_idx": 2773, "end_char_idx": 2941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "293b71db-e864-49b0-a5be-b5befa76036f": {"__data__": {"id_": "293b71db-e864-49b0-a5be-b5befa76036f", "embedding": null, "metadata": {"window": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b41069-4160-49e5-bb5e-cac433ff9195", "node_type": "1", "metadata": {"window": "If I'm looking at the Pharma segment, it looks \nlike margins should be flat or maybe up.  You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order. ", "original_text": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ede4ec5bd2610e3e228096fedc6c60ad255526cccf293c24bbffe5090410196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2bcab34-f33a-4228-874a-efba9af7f609", "node_type": "1", "metadata": {"window": "So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "original_text": "A \nSo thanks for the question. "}, "hash": "1612e9925186b3c16e0564d2e5bbfe31286077fa31e90471f4607683f756a314", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2941, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2bcab34-f33a-4228-874a-efba9af7f609": {"__data__": {"id_": "d2bcab34-f33a-4228-874a-efba9af7f609", "embedding": null, "metadata": {"window": "So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "original_text": "A \nSo thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "293b71db-e864-49b0-a5be-b5befa76036f", "node_type": "1", "metadata": {"window": "You have operating income ki nd of growing in line, but yet for fiscal 2024, \nif we back out the COVID benefit, it's below, and\u202fmeaning this margin shrinkage is expected.  So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e81b8f416ba34635ab08795851b67ea89d906b014de3dde278b65b9aa79f938f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "592fd19c-a68c-4fc7-bbc3-02353e11cb69", "node_type": "1", "metadata": {"window": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "original_text": "Let me maybe answer these in reverse order. "}, "hash": "d48940fb12abeed0c49a8d30e3c6fa1d50a0b200f01e9014516c76600813147c", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo thanks for the question. ", "start_char_idx": 3286, "end_char_idx": 3317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "592fd19c-a68c-4fc7-bbc3-02353e11cb69": {"__data__": {"id_": "592fd19c-a68c-4fc7-bbc3-02353e11cb69", "embedding": null, "metadata": {"window": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "original_text": "Let me maybe answer these in reverse order. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2bcab34-f33a-4228-874a-efba9af7f609", "node_type": "1", "metadata": {"window": "So I'm just \nwondering if that's insulin or something else.  And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "original_text": "A \nSo thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb89f49ebe7adc0006d06b24e75ae33e7d57d8704ef109cfac1a30516096a67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01515455-1055-4819-8d1c-1eb134a080f5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "original_text": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n"}, "hash": "0823a4791fafd2e8237e041a6a15c7c07254a6fd393d7a3d178388bb010e8547", "class_name": "RelatedNodeInfo"}}, "text": "Let me maybe answer these in reverse order. ", "start_char_idx": 3317, "end_char_idx": 3361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01515455-1055-4819-8d1c-1eb134a080f5": {"__data__": {"id_": "01515455-1055-4819-8d1c-1eb134a080f5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "original_text": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "592fd19c-a68c-4fc7-bbc3-02353e11cb69", "node_type": "1", "metadata": {"window": "And then with the long -range plan, is the raising of the  long-range \nplan like from fiscal 2024 forward, or is it inclusive of what just happened in 2023 as well?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "original_text": "Let me maybe answer these in reverse order. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cebd033ba0a114cd873c8710ed764a94106ef10d20fa2636eb3b41acb48fdcd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13f1f4fa-9016-4dd3-9d29-7b2314511f56", "node_type": "1", "metadata": {"window": "A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "original_text": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. "}, "hash": "5ed4efd08ea3f4bcd5799afbd380e11eaf1b11eb451bed5d2862e3d69d43628a", "class_name": "RelatedNodeInfo"}}, "text": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "start_char_idx": 3361, "end_char_idx": 3591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13f1f4fa-9016-4dd3-9d29-7b2314511f56": {"__data__": {"id_": "13f1f4fa-9016-4dd3-9d29-7b2314511f56", "embedding": null, "metadata": {"window": "A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "original_text": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01515455-1055-4819-8d1c-1eb134a080f5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "original_text": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b853accd04bc4aeb0d1ed26c46815efe593ac09beb7019611b3ddb168578eb5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f61235b-256d-4b66-a886-547ddb346f54", "node_type": "1", "metadata": {"window": "Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n"}, "hash": "b5bd03e58ba2c2f3e3314c5bd2ddcbc20f83550749b7798c7a200e6f2f5ba59f", "class_name": "RelatedNodeInfo"}}, "text": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "start_char_idx": 3591, "end_char_idx": 3849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f61235b-256d-4b66-a886-547ddb346f54": {"__data__": {"id_": "7f61235b-256d-4b66-a886-547ddb346f54", "embedding": null, "metadata": {"window": "Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13f1f4fa-9016-4dd3-9d29-7b2314511f56", "node_type": "1", "metadata": {"window": "A \nSo thanks for the question.  Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "original_text": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f49092793b42dfef698fbd34e5f67186b2a14aac0df65b9a4638218c23837258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d", "node_type": "1", "metadata": {"window": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. "}, "hash": "c094b401018950c01578a9a373ae37e83ec30bad0c023cdc87bbd01ae058da07", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "start_char_idx": 3849, "end_char_idx": 3922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d": {"__data__": {"id_": "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d", "embedding": null, "metadata": {"window": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f61235b-256d-4b66-a886-547ddb346f54", "node_type": "1", "metadata": {"window": "Let me maybe answer these in reverse order.  What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e66e64c99e6901223011b82345bb2b5841b9984ebacf3a90fea1d668af986dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00dffc5b-8c6f-42fd-81a7-2fa30e928c20", "node_type": "1", "metadata": {"window": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n "}, "hash": "d83e0f7f2268bbcf7d2f2e1a1afc4a4dbc501b35183854668b1093012464e350", "class_name": "RelatedNodeInfo"}}, "text": "And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "start_char_idx": 3922, "end_char_idx": 4301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00dffc5b-8c6f-42fd-81a7-2fa30e928c20": {"__data__": {"id_": "00dffc5b-8c6f-42fd-81a7-2fa30e928c20", "embedding": null, "metadata": {"window": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d", "node_type": "1", "metadata": {"window": "What we've done here is provide you \nour FY 2024 outlook, and at the same time, looking back at our performance over the previous five years, \nupdating our guidance going forward from fiscal 2024 forward as a\u202flong -term\u202frate.  \n \n As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward. ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "584d2e0e6121b4d742f0a9e0bcdd5b7544401c3578008f22faa9694dc16a35bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd813d48-249a-4ea9-8b3d-82abd7e8300d", "node_type": "1", "metadata": {"window": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "97b760d95a89b7fb77cc05f6fa003b6e47520860068841d4ff94353bca59910c", "class_name": "RelatedNodeInfo"}}, "text": "So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "start_char_idx": 4301, "end_char_idx": 4435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd813d48-249a-4ea9-8b3d-82abd7e8300d": {"__data__": {"id_": "dd813d48-249a-4ea9-8b3d-82abd7e8300d", "embedding": null, "metadata": {"window": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323825da-6b17-4d36-a862-1a0d79370fb3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63211e256b210a7e3d8a30fea7cfa8e69df1de24a2f9c12b972e4a18848e5c3a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00dffc5b-8c6f-42fd-81a7-2fa30e928c20", "node_type": "1", "metadata": {"window": "As we look at the  margins year -over-year, I think there's a few things that will impact this, clearly, the mix of both \nproducts and services that we provide with a heavier and faster -growing specialty product portfolio, as well as the \nmix of customers.  We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8698bd0835748472ed1d029fe89222242aadf1d68114d1098db371c8eeec3cd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e69e437-f39a-4d79-b779-33e32b001885", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "McKesson Corp.  "}, "hash": "720cd9557c46db01274db53cc5e18034773e3ce7f5380149fa4d6339c3fa689c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 1417, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e69e437-f39a-4d79-b779-33e32b001885": {"__data__": {"id_": "7e69e437-f39a-4d79-b779-33e32b001885", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd813d48-249a-4ea9-8b3d-82abd7e8300d", "node_type": "1", "metadata": {"window": "We continue to see g rowth \u2013 faster growth in our largest customers.  \n \n And then the last thing I would say is, we are very proud of the oncology business that we're putting together, \nincluding our Ontada business and Sarah Cannon Research, and we're continuing to invest in thos e capabilities \nand services to support a lot of what Brian just talked about in terms of how we really think about the growth \nopportunities that we have going forward.  So I think those would be the couple things that I would point out that \ncould lead to ma rgin variation from one year to another.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecff42ff6fa6795e46340880a76cd54bc146fa946e30ae557145b9aabba1c4f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aedb8a6a-32da-4259-b428-fd744d864b99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "3f8f6edbf9040e173f25bfd846145aed424df3c7cfe4f01ef98e6be142ddab51", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aedb8a6a-32da-4259-b428-fd744d864b99": {"__data__": {"id_": "aedb8a6a-32da-4259-b428-fd744d864b99", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e69e437-f39a-4d79-b779-33e32b001885", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c39d735f735531dc27a50289553915e0cd2699b6ceccbc612b738ab17eaf2231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b5bbbe-2f47-46af-8efe-8bec52cef542", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question, please.  \n "}, "hash": "8d85c3f68971b32e467640325c3e24201077025af405f455602258c7f6769568", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b5bbbe-2f47-46af-8efe-8bec52cef542": {"__data__": {"id_": "09b5bbbe-2f47-46af-8efe-8bec52cef542", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aedb8a6a-32da-4259-b428-fd744d864b99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "701d50105f31adf3213dd33f126bc66e8df833317fb438a5982423e1b7ac5be9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf09175b-8f45-4877-a922-0d983226a1fd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n "}, "hash": "3c2cdc121ad5e37911922640a2cbac5c6cf83b0cfd74804bea01b192cc4d6a82", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 242, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf09175b-8f45-4877-a922-0d983226a1fd": {"__data__": {"id_": "cf09175b-8f45-4877-a922-0d983226a1fd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b5bbbe-2f47-46af-8efe-8bec52cef542", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f6cc717c2a56bfab549cd2a95f15a469f57a18de6877986ccf20b60da0ad72a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "675dea38-5fe9-4f9d-85b4-208dcb69db69", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "5c6d24ccb802179225b11ed95191d098e2e541a982d54821260de37749e0e326", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "start_char_idx": 271, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "675dea38-5fe9-4f9d-85b4-208dcb69db69": {"__data__": {"id_": "675dea38-5fe9-4f9d-85b4-208dcb69db69", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf09175b-8f45-4877-a922-0d983226a1fd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7e2d14a52e8f5e1366b4adeb8e1b55ee26a8a7c997d631a1470bf2717d18e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7c8720-c5a8-41e5-8094-35c1a2f18043", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "original_text": "Q \nThanks. "}, "hash": "273c5f033b591caad8142e3e9d40c3ab187459e3e34e758bbe550a81da237e1e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 594, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7c8720-c5a8-41e5-8094-35c1a2f18043": {"__data__": {"id_": "ce7c8720-c5a8-41e5-8094-35c1a2f18043", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "original_text": "Q \nThanks. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "675dea38-5fe9-4f9d-85b4-208dcb69db69", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7e54b83cff2c65a80b8f1f90c50e7089be9b122a2690fd211dc6b9d6cce664c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n ", "original_text": "Good\u202fafternoon, everybody. "}, "hash": "e1f1da9000f13c99a1293e2df5f1827bf77e607146548f0bac13dc19087d117c", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 907, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d": {"__data__": {"id_": "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n ", "original_text": "Good\u202fafternoon, everybody. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7c8720-c5a8-41e5-8094-35c1a2f18043", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "original_text": "Q \nThanks. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a43d1e898c430687105024a464638a4437222022e8971308922ab270797a5945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c09f95f-6e42-4877-8664-ebbc6d699596", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. "}, "hash": "4792047e549ef2d4cbd678c12aee0fad75149dbc5feb7a17cc8ae9450e214215", "class_name": "RelatedNodeInfo"}}, "text": "Good\u202fafternoon, everybody. ", "start_char_idx": 918, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c09f95f-6e42-4877-8664-ebbc6d699596": {"__data__": {"id_": "5c09f95f-6e42-4877-8664-ebbc6d699596", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n ", "original_text": "Good\u202fafternoon, everybody. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a942e0c4ab6485f583078ca3318b45d5f2b7d8ff7a9c0f8237f7288f4c1b54db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c1fc86-f0b3-489d-8c06-3442c5717b6b", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "original_text": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. "}, "hash": "f1e2eee4f8831e4fb677360980aff89ddd63d538247d33bf424a69d98afeac30", "class_name": "RelatedNodeInfo"}}, "text": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "start_char_idx": 945, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c1fc86-f0b3-489d-8c06-3442c5717b6b": {"__data__": {"id_": "89c1fc86-f0b3-489d-8c06-3442c5717b6b", "embedding": null, "metadata": {"window": "Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "original_text": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c09f95f-6e42-4877-8664-ebbc6d699596", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f75d0f2f9aafbdd8fdb38fec087a543143ae0fd3c4822113fac8322eb00e912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0641df9-1e70-4231-b79b-9647ea3826d3", "node_type": "1", "metadata": {"window": "Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "original_text": "Thanks.  \n "}, "hash": "3436242ba3deac69589ccdf7d8ee1033aed38c7b8130409ea1c632687b31c967", "class_name": "RelatedNodeInfo"}}, "text": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "start_char_idx": 1069, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0641df9-1e70-4231-b79b-9647ea3826d3": {"__data__": {"id_": "b0641df9-1e70-4231-b79b-9647ea3826d3", "embedding": null, "metadata": {"window": "Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c1fc86-f0b3-489d-8c06-3442c5717b6b", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "original_text": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c618622c15e8a821cc5dd56f47056837dd307b114b2e9439809431506c1ba86a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e", "node_type": "1", "metadata": {"window": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "71efb4ba0ada374d4dc55f588c73b676b34dac36d8baa98ae663443c595890ee", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1306, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e": {"__data__": {"id_": "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e", "embedding": null, "metadata": {"window": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0641df9-1e70-4231-b79b-9647ea3826d3", "node_type": "1", "metadata": {"window": "Good\u202fafternoon, everybody.  Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ab210c7a31d221d57d278d6352cd700261b8ff605f409eb5d1aa784bcbe689e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aebfa07d-62d4-4386-b21a-4818bc221fb1", "node_type": "1", "metadata": {"window": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. "}, "hash": "a82098c9a1d625e8956645f6aa7153ca7c0021c567a91c28b10ecfb65e374f30", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1317, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aebfa07d-62d4-4386-b21a-4818bc221fb1": {"__data__": {"id_": "aebfa07d-62d4-4386-b21a-4818bc221fb1", "embedding": null, "metadata": {"window": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e", "node_type": "1", "metadata": {"window": "Just on the 340B topic, I think some questions on that as far as exposure for \nMcKesson kind of heading into these results.  I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7953f8bea6c526ae978b3bc656c8dcde72ea7a78db091591c29fcf302874684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb541d27-0d5b-40a7-bbf1-ef30e021f78e", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "original_text": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n "}, "hash": "7102aa8d0090ae1325b605d028f703d50a4fd63c37825078d57a1a1673b90602", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "start_char_idx": 1662, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb541d27-0d5b-40a7-bbf1-ef30e021f78e": {"__data__": {"id_": "eb541d27-0d5b-40a7-bbf1-ef30e021f78e", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "original_text": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aebfa07d-62d4-4386-b21a-4818bc221fb1", "node_type": "1", "metadata": {"window": "I guess I'm just curious, for fiscal 2024 guidance, what's baked into \nthe outlook for any sort of 340B imp act and how that compares to fiscal 2023, if that's even material, one way or \nthe other, just wanted to get some color on that.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e5d578e347ba8bad4c8805c1e8bff0b96d5addc4718fef0f2f05ae5f6baf6a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "bc0d5592fe3f6be5869a13e637f398dfa846d3249ed01ac1220a49da69566d45", "class_name": "RelatedNodeInfo"}}, "text": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "start_char_idx": 1783, "end_char_idx": 1899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac": {"__data__": {"id_": "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb541d27-0d5b-40a7-bbf1-ef30e021f78e", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "original_text": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4abe106a4a438569014ae54f4fec55ecd3efe6a6df0d15784ae03ab6d7560b8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9458e0f0-8932-43b6-8276-879e92b28306", "node_type": "1", "metadata": {"window": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question, please.  \n "}, "hash": "db44facd4d3dbabe63e5859a4b7571bafd9d728d8ea217bd3ff10b77180d21b7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 1899, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9458e0f0-8932-43b6-8276-879e92b28306": {"__data__": {"id_": "9458e0f0-8932-43b6-8276-879e92b28306", "embedding": null, "metadata": {"window": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb332cd5bcf5a6399adebe615f71ef85b28ebb0ead4ef638ed4bf8dab520f049", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "848f7a0c-2362-4c6e-a17c-3cda777ea364", "node_type": "1", "metadata": {"window": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n "}, "hash": "89c64595e2c58ce8f549694e3b0d55dc3ed5597f767892bcbf9679a5ba8b9b24", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 242, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "848f7a0c-2362-4c6e-a17c-3cda777ea364": {"__data__": {"id_": "848f7a0c-2362-4c6e-a17c-3cda777ea364", "embedding": null, "metadata": {"window": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9458e0f0-8932-43b6-8276-879e92b28306", "node_type": "1", "metadata": {"window": "A \nYeah, mechanically, clearly, w e feel like we're well -positioned to manage through any impacts that come from \n340B.  Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat. ", "original_text": "A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9c154c4eaa3679f9706535fe1870ab3e36837728d132e52fd988120ce0ab2a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0102954d-3a3a-4d0d-b77a-7642223701ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "5ce333d9bdaaf2dd2372eb5c63801d9ba9632ce6e440647989359ee690d69ceb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "start_char_idx": 2246, "end_char_idx": 2569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0102954d-3a3a-4d0d-b77a-7642223701ab": {"__data__": {"id_": "0102954d-3a3a-4d0d-b77a-7642223701ab", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "848f7a0c-2362-4c6e-a17c-3cda777ea364", "node_type": "1", "metadata": {"window": "Any impacts that will come from that are assumed within our guidance, so there's nothing additional to call \nout. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67ea13a36cf9d945c65934e51aaa7fc6457305799622e5e7a9251e5a6267e32c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "original_text": "LLC  Q \nGreat. "}, "hash": "8d3d6d14626687e2e0638526ba247a61bead15e1ae5cccdd5b23d7e978be240a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 2569, "end_char_idx": 2877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee": {"__data__": {"id_": "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "original_text": "LLC  Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0102954d-3a3a-4d0d-b77a-7642223701ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6f5d0b017dc79a287079e9fdade6437a37cbd290cae2e06eb004a5f5248c2a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c01eabe-df2e-409f-864c-f0752422c284", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "original_text": "Thanks for taking the question. "}, "hash": "264c698b3e42af20ca2d4a9c9febac64f23920258cb657e8fb30ecb40c3d5a3b", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 2877, "end_char_idx": 2892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c01eabe-df2e-409f-864c-f0752422c284": {"__data__": {"id_": "7c01eabe-df2e-409f-864c-f0752422c284", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "original_text": "Thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "original_text": "LLC  Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19e5eaf85b742bb616a8518bb16586c2712bef6c685a78910545251ed9f83539", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa045180-0595-489e-bc72-3af39ee5e943", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n ", "original_text": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? "}, "hash": "6c6a405a8d5979090b5559fa1e0d6fbd321ef49b19c38c82877a6265a236e0d7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2892, "end_char_idx": 2924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa045180-0595-489e-bc72-3af39ee5e943": {"__data__": {"id_": "aa045180-0595-489e-bc72-3af39ee5e943", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n ", "original_text": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c01eabe-df2e-409f-864c-f0752422c284", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Erin Wright with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "original_text": "Thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46e3a44ffcffa72186cd63eef0d9203f40fa23487ae9be91873c45ea6fe21dff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f26e72-3ed5-43b1-a197-4ebd8b13a429", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And is there anything to call out there or changes in fundamentals across the \ngenerics business? "}, "hash": "3a23d275374f5bb9a4e3d0fe9c39a31ab136fba0d1c854f2c53fb27509dba16e", "class_name": "RelatedNodeInfo"}}, "text": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "start_char_idx": 2924, "end_char_idx": 3030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f26e72-3ed5-43b1-a197-4ebd8b13a429": {"__data__": {"id_": "62f26e72-3ed5-43b1-a197-4ebd8b13a429", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa045180-0595-489e-bc72-3af39ee5e943", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n ", "original_text": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c723e2f899de449ce00683e1c08df9e42f0c2e85e4a716b694ff836c066e76fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b94874d2-753c-4203-83bf-086856619fcf", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions. ", "original_text": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? "}, "hash": "f2fdeb4cd0be76128b28fff6645db85c8cf31376effc62a4ca828a7070e08480", "class_name": "RelatedNodeInfo"}}, "text": "And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "start_char_idx": 3030, "end_char_idx": 3128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b94874d2-753c-4203-83bf-086856619fcf": {"__data__": {"id_": "b94874d2-753c-4203-83bf-086856619fcf", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions. ", "original_text": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f26e72-3ed5-43b1-a197-4ebd8b13a429", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And is there anything to call out there or changes in fundamentals across the \ngenerics business? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "535d2474b6cab4044e6d612592432241b7f5a0c5bcbf72bc96e039635ff314d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5", "node_type": "1", "metadata": {"window": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "original_text": "Thanks.  \n "}, "hash": "8ed2ff7669c0cd1d628fd7c156634bc62cb8f23314fede7fb17d1cb5ff72e941", "class_name": "RelatedNodeInfo"}}, "text": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "start_char_idx": 3128, "end_char_idx": 3258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5": {"__data__": {"id_": "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5", "embedding": null, "metadata": {"window": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b94874d2-753c-4203-83bf-086856619fcf", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions. ", "original_text": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness? ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dde529bd69caa3693333c7183b23200fa92a507acbc847b06a98c24e04f17b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18", "node_type": "1", "metadata": {"window": "And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "79e1990203e524bb6905084baa242136f14f2b82c05af13ed858056918fa7063", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1306, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18": {"__data__": {"id_": "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18", "embedding": null, "metadata": {"window": "And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5", "node_type": "1", "metadata": {"window": "Can you comment a little bit on the dynamics of what's driving the strength \nacross the generics program?  And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cf765fc4172a1c98ccfcc1d4fd87ca91b21aaa01038cc6d42447de1d8ba5e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea33748-0e1a-46d6-8aa8-be529dc0236f", "node_type": "1", "metadata": {"window": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "original_text": "A \nThanks for the questions. "}, "hash": "95697704798f475de05c82dadc62fcf29d83e5f468d53db99282e367dfeaaf21", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1317, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea33748-0e1a-46d6-8aa8-be529dc0236f": {"__data__": {"id_": "dea33748-0e1a-46d6-8aa8-be529dc0236f", "embedding": null, "metadata": {"window": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "original_text": "A \nThanks for the questions. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18", "node_type": "1", "metadata": {"window": "And is there anything to call out there or changes in fundamentals across the \ngenerics business?  And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e2d340ef401532b53456bedc67c6951ef986a27d59c06ea15d4e2acdf01973b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52e06362-3073-4c8e-ba6b-79bebfac95d8", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year. ", "original_text": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. "}, "hash": "4dbfb806fd11a9ca90bb67bd7cdf91d535a13911daa5d3ab08b9a5a7158e3098", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the questions. ", "start_char_idx": 3614, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52e06362-3073-4c8e-ba6b-79bebfac95d8": {"__data__": {"id_": "52e06362-3073-4c8e-ba6b-79bebfac95d8", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year. ", "original_text": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea33748-0e1a-46d6-8aa8-be529dc0236f", "node_type": "1", "metadata": {"window": "And have you seen some of the disruption amongst some of the certain larger generic \nmanufactures flow through to your bus iness?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "original_text": "A \nThanks for the questions. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8934b174c7b388c3c960ac2af5f751ae80b1950664cac00afb015248d61abdd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4772ccd-fb58-431f-834d-73041a1ef7c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that. ", "original_text": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. "}, "hash": "9b2f94190398a7c8d42aeb1b466490f0c836282a6317beb89b60b7df574fd857", "class_name": "RelatedNodeInfo"}}, "text": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "start_char_idx": 3643, "end_char_idx": 3759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4772ccd-fb58-431f-834d-73041a1ef7c9": {"__data__": {"id_": "c4772ccd-fb58-431f-834d-73041a1ef7c9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that. ", "original_text": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52e06362-3073-4c8e-ba6b-79bebfac95d8", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year. ", "original_text": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0de1c3a4faa1428522efd7fef3aa48073bfbc522bd0e3ca033c2101704036a4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0432bde7-97d2-46a7-af06-73fcc0f55b07", "node_type": "1", "metadata": {"window": "A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "original_text": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n"}, "hash": "beb1b3ca8824f05394d6b4d04a73e6b1fd3bbc2e39d5205e94112eb314bf19dd", "class_name": "RelatedNodeInfo"}}, "text": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "start_char_idx": 3759, "end_char_idx": 3904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0432bde7-97d2-46a7-af06-73fcc0f55b07": {"__data__": {"id_": "0432bde7-97d2-46a7-af06-73fcc0f55b07", "embedding": null, "metadata": {"window": "A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "original_text": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4772ccd-fb58-431f-834d-73041a1ef7c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that. ", "original_text": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af458466dd254b07e032450c160c380bdb10f1cb4b7804f47e0f6b01606cf4a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b90b5f0-a87f-4348-97a6-9c3dac318f46", "node_type": "1", "metadata": {"window": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "That helps us manag e through any supply shocks that may happen, and those happen every year. "}, "hash": "e3b7961b4976e59149d48d9449557902c9cacda428b5ca0f68592542dba94651", "class_name": "RelatedNodeInfo"}}, "text": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "start_char_idx": 3904, "end_char_idx": 4012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b90b5f0-a87f-4348-97a6-9c3dac318f46": {"__data__": {"id_": "8b90b5f0-a87f-4348-97a6-9c3dac318f46", "embedding": null, "metadata": {"window": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "That helps us manag e through any supply shocks that may happen, and those happen every year. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0432bde7-97d2-46a7-af06-73fcc0f55b07", "node_type": "1", "metadata": {"window": "A \nThanks for the questions.  As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "original_text": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f7a27c65a0a07608f0ca6fca72349bd5b40777be6c75a2af33e1c07e217f8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74", "node_type": "1", "metadata": {"window": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We're able to \nmanage through that. "}, "hash": "1ccb3a06abbd27aeca24d8c7109cfb9932fbf82c1f53c2d65a254b18a2b8d5d2", "class_name": "RelatedNodeInfo"}}, "text": "That helps us manag e through any supply shocks that may happen, and those happen every year. ", "start_char_idx": 4012, "end_char_idx": 4106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74": {"__data__": {"id_": "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74", "embedding": null, "metadata": {"window": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We're able to \nmanage through that. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b90b5f0-a87f-4348-97a6-9c3dac318f46", "node_type": "1", "metadata": {"window": "As I talked about a little bit in my remarks, maybe I'll expand on that, we have a very \nscaled generics operation.  We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "That helps us manag e through any supply shocks that may happen, and those happen every year. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c47834e825b50dfebc9111e61421e5c799f372ad334fe0979d92d1281833683", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4599649a-9783-4bcb-976f-7a7b41152f76", "node_type": "1", "metadata": {"window": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. "}, "hash": "722f9bb6fbe6929a8c35a5411ba88d94d0099f48506a1f6410916cfe969c038a", "class_name": "RelatedNodeInfo"}}, "text": "We're able to \nmanage through that. ", "start_char_idx": 4106, "end_char_idx": 4142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4599649a-9783-4bcb-976f-7a7b41152f76": {"__data__": {"id_": "4599649a-9783-4bcb-976f-7a7b41152f76", "embedding": null, "metadata": {"window": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74", "node_type": "1", "metadata": {"window": "We start w ith a very scaled and efficient sourcing program that we've been running \nnow for a number of years, and we have some great partners.  And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We're able to \nmanage through that. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fb9a111c08ec02b18bdffd289fd7a893eec12591d72c91ffc6dd6d90e6a6878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc224033-00b4-4f8b-8714-1a33c3e6d104", "node_type": "1", "metadata": {"window": "That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n "}, "hash": "735f9d44acaae644e7586cbdbd6e0d0baf0e5f72adec61cdc56ce0c8b423dfe2", "class_name": "RelatedNodeInfo"}}, "text": "For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "start_char_idx": 4142, "end_char_idx": 4282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc224033-00b4-4f8b-8714-1a33c3e6d104": {"__data__": {"id_": "bc224033-00b4-4f8b-8714-1a33c3e6d104", "embedding": null, "metadata": {"window": "That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd651816-f65c-49c8-8d07-55064dda3afb", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff468c4ee0935112288b6fa7a06733a27e9ad965bad9dedd084db6d93cdbc1ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4599649a-9783-4bcb-976f-7a7b41152f76", "node_type": "1", "metadata": {"window": "And we have great partnerships with generic \nmanufactures, very diverse and very broad set of partners.  \n \n That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply. ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32ac324dc2ff1e81533782c3c49f9ceb167f8772814739a72e2e47a4ad7d5d10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9e50e1-bfef-4966-b7c5-70674402d69b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers. ", "original_text": "McKesson Corp.  "}, "hash": "cedf1ddee2a9c0bb78e6d330762f28eb80d20fe6d29dd7a96d4736631f5ec27a", "class_name": "RelatedNodeInfo"}}, "text": "We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "start_char_idx": 4282, "end_char_idx": 4401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9e50e1-bfef-4966-b7c5-70674402d69b": {"__data__": {"id_": "be9e50e1-bfef-4966-b7c5-70674402d69b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc224033-00b4-4f8b-8714-1a33c3e6d104", "node_type": "1", "metadata": {"window": "That helps us manag e through any supply shocks that may happen, and those happen every year.  We're able to \nmanage through that.  For as long as I've been in this business, you will see from time -to-time, you will see a \ngeneric shortage or a generic impact to supply.  We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "original_text": "We've bee n able to manage through that very well given the \nstrength and the breadth of partnerships that we have.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ec8f91cc6e00b5afc5d04ba52a8caf969b14512771cba43687687f039cebfa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75434bbf-5b26-482c-b81d-0d3c76264d36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals. "}, "hash": "d7a754b5953ba3456ac7e1265e87f49d21502025e5b94e4a994de81ffee385e8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75434bbf-5b26-482c-b81d-0d3c76264d36": {"__data__": {"id_": "75434bbf-5b26-482c-b81d-0d3c76264d36", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9e50e1-bfef-4966-b7c5-70674402d69b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b84a90ce6c49899011229403da0fe652445a6e28fb351e96e2bd6db8ad641be4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a619b1f-8e27-4508-90b8-939d0954fff3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n ", "original_text": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n"}, "hash": "e8dea7a44d6fa354b175ac3507d45d16614f26cd4446816c89a9cae0a9180131", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals. ", "start_char_idx": 16, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a619b1f-8e27-4508-90b8-939d0954fff3": {"__data__": {"id_": "2a619b1f-8e27-4508-90b8-939d0954fff3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n ", "original_text": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75434bbf-5b26-482c-b81d-0d3c76264d36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "198b34cff837d56f679a9ca3e3f123f313d4cd6a5176998e317dc127458c630a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "Our focus is to provide low cost, high availability of supply to our customers. "}, "hash": "e24ef7a1a656ea0978df008b2fc72a296e7593b49fd1892597c9fc2bc683f1d4", "class_name": "RelatedNodeInfo"}}, "text": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n", "start_char_idx": 261, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21": {"__data__": {"id_": "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "Our focus is to provide low cost, high availability of supply to our customers. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a619b1f-8e27-4508-90b8-939d0954fff3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n ", "original_text": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcec4c26e9b7626221b41495a927f3cd651d6f493f0ca99073cf1d5b9ee511a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44d1985f-56aa-4156-a393-53d07f96df1f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "That is really the bedrock of the \nsuccess that we have with our generics program. "}, "hash": "912d9dae0d3f2167e113e8a66c3bfbca2619582fff50b6388e550339df41557c", "class_name": "RelatedNodeInfo"}}, "text": "Our focus is to provide low cost, high availability of supply to our customers. ", "start_char_idx": 608, "end_char_idx": 688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44d1985f-56aa-4156-a393-53d07f96df1f": {"__data__": {"id_": "44d1985f-56aa-4156-a393-53d07f96df1f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "That is really the bedrock of the \nsuccess that we have with our generics program. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "Our focus is to provide low cost, high availability of supply to our customers. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8136a65f61895bddbb6b71ac3f068861f558662c5c5d0e94209c35c23255f83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd013330-fbec-4203-a048-91fe505c5751", "node_type": "1", "metadata": {"window": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "And I think we've been able to do that quite well for a number of \nyears.  \n "}, "hash": "a8be7ebf1d7cd09096069508a6b8f6a713888a2fe361752592b5129da13bc91b", "class_name": "RelatedNodeInfo"}}, "text": "That is really the bedrock of the \nsuccess that we have with our generics program. ", "start_char_idx": 688, "end_char_idx": 771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd013330-fbec-4203-a048-91fe505c5751": {"__data__": {"id_": "cd013330-fbec-4203-a048-91fe505c5751", "embedding": null, "metadata": {"window": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "And I think we've been able to do that quite well for a number of \nyears.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44d1985f-56aa-4156-a393-53d07f96df1f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "That is really the bedrock of the \nsuccess that we have with our generics program. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d89e9211a7c9ca5f538bf025f6d9c219a31fd4992cdac7c8cef7fef4bfd7212e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be23a840-e8e5-4500-8b7b-78911e0adea9", "node_type": "1", "metadata": {"window": "Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "ea900895a5266506dd481517a27f3402ae66335d5015f0272da6bf96b867845c", "class_name": "RelatedNodeInfo"}}, "text": "And I think we've been able to do that quite well for a number of \nyears.  \n ", "start_char_idx": 771, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be23a840-e8e5-4500-8b7b-78911e0adea9": {"__data__": {"id_": "be23a840-e8e5-4500-8b7b-78911e0adea9", "embedding": null, "metadata": {"window": "Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd013330-fbec-4203-a048-91fe505c5751", "node_type": "1", "metadata": {"window": "And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "And I think we've been able to do that quite well for a number of \nyears.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4deb630b016865e9c6970b99330f8708caf637601448eed33f21e9f76074aa1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4bd5704-440d-4e51-a643-4115b6f81e21", "node_type": "1", "metadata": {"window": "That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "A \nNext question, please.  \n "}, "hash": "ac2e8b45dd90333b5bf4e558349e3998de7c38a68e002df7484806fd191d5bde", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 848, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4bd5704-440d-4e51-a643-4115b6f81e21": {"__data__": {"id_": "b4bd5704-440d-4e51-a643-4115b6f81e21", "embedding": null, "metadata": {"window": "That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be23a840-e8e5-4500-8b7b-78911e0adea9", "node_type": "1", "metadata": {"window": "Our focus is to provide low cost, high availability of supply to our customers.  That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae903d271861db53639a44ee2bba4ef423ada935f4848bce47644e5d747d49d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7f402aa-c87e-4836-870a-57fd41a3f9a0", "node_type": "1", "metadata": {"window": "And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n "}, "hash": "193aa5fd430198170623f359724d42bae921f1780d0425d83aa1aca70faeeb70", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1166, "end_char_idx": 1195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7f402aa-c87e-4836-870a-57fd41a3f9a0": {"__data__": {"id_": "c7f402aa-c87e-4836-870a-57fd41a3f9a0", "embedding": null, "metadata": {"window": "And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4bd5704-440d-4e51-a643-4115b6f81e21", "node_type": "1", "metadata": {"window": "That is really the bedrock of the \nsuccess that we have with our generics program.  And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0dfc9b025f450fa89e088945a8f8da5540fe2542f6d39d9a3ffbadfabdd359e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4960ea-1bef-4397-8afe-eee58d38adc9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. "}, "hash": "0814a35985794229b5ff57018f0f7e29c77abafe29733a355b936a1bb96daaa6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "start_char_idx": 1195, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4960ea-1bef-4397-8afe-eee58d38adc9": {"__data__": {"id_": "bf4960ea-1bef-4397-8afe-eee58d38adc9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7f402aa-c87e-4836-870a-57fd41a3f9a0", "node_type": "1", "metadata": {"window": "And I think we've been able to do that quite well for a number of \nyears.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cb539b164b9caaf67edc747dbf445e582c9108bb40763aa325de9cc304232d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddd1dea9-c43a-45e9-874c-48dc47987d08", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "original_text": "Thanks so much for the question. "}, "hash": "3f927ec59bc713d72ae987db3a670509ffff03fd5116b0e47700ce94320183a7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "start_char_idx": 1523, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddd1dea9-c43a-45e9-874c-48dc47987d08": {"__data__": {"id_": "ddd1dea9-c43a-45e9-874c-48dc47987d08", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "original_text": "Thanks so much for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4960ea-1bef-4397-8afe-eee58d38adc9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d12a8e1c08abf2a3e500a1839f957df31e13fd753f47b6a3df4dec843495f79c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d47f38e4-8725-44f5-9d65-abc81741a872", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "original_text": "One \u2013 two parts for me. "}, "hash": "130f5dac1d9ed7b8741f5332b99aadd37ff2d8ec829b54e16d87b7131a97e761", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 1837, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d47f38e4-8725-44f5-9d65-abc81741a872": {"__data__": {"id_": "d47f38e4-8725-44f5-9d65-abc81741a872", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "original_text": "One \u2013 two parts for me. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddd1dea9-c43a-45e9-874c-48dc47987d08", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "original_text": "Thanks so much for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "386e6b10f1d48d1142a3df9e136731c6e43b687ea1426438bd7c8ec162f59ef6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feb04de6-2878-4781-8edb-38d25158efc7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n ", "original_text": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. "}, "hash": "7aad08c149be5b61f11d3a9ddd8a3ee2d18b4974bac56598408e7b3cd06f8628", "class_name": "RelatedNodeInfo"}}, "text": "One \u2013 two parts for me. ", "start_char_idx": 1870, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feb04de6-2878-4781-8edb-38d25158efc7": {"__data__": {"id_": "feb04de6-2878-4781-8edb-38d25158efc7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n ", "original_text": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d47f38e4-8725-44f5-9d65-abc81741a872", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "original_text": "One \u2013 two parts for me. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edbabbe02d0768aa761c41feb11cad4de37c36bee8dfee82ab085efaf52cac09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "526db840-1866-4a74-a865-2146620196f2", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter? "}, "hash": "76cf8248e7a75025e8f88ddc5c9b2f12d1063899981ef7a9447379cca3b40e11", "class_name": "RelatedNodeInfo"}}, "text": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "start_char_idx": 1894, "end_char_idx": 2000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "526db840-1866-4a74-a865-2146620196f2": {"__data__": {"id_": "526db840-1866-4a74-a865-2146620196f2", "embedding": null, "metadata": {"window": "Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feb04de6-2878-4781-8edb-38d25158efc7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n ", "original_text": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "619dc116521f813e32cca5d3875723bf13acd666fec1ab3b83dd23ce45773dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb10337c-8f56-4099-8977-32d4235a6ea4", "node_type": "1", "metadata": {"window": "One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? "}, "hash": "310bc05a4017b20e7332886a7b391a6cce2f5ba282cfb5ad43d667cd9611bffc", "class_name": "RelatedNodeInfo"}}, "text": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "start_char_idx": 2000, "end_char_idx": 2083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb10337c-8f56-4099-8977-32d4235a6ea4": {"__data__": {"id_": "eb10337c-8f56-4099-8977-32d4235a6ea4", "embedding": null, "metadata": {"window": "One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "526db840-1866-4a74-a865-2146620196f2", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter? ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "512183fa0917a90e36d2b5db7c7cc7c201307ed667c7aab06e1065d5c9731ffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0435e09d-147c-4168-9f1a-261d6ce0c5f4", "node_type": "1", "metadata": {"window": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "Thank you very much.  \n "}, "hash": "3e5cc4fffab1533ede703d90dbc299dffad6a3de98c30301ff78daf6f1681280", "class_name": "RelatedNodeInfo"}}, "text": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "start_char_idx": 2083, "end_char_idx": 2253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0435e09d-147c-4168-9f1a-261d6ce0c5f4": {"__data__": {"id_": "0435e09d-147c-4168-9f1a-261d6ce0c5f4", "embedding": null, "metadata": {"window": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "Thank you very much.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb10337c-8f56-4099-8977-32d4235a6ea4", "node_type": "1", "metadata": {"window": "One \u2013 two parts for me.  One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan? ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f42f45a8253ad756289c9dc00351648ee4c34bcd79cf5ce80eef38425640b60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db04cad7-5816-4c46-9b51-7b9b9a211686", "node_type": "1", "metadata": {"window": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "010a6c7dd75b6e0c7b410626ddf2b70b83c834593e74878c16572e611d7f594f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you very much.  \n ", "start_char_idx": 2253, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db04cad7-5816-4c46-9b51-7b9b9a211686": {"__data__": {"id_": "db04cad7-5816-4c46-9b51-7b9b9a211686", "embedding": null, "metadata": {"window": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0435e09d-147c-4168-9f1a-261d6ce0c5f4", "node_type": "1", "metadata": {"window": "One is on the \u2013 obviously you had some \nchanges in cost -cutting on the\u202fOpEx\u202flines in the fourth quarter.  How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure. ", "original_text": "Thank you very much.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05f2f63ba8b6825e538f2921cacff7b9319ba1e39ae54958ec5f6fd3d4665631", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fabfd8e9-7591-44fc-adb5-cbcd9b723f64", "node_type": "1", "metadata": {"window": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "original_text": "A \nYeah. "}, "hash": "0fc6156e6142113ec22856b105fa1f2bd21822e5686f67056d64017d71ad830d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2277, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fabfd8e9-7591-44fc-adb5-cbcd9b723f64": {"__data__": {"id_": "fabfd8e9-7591-44fc-adb5-cbcd9b723f64", "embedding": null, "metadata": {"window": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db04cad7-5816-4c46-9b51-7b9b9a211686", "node_type": "1", "metadata": {"window": "How do you see sort of any potential pacing of that \nimpacting the fourth quarter?  And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51b1e5d2ad8df92e8546b2edabbf7a579c4461fa6ed3740a2c009c3f126b3ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1e839e7-9823-46f6-a091-fbf22d5e6729", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business. ", "original_text": "Sure. "}, "hash": "21691d14980c6bcaa423b02c87a76cdb1c5ed986502f674dba5effd4052b2b95", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2622, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1e839e7-9823-46f6-a091-fbf22d5e6729": {"__data__": {"id_": "d1e839e7-9823-46f6-a091-fbf22d5e6729", "embedding": null, "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business. ", "original_text": "Sure. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fabfd8e9-7591-44fc-adb5-cbcd9b723f64", "node_type": "1", "metadata": {"window": "And secondly, can you talk a little bit maybe more specificall y about sort of what you \nhave embedded in the 2024 guidance for biosimilars versus the longer -term plan?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78bf9ecebd83e2a48c05a4f491ace4dd475fd99a2337ab253be3aa2e922d44a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c578c88-9c4d-4b63-ae57-5e6523d5100c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "original_text": "Thanks for the question. "}, "hash": "7e67e6494ad8eeee3746bf6415156be9d31f6104a292effec485bf3614f6f4b0", "class_name": "RelatedNodeInfo"}}, "text": "Sure. ", "start_char_idx": 2631, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c578c88-9c4d-4b63-ae57-5e6523d5100c": {"__data__": {"id_": "4c578c88-9c4d-4b63-ae57-5e6523d5100c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "original_text": "Thanks for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1e839e7-9823-46f6-a091-fbf22d5e6729", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business. ", "original_text": "Sure. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54e96a7d26c3cbb41289d29365c4dcb6379cab4d434c8456e05e8824c4d720c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28cea14d-3f78-41af-8bbb-55b054518c08", "node_type": "1", "metadata": {"window": "A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n", "original_text": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. "}, "hash": "b7313da872f73c56606e9f4aba4a13734a5f0f13cade9126551939fba4d298f0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2637, "end_char_idx": 2662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28cea14d-3f78-41af-8bbb-55b054518c08": {"__data__": {"id_": "28cea14d-3f78-41af-8bbb-55b054518c08", "embedding": null, "metadata": {"window": "A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n", "original_text": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c578c88-9c4d-4b63-ae57-5e6523d5100c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "original_text": "Thanks for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b54bee19973d2d03c335303cec766984ef2f8fe9ccae81daf6e183f082b62d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e55f451-02aa-4396-b625-c179e4b52fc9", "node_type": "1", "metadata": {"window": "Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "original_text": "Pharmaceutical and Prescription Technology business. "}, "hash": "3baf4886a35d7ddbab90efd119002ddcd5dab8bcb63108fb104fee58b2000649", "class_name": "RelatedNodeInfo"}}, "text": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "start_char_idx": 2662, "end_char_idx": 2795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e55f451-02aa-4396-b625-c179e4b52fc9": {"__data__": {"id_": "3e55f451-02aa-4396-b625-c179e4b52fc9", "embedding": null, "metadata": {"window": "Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "original_text": "Pharmaceutical and Prescription Technology business. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28cea14d-3f78-41af-8bbb-55b054518c08", "node_type": "1", "metadata": {"window": "A \nYeah.  Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n", "original_text": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff48ff15c52887ea9502dc5f080c0738eaf6209cdc9cbbfec986cd5b7700dd1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff", "node_type": "1", "metadata": {"window": "Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "original_text": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. "}, "hash": "2c65202f3aab23b4136d26bcf4c52720c3a06e44b4419d00d97cac577110aa59", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Prescription Technology business. ", "start_char_idx": 2795, "end_char_idx": 2848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff": {"__data__": {"id_": "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff", "embedding": null, "metadata": {"window": "Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "original_text": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e55f451-02aa-4396-b625-c179e4b52fc9", "node_type": "1", "metadata": {"window": "Sure.  Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "original_text": "Pharmaceutical and Prescription Technology business. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "263b61c2b6ce784359e9039adc7bc826fa173592048324380220bb0b0d6a1bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc41c946-c8cf-4d12-a920-2cc9c4ae094d", "node_type": "1", "metadata": {"window": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think that would answer \nyour question on that.  \n \n"}, "hash": "067f0bd42a1acfb39e96ce5e2bd7a4d2a2ac421be4d7caa2e12d488cb7cad32a", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "start_char_idx": 2848, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc41c946-c8cf-4d12-a920-2cc9c4ae094d": {"__data__": {"id_": "bc41c946-c8cf-4d12-a920-2cc9c4ae094d", "embedding": null, "metadata": {"window": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think that would answer \nyour question on that.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff", "node_type": "1", "metadata": {"window": "Thanks for the question.  So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "original_text": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a899c0ae367762f93f1cb3a27ae6f5c357746093eea43caf733da4e8b408e191", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8452067e-0d1e-436d-9b92-f24581552442", "node_type": "1", "metadata": {"window": "Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. "}, "hash": "be84391b43ab6a5323c7de2557ec7ce5867c5a1a26d4a3a22953a96cf1f219f9", "class_name": "RelatedNodeInfo"}}, "text": "So I think that would answer \nyour question on that.  \n \n", "start_char_idx": 2942, "end_char_idx": 2999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8452067e-0d1e-436d-9b92-f24581552442": {"__data__": {"id_": "8452067e-0d1e-436d-9b92-f24581552442", "embedding": null, "metadata": {"window": "Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc41c946-c8cf-4d12-a920-2cc9c4ae094d", "node_type": "1", "metadata": {"window": "So,  as I talked about, when we enacted a set of initiatives, we recorded a \ncharge for restructuring that was primarily in our U.S.  Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think that would answer \nyour question on that.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfc86ef9240e7e6a24628514b507c4b9e2324638b1efa07054d63349dcadce7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "423f344b-7aa4-4784-bceb-4556944ac6ac", "node_type": "1", "metadata": {"window": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched. ", "original_text": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n "}, "hash": "a7a00e85716143579dc24912509d590a91437ec384cd285dc261c481ac578195", "class_name": "RelatedNodeInfo"}}, "text": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "start_char_idx": 2999, "end_char_idx": 3184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "423f344b-7aa4-4784-bceb-4556944ac6ac": {"__data__": {"id_": "423f344b-7aa4-4784-bceb-4556944ac6ac", "embedding": null, "metadata": {"window": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched. ", "original_text": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8452067e-0d1e-436d-9b92-f24581552442", "node_type": "1", "metadata": {"window": "Pharmaceutical and Prescription Technology business.  We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf51795671767d8304e51c54d609814dd22995da0606774da0904ee990308371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8c6af5b-16a9-4203-9bfc-7f21557e6231", "node_type": "1", "metadata": {"window": "So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "69af9bf6bdb4b205de0225c1963e1ef100ed311ac25d6f46fa6733821436cd97", "class_name": "RelatedNodeInfo"}}, "text": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "start_char_idx": 3184, "end_char_idx": 3326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8c6af5b-16a9-4203-9bfc-7f21557e6231": {"__data__": {"id_": "c8c6af5b-16a9-4203-9bfc-7f21557e6231", "embedding": null, "metadata": {"window": "So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "423f344b-7aa4-4784-bceb-4556944ac6ac", "node_type": "1", "metadata": {"window": "We \nexpect that those initiatives and activities will be complete by the end  of fiscal 2024.  So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched. ", "original_text": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76aadc7a724f92d1025b218b58cb0584b49e09e4140d194cbebb63ad8ee0af03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73974ff9-048b-42b3-8ec8-485b1eb15ff3", "node_type": "1", "metadata": {"window": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n ", "original_text": "A \nYeah. "}, "hash": "66e537868905cd91fd643fb93af807320866a12cd69812d0a46ac6118ac0c984", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3326, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73974ff9-048b-42b3-8ec8-485b1eb15ff3": {"__data__": {"id_": "73974ff9-048b-42b3-8ec8-485b1eb15ff3", "embedding": null, "metadata": {"window": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8c6af5b-16a9-4203-9bfc-7f21557e6231", "node_type": "1", "metadata": {"window": "So I think that would answer \nyour question on that.  \n \n And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bbfde8d6cda09a1689da920363f0bdd3a958eb86f9a67131eb67b02726079f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a878468e-b6f8-4c10-b6f2-0fd7263bb297", "node_type": "1", "metadata": {"window": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "What we know is in \u2013 obviously 40 approval s, 27 launched. "}, "hash": "d16f272d6dfbd6061ed2ab5667c75c217ca359b0df821b3274428d9453c3d38f", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2622, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a878468e-b6f8-4c10-b6f2-0fd7263bb297": {"__data__": {"id_": "a878468e-b6f8-4c10-b6f2-0fd7263bb297", "embedding": null, "metadata": {"window": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "What we know is in \u2013 obviously 40 approval s, 27 launched. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73974ff9-048b-42b3-8ec8-485b1eb15ff3", "node_type": "1", "metadata": {"window": "And from a biosimilars perspective, we continue to believe that there is great opportunity here, as we continue to \nadd providers to the network, that provides more opportunity for us.  An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0b6f90797e2605450bf0c516f25a4caad72452c2ea477884a6a81d070aca758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8db0d8ae-be7d-4502-a140-2a13f8ac6a66", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n ", "original_text": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. "}, "hash": "299c312b3a4be1d51885452c351188282c99dcdd815eb508b2c0e63ffd2b2da9", "class_name": "RelatedNodeInfo"}}, "text": "What we know is in \u2013 obviously 40 approval s, 27 launched. ", "start_char_idx": 3664, "end_char_idx": 3723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8db0d8ae-be7d-4502-a140-2a13f8ac6a66": {"__data__": {"id_": "8db0d8ae-be7d-4502-a140-2a13f8ac6a66", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n ", "original_text": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a878468e-b6f8-4c10-b6f2-0fd7263bb297", "node_type": "1", "metadata": {"window": "An d we think we're very well -positioned, and \nwe've certainly embedded the opportunities within the guidance that we provided you today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "original_text": "What we know is in \u2013 obviously 40 approval s, 27 launched. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba4d900e61e1920f37413b591d61737edf87e7c8b62df0a3d2a2fc3b4f5ff320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aea3561-f270-4839-a6d3-02f3c4c15a58", "node_type": "1", "metadata": {"window": "A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But what we know is baked into the guidance we've provided.  \n "}, "hash": "7d3a36c08be2e9d4d6a84b9a9f8ad0124946326f7344b80aaa24bb1b723e7894", "class_name": "RelatedNodeInfo"}}, "text": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "start_char_idx": 3723, "end_char_idx": 4020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aea3561-f270-4839-a6d3-02f3c4c15a58": {"__data__": {"id_": "7aea3561-f270-4839-a6d3-02f3c4c15a58", "embedding": null, "metadata": {"window": "A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But what we know is baked into the guidance we've provided.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8db0d8ae-be7d-4502-a140-2a13f8ac6a66", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n ", "original_text": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ef4cce7a5faeed53259dfffcf11de1f0f76b3e49cb7a758a5b12b77af9d3dfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "396d9682-0ca4-4d18-97b7-3c4f8be0423c", "node_type": "1", "metadata": {"window": "What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  "}, "hash": "9f87912c39cd4acc6a9f940552379b71ab7c5b59cf1727c09eb25ecb4df9b6b5", "class_name": "RelatedNodeInfo"}}, "text": "But what we know is baked into the guidance we've provided.  \n ", "start_char_idx": 4020, "end_char_idx": 4083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "396d9682-0ca4-4d18-97b7-3c4f8be0423c": {"__data__": {"id_": "396d9682-0ca4-4d18-97b7-3c4f8be0423c", "embedding": null, "metadata": {"window": "What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aea3561-f270-4839-a6d3-02f3c4c15a58", "node_type": "1", "metadata": {"window": "A \nYeah.  What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But what we know is baked into the guidance we've provided.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bb268104aeac7b32de94552681506528bdb01c3821bb0706c1eabe8a0cfb09c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc", "node_type": "1", "metadata": {"window": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nOperator, we have time for one more final question.  \n "}, "hash": "b691a4459407450f2d9287d52efb02bb239126bd164b9742d4cdad4e2b81d017", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "start_char_idx": 848, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc": {"__data__": {"id_": "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc", "embedding": null, "metadata": {"window": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nOperator, we have time for one more final question.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "396d9682-0ca4-4d18-97b7-3c4f8be0423c", "node_type": "1", "metadata": {"window": "What we know is in \u2013 obviously 40 approval s, 27 launched.  The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13d1ce5db0f8d587f91412bcbf909daaa43fe73e8382a62976dd20a9d42786c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05ed6405-5be7-4337-9ff9-21f1c1ae3883", "node_type": "1", "metadata": {"window": "But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. "}, "hash": "f8e60cddc6713daf6aa6184411214ab4518ad2a9ba4224e4600b5e4dfe722f21", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more final question.  \n ", "start_char_idx": 4401, "end_char_idx": 4459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05ed6405-5be7-4337-9ff9-21f1c1ae3883": {"__data__": {"id_": "05ed6405-5be7-4337-9ff9-21f1c1ae3883", "embedding": null, "metadata": {"window": "But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc", "node_type": "1", "metadata": {"window": "The big event this year will be Humira, which is \ngoing to be a Part D product, not Part B. We have many more services to offer and assets to leverage and use in \nthe Part D arena, so we will track kind of payer response and pricing strategie s and patient adoption over the \ncourse of this year.  But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nOperator, we have time for one more final question.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9962c7de3e02e67d8f2f16faa849c53f9ee2c62beee40e27978896361026932", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ef96cec-51ca-4b98-94e2-11bc06f25587", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That question will come from A.J. "}, "hash": "5f3dc4ee6bc2b1a5d0f99f64ae4b181f1cabb02c17c0b33a4bd53b5d585fb319", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "start_char_idx": 4459, "end_char_idx": 4740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ef96cec-51ca-4b98-94e2-11bc06f25587": {"__data__": {"id_": "8ef96cec-51ca-4b98-94e2-11bc06f25587", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That question will come from A.J. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05ed6405-5be7-4337-9ff9-21f1c1ae3883", "node_type": "1", "metadata": {"window": "But what we know is baked into the guidance we've provided.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "991b7ea2a13d5a9a7a3a1e921687d2d922591ec9853fe1b85299e4b5ea591c46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b596f45a-0e3e-4293-9099-abf101657f22", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Rice with Credit Suisse.  \n "}, "hash": "58552bb549177f65269b16c03c2c07710a088ad479899107b1e26aca2fb0b1c9", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from A.J. ", "start_char_idx": 4740, "end_char_idx": 4774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b596f45a-0e3e-4293-9099-abf101657f22": {"__data__": {"id_": "b596f45a-0e3e-4293-9099-abf101657f22", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Rice with Credit Suisse.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ef96cec-51ca-4b98-94e2-11bc06f25587", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That question will come from A.J. ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb01e45d85d669344636d3c1ed7c1b2825ee6273cdab62eac2e07c55253e9a9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "011f03a7-4198-4595-8856-0ff41e702bf8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "1fb7f1b4e700237eecdd7df4bf5769c25f207de9f8d15ef8a0fc0cfa6bfba701", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse.  \n ", "start_char_idx": 4774, "end_char_idx": 4802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011f03a7-4198-4595-8856-0ff41e702bf8": {"__data__": {"id_": "011f03a7-4198-4595-8856-0ff41e702bf8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2825f81cf95ae11ea63683230d99ddb5d8438d8d6dfc6ac7ba102532375f0cd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b596f45a-0e3e-4293-9099-abf101657f22", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more final question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Rice with Credit Suisse.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be4231c2d46fb3e816ada286d9a8128562adb08a66c53cd06d5ccd41d709d823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab4d1a19-1ea1-4447-9c48-8767f88f501c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question. ", "original_text": "McKesson Corp.  "}, "hash": "a4bba224cfa7fcb78bd1d6f9e9157381491415edbfc1e81f66340d0bf288b7f0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 848, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab4d1a19-1ea1-4447-9c48-8767f88f501c": {"__data__": {"id_": "ab4d1a19-1ea1-4447-9c48-8767f88f501c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "011f03a7-4198-4595-8856-0ff41e702bf8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question will come from A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a44d2c58a1b5039f89f80cae480a544fc0cac26bf531a032ab5471ce8e9f057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdeee984-bcfc-4b9c-8332-56381a89073c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J. "}, "hash": "5fb02f96624dd9dfabe9f44213887b519c33bb2b2408a45e26af979de83ca72f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdeee984-bcfc-4b9c-8332-56381a89073c": {"__data__": {"id_": "bdeee984-bcfc-4b9c-8332-56381a89073c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab4d1a19-1ea1-4447-9c48-8767f88f501c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcee36313159c113ab25e9c77f2bbcdf881004a12fa81d734ab3c386f44157d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc96384d-6ac3-4e56-b291-40217018720f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "original_text": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody. "}, "hash": "7c5f9ddf1e727f71e6dd4df52843d2148cf561567f80b36297a1585d3de148e5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J. ", "start_char_idx": 16, "end_char_idx": 186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc96384d-6ac3-4e56-b291-40217018720f": {"__data__": {"id_": "fc96384d-6ac3-4e56-b291-40217018720f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "original_text": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdeee984-bcfc-4b9c-8332-56381a89073c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c7c7bd7f733f7fb65c1dc08449faec20377a2c087e78cc413da9d8d0c3eb61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdceaf10-1247-4538-aea7-d52854f652a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "original_text": "Thanks for the question. "}, "hash": "dfef227564711ff36f78ac2f003667785cff80a1b61a4efdf425b82064eb711d", "class_name": "RelatedNodeInfo"}}, "text": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody. ", "start_char_idx": 186, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdceaf10-1247-4538-aea7-d52854f652a7": {"__data__": {"id_": "fdceaf10-1247-4538-aea7-d52854f652a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "original_text": "Thanks for the question. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc96384d-6ac3-4e56-b291-40217018720f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "original_text": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fead31db59744c304d05706bba94a29e0cc2a388e1b979865428a05440bd2362", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00138878-9dd0-4abd-b0c2-5948f9de54e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. "}, "hash": "15af298c605999356e3ba5c030bd34896da3f526c7507a2d026be4ff4ca38404", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 235, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00138878-9dd0-4abd-b0c2-5948f9de54e0": {"__data__": {"id_": "00138878-9dd0-4abd-b0c2-5948f9de54e0", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdceaf10-1247-4538-aea7-d52854f652a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "original_text": "Thanks for the question. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "166f379eec2d313650f110bd313f594d789a0890215823cbff3ac7039861b962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "404f998e-4da2-4daa-aefe-69b73086cd5f", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n"}, "hash": "ee9c7d4e1ca91805b7abcee2b600171436ad99a0f5a7b636ae1335e6630c333c", "class_name": "RelatedNodeInfo"}}, "text": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "start_char_idx": 260, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "404f998e-4da2-4daa-aefe-69b73086cd5f": {"__data__": {"id_": "404f998e-4da2-4daa-aefe-69b73086cd5f", "embedding": null, "metadata": {"window": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00138878-9dd0-4abd-b0c2-5948f9de54e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dac6e0d67caa259989728b8ada25577fd02fd13fa2a2bf75641e0d15c18bb986", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a420fb79-6b35-429d-9c37-d9112c85283e", "node_type": "1", "metadata": {"window": "Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "original_text": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n "}, "hash": "585224c6ad20c99dd8ef452a45be2fa577414a74b72dd6e453931835ab1f5fa2", "class_name": "RelatedNodeInfo"}}, "text": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "start_char_idx": 452, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a420fb79-6b35-429d-9c37-d9112c85283e": {"__data__": {"id_": "a420fb79-6b35-429d-9c37-d9112c85283e", "embedding": null, "metadata": {"window": "Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "original_text": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "404f998e-4da2-4daa-aefe-69b73086cd5f", "node_type": "1", "metadata": {"window": "Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c5b9b5aea7b07d4f844fce6800bfdae199f4f5fcf0f1102eb02ae73ca36329", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4517b89f-693f-4bae-874a-c670aa4057db", "node_type": "1", "metadata": {"window": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "38aae1656b7f844d8269d9e0f07980676cd356873f2d85d6bd907f5bb754f563", "class_name": "RelatedNodeInfo"}}, "text": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "start_char_idx": 558, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4517b89f-693f-4bae-874a-c670aa4057db": {"__data__": {"id_": "4517b89f-693f-4bae-874a-c670aa4057db", "embedding": null, "metadata": {"window": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a420fb79-6b35-429d-9c37-d9112c85283e", "node_type": "1", "metadata": {"window": "Thanks for the question.  In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "original_text": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c4d7282e7c8fc65cbe3865dcbaae501092ad4d1eb886df7eb6d0f463dd7a8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0", "node_type": "1", "metadata": {"window": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "original_text": "A \nYeah. "}, "hash": "7049902ecf1c884556df58a8f38bb2deaae094869bd615031d7e086e4b42cdbe", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 793, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0": {"__data__": {"id_": "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0", "embedding": null, "metadata": {"window": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4517b89f-693f-4bae-874a-c670aa4057db", "node_type": "1", "metadata": {"window": "In the prepared remarks, and maybe this is what you were just touching \non a little bit, but you mentioned reprioritizing som e investments in the Prescription Technology Solutions \nbusiness.  I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e36bcc661c3e1473f5ac8a1dd8c69ecfa5fdd00b9b82310678568d668d8517d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "485bceb3-a598-43a0-b6b6-90f3f64d8204", "node_type": "1", "metadata": {"window": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "original_text": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. "}, "hash": "288826fdd2e91818e1076f833044a3bd361ff5d650f803cb55ec2da55d883d81", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1122, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "485bceb3-a598-43a0-b6b6-90f3f64d8204": {"__data__": {"id_": "485bceb3-a598-43a0-b6b6-90f3f64d8204", "embedding": null, "metadata": {"window": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "original_text": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0", "node_type": "1", "metadata": {"window": "I wonder if there was any way to flesh out a little bit more about what specifically you're doing there. \n And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb084c43ef6f0fc89c35da1f4de3b9e3a4a2f8fe7ad944ef105f86a29e9c134e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "original_text": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n"}, "hash": "62b87bbcbf0f52a2d9ec91fe21f5faa4d54c8008d8ac841ea7e8490855404c39", "class_name": "RelatedNodeInfo"}}, "text": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "start_char_idx": 1131, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5": {"__data__": {"id_": "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "original_text": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "485bceb3-a598-43a0-b6b6-90f3f64d8204", "node_type": "1", "metadata": {"window": "And when I look at your 2024 guidance, it actually looks like you're assuming that Pre scription Technology \nSolutions grows faster, 11% to 15%, versus your updated 11% to 12%\u202flong -term\u202ftarget, and I wonder what was \ndriving that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "original_text": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a8755ba068ddfb8f2cb11b9096ad18b2f807a00383a6c2ad4ef95400dc314f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b167e530-b2af-40b2-b34d-1ad09079cc50", "node_type": "1", "metadata": {"window": "A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "original_text": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. "}, "hash": "6efff4618e2521e4b5eff271e3475b8b9830e208e409aabb48fad1affff3a98f", "class_name": "RelatedNodeInfo"}}, "text": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "start_char_idx": 1254, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b167e530-b2af-40b2-b34d-1ad09079cc50": {"__data__": {"id_": "b167e530-b2af-40b2-b34d-1ad09079cc50", "embedding": null, "metadata": {"window": "A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "original_text": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "original_text": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61b8e06cccb9232e9dc19b598bdd2f807e1ce943a358458e940807cbcae65030", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "574526c2-f13c-4427-8005-740f43b1295e", "node_type": "1", "metadata": {"window": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job. ", "original_text": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. "}, "hash": "eb7c9715766c693cf97d96e1993561b9d386450b016dc6769a00a9c4e9e75f3d", "class_name": "RelatedNodeInfo"}}, "text": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "start_char_idx": 1427, "end_char_idx": 1535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "574526c2-f13c-4427-8005-740f43b1295e": {"__data__": {"id_": "574526c2-f13c-4427-8005-740f43b1295e", "embedding": null, "metadata": {"window": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job. ", "original_text": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b167e530-b2af-40b2-b34d-1ad09079cc50", "node_type": "1", "metadata": {"window": "A \nYeah.  Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "original_text": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3042cb39c40f08399bb1ab9068f573de4ff7fc9f35df0056d68f9705b9388ee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a4145de-0805-4e7e-a783-0e59a7b56fd0", "node_type": "1", "metadata": {"window": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "original_text": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n"}, "hash": "7b96319f1fb4eac8643ae074104546bff7da7607fdfd59e46f6cdd5f82b85874", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "start_char_idx": 1535, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a4145de-0805-4e7e-a783-0e59a7b56fd0": {"__data__": {"id_": "2a4145de-0805-4e7e-a783-0e59a7b56fd0", "embedding": null, "metadata": {"window": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "original_text": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "574526c2-f13c-4427-8005-740f43b1295e", "node_type": "1", "metadata": {"window": "Well, I mean, if you think about this business, I mean, first off, we've had really strong growth the last \nseveral years.  We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job. ", "original_text": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd157855cd68355b1ed24b04de060a74fbb3277eb952144fe80bac3f57a6fe4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b", "node_type": "1", "metadata": {"window": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "original_text": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. "}, "hash": "a5aaa6dcf0575ecd1d59dc94ae8b1d8c20a8d60e0ae9816326026e801f466ad3", "class_name": "RelatedNodeInfo"}}, "text": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "start_char_idx": 1640, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b": {"__data__": {"id_": "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b", "embedding": null, "metadata": {"window": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "original_text": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a4145de-0805-4e7e-a783-0e59a7b56fd0", "node_type": "1", "metadata": {"window": "We actually combined and formed this business a couple of years ago, just a couple of years ago, \nby bringing various businesses and assets across\u202fthe company\u202ftogether.  \n \n And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "original_text": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee6a4fb05c8a12939a514a8d74e26c49bf73546426b471c89ba83a5ff2a2fe0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77a85204-851f-4309-aaa7-c86485e5483b", "node_type": "1", "metadata": {"window": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "original_text": "And so unfortunately, that did impact some of our teammate, but this is our job. "}, "hash": "9f930d57f0b4be9dd4b112e8cc7ba68f438b0ba74e665300bc4e110d5ec31e5b", "class_name": "RelatedNodeInfo"}}, "text": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "start_char_idx": 1902, "end_char_idx": 2030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77a85204-851f-4309-aaa7-c86485e5483b": {"__data__": {"id_": "77a85204-851f-4309-aaa7-c86485e5483b", "embedding": null, "metadata": {"window": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "original_text": "And so unfortunately, that did impact some of our teammate, but this is our job. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b", "node_type": "1", "metadata": {"window": "And\u202fas those things continue to come together, we continue to look at our resources, our product offerings.  We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "original_text": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af48b0b046e3bb3fbdda2b1bf90236cad4ac689850c32b2f0b1a45ba4c394bc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "115235a1-0473-483a-9fb5-db17b4d76baa", "node_type": "1", "metadata": {"window": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "original_text": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. "}, "hash": "e57667b2429efb311223a5f27e22df0952476779b5bead3789e697de2f51ac2b", "class_name": "RelatedNodeInfo"}}, "text": "And so unfortunately, that did impact some of our teammate, but this is our job. ", "start_char_idx": 2030, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "115235a1-0473-483a-9fb5-db17b4d76baa": {"__data__": {"id_": "115235a1-0473-483a-9fb5-db17b4d76baa", "embedding": null, "metadata": {"window": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "original_text": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77a85204-851f-4309-aaa7-c86485e5483b", "node_type": "1", "metadata": {"window": "We \nhave conversations with manufacturers about their lifecycle and service needs across that lifecycle.  And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "original_text": "And so unfortunately, that did impact some of our teammate, but this is our job. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f997fba66e15f0f409f19b98b17d5db942ad229d464f6e84011f65a89f3f1f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b87e587-450b-42ee-8ad8-7d0288be32b2", "node_type": "1", "metadata": {"window": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "original_text": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n "}, "hash": "9488734b87a81ca3dd92bbfc0543f46f04a9e574aeb98874d8fb61fc8f35c048", "class_name": "RelatedNodeInfo"}}, "text": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "start_char_idx": 2111, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b87e587-450b-42ee-8ad8-7d0288be32b2": {"__data__": {"id_": "3b87e587-450b-42ee-8ad8-7d0288be32b2", "embedding": null, "metadata": {"window": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "original_text": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "115235a1-0473-483a-9fb5-db17b4d76baa", "node_type": "1", "metadata": {"window": "And we just \nfelt like as we evaluated inve stments we had been making and where we thought investment opportunities were \nfor the future, it just made sense for efficiency and focus purposes to make sure we align those to where our best \npossibilities are.  \n \n And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "original_text": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1d8db3a03fc6d7fb482031b4578b0e5350d84610a5bb1de73fc9531c1bdfaaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34b3e3eb-32eb-4321-8123-388f621db4ab", "node_type": "1", "metadata": {"window": "And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . "}, "hash": "a9b5a6f1b67440a78f3b407a22be4d3825de91259928d5983f7e491b0becf7ef", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "start_char_idx": 2251, "end_char_idx": 2382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34b3e3eb-32eb-4321-8123-388f621db4ab": {"__data__": {"id_": "34b3e3eb-32eb-4321-8123-388f621db4ab", "embedding": null, "metadata": {"window": "And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b87e587-450b-42ee-8ad8-7d0288be32b2", "node_type": "1", "metadata": {"window": "And\u202fwhen you make those realignments, the\u202fs kill set is not always the same, what you're moving from to what \nyou're moving to.  And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "original_text": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55bb2bbb16e991fe3ddf947e093a40fd09658c3ca4cb4285ba4eeb5f62878c25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5", "node_type": "1", "metadata": {"window": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n"}, "hash": "a2ebedca9adeae14912592fa235f2fd8a20edb63d193b2584e40c1749e15e601", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "start_char_idx": 2382, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5": {"__data__": {"id_": "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5", "embedding": null, "metadata": {"window": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34b3e3eb-32eb-4321-8123-388f621db4ab", "node_type": "1", "metadata": {"window": "And so unfortunately, that did impact some of our teammate, but this is our job.  This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp . ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61e93a1d4d162b7232a14edf63d55e877dfe1f9348dd874e93ee00ac6d0f6d2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "645e0600-2ad4-41a0-a4a8-16449b0f0e74", "node_type": "1", "metadata": {"window": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. "}, "hash": "986fa4fd619c25d005b737745d3ab6ccddf35e11eb36154bc0b0a074055870fe", "class_name": "RelatedNodeInfo"}}, "text": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "start_char_idx": 2727, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "645e0600-2ad4-41a0-a4a8-16449b0f0e74": {"__data__": {"id_": "645e0600-2ad4-41a0-a4a8-16449b0f0e74", "embedding": null, "metadata": {"window": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5", "node_type": "1", "metadata": {"window": "This is one of \nour strategies to simplify the portfolio and be focused on efficiency and pos itioning the business for\u202flong -\nterm\u202fgrowth.  So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7790ddefab6d5a3b353b444e5cde0d4feaddcfd488d68a2fa77ee7411bf18f5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "976dbe1f-7c04-4bfc-b61f-2e668afb95f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "original_text": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n "}, "hash": "0372cbb8dac654e8d58987adab8fcacc7530d82f868cd81b24dd05e9ac00a613", "class_name": "RelatedNodeInfo"}}, "text": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "start_char_idx": 2850, "end_char_idx": 3022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "976dbe1f-7c04-4bfc-b61f-2e668afb95f0": {"__data__": {"id_": "976dbe1f-7c04-4bfc-b61f-2e668afb95f0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "original_text": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "645e0600-2ad4-41a0-a4a8-16449b0f0e74", "node_type": "1", "metadata": {"window": "So, we feel very good about the performance this past fiscal year and feel good about the targets we \nhave set for fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c3879998ea833b415b3aaabb69f9f1fa2f9141b3d97b9cac1a17103eb6718eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62", "node_type": "1", "metadata": {"window": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "63a5cba64eb9946fe2b59da030b80c7c0ab20edee2f0ee6312df98cc594db17e", "class_name": "RelatedNodeInfo"}}, "text": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "start_char_idx": 3022, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62": {"__data__": {"id_": "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62", "embedding": null, "metadata": {"window": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "976dbe1f-7c04-4bfc-b61f-2e668afb95f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp .  A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "original_text": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc96b3077a7b788568e4ef20e7761ffea1f8af47f21511da9fed3569b60e0de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c292b9bf-d4f7-4edb-adf9-d8f8d8903133", "node_type": "1", "metadata": {"window": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n", "original_text": "Great. "}, "hash": "9303832e2a7258ecce5ae7b44c86258af419bd2eb1926b895f07b34d99686264", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 3232, "end_char_idx": 3562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c292b9bf-d4f7-4edb-adf9-d8f8d8903133": {"__data__": {"id_": "c292b9bf-d4f7-4edb-adf9-d8f8d8903133", "embedding": null, "metadata": {"window": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n", "original_text": "Great. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62", "node_type": "1", "metadata": {"window": "A \nI guess I would just remind you again, these are\u202flong -term\u202ftarget rates that we expect that we'll be able to achieve. \n And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfa10b9c8a8abd8bb740d94f6ef1c413093b8af3952d5c70ab1c3f63d6ad8157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98343c16-6c36-4cc4-9ee3-d82e02bf3975", "node_type": "1", "metadata": {"window": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "original_text": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. "}, "hash": "287c7c41393089189819626cff2784d53aa89aab8ccb35fb520f363df7f375de", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 3562, "end_char_idx": 3569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98343c16-6c36-4cc4-9ee3-d82e02bf3975": {"__data__": {"id_": "98343c16-6c36-4cc4-9ee3-d82e02bf3975", "embedding": null, "metadata": {"window": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "original_text": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c292b9bf-d4f7-4edb-adf9-d8f8d8903133", "node_type": "1", "metadata": {"window": "And as this business is broad and diverse and we have it as a strategic focus point, we're going to continue to \ninvest in this busine ss from year -to-year that may vary.  But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n", "original_text": "Great. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a76b662fa210930208d295d299aff59668957ad5368cf3e3814f791eac044b36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business. ", "original_text": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson. "}, "hash": "2473472f26e77b72efc7f68c7e40132acddd917a3150b48ad9900a92b98f1949", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "start_char_idx": 3569, "end_char_idx": 3666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba": {"__data__": {"id_": "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business. ", "original_text": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98343c16-6c36-4cc4-9ee3-d82e02bf3975", "node_type": "1", "metadata": {"window": "But over the\u202flong term, we feel comfortable with the \nupdated guidance that we've given you, but it's a business that we're going to continue to make investments in to \ngrow it and to support our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "original_text": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60522a190d14b37fb1b383a52af395a028f18467bc9ec641fb68dbd907a548b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d3a296-4f29-4003-87fc-bbd6e4d23028", "node_type": "1", "metadata": {"window": "Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "original_text": "Thank you, Rachel, for \nfacilitating this call.  \n \n"}, "hash": "494a1aecfbf17d05ac8d744863315638643b62b70026d275483af5cf12927a1d", "class_name": "RelatedNodeInfo"}}, "text": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "start_char_idx": 3666, "end_char_idx": 3753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94d3a296-4f29-4003-87fc-bbd6e4d23028": {"__data__": {"id_": "94d3a296-4f29-4003-87fc-bbd6e4d23028", "embedding": null, "metadata": {"window": "Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "original_text": "Thank you, Rachel, for \nfacilitating this call.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business. ", "original_text": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6efbb0f51492688de8dfe26efd29e184d0f564e03281be1af8007f6e119ce7be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees. ", "original_text": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. "}, "hash": "76fc92ca5549ec7be07733e4978db76e6021d60d40ec04a687166cd10096ab32", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, for \nfacilitating this call.  \n \n", "start_char_idx": 3753, "end_char_idx": 3805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e": {"__data__": {"id_": "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e", "embedding": null, "metadata": {"window": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees. ", "original_text": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94d3a296-4f29-4003-87fc-bbd6e4d23028", "node_type": "1", "metadata": {"window": "Great.  Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "original_text": "Thank you, Rachel, for \nfacilitating this call.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df39e0961d867d3700c1a1870b97d14b94482eac2877425675230809fd6e2559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5feb62a8-ed96-47cb-bb8f-08d0147d2787", "node_type": "1", "metadata": {"window": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I am really pleased \nwith the continued momentum in the business. "}, "hash": "075d659083b63111c7eb0c744a08bc9b4696b4692016110c3a69dfd7609ff73c", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "start_char_idx": 3805, "end_char_idx": 3900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5feb62a8-ed96-47cb-bb8f-08d0147d2787": {"__data__": {"id_": "5feb62a8-ed96-47cb-bb8f-08d0147d2787", "embedding": null, "metadata": {"window": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I am really pleased \nwith the continued momentum in the business. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for joining us this afternoon or evening, depending on where you are.  We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees. ", "original_text": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d54a6db985a7319ef1a3eaa21cb277bb30b5a2f3fd83512ce41f367d48c50fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054", "node_type": "1", "metadata": {"window": "Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n"}, "hash": "8839879377147de96d26fba609e59438f50dea65140234360a640d526795eaec", "class_name": "RelatedNodeInfo"}}, "text": "I am really pleased \nwith the continued momentum in the business. ", "start_char_idx": 3900, "end_char_idx": 3966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054": {"__data__": {"id_": "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054", "embedding": null, "metadata": {"window": "Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5feb62a8-ed96-47cb-bb8f-08d0147d2787", "node_type": "1", "metadata": {"window": "We \nappreciate all of the thoughtful questions, your support and interest in McKesson.  Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I am really pleased \nwith the continued momentum in the business. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "600d785c14565e5afbacd872d78bc8f1804647ffd62a620cb3c550b8ef34cfe3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36336417-7b47-43b6-ba5b-079401170c4d", "node_type": "1", "metadata": {"window": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I want to end though with a note of acknowledgment to the McKesson employees. "}, "hash": "8e33266974a084a72824481b7e092fde3bc5a92aacc627101c5d6fda36a88cd7", "class_name": "RelatedNodeInfo"}}, "text": "Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "start_char_idx": 3966, "end_char_idx": 4058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36336417-7b47-43b6-ba5b-079401170c4d": {"__data__": {"id_": "36336417-7b47-43b6-ba5b-079401170c4d", "embedding": null, "metadata": {"window": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I want to end though with a note of acknowledgment to the McKesson employees. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054", "node_type": "1", "metadata": {"window": "Thank you, Rachel, for \nfacilitating this call.  \n \n I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8324a7ab74caece2d3fdc6eb3f8e119085c6f4586e66832927b9d439a1d64598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cffc938-504f-4520-a4d1-b4c4a49e2e7a", "node_type": "1", "metadata": {"window": "I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve "}, "hash": "de8b80398b6e099094ef4c7cf16af1fce378143ee7f1e03b2bbae1f224842c55", "class_name": "RelatedNodeInfo"}}, "text": "I want to end though with a note of acknowledgment to the McKesson employees. ", "start_char_idx": 4058, "end_char_idx": 4136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cffc938-504f-4520-a4d1-b4c4a49e2e7a": {"__data__": {"id_": "2cffc938-504f-4520-a4d1-b4c4a49e2e7a", "embedding": null, "metadata": {"window": "I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea085e19-d94b-43d8-a4f3-026c3530cece", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88b2c883ce2a7f0d55890ec3594066c0a80d94f32c5f6ad4f3e0d8f5103ba9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36336417-7b47-43b6-ba5b-079401170c4d", "node_type": "1", "metadata": {"window": "I want to conclude by just stating, McKesson had a strong fourth quarter and full year result.  I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "I want to end though with a note of acknowledgment to the McKesson employees. ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f4e844d117a9eb15039fc38d6c3035a8d70d1c27bccfc86296357d5fbf5e64e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3c1bbc1-98cd-480f-b007-97d7d398e220", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining. ", "original_text": "McKesson Corp.  "}, "hash": "e8f4dad091dcd28d4640f550351dcee366a8cb8708f9fe9cf67bc32fc1538fea", "class_name": "RelatedNodeInfo"}}, "text": "It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "start_char_idx": 4136, "end_char_idx": 4279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3c1bbc1-98cd-480f-b007-97d7d398e220": {"__data__": {"id_": "d3c1bbc1-98cd-480f-b007-97d7d398e220", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cffc938-504f-4520-a4d1-b4c4a49e2e7a", "node_type": "1", "metadata": {"window": "I am really pleased \nwith the continued momentum in the business.  Britt and I remain confident in our ability to deliver  \nsustainable\u202flong -term\u202fgrowth.  \n \n I want to end though with a note of acknowledgment to the McKesson employees.  It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "original_text": "It's really thanks to their \ndedication and their commitment to our customers, our partners, and\u202fto each other that enable us to truly improve ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c4a5f301391be32fbefc08a3b05cf802cba88f2935f1515391695ac5807688f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f456db4-1b9e-4a92-9161-74c6653ed195", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time. "}, "hash": "89124e4282f92ba08212e29223ee4b2d5aec2de751e742c4e33e959c41030732", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f456db4-1b9e-4a92-9161-74c6653ed195": {"__data__": {"id_": "3f456db4-1b9e-4a92-9161-74c6653ed195", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3c1bbc1-98cd-480f-b007-97d7d398e220", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b1098b9347c361e553a4db86a385fd3fa64f9dc7e11666e23b2e6cadff9553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e02324-3e0e-4a57-82a8-4ba0154b02e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thank you, Team McKesson. \n"}, "hash": "e80224e5b321efb23228b7e06eaef4d2d73231cbde343179671cc4f970833b10", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time. ", "start_char_idx": 16, "end_char_idx": 258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e02324-3e0e-4a57-82a8-4ba0154b02e8": {"__data__": {"id_": "34e02324-3e0e-4a57-82a8-4ba0154b02e8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thank you, Team McKesson. \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f456db4-1b9e-4a92-9161-74c6653ed195", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n ", "original_text": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53e2702a10ae017abdb24ea62bbd6ec7f30cee973370e4c5cda5e92a9613ddee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4aeada4-580f-435e-8e62-da636621eec0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Everyone else, thanks again for joining. "}, "hash": "700b0e2e554b5b30e345ba2d8a237943f8314159519d90d25756348b86dab1dc", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Team McKesson. \n", "start_char_idx": 258, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4aeada4-580f-435e-8e62-da636621eec0": {"__data__": {"id_": "d4aeada4-580f-435e-8e62-da636621eec0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Everyone else, thanks again for joining. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e02324-3e0e-4a57-82a8-4ba0154b02e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thank you, Team McKesson. \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a2a41fcc6731f897c4ffeb1132785125dd79dff70b704f9d140b7fc7dd30f0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a terrific evening.  \n "}, "hash": "f7fb4fbad6e3856e1dbec29d2474e021c37fe8ba85df8ba18e7fabce5f2acbaf", "class_name": "RelatedNodeInfo"}}, "text": "Everyone else, thanks again for joining. ", "start_char_idx": 285, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0": {"__data__": {"id_": "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a terrific evening.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4aeada4-580f-435e-8e62-da636621eec0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Everyone else, thanks again for joining. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63daeaff697bace5f1ef15ecc23412b052955d1bf46037a57c93c1c549698de6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4", "node_type": "1", "metadata": {"window": "Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. "}, "hash": "5b591f7aa45fb3ea8bc852f5c177efa8684b00ba22be7187a0c0b1420ba0da46", "class_name": "RelatedNodeInfo"}}, "text": "Have a terrific evening.  \n ", "start_char_idx": 326, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4": {"__data__": {"id_": "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4", "embedding": null, "metadata": {"window": "Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a terrific evening.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ff7acfe8fa1d57aa68a42b3dcc3d12bc6d9ab6a7ae514b2cb475d60d76d3322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b38d323f-e587-4f16-a082-7d220eb9125b", "node_type": "1", "metadata": {"window": "Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "original_text": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "402e40be559359bddf323923f862cd95abe9b1c467cade62a5467e239764d3c1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 354, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b38d323f-e587-4f16-a082-7d220eb9125b": {"__data__": {"id_": "b38d323f-e587-4f16-a082-7d220eb9125b", "embedding": null, "metadata": {"window": "Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "original_text": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4", "node_type": "1", "metadata": {"window": "Thank you, Team McKesson. \n Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5768a0722e3c2d7778441651756c6cea96783d3cbf37f71fb4597e393dfe679", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16b84144-1e13-465c-bae6-e11412324639", "node_type": "1", "metadata": {"window": "Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "561efe3fd44a6a6a2f27e7b7c1e2154850803a544b8fcbbd8343dd6ecf3d7ecd", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 671, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16b84144-1e13-465c-bae6-e11412324639": {"__data__": {"id_": "16b84144-1e13-465c-bae6-e11412324639", "embedding": null, "metadata": {"window": "Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b38d323f-e587-4f16-a082-7d220eb9125b", "node_type": "1", "metadata": {"window": "Everyone else, thanks again for joining.  Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "original_text": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "204c9b5e0d7eb4351f6b86e1bd64fc173cb77aa0d24f0c1c9536005450bda466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85cd1409-bdb1-49de-9dc2-6cc23a6e3622", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "2e2d20919eae6b6fd6388df5e8ae760c302e8d52e4fe12988a404283010b79a4", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 742, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85cd1409-bdb1-49de-9dc2-6cc23a6e3622": {"__data__": {"id_": "85cd1409-bdb1-49de-9dc2-6cc23a6e3622", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16b84144-1e13-465c-bae6-e11412324639", "node_type": "1", "metadata": {"window": "Have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80316f4bf21a737f16cbb308c5caf62d33650497781ba066b0bc364b58f455ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c", "node_type": "1", "metadata": {"window": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice. ", "original_text": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. "}, "hash": "213dd2cb67e7376566b907121bbb14e436216aa3d42f82594a79a1d980466da6", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 951, "end_char_idx": 1073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c": {"__data__": {"id_": "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c", "embedding": null, "metadata": {"window": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice. ", "original_text": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85cd1409-bdb1-49de-9dc2-6cc23a6e3622", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c62769eba0a6ea23a97f335b729bab64b3dd9633dd0dae166a7d9ff3d079597f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eb3d135-9e7b-43f5-8b7b-8868322bd13e", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "b135ae2566ba620735694222555676b0e804bff248e60b8107815b9e057f66ca", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "start_char_idx": 1073, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eb3d135-9e7b-43f5-8b7b-8868322bd13e": {"__data__": {"id_": "2eb3d135-9e7b-43f5-8b7b-8868322bd13e", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c", "node_type": "1", "metadata": {"window": "You may now disconnect, and hav e a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice. ", "original_text": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f0d9ff1cf9c01c20ffc0c74ffcc7265baa447efaf0b70f3d52a4e81bb52c77d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a9d6f46-fe6a-4221-9fae-d32addf1db86", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "5c570d64020467bc20b77404d66da4408c9e9e314e22fff5c02c027c1f1f85f4", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 1274, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9d6f46-fe6a-4221-9fae-d32addf1db86": {"__data__": {"id_": "2a9d6f46-fe6a-4221-9fae-d32addf1db86", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eb3d135-9e7b-43f5-8b7b-8868322bd13e", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8e7e8c789dd09ddc7f7c964b142980c855cb5958d5062ca23b939f1ef40b872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34f5256c-028d-4864-92df-e78963e6f611", "node_type": "1", "metadata": {"window": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation ex pressed herein on this date is subject to change without notice. "}, "hash": "79969f8b04574bc89db0b675fccf15d6d85767bf65b375ad430ef58067e7fc66", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 1365, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34f5256c-028d-4864-92df-e78963e6f611": {"__data__": {"id_": "34f5256c-028d-4864-92df-e78963e6f611", "embedding": null, "metadata": {"window": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation ex pressed herein on this date is subject to change without notice. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a9d6f46-fe6a-4221-9fae-d32addf1db86", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7839dc53b8114ffd1220686028b8d231201db737e300548a6e4769f21762eaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17f188b7-7581-4131-a855-b8895e63f87c", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "446072bc6d3182e320b57108492a71ac9fa997e914cb899a77bec7b3ee4d064b", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation ex pressed herein on this date is subject to change without notice. ", "start_char_idx": 1728, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17f188b7-7581-4131-a855-b8895e63f87c": {"__data__": {"id_": "17f188b7-7581-4131-a855-b8895e63f87c", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34f5256c-028d-4864-92df-e78963e6f611", "node_type": "1", "metadata": {"window": "You must evaluate, and  bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completenes s, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation ex pressed herein on this date is subject to change without notice. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2993efac0cb17d28c06048a3e833ef6cb6b48b34196d9627892115422c953d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f35ed205-2847-4165-a2de-18d708dda254", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "d25ac13b48a9a122d8fca3cb4ada5d77bfba11707831975e695efe08be12c35f", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1813, "end_char_idx": 1940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f35ed205-2847-4165-a2de-18d708dda254": {"__data__": {"id_": "f35ed205-2847-4165-a2de-18d708dda254", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17f188b7-7581-4131-a855-b8895e63f87c", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c91ac3cd0394e4918b9b05336a676bec24e257a4283a4f24a8cae6bf1205aa18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3eff749-270a-472b-9378-a83631ad3f4f", "node_type": "1", "metadata": {"window": "Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "39e6a6a71a8b29b1893fc39de12d45e564ec5aa5fbf1aae950f17987a52a0a79", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 1940, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3eff749-270a-472b-9378-a83631ad3f4f": {"__data__": {"id_": "d3eff749-270a-472b-9378-a83631ad3f4f", "embedding": null, "metadata": {"window": "Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f35ed205-2847-4165-a2de-18d708dda254", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is pub lished solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2753423fcf31eed147e88885bb910df7778956772bc26413a3a05d6a882a22c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28240866-68cf-4bc8-b148-23634b36c75e", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "686ad262fb1229e339e61c2f0187da699c1601b9335cf9882d58a1e844dc98fa", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 2103, "end_char_idx": 2536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28240866-68cf-4bc8-b148-23634b36c75e": {"__data__": {"id_": "28240866-68cf-4bc8-b148-23634b36c75e", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3eff749-270a-472b-9378-a83631ad3f4f", "node_type": "1", "metadata": {"window": "Any \ninformation ex pressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "701016bc75df9e14147bfefe3ea25fdbe11d4d8b569bd526cd1e8046f06c59dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "1488e4d612344d35d28554414aacd306648d99076811e79775d6c485af4c14a7", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 2536, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e": {"__data__": {"id_": "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28240866-68cf-4bc8-b148-23634b36c75e", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8ea4a42e89b3cdb6a8618a779d9b02cc0a9e7a82bfcd65315cfcfa226364f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c267494a-e9da-446a-a858-c67d33054bed", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "eb552956caa50e7c06378d47f327b99bc6cf7120212173f778fd48f8748b101c", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 3215, "end_char_idx": 3404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c267494a-e9da-446a-a858-c67d33054bed": {"__data__": {"id_": "c267494a-e9da-446a-a858-c67d33054bed", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, includi ng the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82841cf56503cb7c1adcbf29c212ec791bb17d7611b1e0c2b14b2403f737d623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e9de07f-f8cb-4137-af21-3a75d4783668", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "2e66f756b6ecc0e1b19fdd79ee27cb198f91277aa356e6c746f6d4a9f9a83b59", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 3404, "end_char_idx": 3482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e9de07f-f8cb-4137-af21-3a75d4783668": {"__data__": {"id_": "8e9de07f-f8cb-4137-af21-3a75d4783668", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2e7056e6-611b-4964-9975-862de022c327", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc1e65056e72a1c1cbee00c5aaa1b03546cba87253a83d9cb063d77e27165a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c267494a-e9da-446a-a858-c67d33054bed", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONS EQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81a07252cf9f7a4825db0483d1ad17dd4ffb50dd393ce1844bb18ce84845c45f", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3482, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2edaf5ee-f6bd-4f52-b31d-58e8dc046f98": {"doc_hash": "950ce02435fb2e5d88bcc313a79621c1db053972e7c57f2bb51c70ac966ef794", "ref_doc_id": "01b5d416-1e80-4778-9006-fc61daa8daff"}, "a98623b5-99be-4658-90a4-ede42cdf4eac": {"doc_hash": "281d057126afb82a33b78170db089e30830533b15ebfb56554347683a3e59f48", "ref_doc_id": "01b5d416-1e80-4778-9006-fc61daa8daff"}, "da2de88b-0bc2-468a-8ce6-a72f541e813b": {"doc_hash": "1274579828615326d2bfacdf550f85b8f1b135bcb3b249cf73abfc112f8aaadc", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "4cfa0bf8-b8f4-4946-a606-0195ab6bb916": {"doc_hash": "f879525d20f1632004ec5b61e6015bfb3ae762e8ef36d9c209aa3e70741a6d4c", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "8ad6873e-55ef-4063-82aa-36021d4a5f9d": {"doc_hash": "4c2a2929e61eb27c7b0323124297fb431d322a423f42c3bccbc2804e714c18f3", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "af61f22c-f662-4ee2-9723-95feef61f940": {"doc_hash": "f8e941e701e4c019299f481f4e8310caa1d5ad5373bb3588897e3e325110941f", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "a4727e84-c82f-465a-9c8b-9646cd6618e3": {"doc_hash": "a1987d91c1fd7d4c6a032f1ec65eecf8e384494224c0baa2c0229e5e196bfe84", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "af8f3443-0c5d-40c4-a224-5c1cb7077014": {"doc_hash": "b811107ec5a70c427a8c64f6e7aee5294fbfd98ea06dd125b567c56eb9ad8d89", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "b49be17a-f3c2-4284-b16f-a2afcf9b6895": {"doc_hash": "11bdd9f232a603a8e68fea905adc672a0bd2a297a3cece6c50b19519def98f63", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "11780e35-9889-4c22-b78e-5e5abe27c6db": {"doc_hash": "15c86be29947b6446fcbb9bee93584f11f791670f62791016d8ca89469f2084f", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "30658792-6b3f-4d22-8f6a-d507f3f912c6": {"doc_hash": "ff2531ade4befc2a7a7210184ca012ec4e19f0aefedd0dcc16bdf53fefaea940", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "9eef01c7-223e-44e8-b1fb-962b96f54c68": {"doc_hash": "0d02dd700b8f021026e1df4e6394d0cbbe97c8cf87977bb54eaabdd046f8426d", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "e3622332-983c-4b0d-812f-c01415d8ce55": {"doc_hash": "5ab335c0d16984efd4857b51fd67d46ef6e1e6c3fd502f4bba85aed0774a688e", "ref_doc_id": "92cacbcc-8459-4060-bdf5-085e3d8008d0"}, "42bf4fe6-2eb0-4706-9043-5b7005e34b49": {"doc_hash": "2ef70b90e10d110526293d18f001bc1d79e1dbbd8b6e663c9fa9392bf4682515", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "a0aa65b7-7942-4d72-bc96-4c4b23abeed0": {"doc_hash": "7d10cf837f86f4d27587956760c93e4a59a02533a2a761ea5b1bede8040a044f", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "f697c527-4c4a-450b-97c7-fb635975b4d6": {"doc_hash": "49a18699830d97c188744caef41e23ad9d47a2d1f06d906ee02e42e3669d80b3", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1": {"doc_hash": "dd6de03e776231a368e1373f317cf2a1dab311e34575c9d9c217475d391f174c", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c": {"doc_hash": "cd072ca5e6c137f8bb9cceebd1a9393695c9c17efc4d7ae24224fee057241c4a", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "bfff62fc-4375-489c-bcc4-c2e9d46b464b": {"doc_hash": "8e2e276d9d5ce8f3a8ca10971091ffa01fe67c8aeb4edf0ff3a17c24c462a901", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58": {"doc_hash": "2654514f389aeb698755dd59dd3f480ae86d17463e55c26bc008c886f8b01a75", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad": {"doc_hash": "549b51927a34b536054ee43a110447d2998f9393f1bd7553b30edbd062fbb3db", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "e222da5f-3f00-4ca3-8490-63ce7b16c86b": {"doc_hash": "9c812a898746421bcc5a2d589e75ebcbe388e6e213bf690b0b1a6330eb5c7cad", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "21021643-c8f7-40b6-8035-d054d928011a": {"doc_hash": "f9d3a700396df373ec5818b1ebccb3bb66b85452288ce6169ac870713e677172", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "ba5af0ba-fbc5-420b-81d4-4981222f2568": {"doc_hash": "be64b5dce5f389348d0c0fb325da9ba335812c1c476173524cb1848a7f10b48e", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "419a6e76-87c2-4565-afa5-bad7ce10fbbb": {"doc_hash": "ca30e83fe857751f7b3954195b9990418eec7b4a9cb8f232bbc5e9c44fb0bb6d", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "ba46ad75-431f-49b8-bb1d-c143c46e4e4b": {"doc_hash": "d00c274d364d8b1f1de585f1544c3096f2f0eb44224699e0b81a0634b8c5895c", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "3ac01a8c-1ff0-48ad-938c-a2efa385304b": {"doc_hash": "2d0ee7df46b23fa326ebd1f82d62db70c3e5666134d1e16965dca326734e86b8", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75": {"doc_hash": "23e0d37f15f11784c5411524d762ecd399c458f6de2bbef447e8f22f822c256f", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "42a87841-1f04-4876-95d1-daee31c8a13e": {"doc_hash": "a010f7725aefea7071898312bc881083193d5b61cdbd93c039b662ee58ac2314", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "627aeba7-8346-44b2-8167-78afae96be7f": {"doc_hash": "69fcd78c61adcf3de12145f3bd80fad3b69ddab305dcb3fe770304f5ed1f2cf7", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "65152bff-bb56-4bc0-bf63-87deb9454799": {"doc_hash": "b0e8ea3a1efd6184ac10f269d9b7738f3260ae1f2cc82da8d6e04c2c1af1fe55", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "a31819f2-e2ec-42e9-a1d3-980aa273be52": {"doc_hash": "06416b617512305d58a9de2b24872dcdb09e5d632e9aa705a0f9fbc9a0c4f734", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "94a5228a-61a7-48a2-9be9-51282d40e6b8": {"doc_hash": "fefb682faf148f981d1867d377ce5a7484f9d3e1885f5c0d4886f3c36b58d436", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "0652f7be-cedd-4275-8f93-a3ed3695b3f7": {"doc_hash": "9883681fbb50c2bdabb10a72501c637310352343911b5c5eadc2794fd89df5e5", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "b5235bf2-3eb0-4756-bdb5-dff3544827d0": {"doc_hash": "44e36854253fd329f81796dbaf62a9abfbd67522dcb9a330bd37499188d156f2", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "4d4a76bf-6023-4422-976d-482ba97746b3": {"doc_hash": "163b54a26700c84e4af60b936ce2ac648a3946037359fa1ecde983f6c81f73a5", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "40f2c965-d037-4aa8-99cd-0969d54098de": {"doc_hash": "2e5e4af88f7a43ea22a2ab16ca2be7f6eabbe65a920334905b147b36b1d60ca8", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "27450ae1-ad61-4202-a937-ae82cdda5a31": {"doc_hash": "a8e703a8b848c77c6e8ae6c60c170724d31cf6b334c4ba482cb25f028b5cc5d6", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "2b90f5fe-ce16-4873-bede-877ff9c73b8f": {"doc_hash": "4179cceabfcac266f37fef56453b849c0db542e287da581cd6777b70f6955858", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "edb7a043-364c-41b8-a5b4-f7137e47683b": {"doc_hash": "81589295a50e9a950cbeb6396fbb7b4f01ae9fd01a72cd3e9be1a14aebabdf2a", "ref_doc_id": "ee437d97-be32-4635-ab2c-f5a89059ad3b"}, "6918ef20-e896-423a-87eb-ae76410fa314": {"doc_hash": "fab06ff094f3048fd58ec27bdffed9229184b60e02e897dda01bcfb28904641a", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "228e41f1-a67e-46a4-a63e-702b22916cee": {"doc_hash": "085b41b490811c575de01de8e1fcc46c7979178c0536c951e798444f77caefae", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd": {"doc_hash": "9a99ffa5cd6ec377cf8d95138f68020976961909806b783f26d3f9d4fd8cbae3", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "7e0315a0-0248-4aeb-9719-e429e28bcaf6": {"doc_hash": "addab38dd9621dc85a2e304837edb4788bfb6bf99e24e50f6a3791cb8ca31ee9", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "62df6be1-f2c5-4880-b661-ee42241c93b8": {"doc_hash": "29d21a9add47b9a998af2391ce4e2c6d636241e588e31a6fef9feb46997a75a0", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a": {"doc_hash": "ce8f78ff7330b484987ff9cb0db70e8aff41ef3b840c5f71461a3f182bb9ea6d", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0": {"doc_hash": "7fe070928ab178fc1bcfabc709880f044625689e020a302576744f4cce36aca0", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "7f3c6574-597f-4bd8-af3b-2e07a7a58723": {"doc_hash": "d699171c9ead0b122b73b5b7f08ba7bbb374d6f1122480dbbf552cb089f9157f", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0": {"doc_hash": "a2eb04ab3e90c23a34f775b2de70a1ca9379dc0f5b01ae00b709338e1c896bf1", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "5984bdb5-6632-41c8-87da-0a5d1713ac7f": {"doc_hash": "0cae571426bd06ccfad385bf6f62c0977aab72935393c1ab1fa8132bcab33a52", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "e238d4e0-e4c6-4095-8981-4838fb97d06e": {"doc_hash": "4dd58748b83b894586e02e744484c55a576540835a1319a9fd2cd642ddab9746", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "60ffea83-639d-49e5-a23b-53dafd9d09a2": {"doc_hash": "b4bd30faffa4b776aa2b707f3d529d02a59d1a5a22af5a26f04a08bb52bdb51b", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "a0968846-5bce-4202-9d30-0e8335e393ba": {"doc_hash": "50ddb5c878ffc1a142d14b7e4cd20eed243cd9bf025ffc287083576cf405dad4", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "4f452736-1311-478d-8ab7-83e3e1056de6": {"doc_hash": "eaa13f3fa6c5636dc0afa321e94b112c7d452a687f36a92dc5c9e69fd9b4db99", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "8a640af6-aa1d-470a-9947-d2fbf09b54aa": {"doc_hash": "715e2b7a4e8d74e0c7a492fefc428b09baff61383608bf21bd31dd92c816cb54", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "7b5197bc-302e-484c-a90b-5bee7b0a59fb": {"doc_hash": "84f11179e8f6ba51459d4457872686be060d6dcf60796581447c01dc70f4d6db", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "181259de-5580-4db7-9d2e-a870fada2970": {"doc_hash": "0e1136cfd756f968107dd45f6bcd2f2a517f308139e0d76e64f06a71badc50c9", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "17bf866b-cb77-4af2-93e0-7ef2184d81a2": {"doc_hash": "bc4cf67684c2a8cf7a061fbf688b3db0d7b97fa5dca26a468fb3759b20f5b652", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "cfd1f5a1-b771-4161-8e67-3ab607dc6208": {"doc_hash": "bbfe30505321d0e2081a5f9417488a41ae081829712a17cabd3f5ea78ac8a245", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "9435e7f5-a537-4f93-8657-f5ba9e90e8bb": {"doc_hash": "9597225c6df9b1c8a3681ba50f2d8a9352acf32e9cdbcd8bd6a339d8b975efd3", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "02168467-21fa-464e-960a-789472c1c77d": {"doc_hash": "35f1a49de809522721204327c776311076d41dea54d66de93485444c8b506e46", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8": {"doc_hash": "6ef969034c55fb8ad2e979c0b44496211ee2509e676dd3c1c317274e67efa0fc", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "e65ad2d6-1a18-460b-8bc5-15903611d928": {"doc_hash": "eb15864bff0d6c74973ef604fb2cb99a2b25da9c8e6108ab1f76a047f58de4e9", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "557175d0-2055-4c69-977f-f1fa81c309d5": {"doc_hash": "f8ba69cd54ebd0164de512cad28b6c24659f50d263103edeb8213c3d96e03b71", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "4216193f-eedc-41fc-af5b-52924477e536": {"doc_hash": "fe119bc797d3e7cc431c76e13a142d3793f66abf99aca98c7f2e26135e6ca29a", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "bd96697c-ff88-49df-92b0-add2c7886adc": {"doc_hash": "3cc60b4d2ba84d152fab614087dfe21e8c1509672915f4d7b8248167b5aea13e", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7": {"doc_hash": "37e970109c412133c3a266a387d4054561677bcd71d659a9832a08e55c628815", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "2e847ad1-047b-4cca-8a71-94fb1bf058cc": {"doc_hash": "3bcddd3f69d56a8c717dd98c10a749584b6f5e0c04992199680febed61c154dd", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f": {"doc_hash": "c9b310855e84404583f6fc72e0bcc6dc9f8374a929cc758c821c16f9c8efdbdb", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "cae42834-fc81-40f6-9489-797b67e767e5": {"doc_hash": "4a0403538a0576593da1a80c07cf1654e5d576bb888581d096ebaa40362701a5", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "092feeaf-cc82-4de4-bc96-608278b8f1a9": {"doc_hash": "13e3df9682bfd8665ca79fb74f417e7a7c3f844a424b989c93f7eadaed87619d", "ref_doc_id": "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d"}, "2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2": {"doc_hash": "92ddd50f556a57cf75738a391b9efd91e4b78f712ae0fdb6a2420975e5f9e698", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "78845abe-dc1b-4812-9704-b35c7bd30319": {"doc_hash": "d28ac1b2f041b27c2d41ca4503f93a62836aa5372ba71bbe6647055fe2c13f29", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "a5eaac5e-edc4-49ee-aa05-0cf339ea772c": {"doc_hash": "908d3d0ec5a2b7001c365d32f8620baa7dd6c5455a266e364652649b33c04544", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "82fa50ee-628b-4188-a9bd-fe967bcb105b": {"doc_hash": "c1695ec2505096e123f988d4310b3853d168cb5db90cf03520245dd12a4a74f7", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "93d10916-699a-43d7-9f75-3af9cc9866a8": {"doc_hash": "3944012141872a1c221f1c027fe9ad1dbcf661d925e86fd20f7b07e1f1dcad32", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "0b588da2-86e3-4c95-86a0-4086b5aede87": {"doc_hash": "77269b9aa5f176446f18254096d70535903492925e2039f9e759fd8911d1ba16", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "a88a4eac-2aca-4d74-a7fc-36a15fe81328": {"doc_hash": "0f5b38672e0ed7c624241ec91b4ee5e079385e8e387b43a755a19dae08132930", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "a4ac6a45-75fa-4792-8099-0ca35eb21e33": {"doc_hash": "035d8de9057a2bb5744bba9217e510c6ce9656c0af5b9a26fa2086c2a42e8abe", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "7d36c965-4c59-4819-859f-daa1ee2fdb33": {"doc_hash": "1a8235ba8418757b67903ac2af00bb8751cf790cd20a410aa1bbe17ce54ced61", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e": {"doc_hash": "ecf4339e9cc1330984f593e9b28d64a7bbd8b2c6c25a677bea9ce16683a38c57", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "6116bf6a-379f-4f00-aafe-f438eb1208a2": {"doc_hash": "5a85bfac754e4144a275d553eaea57dc2bf74679894ea4b31a003e0f371646b5", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "3eb60e54-e63a-4605-80fa-1a591695ef29": {"doc_hash": "941005fd8b463aa2c8c4b21fb194c0df16778897ae0026bcfd113b2fb1bf7949", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b": {"doc_hash": "5ed42a09cc30abcb277476df4a4d041f0d44763582196fbd12857c501c92a6c5", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "72225bd9-0034-4e10-9839-872f9e70c5c9": {"doc_hash": "612a35794c7a6cec29c03f2654b77811c54cb62554c219f779b84d6747e1da9a", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "1679835e-3214-4a4a-9ad5-01ad9177923f": {"doc_hash": "e268da1d7bfc8d68bf2c655cfb03de89612c065ee56bc4c1503801d904bc49ea", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "d13b939f-c700-4bf7-9fe8-b518b216bd7c": {"doc_hash": "801f43c5acfbce1c33266c969391c685dc54608002f9af6107d86b5c1f74f868", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "4caab501-3ff3-4ab7-afe7-74d83b29275c": {"doc_hash": "fee5a14f334a6adbb2a50aec0935baf970c8d263cb0cd5dab83ea18e4fc5b5bb", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "4a7e9e09-9124-4919-b196-a206d205fb46": {"doc_hash": "baba64aeb27b1ab9705b683cc4d7df1937bac5abab55a3539f11f7e883c12974", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "64f84532-ee5d-4c20-9902-92337a845d2d": {"doc_hash": "96fd408e68dcfb66659fd88834cc445c06c05a45815242e200393c19f00595d1", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "24a79bd1-96d0-4229-aca4-de4fa5d7d34f": {"doc_hash": "9732fd9a9af5c6bc40d70da319f615ae2d44c350a453b1faa5a713d2965a6344", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5": {"doc_hash": "590bbe588c5f1de9d9fb24f3c66fed01aa0b354d32bff3ad2a478c8c17339b36", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "06d6b076-1b11-4d53-b232-54fa1393f8eb": {"doc_hash": "e40b75c42718cf5965d83569fedddeb37cebec6cec0e435572673986e796ef07", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8": {"doc_hash": "b1e97faac1a21efeb5de956a64e65a77f4e5eac0f3ca698d5f65792689ab7c4f", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "ddc75d76-13e3-4daf-83ff-8ffb66a0f755": {"doc_hash": "bdde7b7d1e91cc3d30169b8ad40dda30b64178797a9566e7d1f33fa3e89c44a5", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65": {"doc_hash": "b0ab88ae0d9f80eb0060035094573a817fc9a402d315d5a6e279f701d5159fc7", "ref_doc_id": "e080c70d-f918-43dd-aee8-a3f7c3abc2b1"}, "636324d9-bb96-4295-98a9-80180d01a5a5": {"doc_hash": "ae655f90475d86f5fbe3b39aaf5bd50eded43d6795bd081b2932a18a0ec49f42", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "051eae26-5f0b-4dc6-bc06-9ca2875e82ed": {"doc_hash": "d65937a2307b3383df540ddef66ca6a1c50247c127e43add3fb0992605434bce", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2": {"doc_hash": "f25f5eb0620e7ce7bf2bcecc4bf98dd32efeed4593f46bb5ac2e3daec210fea2", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1": {"doc_hash": "1c27264f9be79e0be47818fe902bad20acb3c63a49c603bface73dd825ab86ec", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "4bdd8744-ed24-4553-973f-71c2c95b2b68": {"doc_hash": "9d30c1eaa502ae7a4a85bf67337d449df37252cf31d19a26403e2a87349e9d7b", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "d9a9777d-f577-4354-a787-8c41caa3cb73": {"doc_hash": "d5f57bd95f8703b3363eb960a347802204561066d25dfb46016773cd8adde8a0", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "3a3caa5a-74e9-4690-a07d-77c1a1dce07f": {"doc_hash": "0fea11d871159650d862b6281c992b7bd4f5cc2e744d52ba0673da04a0016e0f", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde": {"doc_hash": "7f643441ba2df744e338b1fa437ba9abfce86db2dcf5a43585ac08799d890ca0", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3": {"doc_hash": "9826ea2f19a57ddb545752f999679158c231b957d35e96a35519bd8d3ffe6837", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "dea9859e-3688-49c4-99c8-58624c225565": {"doc_hash": "6497f6f46d9e2e125270de7dae235e12223e4b46bb0d72aa8252942ca7ecfb39", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "af8cf404-4acf-4227-b820-381da79088c2": {"doc_hash": "1f60696476d388f30668ba9d8101a8d097fd3a91620777b8ea1172d854aacd3b", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "6c01806a-3194-46e5-b58f-ad13d777bd34": {"doc_hash": "506a34d9af5525f5a2c8e67eb27f10e033eee5cc444b92974a82f4bafdf69a6b", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "e1213a41-d7b5-452f-aa94-3a2deee7ee8f": {"doc_hash": "64ea085865a25cb03ca851c26f9aa29a7125da8125e4f5e1ef001a78064637a7", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "2d32921e-bc4a-4977-a427-500949454b1d": {"doc_hash": "4e96b4c6f82f211cd0d0b70474bdc479a1a14a840174fc048c32b66cb7ecb8a2", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b": {"doc_hash": "3e8225baf8c5b32eb18569ef269aec2e04a3cc01aea08e0c04474c74f9ac21b2", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "2710b7db-d8f0-45c2-9751-53a679e46d8d": {"doc_hash": "8fbc0827d38204d00a1ef43790d153cac7d821886eaecd1e64d976725a42e839", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "564dba20-9fc7-45b0-85a1-9397dbf738e0": {"doc_hash": "51389978abc22317635f4d9ca2d4f3968ee55e4541204c95fccde4655c2d7d2c", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9": {"doc_hash": "c1d5c816e5be773edcfdc687bffc0b6d7f2c5892dc69fbd7c09c2601018b88b4", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "da74db55-b97b-47c0-80d7-0d04740f1276": {"doc_hash": "3eac2820f5324aee530d43ed256eb503705b41e4a5bab495586a17acf4e9c6f8", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "f588c957-a005-4f0d-9730-65b607bd5825": {"doc_hash": "3847a58323196db569494c54cbb4745aab22d45d265432aa8843de76618a41eb", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "7731c38c-72e3-49a9-b8b8-defcdc0a23c9": {"doc_hash": "71d6163cd4d98e37b904ea962a4af0a8db3e7d6d03a4c9b84aeb7a3eb33234be", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "e7c1884a-0a15-4410-a60d-eaf635d102f0": {"doc_hash": "7b48c36c9e40a95bc3f7feb2e8e0473c4ed2c69f58d1377c5cd11efa2f42669e", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "2d9b5a6d-1a6a-479e-be96-8756c259c65c": {"doc_hash": "0bed6528b493da6d4c1c28754467b8f5b1ebfb12a8a7689e22cc74bcd68650ed", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "94493ee2-3dde-4eec-a88c-707f717ef766": {"doc_hash": "e2f857f0085afe7888e30fa7bdab78ea38aba6ad2ebb182ffaa47a712dec4d14", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "8cfd2274-b6d5-4e39-9534-b68a0feb1093": {"doc_hash": "51959bf0fa87b539aa3faa54db7955b1370f1bd63f0b760b10638748fbf31758", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "38a1473a-44ad-47f6-a725-4ab84720fd12": {"doc_hash": "0d4ba26681bcdfde9deda5091ad536827f0db97d1266c6fd4b6662bddff1108b", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "31c3988f-137f-478b-9263-5aa7253f5b8d": {"doc_hash": "a08008ec0e7f3924f37fb0facde8e7ed820d30bb99996bb48e751f3850160f96", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "29803a04-6a6e-48f5-877f-8e929a1c1989": {"doc_hash": "44a4646d50e1cff336c3622b2db0b45a806b398e90ce90718793a6bbe75b97b0", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "0a61d568-a5b7-49d0-a6e1-5e31f0f47841": {"doc_hash": "2ce3fb53415a1ce35e3b0a28cbf2593ae603bae1805324ecdec088687909c2c8", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "0bc956e2-2a1a-4e48-9556-b1555532c449": {"doc_hash": "f4be3bcff828a03948d1cbd9444221314968c11f2bedf8fb2de118c19848b67d", "ref_doc_id": "cb3a5bc3-7314-44b9-af20-0b41ee8be44b"}, "7a14dced-028b-41a8-8b26-d04712256ac8": {"doc_hash": "fdb499bbc26a88ec9f3319fb9c93e4d02ed1129e5072804273fe36ad9198fff8", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "b661bbfa-65b5-48d1-ac31-da705a07f4ed": {"doc_hash": "1bab654cc6bb13cbd0131dc9acf58ed763804ee563c7b67db7aabaa9346a52b0", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad": {"doc_hash": "60dcdf7ef4f32c595815183bf12993d7bb401ca8aa2a682fe93ba21c2bc832ff", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "15affcf5-8a0b-4f6e-b28a-b7b9146899f2": {"doc_hash": "8f0f9e82c68c4a6f7c5a439013ff5390a305ec6e5b20ff87c0a3d9475ad99d00", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7": {"doc_hash": "75f4a237d4120f9f7d4616cab2bcb5a92e10193a50ae8dd1c0837230f074588a", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "637ba99a-6164-4307-9a75-5789a5065ba7": {"doc_hash": "4fe260e35cfe537263c140dda6c307e5d497e1b1a4d87324793a60e6f13b152b", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04": {"doc_hash": "6084e3bf5948b1bdcdcb74133afe20a9e0009a1c2df732138fcc64110eac62ea", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "b91f60f2-8f86-47de-83cc-b04cbaf7433e": {"doc_hash": "69faf90ea777d455ab1bf985e912045b18e1698b7401b18909bf7e2de37a4869", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "3205d079-3a59-4ca6-9a52-a224ed73b1cf": {"doc_hash": "20be1a4a4e7cf4a5906fa429ff94f36f21ed37a7beb0c9ace830f99e0b93e6b1", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "128bc1b8-c42c-483e-8a7f-b580f0fc606b": {"doc_hash": "20c2fbc8fd816c1f10984e3088e52b821e3c59bcab7aae31a0fcd7e824f36e58", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "ccebdaad-0390-4a9e-8259-573c30d0c708": {"doc_hash": "0eadedaafcba356d6b3cfb968f0fccd9a7969a171c9e347248d020f0f0617364", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "1234179c-76f7-4e14-9441-48f9ff3ffc7d": {"doc_hash": "b82d92c1762ddba926b581b1b8753eb008cce280bfe23bcc49df4a443b1542bc", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "9f188298-307b-4ca2-9ec3-ee581049d5ca": {"doc_hash": "c3a54b0c21cb458c03a34f949ef784efd78fcc6ac65575dff4400da82fcfa792", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "98f41714-191a-470b-9346-10cc6e68509d": {"doc_hash": "f9a5b360e5108a6066c24d66f5f2679a286028548b676594c0e71c9ce3014402", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "ee5c80c0-bbfc-4e46-a2d5-1095f632c533": {"doc_hash": "cf1a3cf021bd0c92267343a31ab3269e2c3d9781d55a244cb599c92461e6e4ac", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "8482b4c5-87b3-4daf-8783-69fd0dbd74f8": {"doc_hash": "824494cce2447cfb4826941e0a306ed750ccdf9eb5e6b2867fa4fb7d8e4e9aa5", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "3dcfe75a-fbdb-48b4-b753-1f21a22ba637": {"doc_hash": "40e429154bda3a4ff71c8d5f5aa3bdecbeb248e2bb2ab936b010e2debe93819a", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c": {"doc_hash": "b52c18d2788b702084c14533402254663d6889206cdae6c71c29f09344f0307d", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "4293ea53-97a1-4b13-a226-52122ae33d9e": {"doc_hash": "94242e4ebf343d30be269739e3ee8ccec58df1bd7a865ad547bd3e7abf9716bc", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "dcff898f-4b96-4a96-80ed-298d9cce1c37": {"doc_hash": "b5832a7646be5e5b5ecefbbb0d200307a3266bc4762c5ebbba03352f788ece64", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "f87522a8-b7bf-4dcc-955b-86555692da50": {"doc_hash": "88227ffb578938d686853c1d813f51ce1e624332f50ae59052d0a79da04ade04", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "3cdbd904-155c-46e6-93d9-dd1bdda28da2": {"doc_hash": "1b47ecb3fc3d3b7246451fd9f8a39a774ceb28f025e96d12b1c9fbc5ac569bfc", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "9b43dbae-6f3f-4113-8f68-4be701fedff4": {"doc_hash": "058af22ae02e03dde37b35f76942c8db46ee0d487fbd1c29ddbef1ea84392d59", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32": {"doc_hash": "bb3a111f86cd243c6e93751b7a0e57babe6899d8d9b767499eb1ceac7273546d", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "3e26ffd4-e3cd-4955-97f4-46f271009d04": {"doc_hash": "c9f1e5217a73e230a7189c8b87c046a754dbb78aa51ad31a7199fe7e1c227d35", "ref_doc_id": "210742f7-42f6-42f5-a2a6-5f7b31e8af66"}, "faae7809-63f6-4171-8a91-0709b652a05d": {"doc_hash": "a64c7e6a73ba452d28fcdfa6717b687b530731e4ca08550c869f3c8b3270a4f2", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "ff472c87-e2d7-4302-95e9-1af87557e88c": {"doc_hash": "801116445f53fdde09f7de82750d4020e6af45369a1f29d1641e83b33051760a", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "c3f294dd-acd0-4969-be87-ba346f69d43f": {"doc_hash": "8d33fa35d8647f600f6151fa98922e0dbe463244a4920018255b0242030b02f2", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "b109cca8-4ebf-48a4-9448-ba59d729df71": {"doc_hash": "75a28dfd2f11930fd9b48d8597d7f686ec525ea4ec4f8b3c2ce7a6724d7e27dc", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "5a885cb9-0a6f-4270-be69-5b3c8d0f9650": {"doc_hash": "e72a855e36495579382141c5cff4488310a77f91fb7570933bd61ce93b9ae3f3", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "62db3ddf-98fb-4ea0-8dee-6cc268529848": {"doc_hash": "aebf50ad39bb1db68aca3466ea2376cb48100f0bda21f14f58e35940e0b1e9e9", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "a919e8f8-740a-42fa-a8ae-9d863df726b8": {"doc_hash": "e8a89847d4909dadd0a257b0d552177a3f0337e8dd9ba62d2e7be33c3918a3e0", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52": {"doc_hash": "ce9afa037fb6dc75719616aea66763c469244109bdfc13dd52d229f7169feac5", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "d24cafa8-d2ca-473d-9268-0a83bc80c1cf": {"doc_hash": "0c46ff17b457a74a6a4a2e5a50fb97e4e4ed70091ef6e0520b09e4b7086b315c", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c": {"doc_hash": "cabb71f97cbe0d7e6d1220f7db1cb35b3ab3ae1f83a65a75575780b609a4a20b", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "c5f4a293-d8fc-4961-8aab-9b54f6922da8": {"doc_hash": "1583f28b74cda0e3d506602d7f6c1bc85b0f028fd05f699cdbf23d6c27fef2e5", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c": {"doc_hash": "387e18028ff6b14bca153a367edcc639e5e881029326a08bb2bbbcb22c8186f0", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3": {"doc_hash": "a59b0ebf5debc5f20f4a033fcb8fcabc9554ded55516b491ca0098420eae888a", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "7098cabe-2265-4004-a516-fe68c98cf7a1": {"doc_hash": "dbf8d9ec80811c730c2b6b14be86e5e159b6dd32575249a9a3c79fde8b0e1f44", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "712ecf80-1177-4df9-9a34-9c6bfa766c54": {"doc_hash": "11ac844647f39da79ef829b674e1393ec62d85a6c07773ff51df94595e6fdbe1", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "ca783919-9d1b-42d2-821b-f033bf99c7f8": {"doc_hash": "24e794be411a4f344f423f58682fa251991b9f3e46fb2a86ebfa1bc4bc807127", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "1003a391-2243-4913-8654-8e3edd5d8983": {"doc_hash": "5d1e48ef7bbe97ec7e27e6245bde3de0809f1af5ab622ce85c244fbb5f196087", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "23f4456e-12f4-45d4-b794-dd7c3bdfe57e": {"doc_hash": "63a7cd1c0cfcee73a29400faebe60c10939626ff5a5895905eb51186c580ef73", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "f2407983-05c4-4922-a0d6-cea00fecf7b2": {"doc_hash": "64ee1d943b9797de7d6dee96c09c0133b7fce7200278f2af051eccfcf8dfa7ed", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1": {"doc_hash": "211dbe3715604ba13ec5fe8d8b59096ea9a437b6b0901eaf8e914cfe317dc020", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "4e1442da-f7de-47cc-ace7-3222254d2f72": {"doc_hash": "8607529e17b15b87667d4f1e858c317ccd34a96f8b75415bec986293d2b0a056", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "4b91caa3-6ebe-468a-834e-9b234e582d3e": {"doc_hash": "e25aac06ad844abed2ee75f94b6108a62dab5ff1a3d2b540936d171ea275ef55", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "c33b8a16-bf16-4821-965e-aa36b4c209eb": {"doc_hash": "d8dc690d1b86725d1a9364569bdafb7c1033aa68e5ae815e47e796b542c26031", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "b5b25399-fb22-46f1-9a89-fccc5aa03dcc": {"doc_hash": "bfa464c63c6c81399c8901abfdb4b50e82e84e2efa572f8807b9d11608af9b26", "ref_doc_id": "dfc04f16-ceba-4a23-a1d0-a98165a7c74e"}, "94645c12-4d12-4f5a-a952-202b259fbb0b": {"doc_hash": "74c93a276c2ce9d47b9b8188dfc1b84b0d96bd59e760583b020088b4444bbd7e", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4": {"doc_hash": "10d947c4bf0e10515ea393f9d54ebead8dcd3cae7ab57ab096f90a37b3d432fe", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2": {"doc_hash": "adea7b61f5e7a6882b3d308e849f07d0d852eabde89788ee8f032bf0063704b9", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "25357344-adb5-474c-96b6-138914b1b45a": {"doc_hash": "761d6d96ab83a9655af68b88080032eb9ea075c0c2e50478eed46f8cf4e8d43a", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "c436f45a-11f4-4dad-a857-ce7acbc4d22e": {"doc_hash": "48f417f69b6cde22dc0fe96caca0bf4d216e72cc260f5069b7363527cab00573", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "3893858a-3120-4057-bdc3-88966abeee39": {"doc_hash": "61becca2620369b8c84d62cb9309fa1000f8c73a5fa6621a71d6d057e944a85b", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "77c5ff63-5724-4444-861a-753376dd38e0": {"doc_hash": "8ac3eabacb64aebb6fa29e75abd0e5dd85be00852cadb46285079dcfcf10a9b9", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "80171b71-a837-4e65-a89f-5e05cb65b183": {"doc_hash": "8dfe192524a720d1dd173b81432a18dfdcdb7ac6915837a970a9c872f049bf78", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "e16973f7-ea2f-4bd0-b598-4ab477601868": {"doc_hash": "ae04e324190b0a3100957c0119469e4c0a09994d1cac527a693926211514d231", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "a97de9c4-0736-4b11-ac28-1f24be980455": {"doc_hash": "a51eb871c6a6479ace6c71ca674fb94b589a040e589b4cb94a54c8abd8ccec04", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "f2837749-2b2e-4621-a6d6-5502d0e29414": {"doc_hash": "03562036886b98c4732f9094d3f70ca1ac0bcf11d370618e8f86325a5958e0b1", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "2102243e-1528-4d9d-8cf3-ab07f11a89b8": {"doc_hash": "77d76e4ac8bc9b73b5029e76787b83c0065fce3b80dd2d599f32273d2672c4ef", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "f52c1806-9b7b-4ecd-8916-7950f69c416a": {"doc_hash": "e89fbbdc74a912e15a2997941767a39e7244fb04362ac16f7b90860e126a17a4", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "ef3549d0-70ac-460b-bc74-aa4c743274d6": {"doc_hash": "bcf7620afd7ec601555b1e94f13ce566c495f6ba88808ce2db6d1c4e72c68da1", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "466d3e8d-ea0c-4230-817d-fa6354400dec": {"doc_hash": "65ba086a023e52d05d71291ba1e8b674a3b2fcc166b18d4018aad89cf1bb2738", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "31632b48-c4c7-4f37-88f2-4268edfd5c2b": {"doc_hash": "19b347f73d50dbb8d97828806f77d1d8c2fb18f1eed783b802c4961f0f478b49", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce": {"doc_hash": "df10fb5698a94422e5a0e27ff2e36be313b11eeecc40a269d3d74391a75f2152", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "905de93d-d934-4102-813c-968ae4c63937": {"doc_hash": "d42f828b27f09394f67e081e7908ae714ea438aa053473f2b0db835d7a8f7696", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "702eecf8-6dcf-4a18-9952-f19e3d033ce1": {"doc_hash": "d34aea372a385e9b26d7b2ae91ce18ecf070044d6b4ce7975b87624fa256a26a", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "4cde3b73-0d39-4fda-9da9-20528b5ca45e": {"doc_hash": "27a45eb99c81dc6dca5946a0f4fe74a631d00216dce6de8aa868fcfc013cae82", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "9c0b15cb-8f3d-41d8-9638-1bb400097188": {"doc_hash": "4e8714bf624c2ceb4fc64bd84b4028dabf423cb25566c17dc771ce5fa8af4f6f", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "f88ffc8d-3966-425d-bfcf-921bd7f630e0": {"doc_hash": "7b717f8f951ac8f0b3ef59f91678eebba20a44e88f81bd6c992b573f85659e19", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "0f403fae-976c-4721-9fd6-d5974ba630dd": {"doc_hash": "ea68c288f85444de5af625b852da942a868431decc728e865816fa14802e1924", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "bb88f6db-13ac-451b-9baa-47a75c6808ed": {"doc_hash": "701f1dc8ef3c3ff652d858da5a73cf64eb94516cd0a6da7f586420042bc77310", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd": {"doc_hash": "6cbba0952af91c88139fa50358c6cf695018736d2c62959a6ea09e93e079cbda", "ref_doc_id": "5c5e837a-56e2-4df8-85df-f49d1c389a2d"}, "416b568b-61d5-429b-8616-2a10f39abff4": {"doc_hash": "928e92b6301d79b7c0391d6fce9855bbc924533c3304ad500c5e71fc8fea0322", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "044fb551-27d3-4bd6-abed-d6b4fce0dd40": {"doc_hash": "ff1cd7d5eb6a3549f40775846146a9e7c7ca692c2dd971196cdc35b449a37ca0", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "5f7e3747-680a-4cf1-a81b-c05fab7aa183": {"doc_hash": "715107bdb1e81fcab34a83c1e32aa23640143a5b56b249e6300916cebf332521", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "ea26b8e9-dc4f-4ace-9df0-a94dd604340e": {"doc_hash": "5453a11e9e05d77d9907042a5fd56281a632e676fa168c440956ff33923236d4", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "c7d12a2a-6cec-447e-b8e8-1db96442a6d1": {"doc_hash": "84452b71394b254e6de57b19c3071bdae40abcd101e37d5c3d8afd3a434007bf", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "7b787712-4d66-488a-b626-c47a66bc9f82": {"doc_hash": "34511a6e1babd8325b48b350bb503d082490403011786fadd512eec21191fdd6", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d": {"doc_hash": "1a1751814858b05a9a1996dda7caaf7d11be323cd2852f4ff67fd136ca6d7aa3", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "779547e4-1f3c-4a4a-9358-0ea09f5a9f07": {"doc_hash": "ce33d83f25f15d41859597a10089e2990aa023f96bf5da26833055bc7445df9b", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "00240f1f-444c-4681-9334-631c17f9a6e9": {"doc_hash": "adccaab30852a6fa3745517540d1eae7701fad82ae3db4f54fd0c050ca65d5e1", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "393e0ac3-3f3f-4b62-937f-28b38cc890b6": {"doc_hash": "b16b33d9ff8b9b6ee0684c913152543d5ba02e03e2f3a0d18c541ac0a565ef40", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "967fc5e3-99e7-4970-8edf-1b8d99808c76": {"doc_hash": "ddccf0b7b3dcc1b83278fd1e0ae06ba2033194bcecf9355e5152382387bdc9da", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "f8f2797f-b1dc-4330-87a8-94ab36e56d1a": {"doc_hash": "854543767213c29d04586ff465b47f2e33db53c2dfac36acd8fcc960bf685d42", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "61884e42-d0ea-478f-aa11-cdd67994d994": {"doc_hash": "5a1d0e98c1ed4a485b09d3a907eeb53da7287bd2382c6a735e8753c10ada0e62", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "d5052f34-9e58-46b0-a55e-8b402ef991d9": {"doc_hash": "19a89d46bf1e546ad238a9fc45d416fbb93493a27dfc9496e7c4cff2ba9e5100", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "65c7e5a7-70f8-488c-92ae-2795f8775d60": {"doc_hash": "6a8fff7dcea6ee8c5efbc7283c046389644255a3ecdad38726224e8c98ab5466", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "92117f62-79fd-44b1-ae12-3a271847f6bd": {"doc_hash": "4dd557822aa8a0b65fd2dd9929e9bb3c086698b0ec4066d95b5b5ba1c3cacce9", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c": {"doc_hash": "3ed23bd61597f6932ed5835450416eac0adc4812509b030100b9a84f6a796ce0", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "7c983f10-f288-4368-8fa1-f89966c7aa98": {"doc_hash": "f63742eaaeb5130265d97540424c3b646f2494c3f5d268da7cee97d2e25d4d23", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "c52326ab-d146-4097-a806-7948a66b47a1": {"doc_hash": "6cf8bc1f855b8ec33c79507d0f278655be2093642747675957e86db70e5775f1", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "acc6b678-47b1-410c-9c8f-aaafb1c58028": {"doc_hash": "5d6bcd1e885b0701981250a8e96f7c1a0f8f8844bbff6f1d2b0ac4b6eabbb5ce", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "6aa29aba-baf8-4b13-be16-a56ee5913c43": {"doc_hash": "066f3218a1e4c4bef9b6511f282188fffdf7eeb6c85bbe21766e29a59ad27511", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba": {"doc_hash": "fd8402461408f41c360a0f8c154062650df16bfe27b1b7176670bf5734bda142", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "599c6f49-6e07-43c4-bff2-15988d9dcca0": {"doc_hash": "107860bc0dc5d0c044f6328e2f4ade2beb178601938268041b8b37da8f337b14", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "f34c969b-8e40-42ca-87c0-28012ec18396": {"doc_hash": "c6a65ffb37495d153c6a1a885f37123bd6ec9f1dc71114b6fd3c8bdc115ed5de", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "5f0c620c-643c-49af-827c-6f49257066c1": {"doc_hash": "1658c794b7c2103324f32288732ada317c33eb57fda12cb4460c71e3d3887c0a", "ref_doc_id": "c5c25936-2a88-4915-8f7c-297444d457b0"}, "92f551f0-4a27-4b47-88ff-83551bcdaeec": {"doc_hash": "98cf43c72c6187055b1823335a9046a1f0e2a5bf0e70f1789491f20dc2929c4f", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "415a3188-13a7-450b-af36-c0dfdb02ae9e": {"doc_hash": "9523163c7fa53202077872d73bc6e418b27ee2985c2a41188529ff6979358c75", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "790bdb3e-df9a-43a5-8a78-1b2683df513b": {"doc_hash": "204aca1ca6884673544926da59dfa52e45cc9b2093434a4d7b0c0a46099c5d1a", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14": {"doc_hash": "fb54077ad66440647ceb76fd6197e9c9ad7b6e522b62bdc32819e2c67689bdfa", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "01dfebfa-c31c-4806-860f-c3b94b63ece2": {"doc_hash": "79f9354493e5468bcee2c0e18d081754a7fd4090affcf3a5609584095e329d7d", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "1c66b039-5b97-4638-8b3c-ce9a1915dab3": {"doc_hash": "19fcb6f8b82d1c43b08747155aea1fe66d49cbff4d7d92f3d5367548b066a801", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "26f842d5-61d7-4b3d-a5e1-60c2b149de37": {"doc_hash": "1c3a8b9a8b6eb606e3eff5f2c41f5610802925affac5ddc7c1ac27326a52ec44", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "01abe337-acf0-44be-8e7e-1961bc501261": {"doc_hash": "572022409803e50ca76f0b0f1343ae42c0ada1adce11423498cd841971ae95a6", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "559bbad6-295f-466a-8db3-711fb864ac03": {"doc_hash": "47fbc6440447fd5e761b554217617fd5199c728882eff7c37d085f654a1592ff", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "c26f760c-f46d-4ce8-85d0-08972a3cb796": {"doc_hash": "143ec8c38636ae2af2fcb1492435b85f77e5308153ba05526e138b2da788d2fb", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "cbf92855-9042-4152-8eca-07bc9328b14a": {"doc_hash": "b03bc9e1f9a47d4f0b2e3189a63d8f799c1f784b4bc005378f07d3101ce589d7", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "c6a1db03-433d-4a1c-a836-417a0d141303": {"doc_hash": "2a3c6c8679ca3a59068c56f6721585586bf5ff9be0bc41e80f2197df27165157", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "08a19543-a8db-4b93-90e9-6ea05281c89f": {"doc_hash": "017a3a1fb99a7026e210595298b8d4628ecd119ff1e8232b2fa0814920be04f0", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "3d19147d-638d-4ac4-9c84-d41de07d8979": {"doc_hash": "bbff41b4fc58d8b7040522accf12399599a703f9f27db0183171873af38869af", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "24239bbe-7e3c-4802-b0a9-a50d879f9c61": {"doc_hash": "7b99ebe06f5d1fd1285320affac758db34f989e77560613fe7ee5c0fad23f395", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "198403cb-266e-421b-b548-54139c57676c": {"doc_hash": "d0c9533094ed390c5faac45ba5a024123df6b6eb4a8c9dde6384a9f2c4b01019", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "9859b5bd-c140-4436-9624-70ec66b55261": {"doc_hash": "dabb607b22bd6a0d7f0e27b75b5219ab19d2818585d287cd89e6fd7ebc95e2fa", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "29c38176-50dd-4d33-92f6-06c3e323dcf1": {"doc_hash": "1a48a3f7bab22f8bed5bb7e2aefb24f78ebc6a6cf1dbb4b8c42cf93df9bc1306", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "260a2a4d-0482-4955-b369-18c907223048": {"doc_hash": "408d3d10e2c3c287a8625f1be2543e14fbf33adae12b5694c01ebe957165e692", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "0757958a-8072-41f2-a200-33320e595ccb": {"doc_hash": "78f1ad68fa55e1a3ac9c34cc3458e5b85b2512d50c02b2fd33001430a6cb6d32", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "756caf27-8a3b-4965-851e-c7974081aa46": {"doc_hash": "7a215be2150ec9a6f51b768ff53712cf0462a6f1d282c3c64f8b5edb4caf1a3c", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "0328e6d9-106f-4e95-a23d-470654d5f33b": {"doc_hash": "6bafa33b8eb72c43fa25331d920530fff272ef83d547938b930cebdf4cdf73bc", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "85d270d0-9b87-4c94-98de-fd844609d0a5": {"doc_hash": "344693c92e6ccb35645c7c5b0dd9e00f0e76f03a3110c3c8bd88d724bba2fc66", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "db5a4442-5fdd-4d10-8635-bb58d4da98f6": {"doc_hash": "cfbe57476b6c7125be8a5028395addffab29b6a1d62e239c37d6ad249a115821", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "755b61f6-b2cf-489c-b8e7-b59b213c6fa1": {"doc_hash": "3c515f10a3f28d94af804fcaef4c08b06241f16d64bacbb2bb51c2f92431dfb9", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "fea1b57f-c7bf-486a-b9f4-04be3c18004b": {"doc_hash": "231e0e837a6ad67f4ea0125b08edff22374380aa312286e1d712768c60772e99", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "9129f271-8da6-4259-a51e-247efeec32bb": {"doc_hash": "b3300db1e0b81b2123e9d811873a6e78fbd514a1361de724fe284b8df5ad4f7a", "ref_doc_id": "994e5fa8-eb2b-488b-804e-b30505caf461"}, "da7d4778-0086-4262-8fe2-88ddbbe88256": {"doc_hash": "8dd84680f177ee9589d40f8adb750fdaba263ad54b7c36d57eabffd99dbee7eb", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "4699b10f-b75c-4022-b270-069300a28ce5": {"doc_hash": "4a7f4161cf916c6a0d457370d9d5363c50480c52753b42f1f3677020d63a61fb", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "5e32e259-f695-4d18-bbcc-6e3efe6347f7": {"doc_hash": "c6eda0665906ac62772f36bdf6855156ca28ab71be4ff40c308c80d729e7e7ee", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "1c15e358-fcb7-4fbc-8083-9480c7cb63b0": {"doc_hash": "afd9aa39dcb5de7597b39a0c6ccf0f8849d160636552c54b994d8fc67ec913d8", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "a755ed57-e4dc-4866-a803-ae2f37375342": {"doc_hash": "1af99665bf7e93e53311553b128b4fc47c1a16dd3168c66a13e666e75fbb5daf", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "346b9384-789c-40c0-94b3-bff05bd61afd": {"doc_hash": "befc15ea578a2573f6b62c617551e5c954207e56a5d51b9f913768a71e765743", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "c23383f9-fde4-48e5-a096-c2558b09deef": {"doc_hash": "ffc35a3431ab9244ac81fff1f6370b054f84aa56728f4360dff32c6137cd2ad4", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "0e8e8851-1325-4b97-8bd1-133daf38dae2": {"doc_hash": "a997a8e1c1188d18a1a8e4d7ac130c25875987b92e1e5e9d2f0a517e97d64948", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "cf6492f1-17e6-4924-a9d9-a27f97e42f3f": {"doc_hash": "fefcb83964cc719aa7339062d72b223cc96392b96b58b6f62d564cc080c0e897", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "d246e36e-8d86-4b99-881d-82444d917ee2": {"doc_hash": "f99463be4753f9270a444fe5b3894dacc5a1ceecba2ceaff02618895b1dfd945", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "fd2090e1-ca4f-4d70-a900-715397a32fde": {"doc_hash": "c14bfe7200ebd416aa00028034a0b4edf526b81f5835ee4941ecd8eab300cdcd", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "433dd75f-febf-40f1-b0fe-fa27e386e1e2": {"doc_hash": "a0d29a8e967a395fbf6036d724d56b51e779c31ad743c6cb7a29a33020e144e6", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "752b4725-a5a8-4de5-bc76-8765348f3fcb": {"doc_hash": "1dbe298d00b044416d86d7ed214685b3fdb1e06c5affcdf8af78cb60a59d0f4c", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "50f86e4d-c969-413e-bf96-ce62ccb2ed7b": {"doc_hash": "b155e86ac55d6176413a9430641e2e84c2ed6f154879bcd394c009541804e254", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "ce85eb3c-30a7-4020-b2e6-dda88f73a611": {"doc_hash": "a9452cf29b5b6ed19ca6dc29e3a4b2a30a12a23e88405e4d7a2c555dcdef00b0", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "95477e9d-f023-416d-8bac-edf0ec65db16": {"doc_hash": "c24f64cc87165c2151b142e7ac22e8d01d4c69bc3c7838ffda6f89b0ac04de57", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "dea97f61-6383-4854-8814-95b4eaba3c29": {"doc_hash": "a0dc917646ebfac16f6d04a7b5f134fe3460fb0f11b6d057d4008e01447bfb07", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "95dc488a-afe7-4269-899d-494b76a0d980": {"doc_hash": "79f98fec521cf692998a1d500292ea1b29f52de42fb98f47de131d4caf5c067a", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "fcb4dabb-9219-47bc-8b33-f0de55acf5db": {"doc_hash": "773545191c66f9d248fe99cb60ad6102c8c65f39ce9485d935c74360728484c5", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7": {"doc_hash": "0f66dd2823bf8d58d07a2837aac07780c0b3bdd408ff16b35a0bb5cb70e9a180", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "4da918c6-f822-45bc-9aae-51ba4e785e2b": {"doc_hash": "4a65aa93fbd4b964173815fe7ca5498c8ef804fd2205b4ad9c395fcecdcaaf73", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8": {"doc_hash": "2c0da61eb182a7a2f242271c6ed43a1d44c667b9c7862d815fe3dfa06da8e428", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "5b2a944f-daba-4432-9324-d782cbdc7025": {"doc_hash": "ed4da098f399a3b230c39250d4ff958edb92a05954fc7401cd5c8e27ae033536", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "8be28f5c-2919-4085-912b-39f3f3bae2a7": {"doc_hash": "d47eab13b8a1ef53fd5cfcd1cb9a62e05a231ead8454582b69e0dfa219379710", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "64bdfb51-7eda-4c64-8bc3-1ce594d5af22": {"doc_hash": "83803e7e662b81d3c9cf4f92fcc080fade0b44fc03b629b33069fc6ca8ee6f60", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "aaa9db80-d6dd-400d-b3fa-b61667335ffe": {"doc_hash": "66ae5f1ec4ac078f0ea32647a64f83813b2b35385a71f037902f0313fe0c506a", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "dbb3d78b-79c2-460c-8d60-6303948f4c7a": {"doc_hash": "0321c08b4c8cd2744b3a0d973c95a8fadf607a548fa587fa7a8831b4c439d64a", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "b838b745-9b31-4039-b4d7-5b516ccd6b13": {"doc_hash": "08b2a8cbbe7ead5650c97fba1e4905e41a6ddc6a79b2724386c32da6ccc19b34", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "e26a07f6-0990-4858-9820-4e92118a14a5": {"doc_hash": "b2e59b3cb23ec2c771055a564e4d25d8580dff8823131f553306a7796cb9c180", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "38ee070b-7c63-4fca-96bb-4afbb99cd9f0": {"doc_hash": "6eac445555c97c29a7f082bd2640816ea1784b23f27bb9aa161784f3fe09ffd7", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "fbb34f94-f934-4ccf-ad0b-a314ab773b24": {"doc_hash": "1153ff58f6ca7ddb284ab164b2a86f9c21203b6a03b9c06589e70ad2ed460ad4", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "7067eefb-ddc5-44c9-a0fa-071052365ba8": {"doc_hash": "e0a08b85b025b82399d9da89d980d68cac093e458adb59776f04e4ee5ee3a2f8", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "ed2e75d4-db62-41fb-a25a-7508ca08d60a": {"doc_hash": "ab2a3eab7184ae877e05bcdf9577d32d5330bf3d25d76f185a4f01e59d1ef80e", "ref_doc_id": "7497161c-fadf-4981-a08d-334af63c9750"}, "9d01d53c-0c5d-4d79-8312-30c8faad46d9": {"doc_hash": "00ab9d183c533f48e33c264fc3b1ab8bffad58274b289be4e2b82c4fc5357f6b", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "03deac2f-2345-44d0-8051-98562c50ebcd": {"doc_hash": "433e94510dfb08d6837ab7496a58b07326e3177ee68fa41ddabc6186963d7cf3", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "2b63b072-f58c-4c82-80a9-ad293690ad24": {"doc_hash": "819cd7c5d1a1cca4b48898487a4f48ac29e61f09087350b46787d2decb6e3bb3", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "b26ce2d9-c767-4d36-9fd1-a4239ff329e1": {"doc_hash": "0cfe3e4b8412c5f9a72b39eb306a156000802e2f1ce7d74e5565a856d6642fc0", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "10ca53e5-c379-4295-a3ea-6873a5e91692": {"doc_hash": "ec60ddaefd7a50a2d66a9c2d07e7ce5edf6201a6395db3d667798cf78cbd4536", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "236222f3-7587-4e7a-8d2d-60f368b19c60": {"doc_hash": "77a114b66ad1999725414e5c5c10a900255b424600f00d8f3fd55ae8249d3202", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "45793a9c-f655-43c8-960b-3fe2c7614b5b": {"doc_hash": "ba7d4e659b5836572ac3808cc8470bf650b07e54f8ddfb2b35838596ca7d030b", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "1458d380-febe-466e-bf19-54bbe43d3138": {"doc_hash": "49e3e908301d54761e0b579c0741b7f55df40a4a7a001fa347c7022efc489dc3", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "6fa65cf3-49f9-4707-a68f-6dc98568c77a": {"doc_hash": "5c7d3b5cc0f70c2590abe47dd01c0b8accd17a3015299633f1a3649415a71c6b", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127": {"doc_hash": "f9d80d77ef3e0d243513f2a13b8330cff7f650a96e3377206bb97f94403bdb93", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "65e68038-40ba-486a-ab85-e18b6d424330": {"doc_hash": "0740f1c313a04721413786f6a7d0df183d66b3ce588c53ab5d16aeb2d654d8fc", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "428d6dca-fecc-4774-b41f-c915386fc249": {"doc_hash": "f53e7463ebbf180703f0299027fa2008033687ea6ba811453fe45108e023937f", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "4d996166-b393-4fa6-a88a-128ecf50d32a": {"doc_hash": "175178e6a7774e5623886f2509f2256b9aa5aad31c88c255f2a741e7521b307f", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "8956faf7-3f97-4896-bfef-48c5fddd9251": {"doc_hash": "27c47794e11178944713ffb069f72ee5526e9d4a7fd082924f4cb10c08d4e69a", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c": {"doc_hash": "12e053a4d917409fb04e41228b232f0beb2bbf619cf07d4c3492a9982a4ff176", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "ddf23c14-600e-4502-a026-997dd76c7e4a": {"doc_hash": "86137d61b6c608480fbf72a3776ef43a68fb78855fe5fda946126e661b99e2ae", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5": {"doc_hash": "6a634ff4e0d03e6927148faf76a2c4cdef784dc616028cc151b11ae87cad8716", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "1f9dded8-ac86-469d-95e2-ee924980b7c8": {"doc_hash": "4b069714e93482198049a765b3c4ed4269483f87e37921dabd3293180a6da713", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "a598e007-9758-46ad-b460-975f34a01ba4": {"doc_hash": "2dc1caf81911a6e67ba5881c4684f60aedd7bc147d85af004dc3cfa4711d0cde", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "c6d76302-a108-4c0b-917c-356ddf21e875": {"doc_hash": "40541d6ac895f9dc997a40fba0c1f04d49f58821c500180d597c342c06a5b9a7", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f": {"doc_hash": "9705f5164c8eeaa2464839dce6136c0f1ceac5c4c3c4c4d3fa8b8d277239119f", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "33a1be49-b0fc-4bc4-bc08-ea857cf8576d": {"doc_hash": "e2b045ee8f03618fcf40c84a110e9673915a136be9d1512dbcbac87f0627ae0b", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "68d10026-b658-4fa0-8412-60a126799d1a": {"doc_hash": "4b4d95d673bb09c347a3153ef81b7d52cbaab72602b48b455b14fbe9b362078c", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "cf00b7b6-49b9-4915-8d78-14fc526b9b7f": {"doc_hash": "8a0a5dc8382eb6284d6d1de85cf5f6108e21a217273c7bf7a70d158b5888f7db", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "ca7b391d-8d1a-4319-be3e-9069e764c668": {"doc_hash": "bda4e279060f528d5dc973a7b2314dff233752c53845b69856c72a594ca6c823", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "d2a05de6-a422-44e0-8782-5a479af92a3d": {"doc_hash": "679d8fc9f01947f1cd3c57f739ad79c6b8aeb1cb4f1bd053a7b18d19da7999c3", "ref_doc_id": "be97aa16-2962-4b6a-b54d-ad25e8321f5e"}, "1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c": {"doc_hash": "e2ef9b1d76f7a399cf48229468d64fda2298e303223ec7e3e19376f5b6568a92", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "61a3a88b-9c47-4a05-b5ef-6563cc0003be": {"doc_hash": "0e1e2171f692690e2ff45fedff5b3e41d1dc13db2521422329aad97a52a5e70e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "fd13addd-b9cb-47fe-8bc0-0ac916f8201f": {"doc_hash": "1d1712299f7a496b6f7b2a38dd65d1920dce4faea3d8f98efe9d89867bf801a3", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "03badf40-fdbc-4ebe-bc43-3c520a42fe05": {"doc_hash": "81c87abadaf0b32857daacda7340abba1e8c039950d20bf4543b0dc736299140", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "a369bf5e-e6bf-4a05-aa93-22680bd10c5f": {"doc_hash": "963385a591c43f61f295adb276b7cf003ddc2a7d673c0d49408946271008ce86", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "6e87ced3-476c-4f71-844f-8fc08f4b8350": {"doc_hash": "3e41eb6af2b2c0f4bcf3f0b3cafe44552fa38de59a1c2c6f8fbbd42fe2e1dd03", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "c57e4331-7708-4ea6-a17e-0dc97770fbfd": {"doc_hash": "41ba67e7e93bc531813027444bae376f1b7fa663d08b3901b2856b5b35d48ab8", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "712b00e6-2aa0-4578-83ea-2638810dc5d6": {"doc_hash": "f5ffc2ab1993437448b7c194aa61834d7d350f1d6ab724caaeecf730fd537452", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "1ffed0fa-5963-43b0-aacf-87e5e33edc59": {"doc_hash": "21744bde5b6c619a9cf04fff93e6041f93ddc8467a367c83581bbef71783dc72", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "f0edaf59-bca1-459c-a49f-67bbd79631ec": {"doc_hash": "fc51ebc08bc03b63ac1385d9b91d72e0d835b892d3c7f077bc83ddbb0187da5b", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a": {"doc_hash": "ce39d07327ba88dc8971a1fa2e698933bb28fcffd94ddd8984ac53f4ca08309e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "7db26373-b309-4960-8a4e-4fcb12e88827": {"doc_hash": "2a24022269226d1cc62b54386975fdab12d81a76bbcaaf39edc1986df021af7e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "87c04c69-da61-4622-9eb3-f19ec7e49832": {"doc_hash": "f5309d904a11172635d12fc9fa188dbb4651d516d87cab7399837a379991b9d0", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "29884a5a-d553-4626-a20f-571f12f1d835": {"doc_hash": "3176ab6d25db5a6e1b2e78d33b3b5dbba8a56e86efa1edfb24f0a968231b16ec", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "cc762b21-d49f-4506-b8d4-c1391eda1e4c": {"doc_hash": "2929179a12c0dfbc498e37214051c96104246c55673bff5471fcfcdfb6617f0f", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "6ac9006e-2f8f-4bed-ab61-58818e67ad9c": {"doc_hash": "7ad1203e1e6f7e32cb23421d625d3fc9b788bb56ddb2e347ea4656698c3d21cb", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "7f7e4a91-0b0a-42d3-8453-382301f395be": {"doc_hash": "532faf84627b4a1e20ce767c2910606ca1d7b58a23eae59f659e72b0e176453e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "1b580475-9361-4483-919d-1527d2307475": {"doc_hash": "8f861d4ce9a798080f7062ebc57779db8b772a4dacbc1f7d372159319eb926d0", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "1b4dcef4-69e5-4425-9e06-3787f2d669d6": {"doc_hash": "0859812fa4d478603b96f69fb4e44d6ab28a8969c6ef32765ba919ea4bc6f40e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd": {"doc_hash": "95d98c312c9faa07b0e8381755d57bd4c5cf9ba0378a2a7d06b9982552cd9931", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "c72de8fd-85ec-4184-a7f4-cba16c167b7f": {"doc_hash": "00de53b02c20d484767a0b67974864de290d3b0ba8205522291803b1399d741a", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "f769c54c-6242-45a9-bab9-a77496b5f480": {"doc_hash": "d7f3be03cb5241fa44dcdfd5d161ca974591f50271f4dd7e91757bd9346265f5", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "72abebe3-d288-4c2c-9436-ebee7d2b4754": {"doc_hash": "6e8089d836de4a3a8736f5a490c46c180a37f1f75f0c4ad2ea51ee9fc00b624f", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "03a25775-2c55-4c55-8bae-46c44e7eb07e": {"doc_hash": "5aa82eff23320ffbcd8320e4650f8538ac84a4471bbfb4ded311cc4bf8612239", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "a79b90e6-c0dc-41e9-b369-a556b7b5c93e": {"doc_hash": "30557de7d4164c0c5cbf8d6f4162cabcb4484a1e2599d3656bb3408bc89079a8", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "1379ecc1-7d8b-487c-9712-30113dc7d09b": {"doc_hash": "488758908faa6d1bed28f97931d4b94255eaa15c5cc1b93f085530fb95642f29", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "20ea64ae-5994-4ce1-aa52-a4b96625f1da": {"doc_hash": "17f3f4565d313f272b6445b56ed72908143f8a56dda677b0ed04e5c71aca1a9e", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "2f85e01b-1695-4ebc-a60c-aca3f021723c": {"doc_hash": "9485ff1e5c12802a0e729f0a70853ed3494bbc061f1c2e5ffda6a44fef4b84a5", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "1410bf2d-c4dd-467e-a3d5-99e8374d3deb": {"doc_hash": "e34f5fc6fdc9207e10961f4cfd09a8bf49dfebd131ba43894a24bf9cf6a3eea1", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "481de532-1905-4ffd-b849-ca7f42467bc6": {"doc_hash": "51a6b381c344fe19151c4a44d587936d35543b86f30c5525f7b3ecd5aff2bae9", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "5659e253-ebdd-413d-8045-ba6d349ab210": {"doc_hash": "90b6550d07dcba312aa7717b984527f36f052bd30059eeaf18fb583b34a00d37", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3": {"doc_hash": "ba95b885d17f688051f73ab0e6b1de4bee1153129c1133ffcceb9a3e518db647", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "30745b78-025e-428a-b86f-b09d8094b779": {"doc_hash": "9b86fd0050a0060b7c7bc8bbc11ac50130001fb9e3916c386143fd240f507a92", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "8e53604f-0714-47eb-9505-41a1f80a4558": {"doc_hash": "26eee0d1541d3afd4cc4daebfb80d08d641fc5d0f55fac9439075b4a3bdce94a", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "706c98d1-f7c3-4d68-b857-7aa3adfbee57": {"doc_hash": "756bbe9d9c6dba9d1b37548053f2af61001cd84f2bf2c840f6c288f37ed2ade4", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "3cfd3f0f-e0d3-47a7-866f-16838d906239": {"doc_hash": "2331d15e16e2cc062b2a14d60fa46c56ce011858bec4bc2ae7cb84e55e1c91ce", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee": {"doc_hash": "60d79a2a71ce20e1df821de5d816adc4724e872d8286f05a284e892a658c3fc2", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "72764918-f315-4bcc-ac28-9b577d46f12e": {"doc_hash": "a76807b3ad899be349af3cb31a0587e423d0dc8b6a721dcbc0a62e5b89aafa2b", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "25ff13c5-a1f2-47a0-b624-5d29887a5117": {"doc_hash": "cf7ea06e6f85cfee0f1ecc2282f9c5cc06c82e065f6e76249b5bc13684a2d9c6", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "5e27d416-2bcb-492b-b853-723ce702b695": {"doc_hash": "9f0ca152c80b9af7a922a0015009fb308f1965150b24833bd50d62eba967cf3a", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "a7cda1d6-5519-4c72-aeef-2a4a6b91a557": {"doc_hash": "8b6daa4228b56280eec176be0a882de39ca14cf4efc85d56390225a9fa6b1c97", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3": {"doc_hash": "584b87e9cbef902c2f5f47e0fec9addeca7bb692534434fdbf77913799c858cd", "ref_doc_id": "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f"}, "509d0ac6-3d31-4ca3-b505-9ae41a8a651c": {"doc_hash": "122b02e7c7674609255b01fd70cf5b6798c227cbcef3ef2c93289ec2e6ef5f09", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "998a721d-9f31-47ca-9631-ec0ddc0947ab": {"doc_hash": "8172ac9da84ed1cd122ed7720bb98902f0b73b06f87c5791d6186093a1dbc79c", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "9598c7c4-2528-4348-98a0-13ac33164059": {"doc_hash": "a10bc98f71a9105ac1c077fae1d878bbb5f578ea0ae22b4183e7b2c41dccb9d3", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "8e612020-f16c-4656-b9bc-c460c7b1b7a2": {"doc_hash": "519c9adef7719d930d0b454df8e6fa0e658e9adf5ee500f597054d0aa9d71b21", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "94800faa-960f-4344-bab4-61585a9b8f19": {"doc_hash": "490d7c6d8c63c391b95bd31c8ae488cb363a570b34a5820a579d48e3b58e4742", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "564d02c4-3b8a-4e0c-864b-6f61ce7554df": {"doc_hash": "7b33d9b27564e8b240782d1253f9dccc48497112931e40a36892632243c0684b", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "9d43bdec-d331-4601-a886-9f4f7d510f58": {"doc_hash": "585bba70c0921803b6f8e126fa2c7e35a945a1ebd9f2dbe15a404ad9b21f19a2", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "848b740c-de4e-420c-bebf-55d6eb6f92f7": {"doc_hash": "fa08d10af3a8220ea9c2aac4285b696b1eefe25f5f05d121aef3b07c3468073a", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "1337df31-8a45-4236-87ff-78e8a4ba73f5": {"doc_hash": "f304e64fc42985d280f6add838b7242c019e01230d6b997d4e6eadc8d56342c0", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b": {"doc_hash": "3fcfd1b1d3d174258f1cb16ef4798ff88adb0018f593e3091f5b33b71b4161a7", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "d5d5d66e-b127-4da1-a27b-c38bc1b23624": {"doc_hash": "2eeef1e007860e69480aabff1818dafa199bba8ed861060eeba891661ae4a9f9", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "501d9f40-cf0d-4324-826c-4e8a763758ce": {"doc_hash": "119788b798142e4e4eb06b85cb0487f056c0c20daf3416301a275bc52747b0f4", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92": {"doc_hash": "f172c81ae81addcf483e617ab0c5e831b05f6d4fece6b05f3c5419a0f2d99b24", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "6ca3b5f2-c800-40d4-91c8-e6efccf5720f": {"doc_hash": "5a3ffbcddcf65e9849983cac76c1b76e8d485d9cf8e3752ce60eca60d0d242e6", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "ca08383a-2d43-40a8-849e-bf87b1a4b3f9": {"doc_hash": "444629b02a3a1e88246f2571820e99cf1fc08917eee70b0c1d6a60a820f29369", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "37158d28-6d09-4447-8f77-8129b3d4a7fd": {"doc_hash": "952a05e8d41a7f26a70e5829553a7eb490f694ac06c9233d28cb427f5d189091", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "4faa5c13-e364-4a85-ad62-271c3b1b676d": {"doc_hash": "a62928dd8cd19d6af15353abe28f77907729a70093220d3594128495d7fed574", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "6c4ed57e-6a2c-47f2-aa64-80555ddb6963": {"doc_hash": "3bb5bfd880b5a702c7ef6af3c7d333031d746651371fe5faefe254ffb1ce69d5", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "aba58546-5100-45b6-b6ba-ef4ee917d4b8": {"doc_hash": "30f99cbde4a79fed00d8e27c51f6da2fcb1236da31fc277a59ac2a5c5153bf8c", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "a6ccaf2b-5030-4a3e-bf78-b91886ec2236": {"doc_hash": "44cb1cb716ab960b0ac23820ca3fb9fed581b455860bdfbe907782f3a95fb089", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27": {"doc_hash": "3514eeb87f0a25fb079108c760bebac1e7918055e0219c651a83d55a002cde9d", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "69d3b9c5-bd6c-4485-968a-e7093b0dd8be": {"doc_hash": "48d2e3cdf9b4e33c3d8793dbcd4b00af85d5b0359f4d127c500cdf0ba83528a1", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "ee1de9c4-f928-41d7-8ff1-a3d68180f126": {"doc_hash": "c43a8989657231d044c8cf38e87f3e99b8559d2df8d25dfc420b05a5f537f21f", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "8efbaa18-809f-454c-b06f-aef9cac23628": {"doc_hash": "448be2be0cdb5176c53c5947174fb0827a42e36168dbc2d28170ff305eccf647", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "a403b965-0ec7-4c82-9ba2-6c7459ebe082": {"doc_hash": "7adb064f73d3d9fd9ab263cd6463fbdfe541e7cde2793bf450951b3fd1fc329b", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "b9564c03-5744-4d7a-ae2a-707f7768d2af": {"doc_hash": "0a80732886e50bd33d4a36b0ce0f9a4dd5f786d7d7f7d5e5d4a24bb7b9e66220", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "88c2fb3e-523e-432e-a61f-f2a8b10bc965": {"doc_hash": "8a1c719792626e02d6521f2f356fa33a4a18c93aa7efced80cac5e63b5199f33", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "92d63111-b3a7-4b04-93bc-27e640940232": {"doc_hash": "9fc5296eaf21e9524dbf5d43a11f7efaff7b296cfdbd3e321871adbffab47610", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "560efba9-eaf8-4e99-b067-87c5118c4120": {"doc_hash": "f653aef1e86c29258541e714eb8e15a0eb792e3fe38bf8c1c88aa2fae84fae58", "ref_doc_id": "391de6b5-664c-4a54-944c-01444b060505"}, "5383fb40-242a-4d6e-b200-b5eb563cd3ff": {"doc_hash": "bb37171bfee6d503cd24a9a4a8f9e853e652242743409a10f541b0670d62ebb9", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "00405df2-e191-4d27-ab4c-41f24126e2ac": {"doc_hash": "18ac960803276f6b729aef040ffb42556515efa792da8b8452626f9bb26e42a0", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "58b251a2-cae6-461a-8cea-288e885c95ff": {"doc_hash": "4f8b3148a4b79b44e464cf734df4c1280729fd71a9f3a610530322ec9e07d803", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "84cd8bec-746a-4d42-b509-7191a7f1c628": {"doc_hash": "4f14f7d7fdbecddd8d8341976875fee23a425aa6ab0cbfe2ac74760905ab32c6", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "17a0c615-aed7-4354-8f54-58e77da6b251": {"doc_hash": "beaeaeabf784432438466967a4497acf21ac938bb8bf36d6d8805e0413bfdc40", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c": {"doc_hash": "a032973a9179a2d437059531b475711d3e4baec3a531680406110ba416f0da51", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "253cb390-bd54-4d38-b0fb-b4f50139a9a5": {"doc_hash": "57cd70c9f41fb79b21c72e2f26806cc63f07e02e25e1dce9ade18e9bc448700f", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "49821383-27dc-4fd8-afc6-c381d3338dd0": {"doc_hash": "16d5f33f6348e98cb5944830641d02a385032170eeff7eb6c06908ccb0d83f0a", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "95b5f1eb-cc49-4a38-ba8a-2ef02f496261": {"doc_hash": "95afa635d8d82a10f8ee4324fb499a9bf25765bca0391b9754243e1856581540", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "adc524a7-a81d-4240-9331-4c3e0b90d25c": {"doc_hash": "9db9876e6be43df2aaba8dc232f3b3b1b570d306ee9f3a40d0e58472e8f0eff5", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "41275ad5-65d1-49dd-af0a-56370f1ba440": {"doc_hash": "81e46c07d3ac3fffa37bcd1fc978156f6c2c9dd5d971f98e9adf37f6237aaaaf", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "599180c8-61d9-4fda-bf9f-ccf875155d08": {"doc_hash": "c5b471a84176936aaf9b7804425f8740d2d5eaece1ba7d27a8f06f0e52d666f0", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "c804cb5e-0e21-4231-8d46-8246d0098a88": {"doc_hash": "d314aedd60044ed839ec3bfb0435f2ecb8c186213ed9dc23920f0ba9af962f74", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939": {"doc_hash": "4723fa011effc68804561fdeeac0d56c9458c147de3cdcc485457d4925fbdcf2", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "efac3c90-4a0a-4437-83e2-e2fd43117a27": {"doc_hash": "d2ee9c1a30c456b6ec339a92526c56dd394a1c2900f0f53b459600efd7ebe494", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "bb4f9142-6d95-46bb-87c5-068f3e8bd908": {"doc_hash": "5115d51ae564a50e3783cf424e5f58e051c76f564ef48b3153fafd95e5e1d127", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "78b083da-3550-4dd3-bf2e-31d0beefea0f": {"doc_hash": "678088eb12724a43f33057bcd71b67f1847cac80f29fe6a95491dd2af4a4bbce", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "8d5548e6-4f99-4d6e-8f98-df528b62ea93": {"doc_hash": "9837072e05acbb5d05388c8e56950190fa67dea4deecf132fdcd08a127690655", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "ffbf5785-dc8f-4b76-9889-084b1252baad": {"doc_hash": "f5fb6c291519d414331cef465538cc3a30c9a6e6994eaf16237be3cd50e8a4d7", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "ccb8548e-6149-49c8-a095-d2cf590de326": {"doc_hash": "3e3821ec216229caa1cac439dc7159f36b309616cb0bd3ff7f670ca3705a768f", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "1d0715f7-aba2-41a8-802d-6c3c043e3d73": {"doc_hash": "3c97b8de526349f65681a265c8bb401d7b5d67c4545945c1528e6c787f270d1c", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "1ed7b1be-e946-43db-b212-6f37ca2e5a94": {"doc_hash": "cd49744e0a36e476c60972b04dcb2a6984ffbde562e306fd405dc73624fc95ea", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "363dee2b-577c-4095-be3d-9128db57e527": {"doc_hash": "60d6c3bf2bc60f910d27af5971e6d917c89c2b4800431a991af2354e9d026636", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "60285116-e264-44f0-a035-ef2283e38d3b": {"doc_hash": "e92554d386b09c0d62f266f855147541eb0deb529bb88b6c3f1a85d6e269e940", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "bd1f9cde-2634-4955-aaf5-f1e7a9c97326": {"doc_hash": "68d7a076fbde960c7627bacceed83948d40f07be7111ac3a9df10d3f4e6111a6", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc": {"doc_hash": "4af1a11fce2b23605b0b2b54979e51b5df3878e6b88625ecd70d0d55b92b8a1e", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "88887736-bfcc-439c-aa69-e473809bd9ba": {"doc_hash": "5fa32693c46eb784049693ccbbca4d5256bfa25cb5b3f2563c0b6fa86452d130", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "3cb16cf7-c878-4528-bac5-ec2e2c72f307": {"doc_hash": "803cb810a365654f0b67a71ecb693d81a73d3ebeda2fa2d12043b808cd85c52c", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "5c3f30a3-3568-48b3-8a5b-89188e137bae": {"doc_hash": "650cfd8eb16a9e5d7c3fffeabae0d0afb1320e1ee7df8f401f6ac5791d2db4ac", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "4d59eb3f-46a5-41dc-9afb-e836e6d92057": {"doc_hash": "a74540331e904dc3979d29fd7604c1deb78b9c8acc16d8826bb18deb14e25bfe", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "69023623-501c-4dbf-b670-e9adb632fec7": {"doc_hash": "0384534ff162cb3191eb575fab1d870189e77008e9b297b612a034600b2ffaa3", "ref_doc_id": "2abc606c-38ea-4660-851b-cb0a7d3574b9"}, "7f2dfd10-4cf0-44c8-975c-42699ccf4aa3": {"doc_hash": "341265fdbb95d5a1747ffd9ff93931a1d4529f492443437c6fe48ce96643fc98", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd": {"doc_hash": "80dd38a3c24fe540b323f53b4b47ba4692fd079fff7fee5d812704f3d127cb22", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3": {"doc_hash": "931643c30f7a28a6b3dab3642ffda0c40e8f6977c02a81540fc96ab25ae03041", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce": {"doc_hash": "9fae844abac47bef0a0bc866ac90b6040133d6d98c3dc17cfe73ec903ddb33bf", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "165128bb-0f24-4e6f-88a0-f3c2333c8d44": {"doc_hash": "ae7b4ac6cb5f1a8ab1158588a6b60d6728083208c9f39ae520478fd098d69f27", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c": {"doc_hash": "096c2a9467163ac690149d13998b08b628a441f36e1416ddea214df1de1440b0", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "62d69da5-5c0b-4b98-932a-5a97c1b6dad5": {"doc_hash": "8bc47a87894cd85feab6f1a28e380614b56a4c1b305f7efd7b25c24a8d9b13df", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "f932a6f4-da64-4196-84e1-bb45bb823862": {"doc_hash": "9953bfbefff9c11256aef4e20a86404a58dd9028e523934e4afac76fb1f19bb2", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "a8b20d32-b48a-42f4-93a4-0938cf926631": {"doc_hash": "3b9140d9e37179419b25ee452738a2ae5c02b339547679ac1c732e25af22194b", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5": {"doc_hash": "4a48e0c7fbe9540411ac7e0555e8732c8813057c0aff2ac81479d9dd000ea7ec", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "1909773d-f224-478d-ab8b-610790cefbea": {"doc_hash": "f01892ee2c9eaf27b0d1f6587d6bda3b3ed25576d323adc2f0db0cfa392d4e6e", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b": {"doc_hash": "49066cefa15524f789c57ea189ee8c50cf5f2b653b012eda2cf9d4174640ec2f", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "d3a841f5-a648-4813-9a17-2ef13f5f570b": {"doc_hash": "b651a401c91d7ccb83433d5df32d64d178e63ad1dbef1a171a2200a30ea62ca0", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "ee3d35c8-0764-49cd-a173-97ea662dda1f": {"doc_hash": "40917f88bfd59724820226aab6cee8e28c18358cc730773a328aee75af0a1e5b", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "67eccf82-b02e-4d23-bb26-e355420ad3f8": {"doc_hash": "f4f375fcf0c3ad7923c533ccc9c599c9658b66a3f3ea110965b133a0eb4279db", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "ab6f415b-5c58-4e0d-9882-e01654ea2832": {"doc_hash": "c75492b6995e6e069a98eb9cf84728ff60dc6d9f9696e019aefd6775668ce364", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf": {"doc_hash": "a24dbca8b85b97449e28c01871e36acdf9b38e7350d4410c84e7d8d068376ade", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97": {"doc_hash": "60db28ddbcc5908bfdc6ee7c1f6b989792b86d7f8df2f6e1e4b0eadb8adc5058", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "471118b1-c54c-488a-b737-3f92a31a4911": {"doc_hash": "33c053c5fb1adf4491c5f5ece36c69a6a3224314966ca37ef3a6ea300c05bbc4", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "332c711e-d8a0-48f8-8dda-12e8a8b6a759": {"doc_hash": "899d5b9cf97f855f4daf1f01ce853193b3a21df1d9fd4df53d441658735bde2a", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "87851154-9bb3-4f66-835f-c372e0a5ff6c": {"doc_hash": "3fedbae1c25be0561477d7a3f59ad7cfa9e4cd96a741cbb43179d37395d1f321", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "5d388c10-b6b0-41d2-aefb-240da36ff804": {"doc_hash": "23d205713700b6d56dc989e9024a93ca5c982decec9d1fb02f74bf033afdbfdb", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "99195272-6f4f-4938-bcbb-645aa8febbdf": {"doc_hash": "f6a6202b7f0d3bbda5168e7e472569aad6e33c2c140538baa4fc0684d33c023f", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4": {"doc_hash": "206a75ba8c55770ad7d3a64456106814a4687580d892083680e2cb4300b0759b", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "fa71b54f-4105-4fac-b408-409bc89c7a8f": {"doc_hash": "36f7b450a294f686456968f25643f4cede4ab67187f13ec9ff465d1e6da9c753", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "3d3f3c1f-3992-4e52-b07b-507a1149d857": {"doc_hash": "3e702970dc18fbff387fa680070cedbcd17b0e051b72715969cb5a19dd9634b9", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "c51be610-4650-46c4-8164-f3fbebac4a67": {"doc_hash": "3366839b0f579cb368a0313ea2a0ac007f70fd70d045a60cd505500c9ad54c2a", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "140ba22c-11a7-4618-a3f2-df3db6e04fb7": {"doc_hash": "23aeefb2f15d2dbfa4b7a59c5c07eb11678cdfaf5593fe39a8ed030232d2b8db", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "ea922582-0fc3-47f4-87dc-fe0c9703663b": {"doc_hash": "d1581368ad63e1537b157cf42522969dc546c28be9e3cef473da03b02cc2a83d", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "cfa64914-dbde-4b16-9761-4c729319553a": {"doc_hash": "0a738edcf7dde306a26ba6335970b81f14d6a49b2680dabfc078b97002b4d1bd", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09": {"doc_hash": "34759a8d04fe87eafd9f5f5fb66a4bc68190a920de180697c3ca433a92939ccb", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "c95cb270-e3f4-43b4-b864-2a411b85632e": {"doc_hash": "b7d609af132a1c526c61db1726e93095dc108a3934f657e8b667a6d9db98548c", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307": {"doc_hash": "a40b02813365693861fdbeb6907668611aaa3b44ccd013323caae7198e975aaf", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8": {"doc_hash": "e621b322df3b2aa545ed7bba5e26871553ce5c87ab74a9b004df650f98a15e1e", "ref_doc_id": "c68551a7-416c-4c3f-a5a2-5b36f26992d7"}, "dcf5297e-9e50-4bce-90e7-e560bb4db893": {"doc_hash": "744e5dae5e0dd7e83639b7d2d3776df88a25431509a0cfdcdd15c29724783f82", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "8131d783-575e-4a65-97a5-7134d59978ce": {"doc_hash": "330c862aaacb0dd46ffaf121b3e80f43566ce9488f8240e5640d60795784597d", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "1262f8cd-5cda-4219-b732-0b44a5a6ee52": {"doc_hash": "f9c86647257c3554a79b4fcb43c117dd5856b8776f31c85f0d25c1fe6d25f86c", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "194e54bb-4ea2-459a-833e-b6568572cdf3": {"doc_hash": "7b068fc4401b104f80d5552204e93f88dba458249eb6ff1dfeefdf73dd9a4fda", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "f3c8734a-3a0d-4296-9148-ab78939fee28": {"doc_hash": "f7578bae49b89aa66aed795f127269db953e8c7e4b04d273c1e003fb3ee1c5c8", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "200e8234-c2ab-4be5-b4b7-9484aeac310b": {"doc_hash": "35268bb62c0dbf6de63e6a6560dd6a243a241e7ec639a9155f48b269d5a09ce9", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "49a5b280-49de-440b-8544-32123dd1fcf3": {"doc_hash": "2980e2e6422fcf840bd595f640c74d419e88435189ddc3d140a7bc73eeb3145d", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "4e981570-17bf-4ea1-8b59-1f3bdd1e934c": {"doc_hash": "1affd6528fc5b5f91e04d135eac0f6da098c93c3558f9ef1277df79e8f0cdb53", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "f0965eb8-0f85-40f6-9584-50bd094f1843": {"doc_hash": "1cef9b4c0a9dc2d2816f7b331b9bcb45842d78210fe65e782f8172d44cc54307", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "1d575ce9-55ac-4906-a191-efb1ddf65eb6": {"doc_hash": "842b6853c74c7889f900996cb522b335890ecfdf3b2498ab99535d5f8118d541", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "f17a854f-71e5-4e1a-b7a1-a9d2d882109b": {"doc_hash": "fd4f3cddbb127e7f46246b7d9f0e7c7d3de64f8d13e141be8792952412352cca", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99": {"doc_hash": "ab7a7911409e5f7876be875d63e809f6d4779fda83d8572036341c947132bff2", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "23891df2-7595-4982-8e7d-3a7ffa2607fa": {"doc_hash": "4b7649a6c9962181e432cd2dc3f5f1476ad51d6dded93aa72df75e6bfa9e2074", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8": {"doc_hash": "838cc13f71ddb2b207a4c6117777289ed30d9eea387e1a848dce98127d4edb26", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "db7e5d4f-8ea3-4988-adc8-a300bd9516ac": {"doc_hash": "0698773d330294128aa068fe7285e1590663ba2b25634b1cbe0c39f2f884d748", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "68c11c06-5220-4b19-83de-5355dcdce32d": {"doc_hash": "56d9af1a05bf78cfba09c6b2027713a4ebf285e5c5c2869269796832dfe91236", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "591650fc-244a-4306-bdec-a580dcf82f29": {"doc_hash": "c17e836458b3fe3962904e4ad30213f2c89fb3e860e2bcc76d7b6aac9b726a94", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "a3aaefff-ec9c-4891-bc8e-26296b20f35e": {"doc_hash": "f0d3dab4eaf8729dd831b23493f05d78e0c2c240a3facfb77ddcc1fa1f95d32e", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8": {"doc_hash": "f5274cb22169e0febb8f7dc7ad17bbe1fb842586c47d3c0794f4f9502f867c9e", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "cd996a72-d1ee-47ef-b0bb-9634659a800a": {"doc_hash": "d1b584479a35ad510e32107b365245ef5f7219bf6b28dc4952ac2e3a5dbec1f7", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "b7d8adc5-5120-4448-b226-06663db47995": {"doc_hash": "87e9aa9652dce8cbc08a84e56c9c84e7b46cf8ac484dbb36ed7c47753d0a9773", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "1a5e4dd2-53a4-4313-b332-4633a2c47daa": {"doc_hash": "3d3bfb866964ebcfaac9dfbdbb0d9d337db828653a4ab1fe832bdeb613770fcd", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "2d3ee402-e0e4-4bdf-aeb3-565c85606176": {"doc_hash": "ae0d38339fece145b46651275f0f3042bb16b0435ab5ca00b60a458c2763c740", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "9409e604-380d-4d76-b4a9-c8a86e281f53": {"doc_hash": "773d9b229785851a302f735f4f1c6ff87f83393ce5a124ecf5755899520e466c", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "72b41069-4160-49e5-bb5e-cac433ff9195": {"doc_hash": "2ede4ec5bd2610e3e228096fedc6c60ad255526cccf293c24bbffe5090410196", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "293b71db-e864-49b0-a5be-b5befa76036f": {"doc_hash": "e81b8f416ba34635ab08795851b67ea89d906b014de3dde278b65b9aa79f938f", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "d2bcab34-f33a-4228-874a-efba9af7f609": {"doc_hash": "fbb89f49ebe7adc0006d06b24e75ae33e7d57d8704ef109cfac1a30516096a67", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "592fd19c-a68c-4fc7-bbc3-02353e11cb69": {"doc_hash": "cebd033ba0a114cd873c8710ed764a94106ef10d20fa2636eb3b41acb48fdcd7", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "01515455-1055-4819-8d1c-1eb134a080f5": {"doc_hash": "b853accd04bc4aeb0d1ed26c46815efe593ac09beb7019611b3ddb168578eb5c", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "13f1f4fa-9016-4dd3-9d29-7b2314511f56": {"doc_hash": "f49092793b42dfef698fbd34e5f67186b2a14aac0df65b9a4638218c23837258", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "7f61235b-256d-4b66-a886-547ddb346f54": {"doc_hash": "9e66e64c99e6901223011b82345bb2b5841b9984ebacf3a90fea1d668af986dd", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d": {"doc_hash": "584d2e0e6121b4d742f0a9e0bcdd5b7544401c3578008f22faa9694dc16a35bb", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "00dffc5b-8c6f-42fd-81a7-2fa30e928c20": {"doc_hash": "8698bd0835748472ed1d029fe89222242aadf1d68114d1098db371c8eeec3cd2", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "dd813d48-249a-4ea9-8b3d-82abd7e8300d": {"doc_hash": "ecff42ff6fa6795e46340880a76cd54bc146fa946e30ae557145b9aabba1c4f6", "ref_doc_id": "323825da-6b17-4d36-a862-1a0d79370fb3"}, "7e69e437-f39a-4d79-b779-33e32b001885": {"doc_hash": "c39d735f735531dc27a50289553915e0cd2699b6ceccbc612b738ab17eaf2231", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "aedb8a6a-32da-4259-b428-fd744d864b99": {"doc_hash": "701d50105f31adf3213dd33f126bc66e8df833317fb438a5982423e1b7ac5be9", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "09b5bbbe-2f47-46af-8efe-8bec52cef542": {"doc_hash": "1f6cc717c2a56bfab549cd2a95f15a469f57a18de6877986ccf20b60da0ad72a", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "cf09175b-8f45-4877-a922-0d983226a1fd": {"doc_hash": "a7e2d14a52e8f5e1366b4adeb8e1b55ee26a8a7c997d631a1470bf2717d18e6e", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "675dea38-5fe9-4f9d-85b4-208dcb69db69": {"doc_hash": "c7e54b83cff2c65a80b8f1f90c50e7089be9b122a2690fd211dc6b9d6cce664c", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "ce7c8720-c5a8-41e5-8094-35c1a2f18043": {"doc_hash": "a43d1e898c430687105024a464638a4437222022e8971308922ab270797a5945", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d": {"doc_hash": "a942e0c4ab6485f583078ca3318b45d5f2b7d8ff7a9c0f8237f7288f4c1b54db", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "5c09f95f-6e42-4877-8664-ebbc6d699596": {"doc_hash": "4f75d0f2f9aafbdd8fdb38fec087a543143ae0fd3c4822113fac8322eb00e912", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "89c1fc86-f0b3-489d-8c06-3442c5717b6b": {"doc_hash": "c618622c15e8a821cc5dd56f47056837dd307b114b2e9439809431506c1ba86a", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "b0641df9-1e70-4231-b79b-9647ea3826d3": {"doc_hash": "0ab210c7a31d221d57d278d6352cd700261b8ff605f409eb5d1aa784bcbe689e", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e": {"doc_hash": "b7953f8bea6c526ae978b3bc656c8dcde72ea7a78db091591c29fcf302874684", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "aebfa07d-62d4-4386-b21a-4818bc221fb1": {"doc_hash": "1e5d578e347ba8bad4c8805c1e8bff0b96d5addc4718fef0f2f05ae5f6baf6a7", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "eb541d27-0d5b-40a7-bbf1-ef30e021f78e": {"doc_hash": "4abe106a4a438569014ae54f4fec55ecd3efe6a6df0d15784ae03ab6d7560b8b", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac": {"doc_hash": "bb332cd5bcf5a6399adebe615f71ef85b28ebb0ead4ef638ed4bf8dab520f049", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "9458e0f0-8932-43b6-8276-879e92b28306": {"doc_hash": "c9c154c4eaa3679f9706535fe1870ab3e36837728d132e52fd988120ce0ab2a3", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "848f7a0c-2362-4c6e-a17c-3cda777ea364": {"doc_hash": "67ea13a36cf9d945c65934e51aaa7fc6457305799622e5e7a9251e5a6267e32c", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "0102954d-3a3a-4d0d-b77a-7642223701ab": {"doc_hash": "f6f5d0b017dc79a287079e9fdade6437a37cbd290cae2e06eb004a5f5248c2a4", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee": {"doc_hash": "19e5eaf85b742bb616a8518bb16586c2712bef6c685a78910545251ed9f83539", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "7c01eabe-df2e-409f-864c-f0752422c284": {"doc_hash": "46e3a44ffcffa72186cd63eef0d9203f40fa23487ae9be91873c45ea6fe21dff", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "aa045180-0595-489e-bc72-3af39ee5e943": {"doc_hash": "c723e2f899de449ce00683e1c08df9e42f0c2e85e4a716b694ff836c066e76fb", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "62f26e72-3ed5-43b1-a197-4ebd8b13a429": {"doc_hash": "535d2474b6cab4044e6d612592432241b7f5a0c5bcbf72bc96e039635ff314d7", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "b94874d2-753c-4203-83bf-086856619fcf": {"doc_hash": "dde529bd69caa3693333c7183b23200fa92a507acbc847b06a98c24e04f17b61", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5": {"doc_hash": "2cf765fc4172a1c98ccfcc1d4fd87ca91b21aaa01038cc6d42447de1d8ba5e6e", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18": {"doc_hash": "7e2d340ef401532b53456bedc67c6951ef986a27d59c06ea15d4e2acdf01973b", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "dea33748-0e1a-46d6-8aa8-be529dc0236f": {"doc_hash": "8934b174c7b388c3c960ac2af5f751ae80b1950664cac00afb015248d61abdd8", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "52e06362-3073-4c8e-ba6b-79bebfac95d8": {"doc_hash": "0de1c3a4faa1428522efd7fef3aa48073bfbc522bd0e3ca033c2101704036a4e", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "c4772ccd-fb58-431f-834d-73041a1ef7c9": {"doc_hash": "af458466dd254b07e032450c160c380bdb10f1cb4b7804f47e0f6b01606cf4a0", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "0432bde7-97d2-46a7-af06-73fcc0f55b07": {"doc_hash": "23f7a27c65a0a07608f0ca6fca72349bd5b40777be6c75a2af33e1c07e217f8d", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "8b90b5f0-a87f-4348-97a6-9c3dac318f46": {"doc_hash": "5c47834e825b50dfebc9111e61421e5c799f372ad334fe0979d92d1281833683", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74": {"doc_hash": "1fb9a111c08ec02b18bdffd289fd7a893eec12591d72c91ffc6dd6d90e6a6878", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "4599649a-9783-4bcb-976f-7a7b41152f76": {"doc_hash": "32ac324dc2ff1e81533782c3c49f9ceb167f8772814739a72e2e47a4ad7d5d10", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "bc224033-00b4-4f8b-8714-1a33c3e6d104": {"doc_hash": "2ec8f91cc6e00b5afc5d04ba52a8caf969b14512771cba43687687f039cebfa2", "ref_doc_id": "bd651816-f65c-49c8-8d07-55064dda3afb"}, "be9e50e1-bfef-4966-b7c5-70674402d69b": {"doc_hash": "b84a90ce6c49899011229403da0fe652445a6e28fb351e96e2bd6db8ad641be4", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "75434bbf-5b26-482c-b81d-0d3c76264d36": {"doc_hash": "198b34cff837d56f679a9ca3e3f123f313d4cd6a5176998e317dc127458c630a", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "2a619b1f-8e27-4508-90b8-939d0954fff3": {"doc_hash": "bcec4c26e9b7626221b41495a927f3cd651d6f493f0ca99073cf1d5b9ee511a8", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21": {"doc_hash": "d8136a65f61895bddbb6b71ac3f068861f558662c5c5d0e94209c35c23255f83", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "44d1985f-56aa-4156-a393-53d07f96df1f": {"doc_hash": "d89e9211a7c9ca5f538bf025f6d9c219a31fd4992cdac7c8cef7fef4bfd7212e", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "cd013330-fbec-4203-a048-91fe505c5751": {"doc_hash": "4deb630b016865e9c6970b99330f8708caf637601448eed33f21e9f76074aa1a", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "be23a840-e8e5-4500-8b7b-78911e0adea9": {"doc_hash": "7ae903d271861db53639a44ee2bba4ef423ada935f4848bce47644e5d747d49d", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "b4bd5704-440d-4e51-a643-4115b6f81e21": {"doc_hash": "b0dfc9b025f450fa89e088945a8f8da5540fe2542f6d39d9a3ffbadfabdd359e", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "c7f402aa-c87e-4836-870a-57fd41a3f9a0": {"doc_hash": "0cb539b164b9caaf67edc747dbf445e582c9108bb40763aa325de9cc304232d7", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "bf4960ea-1bef-4397-8afe-eee58d38adc9": {"doc_hash": "d12a8e1c08abf2a3e500a1839f957df31e13fd753f47b6a3df4dec843495f79c", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "ddd1dea9-c43a-45e9-874c-48dc47987d08": {"doc_hash": "386e6b10f1d48d1142a3df9e136731c6e43b687ea1426438bd7c8ec162f59ef6", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "d47f38e4-8725-44f5-9d65-abc81741a872": {"doc_hash": "edbabbe02d0768aa761c41feb11cad4de37c36bee8dfee82ab085efaf52cac09", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "feb04de6-2878-4781-8edb-38d25158efc7": {"doc_hash": "619dc116521f813e32cca5d3875723bf13acd666fec1ab3b83dd23ce45773dcc", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "526db840-1866-4a74-a865-2146620196f2": {"doc_hash": "512183fa0917a90e36d2b5db7c7cc7c201307ed667c7aab06e1065d5c9731ffc", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "eb10337c-8f56-4099-8977-32d4235a6ea4": {"doc_hash": "3f42f45a8253ad756289c9dc00351648ee4c34bcd79cf5ce80eef38425640b60", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "0435e09d-147c-4168-9f1a-261d6ce0c5f4": {"doc_hash": "05f2f63ba8b6825e538f2921cacff7b9319ba1e39ae54958ec5f6fd3d4665631", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "db04cad7-5816-4c46-9b51-7b9b9a211686": {"doc_hash": "c51b1e5d2ad8df92e8546b2edabbf7a579c4461fa6ed3740a2c009c3f126b3ce", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "fabfd8e9-7591-44fc-adb5-cbcd9b723f64": {"doc_hash": "78bf9ecebd83e2a48c05a4f491ace4dd475fd99a2337ab253be3aa2e922d44a6", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "d1e839e7-9823-46f6-a091-fbf22d5e6729": {"doc_hash": "54e96a7d26c3cbb41289d29365c4dcb6379cab4d434c8456e05e8824c4d720c4", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "4c578c88-9c4d-4b63-ae57-5e6523d5100c": {"doc_hash": "b54bee19973d2d03c335303cec766984ef2f8fe9ccae81daf6e183f082b62d3e", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "28cea14d-3f78-41af-8bbb-55b054518c08": {"doc_hash": "ff48ff15c52887ea9502dc5f080c0738eaf6209cdc9cbbfec986cd5b7700dd1b", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "3e55f451-02aa-4396-b625-c179e4b52fc9": {"doc_hash": "263b61c2b6ce784359e9039adc7bc826fa173592048324380220bb0b0d6a1bc6", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff": {"doc_hash": "a899c0ae367762f93f1cb3a27ae6f5c357746093eea43caf733da4e8b408e191", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "bc41c946-c8cf-4d12-a920-2cc9c4ae094d": {"doc_hash": "dfc86ef9240e7e6a24628514b507c4b9e2324638b1efa07054d63349dcadce7a", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "8452067e-0d1e-436d-9b92-f24581552442": {"doc_hash": "bf51795671767d8304e51c54d609814dd22995da0606774da0904ee990308371", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "423f344b-7aa4-4784-bceb-4556944ac6ac": {"doc_hash": "76aadc7a724f92d1025b218b58cb0584b49e09e4140d194cbebb63ad8ee0af03", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "c8c6af5b-16a9-4203-9bfc-7f21557e6231": {"doc_hash": "8bbfde8d6cda09a1689da920363f0bdd3a958eb86f9a67131eb67b02726079f6", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "73974ff9-048b-42b3-8ec8-485b1eb15ff3": {"doc_hash": "b0b6f90797e2605450bf0c516f25a4caad72452c2ea477884a6a81d070aca758", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "a878468e-b6f8-4c10-b6f2-0fd7263bb297": {"doc_hash": "ba4d900e61e1920f37413b591d61737edf87e7c8b62df0a3d2a2fc3b4f5ff320", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "8db0d8ae-be7d-4502-a140-2a13f8ac6a66": {"doc_hash": "0ef4cce7a5faeed53259dfffcf11de1f0f76b3e49cb7a758a5b12b77af9d3dfe", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "7aea3561-f270-4839-a6d3-02f3c4c15a58": {"doc_hash": "8bb268104aeac7b32de94552681506528bdb01c3821bb0706c1eabe8a0cfb09c", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "396d9682-0ca4-4d18-97b7-3c4f8be0423c": {"doc_hash": "13d1ce5db0f8d587f91412bcbf909daaa43fe73e8382a62976dd20a9d42786c0", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc": {"doc_hash": "b9962c7de3e02e67d8f2f16faa849c53f9ee2c62beee40e27978896361026932", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "05ed6405-5be7-4337-9ff9-21f1c1ae3883": {"doc_hash": "991b7ea2a13d5a9a7a3a1e921687d2d922591ec9853fe1b85299e4b5ea591c46", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "8ef96cec-51ca-4b98-94e2-11bc06f25587": {"doc_hash": "bb01e45d85d669344636d3c1ed7c1b2825ee6273cdab62eac2e07c55253e9a9b", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "b596f45a-0e3e-4293-9099-abf101657f22": {"doc_hash": "be4231c2d46fb3e816ada286d9a8128562adb08a66c53cd06d5ccd41d709d823", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "011f03a7-4198-4595-8856-0ff41e702bf8": {"doc_hash": "3a44d2c58a1b5039f89f80cae480a544fc0cac26bf531a032ab5471ce8e9f057", "ref_doc_id": "ca375f1a-c28b-4978-89e3-4f1eba72e8c5"}, "ab4d1a19-1ea1-4447-9c48-8767f88f501c": {"doc_hash": "fcee36313159c113ab25e9c77f2bbcdf881004a12fa81d734ab3c386f44157d8", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "bdeee984-bcfc-4b9c-8332-56381a89073c": {"doc_hash": "c1c7c7bd7f733f7fb65c1dc08449faec20377a2c087e78cc413da9d8d0c3eb61", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "fc96384d-6ac3-4e56-b291-40217018720f": {"doc_hash": "fead31db59744c304d05706bba94a29e0cc2a388e1b979865428a05440bd2362", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "fdceaf10-1247-4538-aea7-d52854f652a7": {"doc_hash": "166f379eec2d313650f110bd313f594d789a0890215823cbff3ac7039861b962", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "00138878-9dd0-4abd-b0c2-5948f9de54e0": {"doc_hash": "dac6e0d67caa259989728b8ada25577fd02fd13fa2a2bf75641e0d15c18bb986", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "404f998e-4da2-4daa-aefe-69b73086cd5f": {"doc_hash": "c8c5b9b5aea7b07d4f844fce6800bfdae199f4f5fcf0f1102eb02ae73ca36329", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "a420fb79-6b35-429d-9c37-d9112c85283e": {"doc_hash": "7c4d7282e7c8fc65cbe3865dcbaae501092ad4d1eb886df7eb6d0f463dd7a8e4", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "4517b89f-693f-4bae-874a-c670aa4057db": {"doc_hash": "e36bcc661c3e1473f5ac8a1dd8c69ecfa5fdd00b9b82310678568d668d8517d5", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0": {"doc_hash": "fb084c43ef6f0fc89c35da1f4de3b9e3a4a2f8fe7ad944ef105f86a29e9c134e", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "485bceb3-a598-43a0-b6b6-90f3f64d8204": {"doc_hash": "5a8755ba068ddfb8f2cb11b9096ad18b2f807a00383a6c2ad4ef95400dc314f5", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5": {"doc_hash": "61b8e06cccb9232e9dc19b598bdd2f807e1ce943a358458e940807cbcae65030", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "b167e530-b2af-40b2-b34d-1ad09079cc50": {"doc_hash": "3042cb39c40f08399bb1ab9068f573de4ff7fc9f35df0056d68f9705b9388ee4", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "574526c2-f13c-4427-8005-740f43b1295e": {"doc_hash": "fd157855cd68355b1ed24b04de060a74fbb3277eb952144fe80bac3f57a6fe4e", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "2a4145de-0805-4e7e-a783-0e59a7b56fd0": {"doc_hash": "ee6a4fb05c8a12939a514a8d74e26c49bf73546426b471c89ba83a5ff2a2fe0b", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b": {"doc_hash": "af48b0b046e3bb3fbdda2b1bf90236cad4ac689850c32b2f0b1a45ba4c394bc2", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "77a85204-851f-4309-aaa7-c86485e5483b": {"doc_hash": "f997fba66e15f0f409f19b98b17d5db942ad229d464f6e84011f65a89f3f1f5c", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "115235a1-0473-483a-9fb5-db17b4d76baa": {"doc_hash": "f1d8db3a03fc6d7fb482031b4578b0e5350d84610a5bb1de73fc9531c1bdfaaa", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "3b87e587-450b-42ee-8ad8-7d0288be32b2": {"doc_hash": "55bb2bbb16e991fe3ddf947e093a40fd09658c3ca4cb4285ba4eeb5f62878c25", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "34b3e3eb-32eb-4321-8123-388f621db4ab": {"doc_hash": "61e93a1d4d162b7232a14edf63d55e877dfe1f9348dd874e93ee00ac6d0f6d2a", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5": {"doc_hash": "7790ddefab6d5a3b353b444e5cde0d4feaddcfd488d68a2fa77ee7411bf18f5a", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "645e0600-2ad4-41a0-a4a8-16449b0f0e74": {"doc_hash": "8c3879998ea833b415b3aaabb69f9f1fa2f9141b3d97b9cac1a17103eb6718eb", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "976dbe1f-7c04-4bfc-b61f-2e668afb95f0": {"doc_hash": "4bc96b3077a7b788568e4ef20e7761ffea1f8af47f21511da9fed3569b60e0de", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62": {"doc_hash": "cfa10b9c8a8abd8bb740d94f6ef1c413093b8af3952d5c70ab1c3f63d6ad8157", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "c292b9bf-d4f7-4edb-adf9-d8f8d8903133": {"doc_hash": "a76b662fa210930208d295d299aff59668957ad5368cf3e3814f791eac044b36", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "98343c16-6c36-4cc4-9ee3-d82e02bf3975": {"doc_hash": "60522a190d14b37fb1b383a52af395a028f18467bc9ec641fb68dbd907a548b5", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba": {"doc_hash": "6efbb0f51492688de8dfe26efd29e184d0f564e03281be1af8007f6e119ce7be", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "94d3a296-4f29-4003-87fc-bbd6e4d23028": {"doc_hash": "df39e0961d867d3700c1a1870b97d14b94482eac2877425675230809fd6e2559", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e": {"doc_hash": "2d54a6db985a7319ef1a3eaa21cb277bb30b5a2f3fd83512ce41f367d48c50fd", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "5feb62a8-ed96-47cb-bb8f-08d0147d2787": {"doc_hash": "600d785c14565e5afbacd872d78bc8f1804647ffd62a620cb3c550b8ef34cfe3", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054": {"doc_hash": "8324a7ab74caece2d3fdc6eb3f8e119085c6f4586e66832927b9d439a1d64598", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "36336417-7b47-43b6-ba5b-079401170c4d": {"doc_hash": "2f4e844d117a9eb15039fc38d6c3035a8d70d1c27bccfc86296357d5fbf5e64e", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "2cffc938-504f-4520-a4d1-b4c4a49e2e7a": {"doc_hash": "5c4a5f301391be32fbefc08a3b05cf802cba88f2935f1515391695ac5807688f", "ref_doc_id": "ea085e19-d94b-43d8-a4f3-026c3530cece"}, "d3c1bbc1-98cd-480f-b007-97d7d398e220": {"doc_hash": "e1b1098b9347c361e553a4db86a385fd3fa64f9dc7e11666e23b2e6cadff9553", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "3f456db4-1b9e-4a92-9161-74c6653ed195": {"doc_hash": "53e2702a10ae017abdb24ea62bbd6ec7f30cee973370e4c5cda5e92a9613ddee", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "34e02324-3e0e-4a57-82a8-4ba0154b02e8": {"doc_hash": "1a2a41fcc6731f897c4ffeb1132785125dd79dff70b704f9d140b7fc7dd30f0b", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "d4aeada4-580f-435e-8e62-da636621eec0": {"doc_hash": "63daeaff697bace5f1ef15ecc23412b052955d1bf46037a57c93c1c549698de6", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0": {"doc_hash": "8ff7acfe8fa1d57aa68a42b3dcc3d12bc6d9ab6a7ae514b2cb475d60d76d3322", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4": {"doc_hash": "e5768a0722e3c2d7778441651756c6cea96783d3cbf37f71fb4597e393dfe679", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "b38d323f-e587-4f16-a082-7d220eb9125b": {"doc_hash": "204c9b5e0d7eb4351f6b86e1bd64fc173cb77aa0d24f0c1c9536005450bda466", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "16b84144-1e13-465c-bae6-e11412324639": {"doc_hash": "80316f4bf21a737f16cbb308c5caf62d33650497781ba066b0bc364b58f455ac", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "85cd1409-bdb1-49de-9dc2-6cc23a6e3622": {"doc_hash": "c62769eba0a6ea23a97f335b729bab64b3dd9633dd0dae166a7d9ff3d079597f", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c": {"doc_hash": "7f0d9ff1cf9c01c20ffc0c74ffcc7265baa447efaf0b70f3d52a4e81bb52c77d", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "2eb3d135-9e7b-43f5-8b7b-8868322bd13e": {"doc_hash": "f8e7e8c789dd09ddc7f7c964b142980c855cb5958d5062ca23b939f1ef40b872", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "2a9d6f46-fe6a-4221-9fae-d32addf1db86": {"doc_hash": "b7839dc53b8114ffd1220686028b8d231201db737e300548a6e4769f21762eaa", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "34f5256c-028d-4864-92df-e78963e6f611": {"doc_hash": "e2993efac0cb17d28c06048a3e833ef6cb6b48b34196d9627892115422c953d6", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "17f188b7-7581-4131-a855-b8895e63f87c": {"doc_hash": "c91ac3cd0394e4918b9b05336a676bec24e257a4283a4f24a8cae6bf1205aa18", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "f35ed205-2847-4165-a2de-18d708dda254": {"doc_hash": "d2753423fcf31eed147e88885bb910df7778956772bc26413a3a05d6a882a22c", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "d3eff749-270a-472b-9378-a83631ad3f4f": {"doc_hash": "701016bc75df9e14147bfefe3ea25fdbe11d4d8b569bd526cd1e8046f06c59dd", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "28240866-68cf-4bc8-b148-23634b36c75e": {"doc_hash": "e8ea4a42e89b3cdb6a8618a779d9b02cc0a9e7a82bfcd65315cfcfa226364f42", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e": {"doc_hash": "82841cf56503cb7c1adcbf29c212ec791bb17d7611b1e0c2b14b2403f737d623", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "c267494a-e9da-446a-a858-c67d33054bed": {"doc_hash": "81a07252cf9f7a4825db0483d1ad17dd4ffb50dd393ce1844bb18ce84845c45f", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}, "8e9de07f-f8cb-4137-af21-3a75d4783668": {"doc_hash": "e729ead3c5776743eee3835c015f323ec258bd3bdc299c77f6576dc3e82e7446", "ref_doc_id": "2e7056e6-611b-4964-9975-862de022c327"}}, "docstore/ref_doc_info": {"01b5d416-1e80-4778-9006-fc61daa8daff": {"node_ids": ["2edaf5ee-f6bd-4f52-b31d-58e8dc046f98", "a98623b5-99be-4658-90a4-ede42cdf4eac"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.   (MCK ) \nQ4 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n08-May -2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "92cacbcc-8459-4060-bdf5-085e3d8008d0": {"node_ids": ["da2de88b-0bc2-468a-8ce6-a72f541e813b", "4cfa0bf8-b8f4-4946-a606-0195ab6bb916", "8ad6873e-55ef-4063-82aa-36021d4a5f9d", "af61f22c-f662-4ee2-9723-95feef61f940", "a4727e84-c82f-465a-9c8b-9646cd6618e3", "af8f3443-0c5d-40c4-a224-5c1cb7077014", "b49be17a-f3c2-4284-b16f-a2afcf9b6895", "11780e35-9889-4c22-b78e-5e5abe27c6db", "30658792-6b3f-4d22-8f6a-d507f3f912c6", "9eef01c7-223e-44e8-b1fb-962b96f54c68", "e3622332-983c-4b0d-812f-c01415d8ce55"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ee437d97-be32-4635-ab2c-f5a89059ad3b": {"node_ids": ["42bf4fe6-2eb0-4706-9043-5b7005e34b49", "a0aa65b7-7942-4d72-bc96-4c4b23abeed0", "f697c527-4c4a-450b-97c7-fb635975b4d6", "8fa0e6ee-c427-46b6-a58d-b7764c7e61d1", "d1b501e7-d50d-4f0d-bc8b-baf19bcd260c", "bfff62fc-4375-489c-bcc4-c2e9d46b464b", "7e2a21a9-a678-4e5d-ad05-cc9f7d339f58", "90b35f55-ce0f-424c-82a1-9aa87c4ab5ad", "e222da5f-3f00-4ca3-8490-63ce7b16c86b", "21021643-c8f7-40b6-8035-d054d928011a", "ba5af0ba-fbc5-420b-81d4-4981222f2568", "419a6e76-87c2-4565-afa5-bad7ce10fbbb", "ba46ad75-431f-49b8-bb1d-c143c46e4e4b", "3ac01a8c-1ff0-48ad-938c-a2efa385304b", "dd9c28a1-9a47-4b53-b69a-c1e8def3fd75", "42a87841-1f04-4876-95d1-daee31c8a13e", "627aeba7-8346-44b2-8167-78afae96be7f", "65152bff-bb56-4bc0-bf63-87deb9454799", "a31819f2-e2ec-42e9-a1d3-980aa273be52", "94a5228a-61a7-48a2-9be9-51282d40e6b8", "0652f7be-cedd-4275-8f93-a3ed3695b3f7", "b5235bf2-3eb0-4756-bdb5-dff3544827d0", "4d4a76bf-6023-4422-976d-482ba97746b3", "40f2c965-d037-4aa8-99cd-0969d54098de", "27450ae1-ad61-4202-a937-ae82cdda5a31", "2b90f5fe-ce16-4873-bede-877ff9c73b8f", "edb7a043-364c-41b8-a5b4-f7137e47683b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2023 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  \n \n At this time, I would like to turn the call over to Nicole Kramer, Manager of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d0dd40fd-393f-4a35-bad7-6cd4ab4a551d": {"node_ids": ["6918ef20-e896-423a-87eb-ae76410fa314", "228e41f1-a67e-46a4-a63e-702b22916cee", "4fb7761e-f285-4f59-bf82-8db4bb9e7bcd", "7e0315a0-0248-4aeb-9719-e429e28bcaf6", "62df6be1-f2c5-4880-b661-ee42241c93b8", "1e7697f3-ab74-4fad-bc9e-5630e47c7f1a", "a3dde0e4-e1d6-4fa9-be57-5bd480ae42e0", "7f3c6574-597f-4bd8-af3b-2e07a7a58723", "0b1a7f4f-c1e7-4e44-9179-e70ddf25d5b0", "5984bdb5-6632-41c8-87da-0a5d1713ac7f", "e238d4e0-e4c6-4095-8981-4838fb97d06e", "60ffea83-639d-49e5-a23b-53dafd9d09a2", "a0968846-5bce-4202-9d30-0e8335e393ba", "4f452736-1311-478d-8ab7-83e3e1056de6", "8a640af6-aa1d-470a-9947-d2fbf09b54aa", "7b5197bc-302e-484c-a90b-5bee7b0a59fb", "181259de-5580-4db7-9d2e-a870fada2970", "17bf866b-cb77-4af2-93e0-7ef2184d81a2", "cfd1f5a1-b771-4161-8e67-3ab607dc6208", "9435e7f5-a537-4f93-8657-f5ba9e90e8bb", "02168467-21fa-464e-960a-789472c1c77d", "bcbc76a5-c16f-4bec-bc2f-02e7987c30d8", "e65ad2d6-1a18-460b-8bc5-15903611d928", "557175d0-2055-4c69-977f-f1fa81c309d5", "4216193f-eedc-41fc-af5b-52924477e536", "bd96697c-ff88-49df-92b0-add2c7886adc", "87a9494d-27e9-4d1f-afcd-d4ee3c3357e7", "2e847ad1-047b-4cca-8a71-94fb1bf058cc", "be4c1cb9-66e0-4b65-a1d8-0dc8901a557f", "cae42834-fc81-40f6-9489-797b67e767e5", "092feeaf-cc82-4de4-bc96-608278b8f1a9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt will later walk you through more of the financial details, including fiscal 2024 outlook and the updated\u202flong -\nterm\u202fgrowth segment targets.  I wanted to start my remarks today though with the foundation of all of our \nstrategies, which is our focus on people and culture.  Our talent is critical to everything that we do at McKesson. \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e080c70d-f918-43dd-aee8-a3f7c3abc2b1": {"node_ids": ["2708671b-fbdb-4dc9-b01d-a5b1b5c19ee2", "78845abe-dc1b-4812-9704-b35c7bd30319", "a5eaac5e-edc4-49ee-aa05-0cf339ea772c", "82fa50ee-628b-4188-a9bd-fe967bcb105b", "93d10916-699a-43d7-9f75-3af9cc9866a8", "0b588da2-86e3-4c95-86a0-4086b5aede87", "a88a4eac-2aca-4d74-a7fc-36a15fe81328", "a4ac6a45-75fa-4792-8099-0ca35eb21e33", "7d36c965-4c59-4819-859f-daa1ee2fdb33", "4c59f44a-f03c-467e-b5e5-4abd0a5dfb7e", "6116bf6a-379f-4f00-aafe-f438eb1208a2", "3eb60e54-e63a-4605-80fa-1a591695ef29", "82d4cc5f-d5b4-43f5-84cd-3bb4b86c6e0b", "72225bd9-0034-4e10-9839-872f9e70c5c9", "1679835e-3214-4a4a-9ad5-01ad9177923f", "d13b939f-c700-4bf7-9fe8-b518b216bd7c", "4caab501-3ff3-4ab7-afe7-74d83b29275c", "4a7e9e09-9124-4919-b196-a206d205fb46", "64f84532-ee5d-4c20-9902-92337a845d2d", "24a79bd1-96d0-4229-aca4-de4fa5d7d34f", "0ec2d7aa-8f00-4ddd-b31f-554a3c8eecc5", "06d6b076-1b11-4d53-b232-54fa1393f8eb", "b6f3f9e2-b43f-4f43-8d05-5f09f60faef8", "ddc75d76-13e3-4daf-83ff-8ffb66a0f755", "cc877169-e0a1-42d4-bc2d-2b7dd8ac1e65"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nThrough our GPO services, Onmark and Unity, we serve th ousands of oncology physicians and deliver significant \nsavings on oncology drug purchases for practices both within The US Oncology Network and other community -\nbased practices.  \n \n Fiscal 2023 has been a year of significant growth for our practice management business.  The US Oncology \nNetwork welcomed three new practices: Epic Care, Nexus Health and, most recently, the Regional Cancer Care \nAssociates as effective as of April 1, 2023. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cb3a5bc3-7314-44b9-af20-0b41ee8be44b": {"node_ids": ["636324d9-bb96-4295-98a9-80180d01a5a5", "051eae26-5f0b-4dc6-bc06-9ca2875e82ed", "93d3ded5-6d2b-4e05-9bdc-2f9a7d6369e2", "cc40f4b4-3ad7-4a14-892e-b67e6fbc3ca1", "4bdd8744-ed24-4553-973f-71c2c95b2b68", "d9a9777d-f577-4354-a787-8c41caa3cb73", "3a3caa5a-74e9-4690-a07d-77c1a1dce07f", "f5b9ddd1-c65f-49da-b4ec-31f2e3fe6cde", "bfeaf472-f3fb-4bbe-9c00-857e664a3ce3", "dea9859e-3688-49c4-99c8-58624c225565", "af8cf404-4acf-4227-b820-381da79088c2", "6c01806a-3194-46e5-b58f-ad13d777bd34", "e1213a41-d7b5-452f-aa94-3a2deee7ee8f", "2d32921e-bc4a-4977-a427-500949454b1d", "e0e44c22-9f64-4aa5-95bb-3e6b96f2469b", "2710b7db-d8f0-45c2-9751-53a679e46d8d", "564dba20-9fc7-45b0-85a1-9397dbf738e0", "64845a1b-b4b5-4a44-9a1e-0eafec0f1da9", "da74db55-b97b-47c0-80d7-0d04740f1276", "f588c957-a005-4f0d-9730-65b607bd5825", "7731c38c-72e3-49a9-b8b8-defcdc0a23c9", "e7c1884a-0a15-4410-a60d-eaf635d102f0", "2d9b5a6d-1a6a-479e-be96-8756c259c65c", "94493ee2-3dde-4eec-a88c-707f717ef766", "8cfd2274-b6d5-4e39-9534-b68a0feb1093", "38a1473a-44ad-47f6-a725-4ab84720fd12", "31c3988f-137f-478b-9263-5aa7253f5b8d", "29803a04-6a6e-48f5-877f-8e929a1c1989", "0a61d568-a5b7-49d0-a6e1-5e31f0f47841", "0bc956e2-2a1a-4e48-9556-b1555532c449"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nThese actions will allow us to improve operational efficiency and, more importantly, to better focus investments in \nother strategic ar eas and to maximize our resources for growth opportunities.  \n \n These types of decisions are always difficult, and it had a direct impact on some of our employees.  I am deeply \ngrateful for the contributions of all our Prescription Technology Solution (sic) [S olutions] employees have made \nthat have led to the significant growth in this segment for the past several years.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "210742f7-42f6-42f5-a2a6-5f7b31e8af66": {"node_ids": ["7a14dced-028b-41a8-8b26-d04712256ac8", "b661bbfa-65b5-48d1-ac31-da705a07f4ed", "a52bb2c2-5335-4642-9e6d-7e6f3283a6ad", "15affcf5-8a0b-4f6e-b28a-b7b9146899f2", "c2fb7ef6-4c60-4d2c-a988-9ba311c0ccb7", "637ba99a-6164-4307-9a75-5789a5065ba7", "ea9a5ec5-bf0b-4a6a-80a1-573868c48a04", "b91f60f2-8f86-47de-83cc-b04cbaf7433e", "3205d079-3a59-4ca6-9a52-a224ed73b1cf", "128bc1b8-c42c-483e-8a7f-b580f0fc606b", "ccebdaad-0390-4a9e-8259-573c30d0c708", "1234179c-76f7-4e14-9441-48f9ff3ffc7d", "9f188298-307b-4ca2-9ec3-ee581049d5ca", "98f41714-191a-470b-9346-10cc6e68509d", "ee5c80c0-bbfc-4e46-a2d5-1095f632c533", "8482b4c5-87b3-4daf-8783-69fd0dbd74f8", "3dcfe75a-fbdb-48b4-b753-1f21a22ba637", "31bbcf74-d1b2-4dc6-a892-879fc4f8c77c", "4293ea53-97a1-4b13-a226-52122ae33d9e", "dcff898f-4b96-4a96-80ed-298d9cce1c37", "f87522a8-b7bf-4dcc-955b-86555692da50", "3cdbd904-155c-46e6-93d9-dd1bdda28da2", "9b43dbae-6f3f-4113-8f68-4be701fedff4", "8f7b6b28-fe3a-428e-a4df-776ceb9c1e32", "3e26ffd4-e3cd-4955-97f4-46f271009d04"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur results demonstrate the breadth of McKesson's strength a s a leading diversified healthcare services \ncompany, with strong performance and growth in each of our core operating businesses.  For the full year, \nearnings per diluted share increased 9% year -over-year to $25.94, driven by a lower share count and growth in \nthe U.S.  Pharmaceutical segment, partially offset by lower contributions in the International segment as a result of \nthe completed divestitures of McKesson's European businesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "dfc04f16-ceba-4a23-a1d0-a98165a7c74e": {"node_ids": ["faae7809-63f6-4171-8a91-0709b652a05d", "ff472c87-e2d7-4302-95e9-1af87557e88c", "c3f294dd-acd0-4969-be87-ba346f69d43f", "b109cca8-4ebf-48a4-9448-ba59d729df71", "5a885cb9-0a6f-4270-be69-5b3c8d0f9650", "62db3ddf-98fb-4ea0-8dee-6cc268529848", "a919e8f8-740a-42fa-a8ae-9d863df726b8", "5c7c7a62-f27c-4e03-bf50-bf6d136ccb52", "d24cafa8-d2ca-473d-9268-0a83bc80c1cf", "e6e7a38e-dfb8-4d15-8e8a-a3a12bc4884c", "c5f4a293-d8fc-4961-8aab-9b54f6922da8", "3a6156a9-7de1-4cf5-a2fc-2237c6c22f9c", "a81da46d-1ea5-4e37-b1c9-1c2f2da9a3d3", "7098cabe-2265-4004-a516-fe68c98cf7a1", "712ecf80-1177-4df9-9a34-9c6bfa766c54", "ca783919-9d1b-42d2-821b-f033bf99c7f8", "1003a391-2243-4913-8654-8e3edd5d8983", "23f4456e-12f4-45d4-b794-dd7c3bdfe57e", "f2407983-05c4-4922-a0d6-cea00fecf7b2", "ebbcd4ff-57d5-4e6c-9f8c-11d561ee90e1", "4e1442da-f7de-47cc-ace7-3222254d2f72", "4b91caa3-6ebe-468a-834e-9b234e582d3e", "c33b8a16-bf16-4821-965e-aa36b4c209eb", "b5b25399-fb22-46f1-9a89-fccc5aa03dcc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter operating profit increased 4% to $1.3 billion, driven by growth in U.S.  Pharmaceutical segment, \nincluding solid contributions from our generics program and Prescription Technology Solutions growth more than \noffsetting the impact from completed divestitures in the International segment.  \n \n Full year operating profit increased 3% to $5 billion, primarily led  by growth in our North American businesses, \npartially offset by these completed divestitures in our International segment and lower contributions from COVID -\n19-related items year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5c5e837a-56e2-4df8-85df-f49d1c389a2d": {"node_ids": ["94645c12-4d12-4f5a-a952-202b259fbb0b", "d21bc5e7-ed7b-475a-a814-1ebbd90de7e4", "5d21c8e1-ca71-4e6c-bb1b-7d17aba29da2", "25357344-adb5-474c-96b6-138914b1b45a", "c436f45a-11f4-4dad-a857-ce7acbc4d22e", "3893858a-3120-4057-bdc3-88966abeee39", "77c5ff63-5724-4444-861a-753376dd38e0", "80171b71-a837-4e65-a89f-5e05cb65b183", "e16973f7-ea2f-4bd0-b598-4ab477601868", "a97de9c4-0736-4b11-ac28-1f24be980455", "f2837749-2b2e-4621-a6d6-5502d0e29414", "2102243e-1528-4d9d-8cf3-ab07f11a89b8", "f52c1806-9b7b-4ecd-8916-7950f69c416a", "ef3549d0-70ac-460b-bc74-aa4c743274d6", "466d3e8d-ea0c-4230-817d-fa6354400dec", "31632b48-c4c7-4f37-88f2-4268edfd5c2b", "2c38a6c1-3cf3-413b-8b04-6bd3da35c2ce", "905de93d-d934-4102-813c-968ae4c63937", "702eecf8-6dcf-4a18-9952-f19e3d033ce1", "4cde3b73-0d39-4fda-9da9-20528b5ca45e", "9c0b15cb-8f3d-41d8-9638-1bb400097188", "f88ffc8d-3966-425d-bfcf-921bd7f630e0", "0f403fae-976c-4721-9fd6-d5974ba630dd", "bb88f6db-13ac-451b-9baa-47a75c6808ed", "fa3b57a0-f5b0-4119-83a9-26fcf70c99bd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nFourth quarter results were also positively impacted by annual customer verification support activities, as well as \nincreased volume growth, partially due to the commercial success of the brands we serve.  Through our \ncomprehensive suite of solutions and services, McKesson helped patients access their medicine over 24 million \ntimes in the fourth quarter, the highest number of patients assisted in the segment's history.  This segment \nproduced strong fourth quarter results, and full year performance was in line with our original guidance.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c5c25936-2a88-4915-8f7c-297444d457b0": {"node_ids": ["416b568b-61d5-429b-8616-2a10f39abff4", "044fb551-27d3-4bd6-abed-d6b4fce0dd40", "5f7e3747-680a-4cf1-a81b-c05fab7aa183", "ea26b8e9-dc4f-4ace-9df0-a94dd604340e", "c7d12a2a-6cec-447e-b8e8-1db96442a6d1", "7b787712-4d66-488a-b626-c47a66bc9f82", "8c8d2367-3d0b-41e8-8b6b-73a1d3bbd77d", "779547e4-1f3c-4a4a-9358-0ea09f5a9f07", "00240f1f-444c-4681-9334-631c17f9a6e9", "393e0ac3-3f3f-4b62-937f-28b38cc890b6", "967fc5e3-99e7-4970-8edf-1b8d99808c76", "f8f2797f-b1dc-4330-87a8-94ab36e56d1a", "61884e42-d0ea-478f-aa11-cdd67994d994", "d5052f34-9e58-46b0-a55e-8b402ef991d9", "65c7e5a7-70f8-488c-92ae-2795f8775d60", "92117f62-79fd-44b1-ae12-3a271847f6bd", "e62345f4-b8e1-47e6-9423-17d5ee0f7f9c", "7c983f10-f288-4368-8fa1-f89966c7aa98", "c52326ab-d146-4097-a806-7948a66b47a1", "acc6b678-47b1-410c-9c8f-aaafb1c58028", "6aa29aba-baf8-4b13-be16-a56ee5913c43", "4b4d47d9-78c3-45b4-b0bb-ea1cb63bebba", "599c6f49-6e07-43c4-bff2-15988d9dcca0", "f34c969b-8e40-42ca-87c0-28012ec18396", "5f0c620c-643c-49af-827c-6f49257066c1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nnet gains and losses within the McKesson Ventures portfolio, corporate expenses decreased 23% and 19% in the \nfourth quarter and full year, respectively.  \n \n Turning now to our cash position and capital deployment, w hich can be found on slide 13.  For the fiscal year, we \ngenerated record cash flow, reflecting the broad -based strength of our businesses, the focus on working capital \nefficiency and disciplined capital investment. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "994e5fa8-eb2b-488b-804e-b30505caf461": {"node_ids": ["92f551f0-4a27-4b47-88ff-83551bcdaeec", "415a3188-13a7-450b-af36-c0dfdb02ae9e", "790bdb3e-df9a-43a5-8a78-1b2683df513b", "15dbf0ff-d039-4c8b-bfcd-8bf7908acc14", "01dfebfa-c31c-4806-860f-c3b94b63ece2", "1c66b039-5b97-4638-8b3c-ce9a1915dab3", "26f842d5-61d7-4b3d-a5e1-60c2b149de37", "01abe337-acf0-44be-8e7e-1961bc501261", "559bbad6-295f-466a-8db3-711fb864ac03", "c26f760c-f46d-4ce8-85d0-08972a3cb796", "cbf92855-9042-4152-8eca-07bc9328b14a", "c6a1db03-433d-4a1c-a836-417a0d141303", "08a19543-a8db-4b93-90e9-6ea05281c89f", "3d19147d-638d-4ac4-9c84-d41de07d8979", "24239bbe-7e3c-4802-b0a9-a50d879f9c61", "198403cb-266e-421b-b548-54139c57676c", "9859b5bd-c140-4436-9624-70ec66b55261", "29c38176-50dd-4d33-92f6-06c3e323dcf1", "260a2a4d-0482-4955-b369-18c907223048", "0757958a-8072-41f2-a200-33320e595ccb", "756caf27-8a3b-4965-851e-c7974081aa46", "0328e6d9-106f-4e95-a23d-470654d5f33b", "85d270d0-9b87-4c94-98de-fd844609d0a5", "db5a4442-5fdd-4d10-8635-bb58d4da98f6", "755b61f6-b2cf-489c-b8e7-b59b213c6fa1", "fea1b57f-c7bf-486a-b9f4-04be3c18004b", "9129f271-8da6-4259-a51e-247efeec32bb"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nLooking ahead to fiscal 2024 and the scheduled completion of our COVID -19 contracts with the US government in \nJuly of 20 23, we anticipate that the impact from COVID -19-related items, including COVID -19 tests, will be \nimmaterial to fiscal 2024 results.  As such, we will no longer provide earnings per diluted share guidance metrics \nspecific to these items going forward.  \n \n Let m e discuss the outlook for our segments. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7497161c-fadf-4981-a08d-334af63c9750": {"node_ids": ["da7d4778-0086-4262-8fe2-88ddbbe88256", "4699b10f-b75c-4022-b270-069300a28ce5", "5e32e259-f695-4d18-bbcc-6e3efe6347f7", "1c15e358-fcb7-4fbc-8083-9480c7cb63b0", "a755ed57-e4dc-4866-a803-ae2f37375342", "346b9384-789c-40c0-94b3-bff05bd61afd", "c23383f9-fde4-48e5-a096-c2558b09deef", "0e8e8851-1325-4b97-8bd1-133daf38dae2", "cf6492f1-17e6-4924-a9d9-a27f97e42f3f", "d246e36e-8d86-4b99-881d-82444d917ee2", "fd2090e1-ca4f-4d70-a900-715397a32fde", "433dd75f-febf-40f1-b0fe-fa27e386e1e2", "752b4725-a5a8-4de5-bc76-8765348f3fcb", "50f86e4d-c969-413e-bf96-ce62ccb2ed7b", "ce85eb3c-30a7-4020-b2e6-dda88f73a611", "95477e9d-f023-416d-8bac-edf0ec65db16", "dea97f61-6383-4854-8814-95b4eaba3c29", "95dc488a-afe7-4269-899d-494b76a0d980", "fcb4dabb-9219-47bc-8b33-f0de55acf5db", "57e80747-e2a4-49f6-a17a-8f1e6eaa81c7", "4da918c6-f822-45bc-9aae-51ba4e785e2b", "478b2a80-981a-4a4d-81e8-fc8d6d5d89d8", "5b2a944f-daba-4432-9324-d782cbdc7025", "8be28f5c-2919-4085-912b-39f3f3bae2a7", "64bdfb51-7eda-4c64-8bc3-1ce594d5af22", "aaa9db80-d6dd-400d-b3fa-b61667335ffe", "dbb3d78b-79c2-460c-8d60-6303948f4c7a", "b838b745-9b31-4039-b4d7-5b516ccd6b13", "e26a07f6-0990-4858-9820-4e92118a14a5", "38ee070b-7c63-4fca-96bb-4afbb99cd9f0", "fbb34f94-f934-4ccf-ad0b-a314ab773b24", "7067eefb-ddc5-44c9-a0fa-071052365ba8", "ed2e75d4-db62-41fb-a25a-7508ca08d60a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nto leverage the breadth and depth of its services throughout the alternate site market, including growth in the \nprimary care business and lab solutions.  Our contract with the US government for the kitting, storage, and \ndistribution of ancillary supplies ends in July of 2023, and we expect the remaining impact of this contract to be \nimmaterial to fiscal 2024 results.  \n \n And while we anticipate a modest contribution from COVID -19 tests, we anticipate volumes to continue to decline \nand be at a lower level compared to fiscal 2023 and immaterial to fiscal 2024 results. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "be97aa16-2962-4b6a-b54d-ad25e8321f5e": {"node_ids": ["9d01d53c-0c5d-4d79-8312-30c8faad46d9", "03deac2f-2345-44d0-8051-98562c50ebcd", "2b63b072-f58c-4c82-80a9-ad293690ad24", "b26ce2d9-c767-4d36-9fd1-a4239ff329e1", "10ca53e5-c379-4295-a3ea-6873a5e91692", "236222f3-7587-4e7a-8d2d-60f368b19c60", "45793a9c-f655-43c8-960b-3fe2c7614b5b", "1458d380-febe-466e-bf19-54bbe43d3138", "6fa65cf3-49f9-4707-a68f-6dc98568c77a", "4c46cc88-3bc6-4b4c-9ccb-b4f5b3194127", "65e68038-40ba-486a-ab85-e18b6d424330", "428d6dca-fecc-4774-b41f-c915386fc249", "4d996166-b393-4fa6-a88a-128ecf50d32a", "8956faf7-3f97-4896-bfef-48c5fddd9251", "0f5e6bdf-5193-4fd4-8ac8-58dcbf63249c", "ddf23c14-600e-4502-a026-997dd76c7e4a", "62b8df85-e94b-4c8d-aa18-ca3ee595b9a5", "1f9dded8-ac86-469d-95e2-ee924980b7c8", "a598e007-9758-46ad-b460-975f34a01ba4", "c6d76302-a108-4c0b-917c-356ddf21e875", "6a83e112-2c0f-47e7-ac65-0a19bfdb2c9f", "33a1be49-b0fc-4bc4-bc08-ea857cf8576d", "68d10026-b658-4fa0-8412-60a126799d1a", "cf00b7b6-49b9-4915-8d78-14fc526b9b7f", "ca7b391d-8d1a-4319-be3e-9069e764c668", "d2a05de6-a422-44e0-8782-5a479af92a3d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ngrowth opportunities moving forward, we remain confident we'll continue to deliver long -term sustainable growth \nto provide superior value for our custome rs, team members and shareholders alike.  \n \n In conclusion, we are well -positioned in the market with unique strength and scale that only McKesson can \nprovide.  We will continue to invest in our strategies as we expand the reach of our oncology ecosystem and \nbiopharma services platform. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7c043e63-0cc3-4d5f-8f0e-9b4012e2bf6f": {"node_ids": ["1c2ee887-fd46-4955-9bfd-2b6f1aee1d2c", "61a3a88b-9c47-4a05-b5ef-6563cc0003be", "fd13addd-b9cb-47fe-8bc0-0ac916f8201f", "03badf40-fdbc-4ebe-bc43-3c520a42fe05", "a369bf5e-e6bf-4a05-aa93-22680bd10c5f", "6e87ced3-476c-4f71-844f-8fc08f4b8350", "c57e4331-7708-4ea6-a17e-0dc97770fbfd", "712b00e6-2aa0-4578-83ea-2638810dc5d6", "1ffed0fa-5963-43b0-aacf-87e5e33edc59", "f0edaf59-bca1-459c-a49f-67bbd79631ec", "3b15b508-fdfb-4ae3-b6f3-f36b2345de3a", "7db26373-b309-4960-8a4e-4fcb12e88827", "87c04c69-da61-4622-9eb3-f19ec7e49832", "29884a5a-d553-4626-a20f-571f12f1d835", "cc762b21-d49f-4506-b8d4-c1391eda1e4c", "6ac9006e-2f8f-4bed-ab61-58818e67ad9c", "7f7e4a91-0b0a-42d3-8453-382301f395be", "1b580475-9361-4483-919d-1527d2307475", "1b4dcef4-69e5-4425-9e06-3787f2d669d6", "b7ae6624-f9c0-44ee-bee0-ecee47caf1bd", "c72de8fd-85ec-4184-a7f4-cba16c167b7f", "f769c54c-6242-45a9-bab9-a77496b5f480", "72abebe3-d288-4c2c-9436-ebee7d2b4754", "03a25775-2c55-4c55-8bae-46c44e7eb07e", "a79b90e6-c0dc-41e9-b369-a556b7b5c93e", "1379ecc1-7d8b-487c-9712-30113dc7d09b", "20ea64ae-5994-4ce1-aa52-a4b96625f1da", "2f85e01b-1695-4ebc-a60c-aca3f021723c", "1410bf2d-c4dd-467e-a3d5-99e8374d3deb", "481de532-1905-4ffd-b849-ca7f42467bc6", "5659e253-ebdd-413d-8045-ba6d349ab210", "f61f0dff-5b3f-4a1d-9df5-a3e7e8029fb3", "30745b78-025e-428a-b86f-b09d8094b779", "8e53604f-0714-47eb-9505-41a1f80a4558", "706c98d1-f7c3-4d68-b857-7aa3adfbee57", "3cfd3f0f-e0d3-47a7-866f-16838d906239", "e77567b5-fd1c-4e74-9ac6-e01e6c02b6ee", "72764918-f315-4bcc-ac28-9b577d46f12e", "25ff13c5-a1f2-47a0-b624-5d29887a5117", "5e27d416-2bcb-492b-b853-723ce702b695", "a7cda1d6-5519-4c72-aeef-2a4a6b91a557", "c6c0da7e-4fc6-4d94-8a71-28cfe95898e3"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for taking the question.  Congratulations on a really strong guide. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "391de6b5-664c-4a54-944c-01444b060505": {"node_ids": ["509d0ac6-3d31-4ca3-b505-9ae41a8a651c", "998a721d-9f31-47ca-9631-ec0ddc0947ab", "9598c7c4-2528-4348-98a0-13ac33164059", "8e612020-f16c-4656-b9bc-c460c7b1b7a2", "94800faa-960f-4344-bab4-61585a9b8f19", "564d02c4-3b8a-4e0c-864b-6f61ce7554df", "9d43bdec-d331-4601-a886-9f4f7d510f58", "848b740c-de4e-420c-bebf-55d6eb6f92f7", "1337df31-8a45-4236-87ff-78e8a4ba73f5", "4d61a00a-4ae9-4679-85c4-b9f4d128cd8b", "d5d5d66e-b127-4da1-a27b-c38bc1b23624", "501d9f40-cf0d-4324-826c-4e8a763758ce", "f116ba4e-50b3-45bd-9f0e-d2bef3bf5d92", "6ca3b5f2-c800-40d4-91c8-e6efccf5720f", "ca08383a-2d43-40a8-849e-bf87b1a4b3f9", "37158d28-6d09-4447-8f77-8129b3d4a7fd", "4faa5c13-e364-4a85-ad62-271c3b1b676d", "6c4ed57e-6a2c-47f2-aa64-80555ddb6963", "aba58546-5100-45b6-b6ba-ef4ee917d4b8", "a6ccaf2b-5030-4a3e-bf78-b91886ec2236", "c1fe7cb6-cd8b-4d81-b51d-74c2b3858c27", "69d3b9c5-bd6c-4485-968a-e7093b0dd8be", "ee1de9c4-f928-41d7-8ff1-a3d68180f126", "8efbaa18-809f-454c-b06f-aef9cac23628", "a403b965-0ec7-4c82-9ba2-6c7459ebe082", "b9564c03-5744-4d7a-ae2a-707f7768d2af", "88c2fb3e-523e-432e-a61f-f2a8b10bc965", "92d63111-b3a7-4b04-93bc-27e640940232", "560efba9-eaf8-4e99-b067-87c5118c4120"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nfair value for those services that we provide, regardless of what the product is.  That's what we do on a con stant \nbasis, working with our manufacturers.  So, I think we've talked about this now for a number of years, that we've \ncontinued to evolve our manufacturer relationships and our pricing to be reflective of the fair value of the services \nthat we provide; an d as we go forward, that's going to continue to be our focus so that we maintain the economics \nthat we have for the services that we provide.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2abc606c-38ea-4660-851b-cb0a7d3574b9": {"node_ids": ["5383fb40-242a-4d6e-b200-b5eb563cd3ff", "00405df2-e191-4d27-ab4c-41f24126e2ac", "58b251a2-cae6-461a-8cea-288e885c95ff", "84cd8bec-746a-4d42-b509-7191a7f1c628", "17a0c615-aed7-4354-8f54-58e77da6b251", "262f7b81-0f2e-4b7b-a1bc-9d89f747ea7c", "253cb390-bd54-4d38-b0fb-b4f50139a9a5", "49821383-27dc-4fd8-afc6-c381d3338dd0", "95b5f1eb-cc49-4a38-ba8a-2ef02f496261", "adc524a7-a81d-4240-9331-4c3e0b90d25c", "41275ad5-65d1-49dd-af0a-56370f1ba440", "599180c8-61d9-4fda-bf9f-ccf875155d08", "c804cb5e-0e21-4231-8d46-8246d0098a88", "9ed41cfe-5a8b-4534-9e6d-8956d1bcf939", "efac3c90-4a0a-4437-83e2-e2fd43117a27", "bb4f9142-6d95-46bb-87c5-068f3e8bd908", "78b083da-3550-4dd3-bf2e-31d0beefea0f", "8d5548e6-4f99-4d6e-8f98-df528b62ea93", "ffbf5785-dc8f-4b76-9889-084b1252baad", "ccb8548e-6149-49c8-a095-d2cf590de326", "1d0715f7-aba2-41a8-802d-6c3c043e3d73", "1ed7b1be-e946-43db-b212-6f37ca2e5a94", "363dee2b-577c-4095-be3d-9128db57e527", "60285116-e264-44f0-a035-ef2283e38d3b", "bd1f9cde-2634-4955-aaf5-f1e7a9c97326", "e561d624-d01f-407a-b6bc-cf2b2b5f5fdc", "88887736-bfcc-439c-aa69-e473809bd9ba", "3cb16cf7-c878-4528-bac5-ec2e2c72f307", "5c3f30a3-3568-48b3-8a5b-89188e137bae", "4d59eb3f-46a5-41dc-9afb-e836e6d92057", "69023623-501c-4dbf-b670-e9adb632fec7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with TD Cowen.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c68551a7-416c-4c3f-a5a2-5b36f26992d7": {"node_ids": ["7f2dfd10-4cf0-44c8-975c-42699ccf4aa3", "bf80ea7a-8d07-4c1d-b20a-93fb2f15acfd", "1ebbf7b2-8c81-4233-9ae9-996a3b5976f3", "3bf22c89-bcd5-43a8-a02d-c93f7077e9ce", "165128bb-0f24-4e6f-88a0-f3c2333c8d44", "faa4d9dc-6f9e-421f-89fd-b1d3edd3ff3c", "62d69da5-5c0b-4b98-932a-5a97c1b6dad5", "f932a6f4-da64-4196-84e1-bb45bb823862", "a8b20d32-b48a-42f4-93a4-0938cf926631", "3cfc13e8-806c-4a59-b2c6-18d65ae9cbe5", "1909773d-f224-478d-ab8b-610790cefbea", "a3d4ae29-9ca7-4409-9e20-2e4e0bb8de4b", "d3a841f5-a648-4813-9a17-2ef13f5f570b", "ee3d35c8-0764-49cd-a173-97ea662dda1f", "67eccf82-b02e-4d23-bb26-e355420ad3f8", "ab6f415b-5c58-4e0d-9882-e01654ea2832", "4a191ee0-d802-461e-a3f2-7a6d29a5a7bf", "ffd4b6b2-ff8f-4745-8d2b-244f1ed4bf97", "471118b1-c54c-488a-b737-3f92a31a4911", "332c711e-d8a0-48f8-8dda-12e8a8b6a759", "87851154-9bb3-4f66-835f-c372e0a5ff6c", "5d388c10-b6b0-41d2-aefb-240da36ff804", "99195272-6f4f-4938-bcbb-645aa8febbdf", "d0a11c10-bbaf-41d7-8f6e-ec8f619600d4", "fa71b54f-4105-4fac-b408-409bc89c7a8f", "3d3f3c1f-3992-4e52-b07b-507a1149d857", "c51be610-4650-46c4-8164-f3fbebac4a67", "140ba22c-11a7-4618-a3f2-df3db6e04fb7", "ea922582-0fc3-47f4-87dc-fe0c9703663b", "cfa64914-dbde-4b16-9761-4c729319553a", "28eec38a-b9fa-4ad1-86f3-cdc6f480fb09", "c95cb270-e3f4-43b4-b864-2a411b85632e", "9eea1ec5-9ae7-4ff5-828a-2f09e2cc8307", "d260af07-b6f9-4b5b-85c6-1c5a5aa48ce8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "323825da-6b17-4d36-a862-1a0d79370fb3": {"node_ids": ["dcf5297e-9e50-4bce-90e7-e560bb4db893", "8131d783-575e-4a65-97a5-7134d59978ce", "1262f8cd-5cda-4219-b732-0b44a5a6ee52", "194e54bb-4ea2-459a-833e-b6568572cdf3", "f3c8734a-3a0d-4296-9148-ab78939fee28", "200e8234-c2ab-4be5-b4b7-9484aeac310b", "49a5b280-49de-440b-8544-32123dd1fcf3", "4e981570-17bf-4ea1-8b59-1f3bdd1e934c", "f0965eb8-0f85-40f6-9584-50bd094f1843", "1d575ce9-55ac-4906-a191-efb1ddf65eb6", "f17a854f-71e5-4e1a-b7a1-a9d2d882109b", "62a60ba2-2dcc-4ae8-84cd-3c1d2eb05b99", "23891df2-7595-4982-8e7d-3a7ffa2607fa", "94952bb9-dda6-4ef7-9aa4-cb802ade4fe8", "db7e5d4f-8ea3-4988-adc8-a300bd9516ac", "68c11c06-5220-4b19-83de-5355dcdce32d", "591650fc-244a-4306-bdec-a580dcf82f29", "a3aaefff-ec9c-4891-bc8e-26296b20f35e", "b37dd7c2-7f7a-43c7-b64a-600fbe195ce8", "cd996a72-d1ee-47ef-b0bb-9634659a800a", "b7d8adc5-5120-4448-b226-06663db47995", "1a5e4dd2-53a4-4313-b332-4633a2c47daa", "2d3ee402-e0e4-4bdf-aeb3-565c85606176", "9409e604-380d-4d76-b4a9-c8a86e281f53", "72b41069-4160-49e5-bb5e-cac433ff9195", "293b71db-e864-49b0-a5be-b5befa76036f", "d2bcab34-f33a-4228-874a-efba9af7f609", "592fd19c-a68c-4fc7-bbc3-02353e11cb69", "01515455-1055-4819-8d1c-1eb134a080f5", "13f1f4fa-9016-4dd3-9d29-7b2314511f56", "7f61235b-256d-4b66-a886-547ddb346f54", "bf8dcc14-8cb8-4c6f-8f09-cb86d2dc287d", "00dffc5b-8c6f-42fd-81a7-2fa30e928c20", "dd813d48-249a-4ea9-8b3d-82abd7e8300d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bd651816-f65c-49c8-8d07-55064dda3afb": {"node_ids": ["7e69e437-f39a-4d79-b779-33e32b001885", "aedb8a6a-32da-4259-b428-fd744d864b99", "09b5bbbe-2f47-46af-8efe-8bec52cef542", "cf09175b-8f45-4877-a922-0d983226a1fd", "675dea38-5fe9-4f9d-85b4-208dcb69db69", "ce7c8720-c5a8-41e5-8094-35c1a2f18043", "48ede9ff-d4eb-40c9-8dff-cbd5dde2679d", "5c09f95f-6e42-4877-8664-ebbc6d699596", "89c1fc86-f0b3-489d-8c06-3442c5717b6b", "b0641df9-1e70-4231-b79b-9647ea3826d3", "6a6b9e91-aa9b-4e5d-a6b5-868f84efb63e", "aebfa07d-62d4-4386-b21a-4818bc221fb1", "eb541d27-0d5b-40a7-bbf1-ef30e021f78e", "90b48bab-6dfd-41bc-8705-2ee78f4ef6ac", "9458e0f0-8932-43b6-8276-879e92b28306", "848f7a0c-2362-4c6e-a17c-3cda777ea364", "0102954d-3a3a-4d0d-b77a-7642223701ab", "c8dc0de6-d1e1-416c-9f4d-577f364ba5ee", "7c01eabe-df2e-409f-864c-f0752422c284", "aa045180-0595-489e-bc72-3af39ee5e943", "62f26e72-3ed5-43b1-a197-4ebd8b13a429", "b94874d2-753c-4203-83bf-086856619fcf", "91b76f72-b5b8-47af-9e3b-6cf05e4a25f5", "d0c89f27-d7fc-4c75-b8e4-8c7a6636fe18", "dea33748-0e1a-46d6-8aa8-be529dc0236f", "52e06362-3073-4c8e-ba6b-79bebfac95d8", "c4772ccd-fb58-431f-834d-73041a1ef7c9", "0432bde7-97d2-46a7-af06-73fcc0f55b07", "8b90b5f0-a87f-4348-97a6-9c3dac318f46", "b238c0a4-3bbf-40ee-9c24-4cd12c1d3a74", "4599649a-9783-4bcb-976f-7a7b41152f76", "bc224033-00b4-4f8b-8714-1a33c3e6d104"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNicole Kramer  \nManager -Investor Relations, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ca375f1a-c28b-4978-89e3-4f1eba72e8c5": {"node_ids": ["be9e50e1-bfef-4966-b7c5-70674402d69b", "75434bbf-5b26-482c-b81d-0d3c76264d36", "2a619b1f-8e27-4508-90b8-939d0954fff3", "c11ca7b4-b8dd-4721-a99f-c6540d2c8b21", "44d1985f-56aa-4156-a393-53d07f96df1f", "cd013330-fbec-4203-a048-91fe505c5751", "be23a840-e8e5-4500-8b7b-78911e0adea9", "b4bd5704-440d-4e51-a643-4115b6f81e21", "c7f402aa-c87e-4836-870a-57fd41a3f9a0", "bf4960ea-1bef-4397-8afe-eee58d38adc9", "ddd1dea9-c43a-45e9-874c-48dc47987d08", "d47f38e4-8725-44f5-9d65-abc81741a872", "feb04de6-2878-4781-8edb-38d25158efc7", "526db840-1866-4a74-a865-2146620196f2", "eb10337c-8f56-4099-8977-32d4235a6ea4", "0435e09d-147c-4168-9f1a-261d6ce0c5f4", "db04cad7-5816-4c46-9b51-7b9b9a211686", "fabfd8e9-7591-44fc-adb5-cbcd9b723f64", "d1e839e7-9823-46f6-a091-fbf22d5e6729", "4c578c88-9c4d-4b63-ae57-5e6523d5100c", "28cea14d-3f78-41af-8bbb-55b054518c08", "3e55f451-02aa-4396-b625-c179e4b52fc9", "a5c1734a-a2e3-4aa5-a31d-ed9b1e9223ff", "bc41c946-c8cf-4d12-a920-2cc9c4ae094d", "8452067e-0d1e-436d-9b92-f24581552442", "423f344b-7aa4-4784-bceb-4556944ac6ac", "c8c6af5b-16a9-4203-9bfc-7f21557e6231", "73974ff9-048b-42b3-8ec8-485b1eb15ff3", "a878468e-b6f8-4c10-b6f2-0fd7263bb297", "8db0d8ae-be7d-4502-a140-2a13f8ac6a66", "7aea3561-f270-4839-a6d3-02f3c4c15a58", "396d9682-0ca4-4d18-97b7-3c4f8be0423c", "cc4bc36c-b6f8-4691-9e8c-a28cd6f0fabc", "05ed6405-5be7-4337-9ff9-21f1c1ae3883", "8ef96cec-51ca-4b98-94e2-11bc06f25587", "b596f45a-0e3e-4293-9099-abf101657f22", "011f03a7-4198-4595-8856-0ff41e702bf8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nI also talked about the fact that the marketplace has very stable fundamentals.  And so when you think about the \nfocus that we have on a scaled and efficient sourcing program, stable set of market fundamentals, which, again, a \nvery competitive environment but a stable environment, and then our disciplined focus that we have on the sell \nside with our customers, we've been able to manage very effectivel y through this.  \n \n Our focus is to provide low cost, high availability of supply to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ea085e19-d94b-43d8-a4f3-026c3530cece": {"node_ids": ["ab4d1a19-1ea1-4447-9c48-8767f88f501c", "bdeee984-bcfc-4b9c-8332-56381a89073c", "fc96384d-6ac3-4e56-b291-40217018720f", "fdceaf10-1247-4538-aea7-d52854f652a7", "00138878-9dd0-4abd-b0c2-5948f9de54e0", "404f998e-4da2-4daa-aefe-69b73086cd5f", "a420fb79-6b35-429d-9c37-d9112c85283e", "4517b89f-693f-4bae-874a-c670aa4057db", "f825caa6-0fb4-409c-8ea8-95bd6f64c4f0", "485bceb3-a598-43a0-b6b6-90f3f64d8204", "0296d58c-81a1-44aa-ad4f-dfe8bdf9c5e5", "b167e530-b2af-40b2-b34d-1ad09079cc50", "574526c2-f13c-4427-8005-740f43b1295e", "2a4145de-0805-4e7e-a783-0e59a7b56fd0", "73c00a1b-e1fa-4b35-9000-4fdf2f15af7b", "77a85204-851f-4309-aaa7-c86485e5483b", "115235a1-0473-483a-9fb5-db17b4d76baa", "3b87e587-450b-42ee-8ad8-7d0288be32b2", "34b3e3eb-32eb-4321-8123-388f621db4ab", "07bf9b36-b0dc-44e3-ba80-3f6fadfdc6c5", "645e0600-2ad4-41a0-a4a8-16449b0f0e74", "976dbe1f-7c04-4bfc-b61f-2e668afb95f0", "28bf2c26-c62d-4702-b7aa-1e13eaa4cb62", "c292b9bf-d4f7-4edb-adf9-d8f8d8903133", "98343c16-6c36-4cc4-9ee3-d82e02bf3975", "8bd884ce-3667-4a7a-81bd-b0e3d2fbccba", "94d3a296-4f29-4003-87fc-bbd6e4d23028", "f9ae6810-13d8-48f0-ae85-1e2ac9fcb62e", "5feb62a8-ed96-47cb-bb8f-08d0147d2787", "a1e6b55e-8d8c-4e5f-a698-b9a7d0400054", "36336417-7b47-43b6-ba5b-079401170c4d", "2cffc938-504f-4520-a4d1-b4c4a49e2e7a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nA.J.  Rice  \nAnalyst, Credit Suisse  Q \nHi, everybody.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2e7056e6-611b-4964-9975-862de022c327": {"node_ids": ["d3c1bbc1-98cd-480f-b007-97d7d398e220", "3f456db4-1b9e-4a92-9161-74c6653ed195", "34e02324-3e0e-4a57-82a8-4ba0154b02e8", "d4aeada4-580f-435e-8e62-da636621eec0", "cd4cc700-13be-4ac3-9560-a1d1f1f80cb0", "a1b73b31-b1b0-4d7a-aa26-3bdf227a66e4", "b38d323f-e587-4f16-a082-7d220eb9125b", "16b84144-1e13-465c-bae6-e11412324639", "85cd1409-bdb1-49de-9dc2-6cc23a6e3622", "5ac1951d-5f1d-48c0-bc0c-eca01606ca3c", "2eb3d135-9e7b-43f5-8b7b-8868322bd13e", "2a9d6f46-fe6a-4221-9fae-d32addf1db86", "34f5256c-028d-4864-92df-e78963e6f611", "17f188b7-7581-4131-a855-b8895e63f87c", "f35ed205-2847-4165-a2de-18d708dda254", "d3eff749-270a-472b-9378-a83631ad3f4f", "28240866-68cf-4bc8-b148-23634b36c75e", "5f91e5ce-4419-4d60-b3b5-c32a3cc8e89e", "c267494a-e9da-446a-a858-c67d33054bed", "8e9de07f-f8cb-4137-af21-3a75d4783668"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2023 Earnings Call  Corrected Transcript  \n08-May-2023   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncare in every setting \u2013 one product, one partner, and one patient at a time.  Thank you, Team McKesson. \n Everyone else, thanks again for joining. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 336952, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}